

Novel Aryl Ether-Substituted Heterocyclic Compounds As GLP1R Agonists

This application claims the priority of the previous applications submitted to the State Intellectual Property Office of China on August 30, 2021, with the patent application number of 202111017657.5 and the name of "novel aromatic ether substituted heterocyclic compound as GLP1R agonist" and submitted to the State Intellectual Property Office of China on September 29, 2021 with the patent application number of 202111168512.5 and the name of "novel aromatic ether substituted heterocyclic compound as GLP1R agonist". The full text of the earlier applications are incorporated herein by reference.

TECHNICAL FIELD

The invention belongs to the field of medicinal chemistry, specifically comprising novel aryl ether substituted heterocyclic compounds having GLP1R agonistic activity, compositions comprising the class of compounds and methods for applying the class of compounds to the preparation of drugs for the treatment or prevention of diseases associated with GLP1/GLP1R.

BACKGROUND OF THE INVENTION

With the improvement of living standards, overweight or obesity is becoming more and more common in modern society. The number of patients with obesity related complications such as diabetes and fatty liver is increasing. Reports from the World Health Organization (WHO) and ZhiYan advisory predict that the number of obese patients in the world will reach 3.26 billion by 2030; By 2029, the number of global patients with diabetes will exceed 500 million; The number of patients with nonalcoholic fatty liver disease in the world will exceed 1.5 billion. At present, there is no effective drug for fatty liver; There are only 6 drugs approved by FDA for the treatment of obesity, and most of them are controlled drugs with weak efficacy and strong side effects; Although many drugs for the treatment of type 2 diabetes have been approved for marketing, achieved optimal diabetes control-rate ($HbA1c < 7\%$), and the achieved optimal diabetes control-rate of even the most active combination drug is only about 45%. Therefore, for fatty liver, obesity or diabetes, new drugs need to be developed to meet the unmet needs of more patients.

Glucagon-like peptide-1 (GLP-1) is a long peptide hormone containing 30 or 31 amino acids. It is produced and secreted by enteroendocrine L cells and certain neurons in the nucleus tractus solitarius of the brainstem during feeding. GLP-1 stimulates insulin secretion, reduces glucagon secretion, inhibits gastric emptying, reduces appetite, and stimulates beta cell

proliferation in a physiological and glucose-dependent manner. In non-clinical experiments, GLP-1 promotes β -cell persistence by stimulating transcription of genes important for glucose-dependent insulin secretion and promoting β -cell regeneration (Meier, et al. Biodrugs. 2003; 17(2): 93 -102). The GLP1 receptor is a proven ideal target for the treatment of metabolic diseases such as obesity, diabetes, fatty liver, etc., and several GLP1R agonist peptide drugs such as dulaglutide, somalutamide have been approved abroad for the treatment of diabetes and weight loss.

However, these peptides need to be injected with poor compliance, high cost, poor accessibility, and heavy social medical burden. These peptides need to be refrigerated, which is inconvenient to carry and store. In addition, these peptides are difficult for combination use with existing oral small molecule drugs for diseases having complex causes and requiring treatment of multiple drug combinations, such as nonalcoholic fatty liver disease. Therefore, there is an urgent need to develop small-molecule oral GLP1R agonists.

Oral small molecule GLP1 agonists have been reported in a few literatures or patents: for example, Pfizer's PF-06882961 can achieve similar or better efficacy as GLP1 polypeptides (<https://doi.org/10.1101/2020.09.29.319483>). Although the efficacy and safety have been preliminarily verified, PF-06882961 has some druggability deficiencies, such as poor oral absorption, extremely low bioavailability, high clinical dosage, and heavy burden on gastrointestinal tract of patients (GI toxicity), which cannot achieve better glucose - and weight-lowering effect by further increasing the drug amount, and so on. Therefore, it is necessary to develop new small-molecule GLP1 agonists with better druggabilities to meet the needs of more patients.


TECHNICAL EFFECTS

The inventors unexpectedly found that some of the novel aryl ether-substituted heterocyclic compounds of formula (I) of the present invention not only have significant GLP1R agonistic activity, but also have better pharmacokinetics parameters (including longer $T_{1/2}$, higher exposure) and bioavailability than the reference compound PF-06882961 with a known structure . These compounds are expected to have better human PK, and are more suitable as drug candidates for preventing or treating diseases related to GLP1 /GLP1R target or signaling pathway.

SUMMARY OF INVENTION

The object of the present invention is to provide the compound represented by Formula

(I) or its pharmaceutically acceptable salt, solvate, enantiomer and isotopic variations thereof.



Formula (I)

Wherein,

- 5 Ring A and ring B are optionally and independently selected from monocyclic or polycyclic structures of 3 to 18 carbons atoms, and the monocyclic or polycyclic structures can be optionally selected from aromatic rings, heteroaromatic rings, aliphatic rings, heterocyclic rings, fused, spirocyclic or bridged ring structures;

- 10 X and X' are each independently selected from -C(R_{d1})(R_{d2})-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;



L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂ N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;

- 15 X₁, X₂, X₃, X₄, X₅, X₈ and X₉ are each independently selected from -CR₅- or -N-;

- 20 R₀ is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R₀ representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8-membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally optimally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially

saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with 1 to 3 substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH.

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate, preferably, the

carboxyl surrogate is  or ; Wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkylcarboxyl or carboxyl surrogates are optionally optimally substituted with one to more substituents selected from H, deuterium, halogen, OCH₃, Carboxyl, OH, CN and NR_{d8}R_{d9}; Or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8-membered saturated or partially saturated heterocyclyl, the hydrogen on the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl.

Each R₂, R_{2'} and R_{d1}, R_{d2} is the same or different and is independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkylamino, N, N-di(C₁₋₁₀ alkyl)amino, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₃₋₁₀ cycloalkylamino, C₃₋₁₀ heterocycloalkylamino, C₃₋₁₀ cycloalkoxy, C₃₋₁₀

cycloalkylacyl, C₃₋₁₀ cycloalkoxyacetyl, C₃₋₁₀ cycloalkylsulfonyl and C₃₋₁₀ cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally further substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃ and saturated or partially saturated C₃₋₆ cycloalkyl; Or optionally R₂ and R_{2'} or R_{d1} and R_{d2} may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ are the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- heteroaryl, 3- to 8- saturated or partially saturated cycloalkyl, 3- to 8- saturated or partially saturated heterocyclyl, and wherein the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated

or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

R_{d3}, R_{d4}, R_{d5}, R_{d6}, R_{d7}, R_{d8}, R_{d9} and R_{d10} are the same or different, and are optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

the hetero represents any heteroatom optionally and independently selected from O, N, S, P and isotopes thereof;


the halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;

m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5.

In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IA),



Formula (IA)

Wherein,

Ring A and ring B are optionally and independently selected from monocyclic or polycyclic structures of 3 to 18 carbons atoms, and the monocyclic or polycyclic structures can be optionally selected from aromatic rings, heteroaromatic rings, aliphatic rings, heterocyclic rings, fused, spirocyclic or bridged ring structures;

X and X' are each independently selected from -C(R_{d1})(R_{d2})-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;


L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂ N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;

X₁, X₃, X₈ and X₉ are each independently selected from -CR₅- or -N-;

R₀ is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3-to 8- membered saturated or partially saturated heterocyclyl, wherein R₀ representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8-membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally optimally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally optimally substituted with 1 to 3 substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH.

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated

cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate, preferably, the



substituents selected from H, Deuterium, Halogen, OCH₃, Carboxyl, OH, CN and NR_{d8}R_{d9}; Or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8-membered saturated or partially saturated heterocyclyl, hydrogen on the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl.

Each R₂, R_{2'} and R_{d1}, R_{d2} is the same or different and is independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkylamino, N, N-di(C₁₋₁₀ alkyl)amino, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₃₋₁₀ cycloalkylamino, C₃₋₁₀ heterocycloalkylamino, C₃₋₁₀ cycloalkoxy, C₃₋₁₀ cycloalkylacyl, C₃₋₁₀ cycloalkoxyacetyl, C₃₋₁₀ cycloalkylsulfonyl and C₃₋₁₀ cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃ and saturated or partially saturated C₃₋₆ cycloalkyl; Or optionally R₂ and R_{2'} or R_{d1} and R_{d2} may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more groups

selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or Heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d3}, R_{d4}, R_{d5}, R_{d6}, R_{d7}, R_{d8}, R_{d9} and R_{d10} is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted

by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IB),



Formula (IB)

Wherein,

Ring B is optionally and independently selected from monocyclic or polycyclic structures of 3 to 18 carbons atoms, and the monocyclic or polycyclic structures can be optionally selected from aromatic rings, heteroaromatic rings, aliphatic rings, heterocyclic rings, fused, spirocyclic or bridged ring structures;

X and X' are independently selected from -C(R_{d1})(R_{d2})-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;


L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -

$C(=O)N(R_{d3})-$, $-N(R_{d4})-$, $-C(=NR_{d5})-$, $-S(=O)_2 N(R_{d6})-$, $-N(R_{d7})-$, $-O-$, $-S-$, $-C(=O)O-$, $-OC(=O)-$, $-C(=O)-$, $-C(=S)-$, $-S(=O)-$, or $-S(=O)_2-$;

X_1 , X_3 , X_8 , X_9 , X_{10} , X_{11} and X_{12} are independently selected from $-CR_5-$ or $-N-$;

R_0 is independently selected from hydrogen, deuterium, halogen, $-CN$, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, $-NR_{d8}R_{d9}$, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R_0 representing C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, Haloalkyl, carboxyl, alkoxy, alkylamino, $O=$, CN , OH , $-NR_{d8}R_{d9}$, C_{3-10} saturated or partially saturated cycloalkyl, C_{3-10} saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, $O=$, OH , C_{1-3} alkyl, C_{1-3} alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C_{1-3} alkyl group, C_{1-3} alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH_3 and OH .

Each R_1 is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, $-CN$, $-OH$, $-SH$ and $-NH_2$, $-COOH$ or from C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} Alkynyl or C_{1-10} alkoxy, C_{2-10} heteroalkyl, C_{3-10} saturated or partially saturated cycloalkyl, C_{3-10} saturated or partially saturated heterocycloalkyl, C_{1-10} alkyl substituted by C_{3-10} cycloalkyl or C_{3-10} heterocycloalkyl, C_{2-10} heteroalkyl substituted by C_{3-10} cycloalkyl, C_{3-10} heterocyclyl, C_{1-10} alkyl substituted with carboxyl or carboxyl surrogate, preferably, the



alkynyl or C_{1-10} alkoxy, C_{2-10} heteroalkyl, C_{3-10} saturated or partially saturated cycloalkyl, C_{3-10} saturated or partially saturated heterocycloalkyl, C_{1-10} alkyl substituted by C_{3-10} cycloalkyl or C_{3-10} heterocycloalkyl, C_{2-10} heteroalkyl substituted by C_{3-10} cycloalkyl, C_{3-10} heterocyclyl, C_{1-10} alkyl substituted with carboxyl or carboxyl surrogate, preferably, the

10 alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more groups selected from H, deuterium, Halogen, OCH₃, Carboxyl, OH, CN and NR_{d8}R_{d9}; Or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl.

Each R₂, R_{2'} and R_{d1}, R_{d2} is the same or different and is independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkylamino, N, N-di(C₁₋₁₀ alkyl)amino, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₃₋₁₀ cycloalkylamino, C₃₋₁₀ heterocycloalkylamino, C₃₋₁₀ cycloalkoxy, C₃₋₁₀ cycloalkylacyl, C₃₋₁₀ cycloalkoxyacetyl, C₃₋₁₀ cycloalkylsulfonyl and C₃₋₁₀ cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃ and saturated or partially saturated C₃₋₆ cycloalkyl; Or optionally R₂ and R_{2'} or R_{d1} and R_{d2} may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3-to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d3}, R_{d4}, R_{d5}, R_{d6}, R_{d7}, R_{d8}, R_{d9} and R_{d10} is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer optionally selected from 1, 2, 3 and 4;


n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IC),

5



Formula(IC)

Wherein,

----- optionally represents a single bond or a double bond;

10 X and X' are independently selected from -C(R_{d1})(R_{d2})-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;



15 L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂ N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;

X₁, X₃, X₈, X₉, X₁₀, X₁₁, X₁₂, X₁₃ or X₁₄ are independently selected from -CR₅- or -N-;

R₀ is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R₀ representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8-membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, Haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8-

membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH.

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate, preferably, the

carboxyl surrogate is  or ; Wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋

₁₀ alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more substituents selected from H, Deuterium, Halogen, OCH₃, Carboxyl, OH, CN and NR_{d8}R_{d9}; Or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the hydrogen on the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl.

Each R₂, R_{2'} and R_{d1}, R_{d2} is the same or different and is independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkylamino, N, N-di(C₁₋₁₀ alkyl)amino, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylsulfonyl, C₁₋₁₀

alkylsulfinyl, C₃₋₁₀ cycloalkylamino, C₃₋₁₀ heterocycloalkylamino, C₃₋₁₀ cycloalkoxy, C₃₋₁₀ cycloalkylacyl, C₃₋₁₀ cycloalkoxyacetyl, C₃₋₁₀ cycloalkylsulfonyl and C₃₋₁₀ cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃ and saturated or partially saturated C₃₋₆ cycloalkyl; Or optionally R₂ and R_{2'} or R_{d1} and R_{d2} may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from

hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d3}, R_{d4}, R_{d5}, R_{d6}, R_{d7}, R_{d8}, R_{d9} and R_{d10} is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (ID),



Formula(ID)

Wherein,

----- optionally represents a single bond or a double bond;

5 X and X' are independently selected from -C(R_{d1})(R_{d2})-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-; preferred -C(R_{d1})(R_{d2})-, -N(R_{d4})-, -O-, -S-, -S(=O)- or -S(=O)₂-;

L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂ N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-; preferred -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -O-, -S-or -N(R_{d4})-;

X₁, X₃, X₈ and X₁₃ are independently selected from -CR₅-or - N-;

R₀ is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3-to 8- membered saturated or partially saturated heterocyclyl, wherein R₀ representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8- membered heteroaryl, 3- to 8-membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8-membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl,

saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH.

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate; wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more substituents selected from H, deuterium, halogen, OCH₃, carboxyl, OH, CN and NR_{d8}R_{d9}; Or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, a hydrogen on the aryl, saturated or the partially saturated cycloalkyl, or heterocycloalkyl is optionally substituted by hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl.

Each R₂, R_{2'} and R_{d1}, R_{d2} is the same or different and is independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkylamino, N, N-di(C₁₋₁₀ alkyl)amino, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₃₋₁₀ cycloalkylamino, C₃₋₁₀ heterocycloalkylamino, C₃₋₁₀ cycloalkoxy, C₃₋₁₀ cycloalkylacyl, C₃₋₁₀ cycloalkoxyacetyl, C₃₋₁₀ cycloalkylsulfonyl and C₃₋₁₀ cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl,

heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally further substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃ and saturated or partially saturated C₃₋₆ cycloalkyl; Or optionally R₂ and R_{2'} or R_{d1} and R_{d2} may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ Cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or Heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy is optionally substituted with one to more groups selected from hydrogen,

deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d4}, R_{d8}, and R_{d9} is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IE),



Formula (IE)

Wherein,

----- optionally represents a single bond or a double bond;

X and X' are independently selected from -C(R_{d1})(R_{d2})-, -N(R_{d4})-, -N(R_{d7})-, -O-, -S-, -S(=O)- or -S(=O)₂-; preferred -C(R_{d1})(R_{d2})-, -N(R_{d4})-, -O-, -S-, -S(=O)- or -S(=O)₂-;

L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂ N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)- or -S(=O)₂-; preferred -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -O-, -S- or -N(R_{d4})-;

X₁, X₃, X₈ and X₁₃ are independently selected from -CR₅- or -N-;

R is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8-membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8-membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH.

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate; or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3-

to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the hydrogen on the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl.

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl; or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d1}, R_{d2}, R_{d4}, R_{d8} and R_d is the same or different, and is optionally and independently

selected from hydrogen, deuterium, NH_2 , C_{1-10} alkyl, C_{2-10} alkynyl or C_{1-10} alkoxy, C_{1-10} alkylacyl, C_{1-10} alkylsulfonyl, C_{2-10} heteroalkyl, C_{3-10} cycloalkyl, C_{3-10} heterocycloalkyl, C_{1-10} alkyl substituted by C_{3-10} cycloalkyl, or C_{3-10} heterocyclyl substituted by C_{3-10} cycloalkyl or C_{3-10} heterocycloalkyl; wherein, the C_{1-10} alkyl, C_{2-10} alkynyl or C_{1-10} alkoxy, C_{1-10} alkylacyl, C_{1-10} alkylsulfonyl, C_{2-10} heteroalkyl, C_{3-10} cycloalkyl, C_{3-10} heterocycloalkyl, C_{1-10} alkyl substituted by C_{3-10} cycloalkyl, or C_{3-10} heterocyclyl substituted by C_{3-10} cycloalkyl or C_{3-10} heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C_{3-10} saturated or partially substituted saturated cycloalkyl or heterocyclyl;

The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;


q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IF-1) or (IF-



Formula (IF-1)



Formula (IF-2)

Wherein,

----- optionally represents a single bond or a double bond;

5 X and X' are independently selected from $-C(R_{d1})(R_{d2})-$, $-N(R_{d4})-$, $-O-$, $-S-$, $-S(=O)-$ or $-S(=O)_2-$;

L is independently selected from $-OC(R_{d1})(R_{d2})-$, $-C(R_{d1})(R_{d2})O-$, $-O-$, $-S-$ or $-N(R_{d4})-$;

X_1 and X_8 are independently selected from $-CR_5-$ or $-N-$;

R is independently selected from hydrogen, deuterium, halogen, $-CN$, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, $-NR_{d8}R_{d9}$, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R representing C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8-membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, $O=$, CN , OH , $-NR_{d8}R_{d9}$, C_{3-10} saturated or partially saturated cycloalkyl, C_{3-10} saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8-membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, $O=$, OH , C_{1-3} alkyl, C_{1-3} alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C_{1-3} alkyl group, C_{1-3} alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl,

cyano, OCH₃ and OH.

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl; or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and where in the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d1}, R_{d2}, R_{d4}, R_{d8} and R_d is the same or different, and is optionally and independently

selected from hydrogen, deuterium, NH_2 , C_{1-10} alkyl, C_{2-10} alkynyl or C_{1-10} alkoxy, C_{1-10} alkylacyl, C_{1-10} alkylsulfonyl, C_{2-10} heteroalkyl, C_{3-10} cycloalkyl, C_{3-10} heterocycloalkyl, C_{1-10} alkyl substituted by C_{3-10} cycloalkyl, or C_{3-10} heterocyclyl substituted by C_{3-10} cycloalkyl or C_{3-10} heterocycloalkyl; wherein, the C_{1-10} alkyl, C_{2-10} alkynyl or C_{1-10} alkoxy, C_{1-10} alkylacyl, C_{1-10} alkylsulfonyl, C_{2-10} heteroalkyl, C_{3-10} cycloalkyl, C_{3-10} heterocycloalkyl, C_{1-10} alkyl substituted by C_{3-10} cycloalkyl, or C_{3-10} heterocyclyl substituted by C_{3-10} cycloalkyl or C_{3-10} heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C_{3-10} saturated or partially substituted saturated cycloalkyl or heterocyclyl;

The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

In one embodiment of the present invention, the compound or a pharmaceutically acceptable salt, isotopic variations or isomer thereof has the structure of Formula (IG),



Formula (IG)

Wherein,

X and X' are independently selected from $-\text{C}(\text{R}_{d1})(\text{R}_{d2})-$, $-\text{N}(\text{R}_{d4})-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(=\text{O})-$ or

$-\text{S}(=\text{O})_2-$;

L is independently selected from $-\text{OC}(\text{R}_{\text{d1}})(\text{R}_{\text{d2}})-$, $-\text{C}(\text{R}_{\text{d1}})(\text{R}_{\text{d2}})\text{O}-$, $-\text{O}-$, $-\text{S}-$ or $-\text{N}(\text{R}_{\text{d4}})-$;

X_1 and X_8 are each independently selected from $-\text{CR}_5-$ or $-\text{N}-$;

R is independently hydrogen, deuterium, halogen, $-\text{CN}$, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, $-\text{NR}_{\text{d8}}\text{R}_{\text{d9}}$, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R representing C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, $\text{O}=\text{CN}$, OH , $-\text{NR}_{\text{d8}}\text{R}_{\text{d9}}$, C_{3-10} saturated or partially saturated cycloalkyl, C_{3-10} saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, $\text{O}=\text{CN}$, OH , C_{1-3} alkyl, C_{1-3} alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C_{1-3} alkyl group, C_{1-3} alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH_3 and OH .

Each R_1 is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, $-\text{CN}$, $-\text{OH}$, $-\text{SH}$ and $-\text{NH}_2$, $-\text{COOH}$ or from C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl or C_{1-10} alkoxy, C_{2-10} heteroalkyl, C_{3-10} saturated or partially saturated cycloalkyl, C_{3-10} saturated or partially saturated heterocycloalkyl, C_{1-10} alkyl substituted by C_{3-10} cycloalkyl or C_{3-10} heterocycloalkyl, C_{2-10} heteroalkyl substituted by C_{3-10} cycloalkyl, C_{3-10} heterocyclyl, C_{1-10} alkyl substituted with carboxyl or carboxyl surrogate;

Each R_4 is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN , OH , SH and NH_2 , $-\text{COOH}$ or C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl or C_{1-10} alkoxy, C_{2-10} heteroalkyl, C_{3-10} cycloalkyl, C_{3-10} heterocycloalkyl, C_{1-10} alkyl substituted C_{3-10} cycloalkyl or C_{3-10} heterocycloalkyl, and C_{1-10} heteroalkyl substituted by C_{3-10} cycloalkyl or C_{3-10} heterocycloalkyl; wherein, the C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl or C_{1-10} alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN , OH , and C_{3-10} saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or Heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d1}, R_{d2}, R_{d4}, R_{d8} and R_d is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof; m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

According to an embodiment of the present invention,

A is selected from unsubstituted or substituted C₆₋₂₀ aryl, 5- to 20- membered heteroaryl;

5 B is selected from unsubstituted or substituted 3- to 20- membered heterocyclyl, 6- to 18- membered spirocyclyl or bridged cyclyl, C₆₋₂₀ aryl;

X and X' are the same or different and are independently selected from -C(R_{d1})(R_{d2})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -S(=O)- or -S(=O)₂-;

10 L is selected from -C(R_{d1})(R_{d2})-, OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -O-, -S-, -NH-, -C(=O)O-, -OC(=O)-, -C(=O)-, -S(=O)- or -S(=O)₂-; R_{d1} and R_{d2} are the same or different and optionally independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

X₁, X₂, X₃, X₄, X₅, X₈ and X₉ are the same or different and are independently selected from -CR₅- or -N-; each R₅ is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NH₂, -COOH, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

15 R₀ is selected from C₁₋₁₀ alkyl unsubstituted or optionally substituted with one, two or more R₀₁; each R₀₁ is the same or different and is independently selected from C₃₋₂₀ cycloalkyl, 3- to 20- membered heterocyclyl and 5- to 20- membered heteroaryl unsubstituted or optionally substituted with one, two or more R₀₂; each R₀₂ is the same or different, and is independently selected from halogen, deuterium, CN, oxo (=O), C₁₋₁₀ alkyl, halogenated C₁₋₁₀ alkyl, CN-C₁₋
20 ₁₀ alkyl, C₃₋₆ cycloalkyl-C₁₋₁₀ alkyl;

Each R₁ is the same or different and is independently selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NH₂, COOH, C₁₋₁₀ alkyl-COOH or -C₂₋₁₀ alkenyl-COOH unsubstituted or optionally substituted with one, two or more R₁₁; each R₁₁ is the same or different and is independently selected from H, deuterium, halogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

25 Each R₂, R_{2'} is the same or different, and is independently selected from hydrogen, deuterium, halogen, oxo (=O), C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, oxo (=O), CN, OH, SH and NH₂, -COOH, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

30 Each R₆ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, SH, NH₂, -COOH, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₂₋₁₀ alkynyl, 5- to 14-membered heteroaryl;

R_{d3}, R_{d4}, R_{d5}, R_{d6}, R_{d7}, R_{d8}, R_{d9} and R_{d10} are the same or different and are optionally and independently selected from hydrogen, deuterium, CN, OH, SH and NH₂, -COOH, C₁₋₁₀ alkyl,

C₁₋₁₀ alkoxy;

m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5.

5

According to an embodiment of the present invention, A is selected from unsubstituted or substituted C₆₋₁₄ aryl, 5- to 14- membered heteroaryl;

B is selected from unsubstituted or substituted 3- to 14- membered heterocyclyl, 6- to 18- membered spirocyclyl or bridged cyclyl, C₆₋₁₄ aryl;

10 X and X' are the same or different and are independently selected from -C(R_{d1})(R_{d2})-, -O-, -S-;

L is selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -O-, -S-, -NH-; R_{d1} and R_{d2} are the same or different, and are optionally and independently selected from hydrogen, deuterium, C₁₋₁₀ alkyl;

15 X₁, X₂, X₃, X₄, X₅, X₈ and X₉ are the same or different, independently selected from -CR₅- or -N-; each R₅ is the same or different, independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

R₀ is selected from C₁₋₁₀ alkyl unsubstituted or optionally substituted with one, two or more R₀₁; each R₀₁ is the same or different and is independently selected from C₃₋₂₀ cycloalkyl, 20 3- to 20- membered heterocyclyl and 5- to 20- membered heteroaryl unsubstituted or optionally substituted with one, two or more R₀₂; each R₀₂ is the same or different, independently selected from CN, deuterium, oxo (=O), C₁₋₁₀ alkyl, CN-C₁₋₁₀ alkyl, C₃₋₆ cycloalkyl-C₁₋₁₀ alkyl;

Each R₁ is the same or different and independently selected from, halogen, COOH, C₁₋₁₀ alkyl-COOH, -C₂₋₁₀ alkenyl-COOH unsubstituted or optionally substituted with one, two or 25 more R₁₁; each R₁₁ is the same or different, independently selected from H, deuterium, halogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

R₂, R_{2'} are the same or different, and are independently selected from hydrogen, deuterium, halogen, oxo (=O), C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

Each R₄ is the same or different and is optionally and independently selected from 30 hydrogen, deuterium, halogen, oxo (=O), CN, OH, SH and NH₂, -COOH, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

Each R₆ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, CN, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₂₋₁₀ alkynyl, 5- to 14- membered heteroaryl;

m is an integer optionally selected from an integer of 1, 2 and 3;

n is an integer optionally selected from 0, 1, 2, 3 and 4;

q is an integer optionally selected from 0, 1, 2, 3 and 4.

5 According to an embodiment of the present invention, A is selected from phenyl or pyridyl;

B is piperidinyl, azetidiny, phenyl, (1R,5S)-3-azabicyclo[3.2.1]octyl, spirocyclic group or bridged cyclic group; the spirocyclic or the bridged ring contains one or more heteroatoms optionally and independently selected from N, O or S;

X and X' are the same or different and are independently selected from CH₂, O or S;

10 L can be selected from O, S, NH, CH₂, OCH₂, CH₂O;

X₁, X₂, X₃, X₄, X₅, X₈ and X₉ are the same or different and are independently selected from CH, C-F or N

R₀ is selected from C₁₋₃ alkyl unsubstituted or substituted with imidazolyl, pyrazolyl, pyrrolyl, azetidiny, oxetanyl, pyrrolidinyl or cyclopropyl; the imidazolyl, pyrazolyl, pyrrolyl, azetidiny, oxetanyl, pyrrolidinyl or cyclopropyl may be unsubstituted or substituted with oxo (=O) or C₁₋₃ alkyl, CN- C₁₋₃ alkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl;

Each R₁ is the same or different and is independently selected from COOH, F, -C₁₋₃ alkyl-COOH, -C₂₋₃ alkenyl-COOH;

20 R₂, R_{2'} are the same or different, and are independently selected from hydrogen, deuterium, halogen, oxo (=O), C₁₋₃ alkyl;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, oxo (=O), C₁₋₃ alkyl;


Each R₆ is the same or different and is independently selected from hydrogen, deuterium, F, Cl, Br, CN, ethynyl, imidazolyl;

25 m is optionally selected from 1 or 2;


n is optionally selected from 0, 1 or 2;



q is optionally selected from 0, 1 or 2.

According to an embodiment of the present invention, selected from the structures shown below:




30






B can have the following structure: , , , ;


5 L can be selected from O, S, NH, CH₂, OCH₂, CH₂O;




can be selected from the structures shown below:





R₀ can be selected from the structures shown below:



10



R_1 can be selected from COOH, F, , ;



Both R_2 and R_2' are H;




R_4 is H, F, methyl; X_8 is selected from CH or N; X_9 is selected from CH or N;





m is selected from 1 or 2; n is selected from 1 or 2.




5




In one embodiment of the present invention, the above-mentioned compound or a pharmaceutically acceptable salt thereof, or an enantiomer or isotopic variations thereof, is a compound selected from the following structures:




Number	Structure
Compound 1	
Compound 2	

Compound 3	 Chemical structure of Compound 3: A benzimidazole ring system with a carboxylic acid group at position 6 and a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2. The benzimidazole ring is connected via a methylene bridge to a piperidine ring, which is further connected via an oxygen atom to a 2-fluoro-5-(4-cyano-2-fluorophenoxy)methylpyridine moiety.
Compound 4	 Chemical structure of Compound 4: A benzimidazole ring system with a carboxylic acid group at position 6 and a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2. The benzimidazole ring is connected via a methylene bridge to a piperidine ring, which is further connected via an oxygen atom to a 2-fluoro-5-(4-cyano-2-fluorophenoxy)methylpyridine moiety. The benzimidazole ring also has a fluorine substituent at position 7.
Compound 5	 Chemical structure of Compound 5: A benzimidazole ring system with a carboxylic acid group at position 6 and a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2. The benzimidazole ring is connected via a methylene bridge to a piperidine ring, which is further connected via an oxygen atom to a 2-fluoro-5-(4-cyano-2-fluorophenoxy)methylpyridine moiety. The benzimidazole ring also has a fluorine substituent at position 7.




Compound 6	
Compound 7	
Compound 8	
Compound 9	

Compound 10	 Chemical structure of Compound 10: A benzimidazole ring system with a carboxylic acid group (HO-C=O) at position 2 and a fluorine atom (F) at position 6. The benzimidazole ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1 and a (4-(2-chloro-4-fluorophenoxy)-3-fluorophenyl)methyl group at position 4. The (4-(2-chloro-4-fluorophenoxy)-3-fluorophenyl)methyl group is connected to the benzimidazole ring via a methylene group.
Compound 11	 Chemical structure of Compound 11: A pyridine ring system with a carboxylic acid group (HO-C=O) at position 2 and a fluorine atom (F) at position 6. The pyridine ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1 and a (4-(2-chloro-4-fluorophenoxy)-3-fluorophenyl)methyl group at position 4. The (4-(2-chloro-4-fluorophenoxy)-3-fluorophenyl)methyl group is connected to the pyridine ring via a methylene group.
Compound 12	 Chemical structure of Compound 12: A pyridine ring system with a carboxylic acid group (HO-C=O) at position 2 and a fluorine atom (F) at position 6. The pyridine ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1 and a (4-(2-chloro-4-fluorophenoxy)-3-fluorophenyl)methyl group at position 4. The (4-(2-chloro-4-fluorophenoxy)-3-fluorophenyl)methyl group is connected to the pyridine ring via a methylene group.




Compound 13	 Chemical structure of Compound 13: A benzimidazole ring system with a carboxylic acid group at position 6 and a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2. The benzimidazole ring is connected via a methylene bridge to a piperidine ring, which is further connected via an ether linkage to a 4-(4-cyano-2-fluorophenoxy)phenyl group.
Compound 14	 Chemical structure of Compound 14: A benzimidazole ring system with a carboxylic acid group at position 6 and a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2. The benzimidazole ring is connected via a methylene bridge to a piperidine ring, which is further connected via an ether linkage to a 4-(4-cyano-2-fluorophenoxy)phenyl group. A fluorine atom is present at position 7 of the benzimidazole ring.
Compound 15	 Chemical structure of Compound 15: A benzimidazole ring system with a carboxylic acid group at position 6 and a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2. The benzimidazole ring is connected via a methylene bridge to a piperidine ring, which is further connected via an ether linkage to a 3-(4-cyano-2-fluorophenoxy)phenyl group. A fluorine atom is present at position 7 of the benzimidazole ring.




Compound 16	 Chemical structure of Compound 16: A benzimidazole ring system with a carboxylic acid group (HO-C=O) at position 2 and a fluorine atom (F) at position 6. The benzimidazole ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1 and a (4-(2-(4-cyano-2-fluorophenoxy)methyl)phenoxy)methyl group at position 4.
Compound 17	 Chemical structure of Compound 17: A pyrimidine ring system with a carboxylic acid group (HO-C=O) at position 2 and a fluorine atom (F) at position 6. The pyrimidine ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1 and a (4-(2-(4-cyano-2-fluorophenoxy)methyl)phenoxy)methyl group at position 4.
Compound 18	 Chemical structure of Compound 18: A pyrimidine ring system with a carboxylic acid group (HO-C=O) at position 2 and a fluorine atom (F) at position 6. The pyrimidine ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1 and a (4-(2-(4-cyano-2-fluorophenoxy)methyl)phenoxy)methyl group at position 4.




Compound 19	 <chem>CC1=CN=C1CN2C(=N2)c3ccc(cc3C(=O)O)C(=N2)C4CCN(CC4)Oc5ccc6nc(COc7ccc(Cl)c(F)c7)cc6</chem>
Compound 20	 <chem>CC1=CN=C1CN2C(=N2)c3ccc(cc3C(=O)O)c(F)c2C(=N2)C4CCN(CC4)Oc5ccc6nc(COc7ccc(Cl)c(F)c7)cc6</chem>
Compound 21	 <chem>CC1=CN=C1CN2C(=N2)c3ccc(cc3C(=O)O)c2C(=N2)C4CCN(CC4)Oc5ccc6nc(COc7cc(F)ccc7)cc6</chem>




Compound 22	 Chemical structure of Compound 22: A benzimidazole core substituted with a (E)-3-(4-fluorophenyl)acrylic acid moiety, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 4-(2-(4-chloro-3-fluorophenoxy)-5-fluoropyridin-3-yl)piperidin-1-ylmethyl group.
Compound 23	 Chemical structure of Compound 23: A pyrimidine core substituted with a (E)-3-(4-fluorophenyl)acrylic acid moiety, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 4-(2-(4-chloro-3-fluorophenoxy)-5-fluoropyridin-3-yl)piperidin-1-ylmethyl group.
Compound 24	 Chemical structure of Compound 24: A pyrimidine core substituted with a (E)-3-(4-fluorophenyl)acrylic acid moiety, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 4-(2-(4-chloro-3-fluorophenoxy)-5-fluoropyridin-3-yl)piperidin-1-ylmethyl group.




Compound 25	 <chem>CC1=CN=C(C1CN2C(=N2)C(=C(C=C2)C(=O)O)C=C)CN3CCN(CC3)COc4ccc(C#N)c(F)c4</chem>
Compound 26	 <chem>CC1=CN=C(C1CN2C(=N2)C(=C(C=C2)C(=O)O)C=C)CN3CCN(CC3)COc4ccc(C#N)c(F)c4</chem>
Compound 27	 <chem>CC1=CN=C(C1CN2C(=N2)C(=C(C=C2)C(=O)O)C=C)CN3CCN(CC3)COc4cc(F)c(COc5ccc(C#N)cc5)nc4</chem>




Compound 28	 Chemical structure of Compound 28: A benzimidazole core substituted with an (E)-4-(4-fluorophenyl)-3-oxobut-3-en-1-yl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 4, and a 4-(4-cyano-2-fluorophenoxy)piperidin-1-ylmethyl group at position 5.
Compound 29	 Chemical structure of Compound 29: A pyrimidine core substituted with an (E)-4-(4-fluorophenyl)-3-oxobut-3-en-1-yl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 4, and a 4-(4-cyano-2-fluorophenoxy)piperidin-1-ylmethyl group at position 6.
Compound 30	 Chemical structure of Compound 30: A pyrimidine core substituted with an (E)-4-(4-fluorophenyl)-3-oxobut-3-en-1-yl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 4, and a 4-(4-cyano-2-fluorophenoxy)piperidin-1-ylmethyl group at position 6.





Compound 31	 Chemical structure of Compound 31: A benzimidazole core substituted with a (E)-3-(4-((4-chloro-3-fluorophenoxy)methoxy)phenyl)piperidin-2-ylmethyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (E)-3-(4-oxo-4-oxoprop-1-en-1-yl)benzoic acid group at position 6.
Compound 32	 Chemical structure of Compound 32: A benzimidazole core substituted with a (E)-3-(4-((4-chloro-3-fluorophenoxy)methoxy)phenyl)piperidin-2-ylmethyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (E)-3-(4-oxo-4-oxoprop-1-en-1-yl)-4-fluorobenzoic acid group at position 6.
Compound 33	 Chemical structure of Compound 33: A benzimidazole core substituted with a (E)-3-(4-((4-chloro-3-fluorophenoxy)methoxy)-3-fluorophenyl)piperidin-2-ylmethyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (E)-3-(4-oxo-4-oxoprop-1-en-1-yl)benzoic acid group at position 6.





Compound 34	 Chemical structure of Compound 34: A benzimidazole core substituted with a 4-fluorophenyl group, a 4-((4-chloro-2-fluorophenoxy)methyl)phenyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. The benzimidazole ring also features a 4-oxo-4-oxoprop-1-en-1-yl group at the 2-position.
Compound 35	 Chemical structure of Compound 35: A pyrimidine core substituted with a 4-fluorophenyl group, a 4-((4-chloro-2-fluorophenoxy)methyl)phenyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. The pyrimidine ring also features a 4-oxo-4-oxoprop-1-en-1-yl group at the 2-position.
Compound 36	 Chemical structure of Compound 36: A pyrimidine core substituted with a 4-fluorophenyl group, a 4-((4-chloro-2-fluorophenoxy)methyl)phenyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. The pyrimidine ring also features a 4-oxo-4-oxoprop-1-en-1-yl group at the 2-position.





Compound 37	 Chemical structure of Compound 37: A benzimidazole core substituted with an (E)-4-oxo-4-phenylbut-3-en-1-yl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 4-(4-cyano-2-fluorophenoxy)piperidin-1-ylmethyl group.
Compound 38	 Chemical structure of Compound 38: A 6-fluoro-substituted benzimidazole core substituted with an (E)-4-oxo-4-phenylbut-3-en-1-yl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 4-(4-cyano-2-fluorophenoxy)piperidin-1-ylmethyl group.
Compound 39	 Chemical structure of Compound 39: A benzimidazole core substituted with an (E)-4-oxo-4-phenylbut-3-en-1-yl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 4-(3-fluoro-4-(4-cyano-2-fluorophenoxy)phenoxy)piperidin-1-ylmethyl group.





Compound 40	 Chemical structure of Compound 40: A benzimidazole core substituted with a 4-fluorophenyl group, a (E)-3-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. The benzimidazole ring also bears a (E)-3-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group and a (E)-3-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group. The structure is shown with a carboxylic acid group (HO-C(=O)-) attached to the benzimidazole ring.
Compound 41	 Chemical structure of Compound 41: A pyrimidine core substituted with a 4-fluorophenyl group, a (E)-3-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. The pyrimidine ring also bears a (E)-3-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group and a (E)-3-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group. The structure is shown with a carboxylic acid group (HO-C(=O)-) attached to the pyrimidine ring.
Compound 42	 Chemical structure of Compound 42: A pyrimidine core substituted with a 4-fluorophenyl group, a (E)-3-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. The pyrimidine ring also bears a (E)-3-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group and a (E)-3-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group. The structure is shown with a carboxylic acid group (HO-C(=O)-) attached to the pyrimidine ring.

Compound 43	 Chemical structure of Compound 43: A benzimidazole ring system with a carboxylic acid group at position 6. The benzimidazole ring is substituted at position 2 with a (1-ethyl-1H-imidazol-2-yl)methyl group and at position 3 with a (4-(2-(4-chloro-3-fluorophenoxy)methylpyridin-2-yl)piperidin-1-yl)methyl group.
Compound 44	 Chemical structure of Compound 44: A benzimidazole ring system with a carboxylic acid group at position 6 and a fluorine atom at position 7. The benzimidazole ring is substituted at position 2 with a (1-ethyl-1H-imidazol-2-yl)methyl group and at position 3 with a (4-(2-(4-chloro-3-fluorophenoxy)methylpyridin-2-yl)piperidin-1-yl)methyl group.
Compound 45	 Chemical structure of Compound 45: A benzimidazole ring system with a carboxylic acid group at position 6. The benzimidazole ring is substituted at position 2 with a (1-ethyl-1H-imidazol-2-yl)methyl group and at position 3 with a (4-(2-(4-chloro-3-fluorophenoxy)-5-fluoromethylpyridin-2-yl)piperidin-1-yl)methyl group.

Compound 46	
Compound 47	
Compound 48	
Compound 49	





Compound 50	
Compound 51	
Compound 52	
Compound 53	

Compound 54	
Compound 55	
Compound 56	
Compound 57	





Compound 58	
Compound 59	
Compound 60	
Compound 61	

[illegible]





Compound 66	 <chem>O=C(O)c1ccc2nc(CN3CCOC(c4ccc(cc4)COc5ccc(cc5)F)c6ccc(cc6)Cl)nn2c1</chem>
Compound 67	 <chem>O=C(O)c1ccc2nc(CN3CCOC(c4ccc(cc4)COc5ccc(cc5)F)C#N)nn2c1</chem>
Compound 68	 <chem>O=C(O)c1cc(F)c2nc(CN3CCOC(c4ccc(cc4)COc5ccc(cc5)F)C#N)nn2c1</chem>
Compound 69	 <chem>O=C(O)c1ccc2nc(CN3CCOC(c4cc(F)ccc4COc5ccc(cc5)F)C#N)nn2c1</chem>





Compound 70	
Compound 71	
Compound 72	
Compound 73	





Compound 74	 <chem>O=C(O)/C=C/c1ccc(F)c2nc3c1n(CCN3CCOC4=CC=CC=C4F)nc5ccccc52</chem>
Compound 75	 <chem>O=C(O)/C=C/c1ccc(F)c2nc3c1n(CCN3CCOC4=CC=CC=C4F)nc5ccccc52</chem>
Compound 76	 <chem>O=C(O)/C=C/c1ccc(F)c2nc3c1n(CCN3CCOC4=CC=CC=C4F)nc5ccccc52</chem>
Compound 77	 <chem>O=C(O)/C=C/c1ccc(F)c2nc3c1n(CCN3CCOC4=CC=CC=C4F)nc5ccccc52</chem>





Compound 78	
Compound 79	
Compound 80	
Compound 81	





Compound 82	 <chem>O=C(O)/C=C/c1ccc(F)c2nc(CN3CCOC4=CC=CC(=C4F)C5=CC=CC=C5N5)nc2c1</chem>
Compound 83	 <chem>O=C(O)/C=C/c1ccnc2nc(CN3CCOC4=CC=CC(=C4F)C5=CC=CC=C5N5)nc12</chem>
Compound 84	 <chem>O=C(O)/C=C/c1ccnc2nc(CN3CCOC4=CC=CC(=C4F)C5=CC=CC=C5N5)nc12</chem>
Compound 85	 <chem>O=C(O)/C=C/c1ccc2nc(CN3CCOC4=CC=CC=C4F)nc2c1</chem>

Compound 86	 <chem>Clc1ccc(Oc2ccc(Oc3ccc(Oc4ccccc4)cc3)cc2)cc1OCCN1CCN(CC1)Cc2nc3cc(ccc3n2)C(=C/C=C/C(=O)O)C(F)=C</chem>
Compound 87	 <chem>Clc1ccc(Oc2ccc(Oc3ccc(Oc4ccccc4)cc3)cc2)cc1OCCN1CCN(CC1)Cc2nc3cc(ccc3n2)C(=C/C=C/C(=O)O)C(F)=C</chem>
Compound 88	 <chem>Clc1ccc(Oc2ccc(Oc3ccc(Oc4ccccc4)cc3)cc2)cc1OCCN1CCN(CC1)Cc2nc3cc(ccc3n2)C(=C/C=C/C(=O)O)C(F)=C</chem>
Compound 89	 <chem>Clc1ccc(Oc2ccc(Oc3ccc(Oc4ccccc4)cc3)cc2)cc1OCCN1CCN(CC1)Cc2nc3ccncc3n2C(=C/C=C/C(=O)O)C(F)=C</chem>





Compound 90	 <chem>O=C(O)/C=C/c1ccc2nc(CN3CCOC(c4ccc(OC5=CC=C(C=C5)F)C=C4)CC3)c[nH]2[C@H]3OCCO3</chem>
Compound 91	 <chem>O=C(O)/C=C/c1ccc2nc(CN3CCOC(c4ccc(OC5=CC=C(C=C5)C#N)C=C4)CC3)c[nH]2[C@H]3OCCO3</chem>
Compound 92	 <chem>O=C(O)/C=C/c1cc(F)cc2nc(CN3CCOC(c4ccc(OC5=CC=C(C=C5)C#N)C=C4)CC3)c[nH]2[C@H]3OCCO3</chem>
Compound 93	 <chem>O=C(O)/C=C/c1ccc2nc(CN3CCOC(c4cc(F)ccc4OC5=CC=C(C=C5)C#N)CC3)c[nH]2[C@H]3OCCO3</chem>





Compound 94	
Compound 95	
Compound 96	
Compound 97	





Compound 98	
Compound 99	
Compound 100	
Compound 101	





Compound 102	
Compound 103	
Compound 104	
Compound 105	

Compound 106	 <chem>O=C(O)/C=C/c1ccc2nc(nc2c1F)CN(C2CC2)CN3CCO(C3)c4ccc(F)c(C5=CC=C(C=C5)Cl)n4</chem>
Compound 107	 <chem>O=C(O)/C=C/c1ccn2c(nc2n1)CN(C2CC2)CN3CCO(C3)c4ccc(F)c(C5=CC=C(C=C5)Cl)n4</chem>
Compound 108	 <chem>O=C(O)/C=C/c1ccn2c(nc2n1)CN(C2CC2)CN3CCO(C3)c4ccc(F)c(C5=CC=C(C=C5)Cl)n4</chem>
Compound 109	 <chem>O=C(O)/C=C/c1ccc2nc(nc2c1F)CN(C2CC2)CN3CCO(C3)c4ccc(C#N)c(F)n4</chem>





Compound 110	 Chemical structure of Compound 110: A benzimidazole core substituted with a cyclopropylmethyl group on the imidazole ring, a (E)-3-(4-cyano-3-fluorophenoxy)propyl group on the benzimidazole ring, and a (E)-3-(4-cyano-3-fluorophenoxy)propyl group on the benzimidazole ring. The structure also features a carboxylic acid group and a cyano group.
Compound 111	 Chemical structure of Compound 111: A benzimidazole core substituted with a cyclopropylmethyl group on the imidazole ring, a (E)-3-(4-cyano-3-fluorophenoxy)propyl group on the benzimidazole ring, and a (E)-3-(4-cyano-3-fluorophenoxy)propyl group on the benzimidazole ring. The structure also features a carboxylic acid group and a cyano group.
Compound 112	 Chemical structure of Compound 112: A benzimidazole core substituted with a cyclopropylmethyl group on the imidazole ring, a (E)-3-(4-cyano-3-fluorophenoxy)propyl group on the benzimidazole ring, and a (E)-3-(4-cyano-3-fluorophenoxy)propyl group on the benzimidazole ring. The structure also features a carboxylic acid group and a cyano group.
Compound 113	 Chemical structure of Compound 113: A benzimidazole core substituted with a cyclopropylmethyl group on the imidazole ring, a (E)-3-(4-cyano-3-fluorophenoxy)propyl group on the benzimidazole ring, and a (E)-3-(4-cyano-3-fluorophenoxy)propyl group on the benzimidazole ring. The structure also features a carboxylic acid group and a cyano group.





Compound 114	 <chem>N#CC1CC1CN(CCN1CCN2CCN(CC2)COc3ccc(C#N)c(F)c3)c4ccc(C=C/C(=O)O)cn4</chem>
Compound 115	 <chem>N#CC1CC1CN(CCN1CCN2CCN(CC2)COc3ccc(COc4cc(Cl)cc(F)c4)cc3)c4ccccc4C=C/C(=O)O</chem>
Compound 116	 <chem>N#CC1CC1CN(CCN1CCN2CCN(CC2)COc3ccc(COc4cc(Cl)cc(F)c4)cc3)c5cc(F)ccc5C=C/C(=O)O</chem>
Compound 117	 <chem>N#CC1CC1CN(CCN1CCN2CCN(CC2)COc3cc(F)ccc3COc4cc(Cl)cc(F)c4)c5ccccc5C=C/C(=O)O</chem>





Compound 118	
Compound 119	
Compound 120	
Compound 121	





Compound 122	
Compound 123	
Compound 124	
Compound 125	





Compound 126	 <chem>NC#CCCC12C=CN(C1)C=C(C2)C(=O)O/C=C/C=C/C3CCN(C3)COC4=CC=C(C=C4)COc5ccc(C#N)c(F)c5</chem>
Compound 127	 <chem>NC#CCCC12C=CN(C1)C=C(C2)C(=O)O/C=C/C=C/C3CCN(C3)COC4=CC=CC(=C4)N=C5C=CC(=C5)OC6=CC=C(C=C6)F=C7C=CC(=C7)Cl</chem>
Compound 128	 <chem>NC#CCCC12C=CN(C1)C=C(C2)C(=O)O/C=C/C=C/C3CCN(C3)COC4=CC=CC(=C4)N=C5C=CC(=C5)OC6=CC=C(C=C6)F=C7C=CC(=C7)Cl</chem>
Compound 129	 <chem>NC#CCCC12C=CN(C1)C=C(C2)C(=O)O/C=C/C=C/C3CCN(C3)COC4=CC=CC(=C4)N=C5C=CC(=C5)OC6=CC=C(C=C6)F=C7C=CC(=C7)Cl</chem>





Compound 130	
Compound 131	
Compound 132	
Compound 133	





Compound 134	
Compound 135	
Compound 136	
Compound 137	





Compound 138	
Compound 139	
Compound 140	
Compound 141	





Compound 142	
Compound 143	
Compound 144	
Compound 145	





Compound 146	
Compound 147	
Compound 148	
Compound 149	





Compound 150	
Compound 151	
Compound 152	
Compound 153	





Compound 154	
Compound 155	
Compound 156	
Compound 157	





Compound 158	
Compound 159	
Compound 160	
Compound 161	





Compound 162	
Compound 163	
Compound 164	
Compound 165	





Compound 166	
Compound 167	
Compound 168	
Compound 169	





Compound 170	
Compound 171	
Compound 172	
Compound 173	




Compound 174	
Compound 175	
Compound 176	
Compound 177	





Compound 178	
Compound 179	
Compound 180	
Compound 181	




Compound 182	
Compound 183	
Compound 184	
Compound 185	





Compound 186	 <chem>N#Cc1ccc(OCc2ccncc2Oc3ccccc3N4CCN(CC4)Cc5nn6c(ccc56)CC(=O)O)c(F)c1</chem>
Compound 187	 <chem>Clc1ccc(OCc2ccccc2Oc3ccccc3N4CCN(CC4)Cc5n6c(ccc56)CC(=O)O)c(F)c1</chem>
Compound 188	 <chem>Clc1ccc(OCc2ccccc2Oc3ccccc3N4CCN(CC4)Cc5n6c(ccc56)CC(=O)O)c(F)c1</chem>
Compound 189	 <chem>Clc1ccc(OCc2cc(F)ccc2Oc3ccccc3N4CCN(CC4)Cc5n6c(ccc56)CC(=O)O)c(F)c1</chem>




Compound 190	
Compound 191	
Compound 192	
Compound 193	




Compound 194	 Chemical structure of Compound 194: A 1H-imidazole ring substituted with an ethyl group at position 2 and a (2-fluorophenyl)methyl group at position 4. The imidazole ring is connected via its 4-position to a piperidine ring. The piperidine ring is further connected via its 4-position to a 2-(4-chloro-3-fluorophenoxy)pyridine moiety.
Compound 195	 Chemical structure of Compound 195: A 1H-imidazole ring substituted with an ethyl group at position 2 and a (2-fluorophenyl)methyl group at position 4. The imidazole ring is connected via its 4-position to a piperidine ring. The piperidine ring is further connected via its 4-position to a 2-(4-chloro-3-fluorophenoxy)pyridine moiety.
Compound 196	 Chemical structure of Compound 196: A 1H-imidazole ring substituted with an ethyl group at position 2 and a (2-fluorophenyl)methyl group at position 4. The imidazole ring is connected via its 4-position to a piperidine ring. The piperidine ring is further connected via its 4-position to a 2-(4-chloro-3-fluorophenoxy)pyridine moiety.




Compound 197	 <chem>CC1=CN=C(C1CN2C(=N3C=CC=C(C=C3C(=O)O)N2)CN4CCOC5=CC=C(C=C5)C(F)=C(C=C5)OC6=CC=C(C=C6)Cl)N</chem>
Compound 198	 <chem>CC1=CN=C(C1CN2C(=N3C=CC(=CN3)C(=O)O)N2)CN4CCOC5=CC=C(C=C5)C(F)=C(C=C5)OC6=CC=C(C=C6)Cl</chem>
Compound 199	 <chem>CC1=CN=C(C1CN2C(=N3C=CC=C(C=C3C(=O)O)N2)CN4CCOC5=CC=C(C=C5)C(F)=C(C=C5)C#N)N</chem>
Compound 200	 <chem>CC1=CN=C(C1CN2C(=N3C=CC(F)=CC3C(=O)O)N2)CN4CCOC5=CC=C(C=C5)C(F)=C(C=C5)C#N</chem>





Compound 201	 Chemical structure of Compound 201: A pyrazole ring substituted with a 2-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group and a 2-(4-(2-oxo-2-(carboxymethyl)phenyl)pyridin-5-yl)piperidin-1-ylmethyl group.
Compound 202	 Chemical structure of Compound 202: A pyrazole ring substituted with a 2-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group and a 2-(4-(2-oxo-2-(4-fluorophenyl)pyridin-5-yl)pyridin-5-yl)piperidin-1-ylmethyl group.
Compound 203	 Chemical structure of Compound 203: A pyrazole ring substituted with a 2-(4-cyano-3-fluorophenoxy)piperidin-1-ylmethyl group and a 2-(4-(2-oxo-2-(4-fluorophenyl)pyridin-5-yl)pyridin-5-yl)piperidin-1-ylmethyl group.





Compound 204	
Compound 205	
Compound 206	
Compound 207	

Compound 208	 Chemical structure of Compound 208: A 4-fluorophenyl ring substituted with a carboxymethyl group (-CH₂COOH) at the 1-position and a 1-((4-(2-chloro-4-fluorophenoxy)phenyl)piperidin-4-yl)-2-(1-ethyl-1H-imidazol-2-yl)methyl group at the 3-position.
Compound 209	 Chemical structure of Compound 209: A pyridine ring substituted with a carboxymethyl group (-CH₂COOH) at the 3-position and a 1-((4-(2-chloro-4-fluorophenoxy)phenyl)piperidin-4-yl)-2-(1-ethyl-1H-imidazol-2-yl)methyl group at the 2-position.
Compound 210	 Chemical structure of Compound 210: A pyridine ring substituted with a carboxymethyl group (-CH₂COOH) at the 3-position and a 1-((4-(2-chloro-4-fluorophenoxy)phenyl)piperidin-4-yl)-2-(1-ethyl-1H-imidazol-2-yl)methyl group at the 2-position. This structure is identical to Compound 209.





Compound 211	 Chemical structure of Compound 211: A benzimidazole core substituted with a 2-oxo-2-(carboxymethyl)phenyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (4-(4-cyano-2-fluorophenoxy)benzyl)piperidin-1-yl group at position 3.
Compound 212	 Chemical structure of Compound 212: A benzimidazole core substituted with a 2-fluoro-2-(carboxymethyl)phenyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (4-(4-cyano-2-fluorophenoxy)benzyl)piperidin-1-yl group at position 3.
Compound 213	 Chemical structure of Compound 213: A benzimidazole core substituted with a 2-(carboxymethyl)phenyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (3-fluoro-4-(4-cyano-2-fluorophenoxy)benzyl)piperidin-1-yl group at position 3.





Compound 214	 Chemical structure of Compound 214: A benzimidazole core substituted with a 2-fluorophenyl group, a 2-((4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-yl)methyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. A carboxylic acid group is attached to the 6-position of the benzimidazole ring.
Compound 215	 Chemical structure of Compound 215: A pyrimidine core substituted with a 2-fluorophenyl group, a 2-((4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-yl)methyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. A carboxylic acid group is attached to the 6-position of the pyrimidine ring.
Compound 216	 Chemical structure of Compound 216: A pyrimidine core substituted with a 2-fluorophenyl group, a 2-((4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-yl)methyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. A carboxylic acid group is attached to the 6-position of the pyrimidine ring.




Number	Structure
Compound S1	
Compound S2	
Compound S3	
Compound S4	





Compound S5	
Compound S6	
Compound S7	
Compound S8	





Compound S9	 <chem>N#Cc1ccc(cc1C#N)COC2=CC=C(C=C2)OCC3=CC=CC=C3OCC4CCNCC4C5=CN6C(=C(C=C6)C(=O)O)N5C7COC7</chem>
Compound S10	 <chem>N#Cc1ccc(cc1C#N)COC2=CC=C(C=C2)OCC3=CC=CC=C3OCC4CCNCC4C5=CN6C(=C(C=C6)/C=C/C(=O)O)N5C7COC7</chem>
Compound S11	 <chem>N#Cc1ccc(cc1C#N)COC2=CC=CC=C2OCC3=CC=CC=C3OCC4CCNCC4C5=CN6C(=C(C=C6)C(=O)O)N5C7COC7</chem>
Compound S14	 <chem>N#Cc1ccc(cc1C#N)COC2=CC=C(C=C2)OCC3=CC=CC=C3OCC4CCNCC4C5=CN6C(=C(C=C6)F)N5C7COC7</chem>





Compound S15	
Compound S16	
Compound S17	
Compound S20	





Compound S21	
Compound S22	
Compound S23	
Compound S24	




Compound S25	 Chemical structure of Compound S25: A 4-fluorophenyl ring substituted with a carboxylic acid group (HO-C(=O)-) and a 1-((4-fluorophenyl)methoxy)piperidin-4-ylmethyl-1H-imidazole-2-ylmethyl group. The piperidine ring is connected via its 4-position to an oxygen atom, which is linked to a 4-fluorophenyl ring. This phenyl ring is further substituted with a methoxy group (-OCH₂-) and a cyano group (-C≡N).
Compound S26	 Chemical structure of Compound S26: A 4-fluorophenyl ring substituted with a carboxylic acid group (HO-C(=O)-) and a 1-((4-fluorophenyl)methoxy)piperidin-4-ylmethyl-1H-imidazole-2-ylmethyl group. The piperidine ring is connected via its 4-position to an oxygen atom, which is linked to a 4-fluorophenyl ring. This phenyl ring is further substituted with a methoxy group (-OCH₂-) and a cyano group (-C≡N).
Compound S27	 Chemical structure of Compound S27: A 4-fluorophenyl ring substituted with a carboxylic acid group (HO-C(=O)-) and a 1-((4-fluorophenyl)methoxy)piperidin-4-ylmethyl-1H-imidazole-2-ylmethyl group. The piperidine ring is connected via its 4-position to an oxygen atom, which is linked to a 4-fluorophenyl ring. This phenyl ring is further substituted with a methoxy group (-OCH₂-) and a cyano group (-C≡N).





Compound S28	
Compound S29	
Compound S32	
Compound S33	





Compound S34	 Chemical structure of Compound S34: A benzimidazole ring system with a carboxylic acid group at position 6 and a fluorine atom at position 7. The benzimidazole ring is connected via its 2-position to a piperidine ring. The piperidine ring is further connected via its 4-position to a 4-fluorophenyl group. The 4-fluorophenyl group is connected via its 1-position to a 4-chloro-2-fluorophenyl group.
Compound S35	 Chemical structure of Compound S35: A benzimidazole ring system with a carboxylic acid group at position 6 and a fluorine atom at position 7. The benzimidazole ring is connected via its 2-position to a piperidine ring. The piperidine ring is further connected via its 4-position to a 4-fluorophenyl group. The 4-fluorophenyl group is connected via its 1-position to a 4-chloro-2-fluorophenyl group.
Compound S36	 Chemical structure of Compound S36: A benzimidazole ring system with a carboxylic acid group at position 6 and a fluorine atom at position 7. The benzimidazole ring is connected via its 2-position to a piperidine ring. The piperidine ring is further connected via its 4-position to a 4-fluorophenyl group. The 4-fluorophenyl group is connected via its 1-position to a 4-chloro-2-fluorophenyl group.
Compound S37	 Chemical structure of Compound S37: A benzimidazole ring system with a carboxylic acid group at position 6 and a fluorine atom at position 7. The benzimidazole ring is connected via its 2-position to a piperidine ring. The piperidine ring is further connected via its 4-position to a 4-fluorophenyl group. The 4-fluorophenyl group is connected via its 1-position to a 4-chloro-2-fluorophenyl group.





Compound S40	 <chem>OC(=O)c1ccc2nc(CN(C#CC3CC3)CCN4CCOC5=CC=CC=C5OC6C(=CC(=CC=C6)F)C=C7C=CC(=C7)Cl)nc2c1F</chem>
Compound S41	 <chem>OC(=O)c1ccc2nc(CN(C#CC3CC3)CCN4CCOC5=CC=CC=C5OC6C(=CC(=CC=C6)F)C=C7C=CC(=C7)Cl)nc2c1F</chem>
Compound S42	 <chem>OC(=O)c1ccc2nc(CN(C#CC3CC3)CCN4CCOC5=CC=CC=C5OC6C(=CC(=CC=C6)F)C=C7C=CC(=C7)Cl)nc2c1F</chem>
Compound S43	 <chem>OC(=O)c1ccc2nc(CN(C#CC3CC3)CCN4CCOC5=CC=CC=C5OC6C(=CC(=CC=C6)F)C=C7C=CC(=C7)Cl)nc2c1F</chem>





Compound S44	
Compound S45	
Compound S48	
Compound S49	





Compound S50	 Chemical structure of Compound S50: A benzimidazole core substituted with a carboxylic acid group, a 4-chlorophenyl group, and a 4-fluorophenyl group. The benzimidazole ring is connected via a methylene bridge to a piperidine ring, which is further connected via an ether linkage to a 4-chlorophenyl group.
Compound S51	 Chemical structure of Compound S51: A benzimidazole core substituted with a carboxylic acid group, a 4-chlorophenyl group, and a 4-fluorophenyl group. The benzimidazole ring is connected via a methylene bridge to a piperidine ring, which is further connected via an ether linkage to a 4-chlorophenyl group.
Compound S52	 Chemical structure of Compound S52: A benzimidazole core substituted with a carboxylic acid group, a 4-chlorophenyl group, and a 4-fluorophenyl group. The benzimidazole ring is connected via a methylene bridge to a piperidine ring, which is further connected via an ether linkage to a 4-chlorophenyl group.





Compound S53	
Compound S56	
Compound S57	
Compound S58	





Compound S59	
Compound S60	
Compound S61	
Compound S62	





Compound S63	
Compound S64	
Compound S65	
Compound S66	





Number	Structure
Compound C1	
Compound C2	
Compound C3	
Compound C4	





Compound C5	
Compound C6	
Compound C7	
Compound C8	





Compound C9	
Compound C10	
Compound C11	
Compound C12	





Compound C13	
Compound C14	
Compound C15	
Compound C16	





Compound C17	
Compound C18	
Compound C19	
Compound C20	





Compound C21	
Compound C22	
Compound C23	
Compound C24	





Compound C25	
Compound C26	
Compound C27	
Compound C28	





Compound C29	 Chemical structure of Compound C29: A benzimidazole core with a carboxylic acid group at position 6. The benzimidazole ring is substituted at position 2 with a 4-isopropyl-1H-imidazol-2-ylmethyl group and at position 3 with a (4-(4-ethynyl-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group.
Compound C30	 Chemical structure of Compound C30: A benzimidazole core with a carboxylic acid group at position 6. The benzimidazole ring is substituted at position 2 with a 4-isopropyl-1H-imidazol-2-ylmethyl group and at position 3 with a (4-(4-bromo-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group.
Compound C31	 Chemical structure of Compound C31: A benzimidazole core with a carboxylic acid group at position 6. The benzimidazole ring is substituted at position 2 with a 4-isopropyl-1H-imidazol-2-ylmethyl group and at position 3 with a (4-(4-cyano-2-fluorophenoxy)pyridin-2-yl)piperidin-1-ylmethyl group.
Compound C32	 Chemical structure of Compound C32: A benzimidazole core with a carboxylic acid group at position 6. The benzimidazole ring is substituted at position 2 with a 4-isopropyl-1H-imidazol-2-ylmethyl group and at position 3 with a (4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group.

Compound C33	
Compound C34	
Compound C35	
Compound C36	





Compound C37	
Compound C38	
Compound C39	
Compound C40	





Compound C41	
Compound C42	
Compound C43	
Compound C44	





Compound C45	
Compound C46	
Compound C47	
Compound C48	





Compound C49	
Compound C50	
Compound C51	
Compound C52	





Compound C53	
Compound C54	
Compound C55	
Compound C56	





Compound C57	 Chemical structure of Compound C57: A benzimidazole ring system with a carboxylic acid group at the 6-position. The benzimidazole ring is substituted at the 2-position with a 1-ethyl-1H-imidazol-2-ylmethyl group and at the 3-position with a (4-(2-chloro-4-fluorophenoxy)pyridin-2-yl)methyl group.
Compound C58	 Chemical structure of Compound C58: A benzimidazole ring system with a carboxylic acid group at the 6-position. The benzimidazole ring is substituted at the 2-position with a 1-ethyl-1H-imidazol-2-ylmethyl group and at the 3-position with a (4-(2-cyano-4-fluorophenoxy)pyridin-2-yl)methyl group.
Compound C59	 Chemical structure of Compound C59: A benzimidazole ring system with a carboxylic acid group at the 6-position. The benzimidazole ring is substituted at the 2-position with a 1-ethyl-1H-imidazol-2-ylmethyl group and at the 3-position with a (4-(2-chloro-4-fluorophenoxy)pyridin-2-yl)methyl group.
Compound C60	 Chemical structure of Compound C60: A benzimidazole ring system with a carboxylic acid group at the 6-position. The benzimidazole ring is substituted at the 2-position with a 1-ethyl-1H-imidazol-2-ylmethyl group and at the 3-position with a (4-(2-chloro-4-fluorophenoxy)pyridin-2-yl)methyl group.





Compound C61	
Compound C62	
Compound C63	
Compound C64	

Compound C65	
Compound C66	
Compound C67	
Compound C68	

Compound C69	 Chemical structure of Compound C69: A benzimidazole ring system with a carboxylic acid group (HO-C(=O)-) at the 6-position. The benzimidazole core is substituted at the 2-position with a 1-ethyl-1H-imidazol-2-ylmethyl group and at the 3-position with a (4-(4-cyano-2-fluorophenoxy)methyl)pyridin-2-ylmethyl group.
Compound C70	 Chemical structure of Compound C70: A benzimidazole ring system with a carboxylic acid group (HO-C(=O)-) at the 6-position. The benzimidazole core is substituted at the 2-position with a 1-ethyl-1H-imidazol-2-ylmethyl group and at the 3-position with a (4-(4-chloro-2-fluorophenoxy)methyl)pyridin-2-ylmethyl group.
Compound C71	 Chemical structure of Compound C71: A benzimidazole ring system with a carboxylic acid group (HO-C(=O)-) at the 6-position. The benzimidazole core is substituted at the 2-position with a 1-ethyl-1H-imidazol-2-ylmethyl group and at the 3-position with a (4-(4-cyano-2-fluorophenoxy)methyl)pyridin-2-ylmethyl group.
Compound C72	 Chemical structure of Compound C72: A benzimidazole ring system with a carboxylic acid group (HO-C(=O)-) at the 6-position. The benzimidazole core is substituted at the 2-position with a (2-cyanoethyl)cyclopropylmethyl group and at the 3-position with a (4-(4-cyano-2-fluorophenoxy)methyl)pyridin-2-ylmethyl group.

Compound C73	 <chem>Clc1ccc(F)c(OCc2ccncc2Oc3ccncc3CN4C5C(C4)C5C#N)c6ccccc6C(=O)O</chem>
Compound C74	 <chem>N#Cc1ccc(F)c(OCc2ccncc2Oc3ccncc3CN4C5C(C4)C5C#N)c6ccccc6C(=O)O</chem>
Compound C75	 <chem>Clc1ccc(F)c(OCc2ccncc2Oc3ccncc3CN4C5C(C4)C5C#N)c6ccccc6C(=O)O</chem>
Compound C76	 <chem>Clc1ccc(F)c(OCc2ccncc2Oc3ccncc3CN4C5C(C4)C5C#N)c6ccccc6C(=O)O</chem>

Compound C77	 <chem>N#CCCC12CC1CC2N1c3ccc(cc3C(=O)O)N2CN3CCCC3Oc4ccncc4COc5ccc(cc5F)C#N</chem>
Compound C78	 <chem>C1COCC1N2C(=Nc3ccc(cc3C(=O)O)N2)CN4CCCC4Oc5ccncc5COc6ccncc6C#N</chem>
Compound C79	 <chem>C1COCC1N2C(=Nc3ccc(cc3C(=O)O)N2)CN4CCCC4Oc5ccncc5COc6ccncc6Cl</chem>
Compound C80	 <chem>C1COCC1N2C(=Nc3ccc(cc3C(=O)O)N2)CN4CCCC4Oc5ccncc5COc6ccc(cc6F)n7ccn7</chem>

Compound C81	 <chem>O=C(O)c1ccc2nc(CN3CCOC(c4ccc(F)c(F)c4)c5cccnc5)n(c2c1)C3[C@H]4OCCO4</chem>
Compound C82	 <chem>N#Cc1ccc(Oc2cccnc2C3CCN(C3)Cc4nc5ccccc5n4)cc1CN6CCOC6</chem>
Compound C83	 <chem>N#Cc1ccc(Oc2cc(F)nc2C3CCN(C3)Cc4nc5ccccc5n4)cc1CN6CCOC6[C@H]7OCCO7</chem>
Compound C84	 <chem>Clc1ccc(Oc2cccnc2C3CCN(C3)Cc4nc5ccccc5n4)cc1CN(CCN#C)CC4CC4</chem>

The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of at least one of the compounds represented by Formula (I), its pharmaceutically acceptable salts, solvates, enantiomers, and isotopic variations .

5 According to an embodiment of the invention, the pharmaceutical composition is formulated for administration by a route selected from the group consisting of oral, injection, rectal, nasal, pulmonary, topical, buccal and sublingual, vaginal, parenteral, subcutaneous, intramuscular, intravenous, intradermal, intrathecal, and epidural.

According to an embodiment of the present invention, the pharmaceutical composition is preferably administered orally.

10 The oral dosage form is not particularly limited, and any oral dosage form well known in the art can be used, preferably including tablets, capsules, suspensions or oral solutions and other oral dosage forms known in the art. As an oral dosage form, the dosage standard used is, for example, 500-1500 mg/day, preferably 700-1200 mg/day, preferably 800-1000 mg/day, most preferably 1000 mg/day.

15 The administration time of the pharmaceutical composition according to the present invention may depend on the degree of the disease, preferably at least 1 month, for example, 1, 2, 3, 4, 5, or 6 months, and the longest may be lifelong medication due to the needs of the disease.

20 According to an embodiment of the present invention, the pharmaceutical composition may further comprise pharmaceutically acceptable excipients selected from at least one including but not limited to the following excipients: filler, disintegrant, binder, lubricant, surfactants, flavoring agents, wetting agents, pH regulators, solubilizers or cosolvents, osmotic pressure regulators. Those skilled in the art can easily determine how to select the corresponding excipients and their corresponding amounts according to the needs of specific dosage forms.

25 According to embodiments of the present invention, the pharmaceutical composition may further contain one or more additional therapeutic agents.

Another object of the present invention is to provide use of the above-mentioned compounds for manufacturing a medicament for preventing or treating GLP1/GLP1R signaling pathway related diseases. The GLP1/GLP1R signaling pathway related diseases include but are not limited to overweight, obesity, diabetes (T1 D and/or T2DM, including prediabetes), idiopathic T1 D (type 1B), latent autoimmune diabetes in adults (LADA), early-onset T2DM (EOD), youthful atypical diabetes mellitus (YOAD), maturity-onset diabetes mellitus (MODY), malnutrition-related diabetes mellitus, gestational diabetes mellitus, hyperglycemia, insulin

resistance, hepatic insulin resistance, glucose tolerance Impairment, diabetic neuropathy, diabetic nephropathy, renal disease (e.g., acute kidney disease, renal tubular dysfunction, proinflammatory changes in proximal tubules), diabetic retinopathy, adipocyte dysfunction, visceral fat deposition, sleep apnea suspension, obesity (including hypothalamic and monogenic obesity) and associated comorbidities (e.g., osteoarthritis and urinary incontinence), eating disorders (including binge drinking syndrome, bulimia nervosa, and syndromic obesity such as Prader-Willi and Bardet-Biedl syndrome), weight gain due to use of other drugs (e.g., steroid and antipsychotic use), hyperglycemia, dyslipidemia (including hyperlipidemia, hypertriglyceridemia, total Increased cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, hyperinsulinemia, NAFLD (including steatosis, NASH, fibrosis, liver cirrhosis, hepatocellular carcinoma and other related diseases), cardiovascular disease, atherosclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction (e.g., necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, Traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, postprandial lipids, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's disease, left ventricular hypertrophy, peripheral artery disease , macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attack, restenosis, sugar Impaired metabolism, impaired fasting glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcers, ulcerative colitis, hyperapolipoprotein B lipoproteinemia, Alzheimer's disease Prophylaxis or treatment of silent disease, schizophrenia, cognitive impairment, inflammatory bowel disease, short bowel syndrome, Crohn's disease, colitis, irritable bowel syndrome, polycystic ovary syndrome, and addiction treatment (e.g., alcohol and/or drug abuse) and other conditions.

The present invention also provides the use of the compound represented by the Formula (I), its pharmaceutically acceptable salts, solvates, enantiomers and isotopic variations, and the pharmaceutical compositions in the prevention and/or treatment of diseases related to GLP1/GLP1R signaling pathway. The GLP1/GLP1R signaling pathway-related diseases have the above-mentioned definitions.

The present invention also provides a method for preventing and/or treating diseases related to the GLP1/GLP1R signaling pathway, comprising administering to a patient a preventive or therapeutically effective amount of the compound represented by Formula (I), a

pharmaceutically acceptable salt, a solvate, enantiomers and isotopic variations, thereof at least one of the compounds, or administering to the patient a prophylactically or therapeutically effective amount of the above-mentioned pharmaceutical composition. The GLP1/GLP1R signaling pathway-related diseases have the above-mentioned definitions.

5 In some embodiments, the patient is a mammal, preferably a human.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows comparison curve of the effects of the compounds of the present invention and known drugs on the IPGTT blood sugar of hGLP1R mice.

10 Figure 2 shows comparison of the effects of the compounds of the present invention and known drugs on the insulin-stimulating release of IPGTT in hGLP1R mice.

Figure 3 shows comparison curve of the effect of the compounds of the present invention and known drugs on blood glucose of cynomolgus monkey IVGTT.

DETAILED DESCRIPTION OF THE INVENTION

15

Definition and Description:

C₁₋₁₀ is selected from C₁, C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉ and C₁₀; C₂₋₁₀ is selected from C₂, C₃, C₄, C₅, C₆, C₇, C₈, C₉ and C₁₀; C₃₋₁₀ is selected from C₃, C₄, C₅, C₆, C₇, C₈, C₉ and C₁₀;

The term 'alkyl' as used herein refers to a linear or branched chain monovalent hydrocarbon group. Examples include, but are not limited to, methyl, ethyl, propyl, butyl, 2-methyl-propyl, 1,1-dimethylethyl, pentyl, and hexyl.

20

The term 'alkylene' as used herein refers to a linear or branched chain divalent hydrocarbon group of formula -(CH₂)_n-. Examples include, but are not limited to, ethylene and propylene.

25 The term 'one to more' or 'one to multiple' as used herein refers to more than 1, such as 1, 2, 3, 4, 5 or more.

The term 'carbocycle (radical)' or "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon group, the carbocycle may contain 3 to 20 carbon atoms, preferably 3 to 12 (e.g. 3, 4, 5, 6, 7, 8, 9, 10, 11, 12) carbon atoms, more preferably 3 to 6 carbon atoms. The carbocycle may be monocyclic or polycyclic, it may be a saturated cycloalkyl or may optionally contain one, two or more double and/or triple bonds in its ring, thereby forming so-called cycloalkenyl or cycloalkynyl. Where carbocycles have multiple rings, the rings can form spiro, fused and bridged ring structures. For example, non-limiting examples of monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl,

30

cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptyl alkenyl, cyclooctyl, cyclooctatetraenyl, etc.; non-limiting examples of polycyclic carbocycles include decalin or isobornyl.

The term 'heterocycle (radical)' refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent containing 3 to 20 ring atoms, wherein one or more of the ring atoms is a heteroatom or group of atoms selected from N, O, NH, S, S(O) or S(O)₂, but excluding ring parts of -O-O-, -O-S- or -S-S-, the remaining ring atoms are carbon. Preferably 3 to 12 ring atoms, of which 1 to 4 are heteroatoms, are comprised (e.g. 1, 2, 3 and 4); more preferably 3 to 6 ring atoms (e.g. 3, 4, 5, 6). A heterocyclyl group can be attached to the remainder of the molecule through any of the carbon atoms or a nitrogen atom (if present) or an oxygen or sulfur atom (especially in the case of an onium salt formation). The heterocyclyl group may include fused or bridged rings and/or spiro rings. Non-limiting examples of monocyclic heterocyclyl groups include azetidiny, oxetanyl, pyrrolidiny, imidazolidiny, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, dioxolyl, tetrahydropyranyl, pyrroline, piperidiny, piperazinyl, morpholinyl, thiomorpholinyl, dithianyl trithianyl, homopiperazinyl, diazepanyl, etc., preferably piperidiny and pyrrolidiny. Polycyclic heterocyclyls include spiro, fused and bridged heterocyclyls, and may also be benzo-fused heterocyclyls such as dihydroisoquinoliny. The heterocyclyl may be bicyclic, non-limiting examples of which include hexahydrocyclopento[c]pyrrol-2(1H)-yl, hexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl. Heterocyclyl can also be partially unsaturated, i.e. it can contain one or more double bonds, non-limiting examples of which include dihydrofuranyl, dihydropyranyl, 2,5-dihydro-1H-pyrrolyl, 4H-[1,3,4]thiadiazinyl, 4,5-dihydrooxazolyl or 4H-[1,4]thiazinyl.

Heterocyclyl may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkanethio, heterocycloalkylthio, oxo, carboxyl or carboxylate.

As used herein, the term 'heteroaryl/heteroaromatic ring' refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 20 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, nitrogen and phosphorus. Heteroaryl is preferably 5- to 10- membered (e.g. 5-, 6-, 7-, 8-, 9- or 10- membered), more preferably 5- or 6- membered. Non-limiting examples of heteroaryl groups include, but are not limited to, thienyl, furyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl oxazolyl,

thiadiazolyl, thi-4H-pyrazolyl, etc. and their benzo derivatives such as benzofuranyl, benzothienyl, benzoxazolyl, benzisoxazolyl, benzoyl imidazolyl, benzotriazolyl, indazolyl, indolyl, isoindolyl, etc.; or pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and their benzo derivatives, such as quinolinyl, quinazolinyl, isoquinolinyl, etc; or azinyl, indoazinyl, purinyl, etc., as well as their benzo derivatives; or cinolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl, pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, and / or phenoxazinyl, etc.

Heteroaryl/heteroaryl rings may be optionally substituted or unsubstituted, when substituted, the substituents are preferably one, two or more groups independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate.

Unless otherwise stated, a heterocyclyl, heteroaryl or heteroaryl ring includes all possible isomeric forms thereof, e.g. positional isomers thereof. Thus, for some illustrative non-limiting examples, can be included in its 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, 11-, 12- and etc. (if present) substituted at one, two or more positions, or bonded to other groups, including pyridin-2-yl, pyridin-2-yl, pyridin-3-yl, Pyridin-3-yl, pyridin-4-yl and pyridin-4-yl; thienyl or thienylene includes thien-2-yl, thien-2-yl, thien-3-yl and thien-3 - base; pyrazol-1-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl.

As used herein, the term 'pharmaceutically acceptable' refers to those compounds, materials, compositions and/or dosage forms that, within the scope of sound medical judgment, are suitable for use in contact with human and animal tissue, without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit/risk ratio.

The term 'pharmaceutically acceptable salts' refers to salts of the compounds of the present invention, prepared from compounds with specific substituents discovered by the present invention and relatively non-toxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral forms of such compounds with a sufficient amount of base in neat solution or in a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic ammonia or magnesium salts or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in neat solution or in a suitable inert solvent. Examples of

pharmaceutically acceptable acid addition salts include inorganic acid salts including, for example, hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts including, for example,

5 acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, ortho Phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid, methanesulfonic acid and similar acids; also includes salts of amino acids such as arginine, etc., and salts of organic acids such as glucuronic acid (See Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science

10 66: 1-19 (1977)). Certain specific compounds of the present invention contain both basic and acidic functional groups and thus can be converted into either base or acid addition salts.

The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compounds in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as

15 solubility in polar solvents.

As used herein, "pharmaceutically acceptable salts" pertain to derivatives of compounds of the present invention wherein the parent compound is modified by salt formation with an acid or salt formation with a base. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of bases such as amines, alkali metal or organic

20 salts of acid groups such as carboxylic acids, and the like. Pharmaceutically acceptable salts include conventional non-toxic salts such as Na salts, potassium salts, amine salts, quaternary ammonium salts of the parent compound, and the like. Conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids, inorganic and organic bases selected from the group consisting of 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid,

25 glucoheptose, gluconic acid, glutaric acid Amino acid, glycolic acid, hydrobromic acid, hydrochloric acid, hydroiodide, hydroxy, hydroxynaphthalene, isethionic acid, lactic acid, lactose, dodecylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, acetic acid, succinic acid, sulfamic acid, p-aminobenzenesulfonic acid , sulfuric acid, tannin, tartaric acid and p-toluenesulfonic acid etc. described inorganic base and organic base are selected from Na,

30 potassium, magnesium, calcium etc. or amine, diethylamine, triethylamine, ethanolamine etc.

The pharmaceutically acceptable salts of the present invention can be synthesized from the acid or base containing parent compound by conventional chemical methods. Generally, such salts are prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of the appropriate base or acid in water or an organic solvent or a mixture of the two. Generally, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred.

In addition to salt forms, the compounds provided herein also exist in prodrug forms. Prodrugs of the compounds described herein are readily chemically altered under physiological conditions to convert to the compounds of the present invention. In addition, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an in vivo environment.

Certain compounds of the present invention may exist in unsolvated as well as solvated forms, including hydrated forms. In general, solvated and unsolvated forms are equivalent and are intended to be included within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms.

As used herein, the term 'solvate' refers to an association of one or more solvent molecules with a compound of the present invention. Solvate-forming solvents include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol. Thus, the term 'hydrate' refers to an association in which the solvent molecule is water.

Certain compounds of the present invention may have asymmetric carbon atoms (optical centers) or double bonds. Racemates, diastereomers, geometric isomers and individual isomers are included within the scope of the present invention.

Schematic representations of racemates, ambiscalemic and scalemic or enantiomerically pure compounds herein are from Maehr, J. Chem. Ed. 1985, 62: 114-120. 1985, 62: 114-120. Unless otherwise stated, wedge and dashed bonds are used to indicate the absolute configuration of a stereocenter. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, they include E, Z geometric isomers unless otherwise specified. Likewise, all tautomeric forms are included within the scope of the present invention.

The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers isomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, such as enantiomerically or

diastereomerically enriched mixtures, all of which belong to within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers, as well as mixtures thereof, are included within the scope of the present invention.

5 Optically active (R)- and (S)-isomers as well as D and L isomers can be prepared by chiral synthesis or chiral reagents or other conventional techniques. If one enantiomer of a compound of the present invention is desired, it can be prepared by asymmetric synthesis or derivatization with a chiral auxiliary, wherein the resulting mixture of diastereomers is separated and the auxiliary group is cleaved to provide pure desired enantiomer. Alternatively, when the molecule
10 contains basic functional groups (such as amino groups) or acidic functional groups (such as carboxyl groups), diastereomeric salts are formed with appropriate optically active acids or bases, followed by stepwise steps well known in the art. The diastereoisomers are resolved by crystallization or chromatography, followed by recovery of the pure enantiomers. In addition, separation of enantiomers and diastereomers is usually accomplished by the use of
15 chromatography using a chiral stationary phase, optionally in combination with chemical derivatization (e.g., carbamate formation from amines).

 The compounds of the present invention may contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute the compound. For example, compounds may be labeled with radioactive isotopes, such as tritium (^3H), iodine-125 (^{125}I) or C-14 (^{14}C).
20 All isotopic variations of the compounds of the invention, whether radioactive or not, are intended to be encompassed within the scope of the invention.

 The term "pharmaceutically acceptable carrier" refers to any formulation or carrier medium that provides the appropriate delivery of an effective amount of an active agent as defined herein, does not negatively interfere with the effectiveness of the biological activity of
25 the active agent, and that is sufficiently non-toxic to the host. Representative carriers include water, oils, both vegetable and mineral, cream bases, lotion bases, ointment bases and the like. These bases include suspending agents, thickeners, penetration enhancers, and the like. Their formulation is well known to those in the art of topical pharmaceuticals. Additional information concerning carriers can be found in Remington: The Science and Practice of Pharmacy. 21st
30 Ed., Lippincott, Williams & Wilkins (2005) which is incorporated herein by reference.

 When any variable (e.g., R) occurs more than once in the composition or structure of the compound, its definition in each case is independent. Thus, for example, if a group is substituted with 0-2 R, the group may optionally be substituted with up to two R, and in each case the R has an independent option. In addition, the combination of substituents and/or their

variants is allowed only if such a combination will produce a stable compound.

When a bond of a substituent could be cross-linked to two atoms on a ring, such substituent may be bonded to any atoms in the ring. Where the listed substituent does not specify through which atom it is connected to the general structure formula including the compound that is not specifically mentioned, the substituent may be bonded through any one of its atoms. The combination of substituents and/or variant thereof is allowed only if such a combination results in a stable compound.

The term "halo" or 'halogen' refers to fluorine, chlorine, bromine and iodine.

In order to illustrate the disclosure in more detail, the following examples are given, but the scope of the disclosure is not limited thereto. The compounds of the disclosure can be prepared by various synthetic methods well-known to those skilled in the art, including the embodiments described below, the embodiments combining the embodiments described below with other synthetic methods, and equivalent alternatives known to those skilled in the art. Preferred embodiments include but are not limited to those embodiments of the present invention.

Unless otherwise specified, all solvents used in the present invention are commercially available, and no further purification is required for use. The reaction is usually carried out using an anhydrous solvent under an inert atmosphere of nitrogen. NMR spectra were measured on a Bruker-Avance-400 (400 MHz) spectrometer and chemical shifts are reported in δ (ppm). Mass spectrometry was performed with an Agilent 1200 series (plus 6110 and 1956A) LC/MS or a Shimadzu MS (DAD: SPD-M20A(LC)) and a Shimadzu Micromass 2020 detector. The mass spectrometer is equipped with an electrospray ionization (ESI) source operating in positive and negative modes.

Abbreviations used are as follows: aq is aqueous; TLC is thin layer chromatography; RT is room temperature; MeOH is methanol; EtOH is ethanol; EtOAc is ethyl acetate; THF is tetrahydrofuran; eq for equivalent or equivalents; CDI is carbonyldiimidazole; DCM is Dichloromethane; PE is petroleum ether; DIAD is diisopropyl azodicarboxylate; DMF is N,N-dimethylformamide; DMSO is dimethyl sulfoxide; CBz is benzyloxycarbonyl; Boc is tert-butyl; HOAc is acetic acid; Ms is methylsulfonyl; NMP is N-methylpyrrolidone; DMAP is 4-(dimethylamino)pyridine; Boc₂O is di-tert-butyl dicarbonate; TFA is trifluoroacetic acid; DIPEA is Diisopropylethylamine; SOCl₂ is thionyl chloride; CS₂ is carbon disulfide; TsOH is 4-toluenesulfonic acid; MTBE is tert-butyl methyl ether; FA is formic acid; ACN is acetonitrile; i-PrOH is 2-propanol.

Compounds can be named manually or by ChemDraw® software, or if purchased

commercially the supplier's catalog name is used. Usually, TLC or LC-MS is used to determine whether the reaction is completed.


EXAMPLES

5 In order to illustrate the present invention in more detail, the following examples are given, but the scope of the present invention is not limited thereto.

Example 1-1. Synthesis of methyl (*S,E*)-3-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylate (intermediate A-1):

1). (E) Preparation of methyl (E)-3-(3-fluoro-4-nitrophenyl)acrylate:

10



15


To a solution of methyl diethylphosphonoacetate (1 g, 4.76 mmol) in dry THF (10 mL) at 0 °C sodium hydride (60% w/w dispersed in mineral oil, 210 mg, 5.24 mmol) was added. The mixture was stirred at 0 °C for 30 mins, then 3-fluoro-4-nitrobenzaldehyde (885 mg, 5.24 mmol) was added slowly to above mixture, maintaining the reaction temperature around 0 °C. After the addition was completed, the mixture was naturally warmed to room temperature and stirred for 16 hours. Cool to 0 °C, the mixture was quenched with water (50 mL) and extracted with ethyl acetate (2 × 30 mL). The combined organic layer was concentrated in vacuo to give a residue. The residue was subjected to silica gel column chromatography (PE/EA=3/1) to obtain methyl (E)-3-(3-fluoro-4-nitrophenyl)acrylate (800 mg, 74.8 %yield).

20

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.18(t, *J*=8.2 Hz, 1 H), 8.05(d, *J*=12.8 Hz, 1 H), 7.80(d, *J*=8.6 Hz, 1 H), 7.73(d, *J*=16.0 Hz, 1 H), 6.93(d, *J*=16.0 Hz, 1 H), 3.76(s, 3 H).

2). Synthesis of methyl (S,E)-3-(4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)acrylate:

25




The mixture of methyl (E)-3-(3-fluoro-4-nitrophenyl)acrylate (300 mg, 1.33 mmol), (*S*)-oxetan-2-ylmethanamine (116 mg, 1.33 mmol) and K₂CO₃ (368 mg, 2.67 mmol) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. The mixture was diluted with water (50 mL) and extracted with EA (3 × 10 mL). The combined organic layers

were washed with brine (50 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo to give a residue. The residue was purified by pre-TLC (PE/EA=1/1) to give methyl (S,E)-3-(4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)acrylate (320 mg, 82.4% yield), LC-MS m/z: 293 [M+H]⁺.

5


3). Synthesis of methyl (S,E)-3-(4-amino-3-((oxetan-2-ylmethyl)amino)phenyl)acrylate:



The mixture of methyl (S,E) (4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)acrylate (Intermediate 2) (320 mg, 1.1 mmol), Fe (173 mg) and NH₄Cl (164 mg) in ethanol/water (v: v=10/1, 5 mL) was heated to 80 °C and stirred for 16 hours. The reaction mixture was cooled to room temperature, poured into saturated NaHCO₃ (30 mL), and then extracted with EA (3 × 10 mL). The combined organic layer was concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (DCM/MeOH=20/1) to obtain methyl (S, E)-3-(4-amino-3-((oxetan-2-ylmethyl)amino)phenyl)acrylate (270 mg, 93.7% yield). LC-MS m/z: 263 [M+H]⁺.

15

4). Synthesis of methyl (S,E)-3-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylate (intermediate A-1):



20


To a solution of methyl (S, E)-3-(4-amino-3-((oxetan-2-ylmethyl)amino)phenyl)acrylate (intermediate 3) in dry THF (5 mL) chloroacetic anhydride (173 mg, 1.01 mmol) was slowly added at 0 °C. The reaction mixture was stirred at 0 °C for 30 mins, after which it was heated to 60 °C and stirred for 3 hours. Cooled to room temperature, quenched with water (20 ml) and extracted with EA (2 × 10 ml). The combined organic layer was directly concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (DCM/MeOH=50/1) to obtain methyl (S, E)-3-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylate (intermediate A-1) (240 mg, 81.9%

25

yield). LC-MS m/z : 321 $[M+H]^+$.


Example 1-2. Synthesis of methyl 4-(2-chloroacetamide)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-benzoate (Intermediate A-2):

1). Synthesis of methyl 3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate:




To a mixture of (1-ethyl-1H-imidazol-5-yl)methanamine (240 mg, 1.21 mmol) and methyl 3-fluoro-4-nitrobenzoate (241.2 mg, 1.21 mmol) in THF (6 mL) and MeOH (4 mL) TEA (1.2 g, 12.1 mmol) was added. The reaction mixture was warmed to 60 °C and stirred over weekend. The reaction mixture was poured into saturated brine (100 mL) and extracted with EA (2 × 80 mL). The organic layer was concentrated in vacuo to give a residue. The residue was purified by flash column chromatography on silica gel (eluted with EA/PE=3/1) to obtain methyl 3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (320 mg, 87.0% yield). LC-MS m/z : 305 $[M+H]^+$.

2). Synthesis of methyl 4-amino-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



To a solution of methyl 3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (320 mg, 1.05 mmol) in MeOH (10 mL) wet Pd/C (50 mg) was added under N₂ atmosphere. The reaction solution was degassed with H₂ three times, and then raised to 45 °C for 3 hours under H₂ atmosphere. The mixture was filtered, and the filtrate was concentrated in vacuo to give a residue. The residue was purified by flash column chromatography on silica gel (eluted with DCM/MeOH=10/1) to obtain methyl 4-amino-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)methyl)benzoate (270 mg, 93.8% yield). LC-MS m/z : 275 $[M+H]^+$.


3). Synthesis of methyl 4-(2-chloroacetamide)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (Intermediate A-2):



The solution of methyl 4-amino-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (230.0 mg, 0.84 mmol) and 2-chloroacetic anhydride (285.4 mg, 1.68 mmol) in THF (10 mL) was stirred at room temperature for 16 hours. The reaction solution was poured into saturated brine (100 mL) and extracted with DCM (2×80 mL). The combined organic layers were concentrated in vacuo to obtain methyl 4-(2-chloroacetamide)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (230.0 mg, 78.2% yield), LC-MS m/z : 351 $[M+H]^+$.


Example 1-3. Synthesis of methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate A-3):

1). Synthesis of methyl (S)-4-nitro-3-((oxetan-2-ylmethyl)amino)benzoate:




A solution of methyl 3-fluoro-4-nitrobenzoate (4.0 g, 20 mmol) and (S)-oxetan-2-ylmethanamine (1.7 g, 20 mmol) in DMF (40 mL) was added K_2CO_3 (5.5 g, 40 mmol). The reaction was stirred at room temperature for 12 hours. The reaction solution was poured into saturated brine (200 mL) and extracted with ethyl acetate (2×80 mL). The combined organic layers were washed with saturated brine (2×200 mL), dried over anhydrous sodium sulfate, and concentrated in vacuo to obtain crude product methyl (S)-4-nitro-3-((oxetan-2-ylmethyl)amino)benzoate (5.2 g). LC-MS m/z : 267 $[M+H]^+$.

2). Synthesis of methyl (S)-4-amino-3-((oxetan-2-ylmethyl)amino)benzoate:



To a solution of methyl (S)- 4-nitro-3-((oxetan-2-ylmethyl)amino)benzoate (5.2 g, 20 mmol) in methanol (50 mL) wet Pd/C (520 mg) was added under N₂ atmosphere. The mixture was degassed with H₂ three times, the reaction mixture was stirred at room temperature for 12 hours under H₂ atmosphere. The catalyst was removed by filtration, and the filtrate was concentrated in vacuo to obtain methyl (S)-4-amino-3-((oxetan-2-ylmethyl)amino)benzoate (3.9 g, 82.3% yield), LC-MS m/z: 237 [M+H]⁺.


3). Synthesis of methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate A-3):



To a solution of methyl (S)-4-amino-3-((oxetan-2-ylmethyl)amino)benzoate (1.5 g, 6 mmol) in THF (12 mL) at 0 °C 2-chloroacetic anhydride (1.1 g, 6.6 mmol) was added. The reaction mixture was stirred at room temperature for 12 hours. The mixture was concentrated in vacuo and purified by silica gel column chromatography (EA/PE=1/1) to obtain methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate A-3) (1.6 g, 90 % yield). LC-MS m/z: 295 [M+H]⁺.

Example 1-4. Synthesis of methyl(E)-3-(4-(2-chloroacetamide)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-phenyl)acrylate (Intermediate A -4):


1). Synthesis of methyl (E)- 3-(3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrophenyl)acrylate:



TEA (1.80 g, 17.80 mmol, 10.0 eq) was added to a mixture of methyl (E)-3-(3-fluoro-4-nitrophenyl)acrylate (Intermediate 1) (400 mg, 1.78 mmol) and (1-Ethyl-1H-imidazol-5-yl)methanamine (354 mg, 1.78 mmol) in THF (6 mL) and MeOH (4 mL). After stirring uniformly, the reaction mixture was heated to 60 °C and stirred for 48 hours. The resulting mixture was poured into brine (50 mL) and extracted with EA (2 × 20 mL). The combined

organic layer was concentrated in vacuo and then purified by silica gel column chromatography (DCM/MeOH=10/1) to obtain methyl (E)-3-(3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrophenyl)acrylate (400 mg, 68.1% yield). LC-MS m/z: 331 [M+H]⁺.

2) Synthesis of methyl (E)-3-(3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-aminophenyl)acrylate:




The mixture of methyl (E)-3-(3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrophenyl)acrylate (400 mg, 1.21 mmol), iron powder (203 mg, 3.63 mmol) and NH₄Cl (192 mg, 3.62 mmol) in EtOH/H₂O (v/v=10/1, 5 mL) was raised to 80 °C and stirred for 5 hours.

The reaction was cooled to room temperature, poured into saturated NaHCO₃ solution (30 mL) and extracted with EA (3 × 10 mL). The combined organic layers were washed with brine (3 × 10 mL), dried over Na₂SO₄, filtered, and concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (DCM/MeOH=20/1) to obtain methyl (E)-3-(3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-aminophenyl)acrylate (60 mg, 16.5% yield).

LC-MS m/z: 301 [M+H]⁺.


3). Synthesis of methyl (E)-3-(4-(2-chloroacetamide)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)phenyl)-acrylate (Intermediate A-4):



The mixture of methyl (E)-3-(3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-4-aminophenyl)acrylate (50 mg, 0.17 mmol) and 2-chloroacetic anhydride (58 mg, 0.34 mmol) in THF (2 mL) was stirred at room temperature for 16 hours. The resulting mixture was poured into brine (10 mL) and extracted with DCM (2 × 5 mL). The combined organic layer was directly concentrated to give methyl (E)-3-(4-(2-chloroacetamide)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)phenyl)-acrylate (Intermediate A-4) (50 mg, 79.8% yield). LC-MS m/z: 377 [M+H]⁺.

Example 1-5. Synthesis of methyl (S)-2-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acetate (intermediate A-5)


1). Synthesis of methyl 2-(3-fluoro-4-nitrophenyl)acetate:



To a solution of 2-(3-fluoro-4-nitrophenyl)acetic acid (800 mg, 4.02 mmol) in methanol (10 mL) at 0 °C thionyl chloride (957 mg, 8.04 mmol) was slowly added. The mixture was stirred at room temperature for 3 hours, then the reaction mixture was quenched with water (50 mL) at 0 °C and then extracted with ethyl acetate (2 × 20 mL). The combined organic layers were dried over anhydrous sodium sulfate and filtered to give a filtrate. The filtrate was concentrated in vacuo to obtain methyl 2-(3-fluoro-4-nitrophenyl)acetate (840 mg, 98.1% yield).


¹H NMR (400 MHz, DMSO-*d*₆): δ 8.13(t, *J*=8.2 Hz, 1H), 7.55(dd, *J*=12.4, 1.6 Hz, 1H), 7.37(dd, *J*= 8.4, 1.0 Hz, 1H), 3.90(s, 2H), 3.65(s, 3H).

2). Synthesis of methyl (S)-2-(4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)acetate:




The mixture of methyl 2-(3-fluoro-4-nitrophenyl)acetate (1.05 g, 4.93 mmol), (S)-oxetan-2-ylmethanamine (468 mg, 5.38 mmol) and potassium carbonate (1.35 g, 9.78 mmol) in N, N-dimethylformamide (10 mL) was stirred at room temperature for 3 hours. The resulting mixture was diluted with water (100 mL) and extracted with dichloromethane (3 × 10 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (PE/EA=2/1) to obtain methyl (S)-2-(4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)acetate (300 mg, 21.9% yield). LC-MS *m/z*: 280 [M+H]⁺.

3). Synthesis of methyl (S)-2-(4-amino-3-((oxetan-2-ylmethyl)amino)phenyl)acetate:



To a solution of methyl (S)-2-(4-nitro-3-((oxetan-2-ylmethyl)amino)phenyl)acetate (300 mg, 1.07 mmol) in methanol (10 mL) wet Pd/C (116 mg) was added under N₂ atmosphere solution. The mixture was degassed with H₂ three times and stirred at room temperature under H₂ atmosphere (1 atm) for 16 hours. The reaction solution was filtered, and the filter cake was washed with methanol (50 mL). The filtrate was concentrated in vacuo and then purified by silica gel column chromatography (PE/EA=1/1) to obtain methyl (S)-2-(4-amino-3-((oxetan-2-ylmethyl)amino)phenyl)acetate (120 mg, 45.0% yield). LC-MS m/z: 251 [M+H]⁺.


4). Synthesis of Methyl (S)-2-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acetate (Intermediate A-5):



To a solution of methyl (S)-2-(4-amino-3-((oxetan-2-ylmethyl)amino)phenyl)acetate (120 mg, 0.48 mmol) in anhydrous THF (5 mL) 2-chloroacetic anhydride (91 mg, 0.53 mmol) was slowly added at 0 °C. The mixture was stirred at 0 °C for 30 min, then heated to 60 °C for 3 h. Cooled to room temperature and quenched with water (20 mL), then extracted with ethyl acetate (2 × 10 mL). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (DCM/MeOH=50/1) to obtain methyl (S)-2-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acetate (Intermediate A-5) (100 mg, 67.6% yield). LC-MS m/z: 309 [M+H]⁺.

Example 1-6. Synthesis of methyl 2-(chloromethyl)-1-(1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]-imidazole-6-carboxylate (Intermediate A-6):


1). Synthesis of (1-(cyanomethyl)cyclopropyl)methanesulfonate:



To a mixture of 2-(1-(hydroxymethyl)cyclopropyl)acetonitrile (2.00 g, 18.00 mmol) and triethylamine (4.00 g, 39.25 mmol) in DCM (20 mL) MsCl (3.12 g, 27.23 mmol) was added dropwise at 0 °C. Then the mixture was stirred at 0 °C for 1 hour and then stirred at room temperature for 2 hours. The mixture was diluted with DCM (50 mL) and washed with brine (25 mL). The organic layer were dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give (1-(cyanomethyl)cyclopropyl)methanesulfonate (3.26 g, 17.23 mmol).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.15(s, 2H), 3.08(s, 3H), 2.59(s, 2H), 0.82(d, J = 4.0 Hz, 4H).


2). Synthesis of 2-(1-(azidomethyl)cyclopropyl)acetonitrile:



A solution of (1-(cyanomethyl)cyclopropyl)methanesulfonate (3.32 g, 17.54 mmol) and sodium azide (4.81 g, 73.99 mmol) in N, N-dimethylformamide (20 mL) was heated to 120 °C for 16 hours. The mixture was cooled to room temperature and quenched by the addition of water, extracted with dichloromethane (30 mL x3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtained 2-(1-(azidomethyl)cyclopropyl)acetonitrile (1.60 g, 11.75 mmol, 66.9% yield).

$^1\text{H NMR}$ (400 MHz, CDCl_3) δ 3.31(s, 2H), 2.53(s, 2H), 0.70(d, J = 1.2 Hz, 4H).


3). Synthesis of 2-(1-(aminomethyl)cyclopropyl)acetonitrile:



To a mixture of 2-(1-(azidomethyl)cyclopropyl)acetonitrile (1.60 g, 11.75 mmol) in methanol (15 mL)/water (9 mL) tributyl phosphine (7.13 g, 35.24 mmol) was added dropwise at room temperature. The resulting mixture was heated to 65 °C and stirred for 3 hours. The mixture was filtered, and the filter cake was washed with methanol (10 mL). The filtrate was concentrated in vacuo to obtained 2-(1-(aminomethyl)cyclopropyl)acetonitrile (821 mg, 7.45 mmol, 63.5% yield).


$^1\text{H NMR}$ (400 MHz, $\text{DMSO}-d_6$) δ 2.39(s, 2H), 2.25(s, 2H), 0.22(t, J = 5.2 Hz, 2H), 0.17(t, J = 5.2 Hz, 2H).

4). Synthesis of methyl 3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-4-nitrobenzoate:



To a mixture of 3-fluoro-4-nitrobenzoate (300 mg, 1.51 mmol) and 2-((1-(aminomethyl)cyclopropyl)acetonitrile (166 mg, 1.51 mmol) in N,N-dimethylformamide (5 mL) potassium carbonate (625 mg, 4.53 mmol) was added. The mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water (15 mL) and then extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (2 × 30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (PE/EA=5/1) to give methyl 3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-4-nitrobenzoate (250 mg, 0.86 mmol, 57.6% yield). LC-MS m/z: 290 [M+H]⁺.


5). Synthesis of methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate:



To a mixture of methyl 3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-4-nitrobenzoate (200 mg, 0.69 mmol) dissolved in methanol (8 mL) zinc powder (449 mg, 6.87 mmol) and acetic acid (415 mg, 6.91 mmol) were added at room temperature. The mixture was stirred at room temperature for 1 hour. The mixture was diluted with water (15 mL) and extracted with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse phase column chromatography with the following conditions: Column: Spherical C18, 20 - 40 μm, 120 g; Mobile Phase A: water (10 mM FA); Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 40% B - 60% B within 20 minutes; detector: 254 nm. The fractions containing desired product were collected at 52% B and concentrated in vacuo to afford compound methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (141 mg, 0.54 mmol, 78.6% yield). LC-

MS m/z: 260 [M+H]⁺.


6). Synthesis of methyl 2-(chloromethyl)-1-(1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate A-6):



To a solution of methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (140 mg, 0.54 mmol) in dry THF (5 mL) 2-chloroacetic anhydride (92 mg, 0.54 mmol) was added batchwise at room temperature. The mixture was stirred at 60 °C for 16 hours. The reaction mixture was quenched by water (5 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were combined and washed with brine, dried over anhydrous Na₂SO₄, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse phase flash chromatography with the following conditions: column: Spherical C18, 20-40 μm, 120 g; mobile phase A: water (10 mM FA); mobile phase B: acetonitrile; flow rate: 80 mL/min; gradient: 20 minutes 40%- 60% B; detector: 254 nm). The mobile phase containing the desired product was collected under 50% B mobile phase and then concentrated in vacuo to obtain methyl 2-(chloromethyl)-1-(1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate A-6) (90 mg, 0.54 mmol, 52.5% yield). LC-MS m/z: 318 [M+H]⁺.

Example 1-7. Synthesis of methyl 4-(2-chloroacetamide)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-fluorobenzoate (Intermediate A-7):


1). Synthesis of 2-(1-((5-Bromo-3-fluoro-2-nitrophenyl)amino)methyl)cyclopropyl)acetonitrile:



To a mixture of 5-bromo-1,3-difluoro-2-nitrobenzene (1.00 g, 4.20 mmol) and 2-(1-(aminomethyl)-cyclopropyl)acetonitrile (464.2 mg, 4.21 mmol) in dimethyl sulfoxide (20 mL) N,N-diisopropylethylamine (1.63 g, 12.61 mmol) was added. The mixture was stirred at 70 °C for 4 hours. The reaction mixture was diluted with water (15 mL) and extracted with ethyl


acetate (3 × 30 mL). The combined organic layers were washed with brine (2 × 30 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (PE/EA=5/1) to obtain 2-(1-((5-bromo-3-fluoro-2-nitrophenyl)amino)methyl)-cyclopropyl)acetonitrile (542.0 mg, 1.65 mmol, 39.3% yield). LC-MS m/z: 328, 330 [M+H]⁺.

2). Synthesis of 2-(1-((2-amino-5-bromo-3-fluorophenyl)amino)methyl)cyclopropyl)acetonitrile:



To a solution of 2-(1-((5-bromo-3-fluoro-2-nitrophenyl)amino)methyl)cyclopropyl)acetonitrile (542.0 mg, 1.65 mmol) in methanol (10 mL) was added zinc powder (1.08 g, 16.52 mmol) and acetic acid (996.0 mg, 16.59 mmol). The mixture was stirred at room temperature for 30 minutes. The reaction mixture was diluted with water (10 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with brine (2 × 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (PE/EA=2/1) to obtain 2-(1-((2-amino-5-bromo-3-fluorophenyl)amino)methyl)-cyclopropyl)acetonitrile (358.0 mg, 1.21 mmol, 72.9% yield). LC-MS m/z: 298 [M+H]⁺.


3). Synthesis of methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-fluorobenzoate:



To a mixture of 2-(1-((2-amino-5-bromo-3-fluorophenyl)amino)methyl)cyclopropyl)acetonitrile (358.0 mg, 1.21 mmol) in N,N-dimethylformamide (3 mL)/methanol (10 mL) triethylamine (366.6 mg, 3.62 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (88.5 mg, 0.12 mmol) were added at room temperature. The mixture was warmed to 90 °C for 16 hours under carbon monoxide

atmosphere. Cooled to room temperature, the reaction mixture was diluted with water (15 mL) and extracted with ethyl acetate (30 mL x3). The combined organic layers were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (PE/EA=1/1) to obtain methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-fluorobenzoate (100.0 mg, 0.36 mmol, 29.8% yield), LC-MS m/z: 278 [M+H]⁺.


4). Synthesis of methyl 4-(2-chloroacetamide)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-fluoro-benzoate (Intermediate A-7):



A solution of methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-fluorobenzoate (85.0 mg, 0.31 mmol) in THF (4 mL) 2-chloroacetic anhydride (52.5 mg, 0.31 mmol) was added dropwise at room temperature. The mixture was stirred at 60°C for 16 hours. The mixture was quenched by adding water (5 mL) and extracted with ethyl acetate (3 × 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse phase flash chromatography under the following conditions (column: Spherical C18, 20-40 um, 120 g; mobile phase A: water (10 mM FA); mobile phase B: acetonitrile; flow rate: 80 mL/min; Gradient: 40% B - 60% B in 20 minutes; detector: 254 nm). The mobile phase containing the desired product was collected under 52% B mobile phase and concentrated in vacuo to obtain methyl 4-(2-chloroacetamide)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-fluorobenzoate (Intermediate A-7) (141 mg, 0.54 mmol, 78.6% yield). LC-MS m/z: 354 [M+H]⁺.


Example 1-8. Synthesis of methyl 2-(chloromethyl)-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate A-8)

1). Synthesis of methyl 4-nitro-3-((oxetan-3-ylmethyl)amino)benzoate:




The mixture of methyl 3-fluoro-4-nitrobenzoate (1.60 g, 8.05 mmol), oxetan-3-ylmethanamine (700 mg, 8.05 mmol) and potassium carbonate (2.22 g, 16.10 mmol) in N, N-dimethylformamide (20 mL) was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (200 mL) and extracted with ethyl acetate (50 mL $\times$ 3). The combined organic layers were washed with brine (50 mL $\times$ 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/2) to obtain methyl 4-nitro-3-((oxetan-3-ylmethyl)amino)benzoate (1.50 g, 70.1% yield). LC-MS m/z: 267 [M+H]⁺.

2). Synthesis of methyl 4-amino-3-((oxetan-3-ylmethyl)amino)benzoate:



To a solution of methyl 4-nitro-3-((oxetan-3-ylmethyl)amino)benzoate (1.50 g, 5.64 mmol) in methanol (30 mL) palladium on carbon (200 mg) was added under N₂ atmosphere. The resulting mixture was degassed H₂ three times and stirred at room temperature for 4 hours under H₂ atmosphere. The reaction was filtered, and the filter cake was washed with methanol (20 mL). The filtrate was concentrated to obtain methyl 4-amino-3-((oxetan-3-ylmethyl)amino)benzoate (1.20 g, 90.2% yield), which was used in the next reaction without purification. LC-MS m/z: 237 [M+H]⁺.

3). Synthesis of methyl 2-(chloromethyl)-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:




To a solution of methyl 4-amino-3-((oxetan-3-ylmethyl)amino)benzoate (1.20 g, 5.08 mmol) in dry THF (20 mL) 2-chloroacetic anhydride (869 mg, 5.08 mmol) was added slowly at 0 °C. After stirred at 0 °C for 30 minutes, the mixture was heated to 70 °C and stirred for 3 hours. The mixture was quenched with water (100 mL) at room temperature and extracted with ethyl acetate (2 $\times$ 0 mL). The organic layer was concentrated in vacuo and purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl 2-(chloromethyl)-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (1.00 g, 67.0%

yield), LC-MS m/z: 295 [M+H]⁺.


Example 1-9. Synthesis of methyl 2-(chloromethyl)-1-((3-methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate A- 9):

1). Synthesis of methyl 3-((3-methoxy-3-yl)methyl)amino)-4-nitrobenzoate:




The mixture of methyl 3-fluoro-4-nitrobenzoate (2.00 g, 10.00 mmol), (3-methyloxan-3-yl)carboxamide (1.00 g, 10.00 mmol) and potassium carbonate (4.14 g, 30.00 mmol) in N,N-dimethylformamide (20 mL) was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (200 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (50 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=2/1) to obtain methyl 3-((3-methoxy-3-yl)methyl)amino)-4-nitrobenzoate (1.96 g, 70.4% yield). LC-MS m/z: 281 [M+H]⁺.

2). Synthesis of methyl 4-amino-3-((3-methyloxetan-3-yl)methyl)amino)benzoate:



A solution of methyl 3-((3-methoxy-3-yl)methyl)amino)-4-nitrobenzoate (1.96 g, 7.04 mmol) in methanol (20 mL) was added palladium on carbon (400 mg). The resulting mixture was degassed and flushed with hydrogen three times, and then stirred at room temperature for 4 hours. The reaction was filtered, and the filter cake was washed with methanol (20 mL). The filtrate was concentrated to give methyl 4-amino-3-((3-methyloxetan-3-yl)methyl)amino)benzoate (1.55 g, 85.2% yield), which was directly used for the next step without further purification, LC-MS m/z: 251 [M+H]⁺.


3). Synthesis of methyl 2-(chloromethyl)-1-((3-methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate(Intermediate A-10):



To a solution of methyl 4-amino-3-((3-methyloxetan-3-yl)methyl)amino)benzoate (200 mg, 0.80 mmol) in dry THF (5 mL) 2-chloroacetic anhydride (137 mg, 0.80 mmol) was added dropwise at 0 °C. The mixture was stirred at room temperature for 1 hour. The solvent was removed by concentration in vacuo to give a residue. The residue was added dioxane (5 mL) then heated to 100 °C for 3 hours. The mixture was quenched with water (20 mL) at room temperature and extracted with ethyl acetate (2 × 10 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl 2-(chloromethyl)-1-((3-methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate A-10) (200 mg, 81.2% yield). LC-MS m/z: 309 [M+H]⁺.


Example 1-10. Synthesis of methyl 4-(2-chloroacetamide)-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)-benzoate (Intermediate A-10):

1). Synthesis of 1,2-dimethyl-1H-imidazole-5-carbaldehyde:




To a solution of 5-bromo-1,2-dimethyl-1H-imidazole (500 mg, 2.86 mmol) in dry tetrahydrofuran (10 mL) n-butyllithium (1.26 mL, 3.15 mmol, 2.5M in hexane) was added at -78 °C. The mixture was stirred at -78 °C for 30 min, then N, N-dimethylformamide (626 mg, 8.58 mmol) was slowly added to the mixture at 0 °C. The mixture was stirred at room temperature for 2 hours. When completion, the reaction was quenched with water (50 mL) at 0 °C and extracted with ethyl acetate (2 × 30 mL). The combined organic layer was concentrated in vacuo and purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain 1,2-dimethyl-1H-imidazole-5-carbaldehyde (300 mg, 84.6 yield %), LC-MS m/z: 125 [M+H]⁺.

2). Synthesis of (E)-N-((1,2-dimethyl-1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfinamide:




The mixture of 1,2-dimethyl-1H-imidazole-5-carbaldehyde (300 mg, 2.42 mmol), 2-methylpropane-2-sulfoxide (439 mg, 3.63 mmol) and tetraisopropyl titanate (2.06 g, 7.26 mmol) in THF (5 mL) was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (2 mL) and filtered. The filtrate was concentrated in vacuo and purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain (E)-N-((1,2-dimethylene) (500 mg, 91.0% yield). LC-MS m/z: 228 [M+H]⁺.

3). Synthesis of N-((1,2-Dimethyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide:



The mixture of (E)-N-((1,2-dimethyl-1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (500 mg, 2.20 mmol) and boron sodium hydride (167 mg, 4.40 mmol) in methanol (10 mL) was stirred at room temperature for 2 hours. When completion, the reaction was quenched with water (50 mL) at room temperature and extracted with dichloromethane (2 × 20 mL). The combined organic layer was concentrated in vacuo to obtain N-((1,2-dimethyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (400 mg, 55.3% yield), which was directly used in the next step without further purification. LC-MS m/z: 230 [M+H]⁺.

4). Synthesis of 1,2-Dimethyl-1H-imidazol-5-yl)methanamine hydrochloride:




The mixture of N-((1,2-Dimethyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (400 mg, 1.75 mmol) in HCl (5 mL, 3M in MeOH) was stirred at room temperature for 1 hour. The reaction was filtered to give (1,2-dimethyl-1H-imidazol-5-

yl)methanamine hydrochloride (200 mg, 57.8% yield).


^1H NMR(400 MHz, DMSO- d_6): δ 8.86(s, 2H), 7.63(s, 1H), 4.19(s, 2H), 3.77(s, 3H), 2.63(s, 3H).

5 **5). Synthesis of methyl 3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate:**




To a mixture of (1,2-dimethyl-1H-imidazol-5-yl)methanamine hydrochloride (200 mg, 1.01 mmol) and methyl 3-fluoro-4-nitrobenzoate (201 mg, 1.01 mmol) in THF (3 mL) and methanol (2 mL) triethylamine (510 mg, 5.05 mmol) was added. The mixture was stirred at 60 °C for 3 h. The resulting mixture was poured into brine (50 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layer was concentrated in vacuo and purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain 3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino) -4-Nitrobenzoic acid methyl ester (200 mg, 65.1% yield). LC-MS m/z: 305 [M+H]⁺.

6). Synthesis of methyl 4-amino-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



To a solution of methyl 3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (200 mg, 0.66 mmol) in methanol (10 ml) palladium on carbon (20 mg) was added. The resulting mixture was degassed and flushed with hydrogen three times and stirred at room temperature for 3 hours. The reaction mixture was filtered, and washed with methanol (50 mL). The filtrate was concentrated in vacuo to obtain methyl 4-amino-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)benzoate (150 mg, 82.9% yield) that was directly used in the next step without purification. LC-MS m/z: 275 [M+H]⁺.


7). Synthesis of methyl 4-(2-chloroacetamide)-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



A solution of methyl 4-amino-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)benzoate (150 mg, 0.55 mmol) and 2-chloroacetic anhydride (142 mg, 0.83 mmol) in THF (3 mL) was stirred at room temperature for 2 hours. The resulting mixture was concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-chloroacetamide)-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)-amino)benzoate (150 mg, 77.9% yield), LC-MS m/z: 351 [M+H]⁺.


Example 1-11. Synthesis of methyl 5-(2-chloroacetamide)-6-(1-(cyanomethyl)cyclopropyl)methyl)amino-picolinate:

1). Synthesis of methyl 6-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-nitropicolinate:




To a solution of methyl 6-chloro-5-nitropicolinate (850 mg, 3.94 mmol) and 2-(1-(aminomethyl) cyclopropyl)acetonitrile (433 mg, 3.94 mmol) in DMSO (10 mL) N,N-diisopropylethylamine (1.52 g, 11.81 mmol) was added. The reaction was stirred at 60 °C for 16 hours. The resulting mixture was poured into brine (20 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic layer was concentrated and purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl 6-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-nitropicolinate (190 mg, 16.7% yield). LC-MS m/z: 291 [M+H]⁺.

2). Synthesis of methyl 5-amino-6-((1-(cyanomethyl)cyclopropyl)methyl)amino)picolinate:




To a solution of methyl 6-((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-nitropicolinate (190 mg, 0.65 mmol) in methanol (5 mL) zinc powder (428 mg, 6.55 mmol) and acetic acid (393 mg, 6.55 mmol) were added at room temperature and the resulting solution was stirred at room temperature for 2 hours. After completion, the resulting mixture was filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=2/1) to obtain methyl 5-amino-6-((1-(cyanomethyl)cyclopropyl)methyl)aminopicolinate (130 mg, 53.7% yield). LC-MS m/z: 261 [M+H]⁺.

3). Synthesis of methyl 5-(2-chloroacetamido)-6-((1-(cyanomethyl)cyclopropyl)methyl)aminopicolinate (Intermediate A-11):



To a solution of methyl 5-amino-6-((1-(cyanomethyl)cyclopropyl)methyl)aminopicolinate (80 mg, 0.31 mmol) in tetrahydrofuran (5 mL) 2-chloroacetic anhydride (79 mg, 0.46 mmol) was added. The resulting mixture was stirred at room temperature for 2 hours. After completion, the mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl 5-(2-chloroacetamido)-6-((1-(cyanomethyl)cyclopropyl)methyl)aminopicolinate (Intermediate A-11) (150 mg, 88% yield). LC-MS m/z: 337 [M+H]⁺.


Example 1-12. Synthesis of methyl (S)-2-(chloromethyl)-3-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (Intermediate A-12)



To a solution of methyl (S)-5-amino-6-((oxetan-2-ylmethyl)amino)picolinate (100 mg, 0.42 mmol) in tetrahydrofuran (10 mL) 2-chloroacetic anhydride (101 mg, 0.63 mmol) was


added. The reaction mixture was stirred at 60 °C for 3 hours. The resulting mixture was directly concentrated in vacuo to give methyl (S)-2-(chloromethyl)-3-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (Intermediate A-12) (140 mg).

Example 1-13. Synthesis of methyl 5-(2-chloroacetamide)-6-((1-ethyl-1H-imidazol-5-yl)methyl)amino-picolinate(Intermediate A-13):




To a solution of methyl 5-amino-6-((1-ethyl-1H-imidazol-5-yl)methyl)amino)picolinate(150 mg, 0.54 mmol) in THF (5 mL) 2-chloroacetic anhydride (138 mg, 0.82 mmol) was added dropwise. The mixture was stirred at 25°C for 16 hours. Then the mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 5-(2-chloroacetamide)-6-((1-ethyl-1H-imidazol-5-yl)methyl)amino-picolinate (180 mg, 94.7% yield). LC-MS m/z: 352 [M+H]⁺.

Example 1-14. Synthesis of methyl 4-(2-chloroacetamide)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-benzoate (Intermediate A-14):




To a solution of methyl 4-amino-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (500 mg, 1.93 mmol) in THF (5 mL) 2-chloroacetic anhydride (494 mg, 2.89 mmol) was added. The mixture was stirred at room temperature for 2 hours. After completion, the mixture was concentrated and purified by silica gel column chromatography (petroleum ether/ethyl acetate=2/1) to obtain methyl 4-(2-chloroacetamide)-3-((1-(cyanomethyl)cyclopropyl)methyl)-amino)-benzoate (Intermediate A-14) (400 mg, 61.8% yield). LC-MS m/z: 336 [M+H]⁺.

Example 1-15. Synthesis of (S)-N-(4-Bromo-2-fluoro-6-((oxetan-2-ylmethyl)amino)phenyl)-2-chloroacetamide e (Intermediate A-15):



To a solution of (S)-5-bromo-3-fluoro-N¹-(oxetan-2-ylmethyl)benzene-1,2-diamine (300 mg, 1.09 mmol) in dry THF(5 mL) 2-chloroacetic anhydride (241 mg, 1.42 mmol) was added. The mixture was stirred at room temperature for 1 hour. The mixture was diluted with water (10 mL) then extracted with ethyl acetate (10 mL × 3). The combined organic layer was concentrated in vacuo and purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain (S)-N-(4-bromo-2-fluoro-6-((oxetan-2-ylmethyl)amino)phenyl)-2-chloroacetamide (230 mg, 59.9% yield). LC-MS m/z: 353 [M+H]⁺.


Example 1-16. Synthesis of N-(4-bromo-2-((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-chloroacetamide (Intermediate A-16):



To a solution of 2-(1-((2-amino-5-bromo-3-fluorophenyl)amino)methyl)cyclopropyl)acetonitrile (150 mg, 0.50 mmol) in dry THF(5 mL) 2-chloroacetic anhydride (129 mg, 0.76 mmol) was slowly added. The mixture was stirred at room temperature for 1 hour. The mixture was diluted with water (10 mL) then extracted with ethyl acetate (3 × 10 mL). The combined organic layer was concentrated in vacuo and purified by silica gel column chromatography (petroleum ether/ethyl acetate=3/1) to give N-(4-bromo-2-((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-chloroacetamide (218 mg, crude). LC-MS m/z: 376 [M+H]⁺.


Example 1-17. Synthesis of methyl 4-(2-chloroacetamide)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorobenzoate (Intermediate A-17):

1). Synthesis of methyl 4-amino-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorobenzoate:




Potassium acetate (470 mg, 4.80 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (117 mg, 0.16 mmol) were added to a mixture of 5-bromo-N'-((1-ethyl-1H-imidazol-5-yl)methyl)-3-fluorobenzene-1,2-diamine (500 mg, 1.60 mmol) in methanol (5 mL) and N,N-dimethylformamide (5 mL). The mixture was degassed with carbon monoxide three times and stirred at 90 °C for 16 hours under carbon monoxide atmosphere. After completion, the mixture was diluted with water (30 mL) and extracted with ethyl acetate (30 mL×2). The combined organic layers were washed with brine (20 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give methyl 4-amino-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino-5-fluorobenzoate (150 mg, 32.1% yield). LC-MS m/z: 293 [M+H]⁺.

2). Synthesis of methyl 4-(2-chloroacetamide)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorobenzoate:




To a solution of methyl 4-amino-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorobenzoate (150 mg, 0.51 mmol) in THF (5 mL) 2-chloroacetic anhydride (176 mg, 1.02 mmol) was slowly added at room temperature. The reaction was stirred at room temperature for 3 hours. After completion, the reaction was quenched with water (30 mL) and extracted with ethyl acetate (2×20 mL). The organic phase was concentrated in vacuo and then purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-chloroacetamide)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorobenzoate (130 mg, 69.3% yield). LC-MS m/z: 369 [M+H]⁺.

Example 1-18. Synthesis of methyl 4-(2-chloroacetamido)-3-((1-(cyclopropylmethyl)-


1H-imidazol-5-yl)-methyl)aminobenzoate (Intermediate A-18);

To a solution of methyl 4-amino-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)aminobenzoate (500 mg, 1.67 mmol) in dry THF (10 mL) chloroacetic anhydride (715 mg, 4.18 mmol) was slowly added at room temperature. The resulting mixture was stirred at room temperature for 2 hours. After completion, the solvent was removed by concentration in vacuo, The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-chloroacetamido)-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)-methyl)aminobenzoate (Intermediate A-18) (400 mg, 63.5% yield). LC-MS m/z: 377 [M+H]⁺.


Example 1-19. Synthesis of methyl 2-(chloromethyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (Intermediate A-19):

To a solution of methyl 4-amino-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)aminobenzoate (500 mg, 1.67 mmol) in dry THF (10 mL) 2-chloroacetic anhydride (715 mg, 4.18 mmol) was added at room temperature solution. The resulting mixture was stirred at room temperature for 2 hours then raised to 60°C stirred overnight. After completion, the solvent was removed by concentration in vacuo and the residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 2-(chloromethyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 16.7% yield). LC-MS m/z: 359 [M+H]⁺.


Example 1-20. Synthesis of methyl 2-(chloromethyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate (Intermediate A-20):

1). Synthesis of methyl 3-(methylamino)-4-nitrobenzoate:

The solution of methyl 3-fluoro-4-nitrobenzoate (2.00 g, 10.00 mmol) and methylamine (10 mL, 2 M in tetrahydrofuran) in THF (30 mL) was stirred at room temperature for 2 hours. After completion, it was concentrated in vacuo and was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl 3-(methylamino)-4-nitrobenzoate (1.80 g, 85.0% yield). LC-MS m/z: 211 [M+H]⁺.

2). Synthesis of methyl 4-amino-3-(methylamino)benzoate:

To a solution of methyl 3-(methylamino)-4-nitrobenzoate (1.80 g, 8.57 mmol) in methanol (20 mL) was added palladium on carbon (900 mg) at room temperature under N₂ atmosphere. The resulting mixture was degassed and flushed with hydrogen three times and stirred at room temperature for 3 hours. After completion, the reaction solution was filtered, and the filter cake was washed with methanol (20 mL). The filtrate was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=16/9) to obtain methyl 4-amino-3-(methylamino)benzoate (1.2 g, 77.8% yield). LC-MS m/z: 181 [M+H]⁺.


3). Synthesis of methyl 2-(chloromethyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate:

To a solution of methyl 4-amino-3-(methylamino)benzoate (1.2 g, 2.83 mmol) in dry THF (20 mL) was slowly added chloroacetic anhydride (2.27 g, 5.66 mmol) at room temperature. The reaction was stirred at room temperature for 2 hours, then the reaction mixture

was heated to 60 °C for 16 hours. After completion, it was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=3/1) to obtain methyl 2-(chloromethyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate (1.4 g, 88.2% yield). LC-MS m/z: 239 [M+H]⁺.


5 **Example 1-21. Synthesis of methyl 4-(2-chloroacetamide)-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)-benzoate(Intermediate A-21):**

1). Synthesis of (E)-N-((1-isopropyl-1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide:



10 The mixture of (E)-N-((1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (5.00 g, 25.12 mmol), potassium carbonate (10.40 g, 75.36 mmol) and 2-iodopropane (8.54 g, 50.25 mmol) in N,N-dimethylacetamide (100 mL) was stirred at room temperature for 16 hours. After completion, it was diluted with water (200 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (50 mL×3), dried over
15 anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=12/1) to give (E)-N-((1-isopropyl-1H-imidazol-5-yl)methylene)-2-methan propane-2-sulfoxide amide (4.8 g, 73.4% yield). LC-MS m/z: 242 [M+H]⁺.


20 **2). Synthesis of N-((1-isopropyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide:**



To a solution of (E)-N-((1-isopropyl-1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (4.80 g, 19.92 mmol) in methanol (30 mL) sodium borohydride (2.28 g, 59.75 mmol) was slowly added at room temperature. The resulting mixture was stirred at room


temperature for 2 hours. After completion, water (200 mL×2) was added to quench the reaction, and extracted with ethyl acetate (200 mL). The combined organic layers were washed with brine (200 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain N-((1-isopropyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (4.5 g, 87.5% yield), LC-MS m/z: 244 [M+H]⁺.

3). Synthesis of (1-isopropyl-1H-imidazol-5-yl)methanamine hydrochloride:




The mixture of N-((1-isopropyl-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (4.50 g, 18.44 mmol) and HCl (50 mL, 3 M in methanol) was stirred for 16 hours at room temperature. After completion, the reaction mixture was concentrated in vacuo to obtain (1-isopropyl-1H-imidazol-5-yl)methanamine hydrochloride (2.4 g, 93.6% yield). LC-MS m/z: 140 [M+H]⁺.

4). Synthesis of methyl 3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate:




The mixture of (1-isopropyl-1H-imidazol-5-yl)methanamine hydrochloride (3.0 g, 17.27 mmol), methyl 3-fluoro-4-nitrobenzoate (4.14 g, 20.72 mmol) and potassium carbonate (4.79 g, 34.53 mmol) in N,N-dimethylformamide (50 mL) was stirred at room temperature for 16 hours. After completion, it was diluted with water (200 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (50 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=12/1) to obtain methyl 3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (1.2 g, 21.9% yield). LC-MS m/z: 319 [M+H]⁺.

5). Synthesis of methyl 4-amino-3-((1-isopropyl-1H-imidazol-5-

yl)methyl)amino)benzoate:


To a solution of methyl 3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate (1.2 g, 3.78 mmol) in methanol (30 mL) palladium on carbon (600 mg, 5.6 mmol) was added at room temperature. The resulting mixture was degassed and flushed with hydrogen three times, and the reaction was stirred at room temperature for 3 hours under H₂ atmosphere. After completion, filter and wash the filter cake with methanol (50 mL). After the filtrate was concentrated to give a residue in vacuo, the residue was purified by silica gel column chromatography (dichloromethane/methanol=13/1) to obtain 4-amino-3-((1-isopropyl-1H-imidazol-5-yl)methyl) amino) methyl benzoate (750 mg, 69.0% yield). LC-MS m/z: 289 [M+H]⁺.

6. Synthesis of methyl 4-(2-chloroacetamido)-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate:

To a solution of methyl 4-amino-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate (400 mg, 1.39 mmol) in dry THF(8 mL) added chloroacetic anhydride (595 mg, 3.48 mmol) was slowly at room temperature. The reaction was stirred at for 3 hours. After completion, the reaction solution was concentrated in vacuo, The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain 4-(2-chloroacetamido)-3-((1-isopropyl-1H)-imidazol-5-yl)methyl)amino)methyl benzoate (450 mg, 88.8% yield). LC-MS m/z: 365 [M+H]⁺.


Example 1-22. Synthesis of methyl 4-(2-chloroacetamido)-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)aminobenzoate (Intermediate A-22):

1). Synthesis of (E)-N-((1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide:




To a mixture of 1H-imidazole-5-carbaldehyde (5.00 g, 52.08 mmol) and 2-methylpropane-2-sulfoxide amide (9.39 g, 78.12 mmol) in THF (100 mL) titanium tetraisopropoxide (44.40 g, 156.25 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 16 hours. After completion, it was diluted with water (100 mL), filtered, and the filter cake was washed with ethyl acetate (150 mL). And the aqueous layer was extracted with ethyl acetate (100 mL×2). The combined organic layers were washed with brine (250 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=12/1) to obtain (E)-N-((1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (9.00 g, 86.4% yield). LC-MS m/z: 200 [M+H]⁺.

2). Synthesis of (E)-N-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide:




To a mixture of (E)-N-((1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (3.00 g, 15.10 mmol) and potassium carbonate (6.25 g, 45.30 mmol) in N,N-dimethylformamide (50 mL) (bromomethyl)cyclopropane (4.08 g, 30.20 mmol) was added. The resulting mixture was stirred at room temperature for 16 hours. After completion, the resulting mixture was diluted with water (200 mL) and extracted with ethyl acetate (150 mL×3). The combined organic layers were washed with brine (150 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=13/1) to give (E)-N-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (2.8 g, yield 73.4%). LC-MS m/z: 254 [M+H]⁺.

3). Synthesis of N-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide




To a solution of (E)-N-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methylene)-2-methylpropane-2-sulfoxide amide (2.80 g, 11.60 mmol) in methanol (20 mL) sodium borohydride (1.26 g, 33.2 mmol) was added slowly. The reaction was stirred at room temperature for 2 hours. After completion, water (200 mL) was added to quench the reaction, and extracted with ethyl acetate (60 mL×3). The combined organic layers were washed with brine (200 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain N-((1-(Cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (2.55 g, 90.9% yield). LC-MS m/z: 256 [M+H]⁺.

4). Synthesis of (1- (cyclopropylmethyl) - 1h-imidazol-5-yl) methylamine hydrochloride:




The mixture of N-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-methylpropane-2-sulfoxide amide (2.55 g, 10.00 mmol) and HCl (30 mL, 3 M in methanol) was stirred for 16 hours at room temperature. After completion, the mixture was concentrated to obtain (1-(cyclopropylmethyl)-1H-imidazol-5-yl)methanamine hydrochloride (1.87 g, 99.3% yield). LC-MS m/z: 152 [M+H]⁺.

5). Synthesis of methyl 3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino)-4-nitrobenzoate:



The mixture of (1-(cyclopropylmethyl)-1H-imidazol-5-yl)methanamine hydrochloride (1.87 g, 9.93 mmol), methyl 3-fluoro-4-nitrobenzoate (2.98 g, 14.90 mmol) and potassium carbonate (2.76 g, 19.87 mmol) in N,N-dimethylformamide (30 mL) was stirred at room temperature for 16 hours. After completion, the resulting mixture was diluted with water (200 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=13/1) to obtain methyl 3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methylamino)-4-nitrobenzoate (1.5 g, 45.7% yield). LC-MS m/z : 331 $[M+H]^+$.

6). Synthesis of methyl 4-amino-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)aminobenzoate:




15

To a solution of methyl 3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methylamino)-4-nitrobenzoate (1.50 g, 4.55 mmol) in methanol (40 mL) palladium on carbon (750 mg) was added at room temperature. The resulting mixture was degassed and flushed with hydrogen three times, and the reaction was stirred at room temperature for 4 hours. After completion, the reaction was filtered, and the filter cake was washed with methanol (50 mL). The filtrate was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=13/1) to obtain 4-amino-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)aminobenzoate (1.1 g, 80.7% yield). LC-MS

20

m/z: 301 [M+H]⁺.


7). Synthesis of methyl 4-(2-chloroacetamide)-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-aminobenzoate:



To a solution of methyl 4-amino-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)aminobenzoate (150 mg, 0.50 mmol) in dry THF (5 ml) chloroacetic anhydride (257 mg, 1.50 mmol) was added at room temperature. The reaction was stirred at room temperature for 16 hours. After completion, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=15/1) to obtain methyl 4-(2-chloroacetamide)-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-aminobenzoate (180 mg, 95.5% yield). LC-MS m/z: 377 [M+H]⁺.

Example 1-23. Synthesis of methyl 4-(2-chloroacetamide)-3-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)amino-benzoate (Intermediate A-23):


1). Synthesis of dimethyl ethyl-L-glutamate:



The mixture of dimethyl L-glutamate hydrochloride (5.00 g, 23.70 mmol) and potassium hydroxide (770 mg, 26.07 mmol) in methanol (100 mL) was stirred for 15 minutes at room temperature. Then acetaldehyde (1.56 g, 35.55 mmol) was added to the above mixture. The resulting mixture was stirred at room temperature for 2 hours. After completion, the reaction was quenched with water (200 mL) at room temperature, and extracted with ethyl acetate (100 mL×2). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to in vacuo to give dimethyl N-ethyl-L-glutamate (3.50 g, 72.7% yield)


¹H NMR (400 MHz, CDCl₃): δ 3.73 (s, 3 H), 3.67 (s, 3 H), 2.65-12.59 (m, 1 H), 2.50-2.42 (m, 3 H), 2.01-1.86 (m, 2 H), 1.07 (t, *J*=7.2 Hz, 3 H).

2). Synthesis of methyl 1-ethyl-5-oxopyrrolidine-2-carboxylate:




The solution of dimethyl ethyl-L-glutamate (3.50 g, 17.24 mmol) in toluene (50 mL) was stirred at 110 °C for 16 hours at room temperature. After completion, the solvent was removed in vacuo to obtain methyl 1-ethyl-5-oxopyrrolidine-2-carboxylate (2.00 g, 67.8% yield). LC-MS m/z : 172 $[M+H]^+$.

3). Synthesis of 1-ethyl-5-(hydroxymethyl)pyrrolidin-2-one:




To a solution of methyl 1-ethyl-5-oxopyrrolidine-2-carboxylate (1.00 g, 5.85 mmol) in tetrahydrofuran (10 mL) at 0 °C lithium aluminum hydride (222 mg, 5.85 mmol) was added. The resulting mixture was stirred at room temperature for 1 hour. Upon completion of the reaction, the reaction mixture was quenched by adding water (2 mL) and aqueous sodium hydroxide (2 mL, 15%). The reaction was filtered and concentrated under reduced pressure to give 1-ethyl-5-(hydroxymethyl)pyrrolidin-2-one (600 mg, 71.7% yield). LC-MS m/z : 144 $[M+H]^+$.

4). Synthesis of methyl (1-ethyl-5-oxopyrrolidin-2-yl)sulfonate:




To a solution of 1-ethyl-5-(hydroxymethyl)pyrrolidin-2-one (600 mg, 4.20 mmol) in dichloromethane (10 mL) triethylamine (848 mg, 8.40 mmol) and methanesulfonyl chloride (580 mg, 5.04 mmol) was added at 0 °C. The resulting mixture was stirred at room temperature for 1 hour. After completion, the reaction mixture was quenched with water (20 mL) at room temperature, and then extracted with dichloromethane (10 mL $\times$ 2). The combined organic layers were dried over with anhydrous sodium sulfate, filtered, and concentrated in vacuo to give methyl (1-ethyl-5-oxopyrrolidin-2-yl)sulfonate (500 mg, 53.9% yield). LC-MS m/z : 222 $[M+H]^+$.

5). Synthesis of 5-(azidomethyl)-1-ethylpyrrolidin-2-one:




The mixture of methyl (1-ethyl-5-oxopyrrolidin-2-yl)sulfonate (500 mg, 2.26 mmol) and sodium azide (220 mg, 3.39 mmol) in N,N-dimethylformamide (10 mL) was stirred at $120\text{ }^\circ\text{C}$ for 16 hours. After completion, it was diluted with saturated sodium bicarbonate (50 mL) solution at room temperature and extracted with ethyl acetate (10 mL $\times$ 3). The combined organic layers were washed with brine (20 mL $\times$ 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo to obtain 5-(azidomethyl)-1-ethylpyrrolidin-2-one (500 mg, crude). LC-MS m/z : 169 $[\text{M}+\text{H}]^+$.

6). Synthesis of 5-(aminomethyl)-1-ethylpyrrolidin-2-one:



To a mixture of 5-(azidomethyl)-1-ethylpyrrolidin-2-one (500 mg, 2.98 mmol) in THF (10 mL) and water (2 mL) triphenylphosphine (1.56 g, 5.96 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 2 hours. After completion, the solvent was removed by concentration. The residue was purified by silica gel column chromatography to obtain 5-(aminomethyl)-1-ethylpyrrolidin-2-one (265 mg, 99.9% yield). LC-MS m/z : 143 $[\text{M}+\text{H}]^+$.


7). Synthesis of methyl 3-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)amino)-4-nitrobenzoate:



The mixture of 5-(aminomethyl)-1-ethylpyrrolidin-2-one (500 mg, 3.52 mmol), methyl 3-fluoro-4-nitrobenzoate (700 mg, 3.52 mmol) and potassium carbonate (972 mg, 7.04 mmol) in N, N-dimethylformamide (10 mL) was stirred at room temperature for 16 hours. After completion, the resulting mixture was diluted with water (100 mL) and extracted with ethyl acetate (20 mL $\times$ 2). The combined organic layers were washed with brine (50 mL $\times$ 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The


residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 3-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)amino)-4-nitrobenzoate (120 mg, 10.6% yield).

8). **Synthesis of methyl 4-amino-3-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)amino)benzoate:**



To a solution of methyl 3-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)amino)-4-nitrobenzoate (120 mg, 0.37 mmol) in methanol (10 mL) Pd/C (20 mg) was added at room temperature. The resulting mixture was degassed and flushed with hydrogen three times, and the reaction was stirred at room temperature for 16 hours. The reaction solution was filtered by celite with washed with MeOH (30 mL) and concentrated in vacuo to obtain methyl 4-amino-3-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)amino)benzoate (100 mg, 92.9% yield). LC-MS m/z : 292 $[M+H]^+$.


9). **Synthesis of methyl 4-(2-chloroacetamide)-3-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)aminobenzoate:**



To a solution of methyl 4-amino-3-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)amino)benzoate (100 mg, 0.31 mmol) in dry THF (3 mL) chloroacetic anhydride (106 mg, 0.62 mmol) was slowly added. The reaction was stirred at room temperature for 2 hours. After completion, the reaction mixture was directly concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-chloroacetamide)-3-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)aminobenzoate (100 mg, 87.9% yield). LC-MS m/z : 368 $[M+H]^+$.


Example 1-24. Synthesis of methyl (S)-4-(2-chloroacetamide)-3-((1-ethylpyrrolidin-2-yl)methyl)amino-benzoate (Intermediate A-24):

1). **Synthesis of methyl (S)-3-((1-ethylpyrrolidin-2-yl)methyl)amino)-4-nitrobenzoate:**




The mixture of methyl 3-fluoro-4-nitrobenzoate (7.77 g, 39.04 mmol), (S)-(1-ethylpyrrolidin-2-yl)carboxamide (5.00 g, 39.04 mmol) and potassium carbonate (16.16 g, 117.12 mmol) in N,N-dimethylformamide (70 mL) was stirred at room temperature for 16 hours. After completion, it was diluted with water (200 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (50 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane: methanol=10:1) to obtain methyl (S)-3-((1-ethylpyrrolidin-2-yl)methyl)amino-4-nitrobenzoate (9.30 g, 77.7% yield). LC-MS m/z: 308 [M+H]⁺.

2). Synthesis of methyl (S)-4-amino-3-((1-ethylpyrrolidin-2-yl)methyl)aminobenzoate:



To a solution of methyl (S)-3-((1-ethylpyrrolidin-2-yl)methyl)amino-4-nitrobenzoate (3.07 g, 10.00 mmol) in methanol (50 mL) palladium on carbon (1.50 g, 14.00mmol) was added at room temperature. The resulting mixture was degassed and flushed with hydrogen three times, and the reaction was stirred at room temperature for 4 hours. After completion, filtered, and washed the filter cake with methanol (50 mL). The filtrate was concentrated in vacuo to give a residue. The residue was purified by silica gel column chromatography(dichloromethane/methanol=20/1) to obtain methyl (S)-4-amino-3-((1-ethylpyrrolidin-2-yl)methyl)aminobenzoate (2.3 g, 80.0% yield). LC-MS m/z: 278 [M+H]⁺.

3). Synthesis of methyl (S)- 4-(2-chloroacetamide)-3-((1-ethylpyrrolidin-2-yl)methyl)aminobenzoate:




To a solution of methyl (S)-4-amino-3-((1-ethylpyrrolidin-2-yl)methyl)aminobenzoate (120 mg, 0.43 mmol) in dry THF (20 mL) chloroacetic anhydride (111 mg, 0.65 mmol) was slowly added at room temperature. The mixture was stirred at room temperature for 2 hours.

- 5 After completion, the mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain (S)-4-(2-chloroacetamide)-3-((1-ethylpyrrolidin-2-yl)methyl)aminobenzoate (140 mg, 91.5% yield). LC-MS m/z : 354 $[M+H]^+$.


10 **Example 1-25. Synthesis of (S)-N-(4-Bromo-2-methyl-6-((oxetan-2-ylmethyl)amino)phenyl)-2-chloroacetamide (Intermediate A-25):**

1). Synthesis of (S)-5-bromo-3-methyl-2-nitro-N-(oxetan-2-ylmethyl)aniline:




- 15 The mixture of 5-bromo-1-fluoro-3-methyl-2-nitrobenzene (500 mg, 2.14 mmol), (S)-oxetan-2-yl-methanamine (186 mg, 2.14 mmol) and potassium carbonate (590 mg, 4.28 mmol) in N, N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. After completion, water (5 mL) was added to quench the reaction, and it was extracted with ethyl acetate (20 mL×3). The combined organic layers were washed with brine (20 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=4/1)
- 20 to obtain (S)-5-bromo-3-methyl-2-nitro-N-(oxetan-2-ylmethyl)aniline (490 mg, 6.2% yield). LC-MS m/z : 301 $[M+H]^+$.

2). Synthesis of (S)-5-bromo-3-methyl-N-(oxetan-2-ylmethyl)benzene-1,2-diamine:



To a solution of (S)-5-bromo-3-methyl-2-nitro-N-(oxetan-2-ylmethyl)aniline (490 mg, 1.63 mmol) in methanol (5 mL) was added zinc dust (1.06 g, 16.30 mmol). The resulting mixture was stirred at room temperature for 2 hours. After completion, the reaction solution was filtered, and then the filtrate was adjusted to pH=7-8 with aqueous ammonia. After this, the mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain (S)-5-bromo-3-methyl-N-(oxetan-2-ylmethane) yl)benzene-1,2-diamine (269 mg, 60.7% yield), LC-MS m/z: 271 [M+H]⁺.


3). Synthesis of (S)-N-(4-bromo-2-methyl-6-((oxetan-2-ylmethyl)amino)phenyl)-2-chloroacetamide:



To a solution of (S)-5-bromo-3-methyl-N-(oxetan-2-ylmethyl)benzene-1,2-diamine (109 mg, 0.40 mmol) in THF (3 mL) chloroacetic anhydride (75 mg, 0.44 mmol) was added dropwise at room temperature. The resulting mixed solution was stirred and reacted at room temperature for 1 hour. After completion, the reaction solution was concentrated, and then was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain (S)-N-(4-bromo-2-methyl-6-((oxetan-2-ylmethyl)amino)phenyl)-2-chloroacetamide (98 mg, 70.4% yield), LC-MS m/z: 349 [M+H]⁺.


Example 1-26. Synthesis of methyl (S)-2-(chloromethyl)-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazo-le-6-carboxylate (intermediate A-26):

1). Synthesis of methyl (S)-4-amino-3-methyl-5-((oxetan-2-ylmethyl)amino)benzoate:



The solution of (S)-5-bromo-3-methyl-N-(oxetan-2-ylmethyl)benzene-1,2-diamine (130 mg, 0.48 mmol), 1, 1'-bis(diphenylphosphino)ferrocene palladium dichloride (37 mg, 0.05 mmol) and potassium acetate (141 mg, 1.44 mmol) in N,N-dimethylformamide (2 mL) and methanol (2 mL) was stirred at 90°C for 16 hours under CO atmosphere (58.76 psi). After completion, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl (S)-4-amino-3-methyl-5-((oxetan-2-ylmethyl)amino)benzoate (50 mg, 41.5% yield). LC-MS m/z: 251 [M+H]⁺.


2). Synthesis of methyl (S)-2-(chloromethyl)-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



To a solution of methyl (S)-4-amino-3-methyl-5-((oxetan-2-ylmethyl)amino)benzoate (50 mg, 0.20 mmol) in THF (2 mL) chloroacetic anhydride (51 mg, 0.30 mmol) was added dropwise. The resulting mixture solution was stirred at room temperature for 1 hour. After completion, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain (S)-2-(chloromethyl)-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (20 mg, 32.6% yield). LC-MS m/z: 309 [M+H]⁺.

Example 1-27. Synthesis of methyl 4-(2-chloroacetamide)-3-(1-ethyl-1H-pyrazol-5-yl)methylaminobenzoate (Intermediate A-27):


1). Synthesis of methyl 1-ethyl-1H-pyrazole-5-carboxylate:



To a solution of 1-Ethyl-1H-pyrazole-5-carboxylic acid (770 mg, 5.50 mmol) in methanol (8 mL) (diazomethyl)trimethylsilane (27.5 mL, 55.00 mmol, 2.0 M in tetrahydrofuran) was dropwise added at 0 °C. The resulting mixture was stirred at room temperature for 1 hour, then quenched with water (100 mL) and extracted with ethyl acetate (50 mL×2). The combined organic layers were washed with brine (50 mL×2), dried over anhydrous sodium sulfate,


filtered, and concentrated in vacuo to obtain methyl 1-ethyl-1H-pyrazole-5-carboxylate (600 mg, 70.8% yield), LC-MS m/z: 155 [M+H]⁺.

2). Synthesis of (1-ethyl-1H-pyrazol-5-yl)methanol:




To a solution methyl 1-ethyl-1H-pyrazole-5-carboxylate (600 mg, 3.90 mmol) in dry THF (8 mL) lithium aluminum hydride powder (296 mg, 7.80 mmol) was added at $0\text{ }^\circ\text{C}$. The reaction was stirred at room temperature for 1 hour. After completion, the reaction was quenched with water (2 mL) and aqueous sodium hydroxide (2 mL, 15%). The mixture was filtered, and concentrated in vacuo to give (1-ethyl-1H-pyrazol-5-yl)methanol (400 mg, 81.4% yield). LC-MS m/z: 127 [M+H]⁺.

3). Synthesis of 5-(chloromethyl)-1-ethyl-1H-pyrazole:




To a solution of (1-Ethyl-1H-pyrazol-5-yl)methanol (400 mg, 3.17 mmol) in dichloromethane (20 mL) triethylamine (640 mg, 6.34 mmol) and methanesulfonyl chloride (729 mg, 6.34 mmol) were added at $0\text{ }^\circ\text{C}$. The reaction was stirred at room temperature for 2 hours. After completion, the reaction was quenched with water (100 mL) and extracted with dichloromethane (50 mL $\times$ 2). The combined organic layer was washed with brine (50 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain 5-(chloromethyl)-1-ethyl-1H-pyrazole (400 mg, 87.0% yield), LC-MS m/z: 145 [M+H]⁺.


4). Synthesis of 5-(azidomethyl)-1-ethyl-1H-pyrazole:




The mixture of 5-(chloromethyl)-1-ethyl-1H-pyrazole (400 mg, 2.76 mmol) and sodium azide (359 mg, 5.52 mmol) in N, N-dimethyl formamide was stirred at $120\text{ }^\circ\text{C}$ for 16 hours. After completion, it was diluted with saturated sodium bicarbonate solution (10 mL) and extracted with ethyl acetate (10 mL $\times$ 3). The combined organic layers were washed with brine (10 mL $\times$ 3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain 5-(azidomethyl)-1-ethyl-1H-pyrazole (370 mg, 88.8% yield). LC-MS m/z: 152 [M+H]⁺.

5). Synthesis of (1-ethyl-1H-pyrazol-5-yl)methanamine:

To a mixture of 5-(Azidomethyl)-1-ethyl-1H-pyrazole (320 mg, 2.12 mmol) in THF (4 mL) and water (0.4 mL) triphenylphosphine (1.1 g, 4.24 mmol) was added at room temperature. The reaction was stirred at room temperature for 5 hours. After completion, the solvent was removed by concentration in vacuo to obtain (1-ethyl-1H-pyrazol-5-yl)methanamine (265 mg, 99.9% yield).

6). Synthesis of methyl 3-((1-ethyl-1H-pyrazol-5-yl)methyl)amino)-4-nitrobenzoate:


The mixture of (1-ethyl-1H-pyrazol-5-yl)methanamine (265 mg, 2.12 mmol), methyl 3-fluoro-4-nitrobenzoate (422 mg, 2.12 mmol) and potassium carbonate (585 mg, 4.24 mmol) in N,N-dimethylformamide (7 mL) was stirred at room temperature for 16 hours. After completion, it was diluted with water (60 mL) and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with brine (20 mL $\times$ 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give methyl 3-((1-ethyl-1H-pyrazol-5-yl)methyl)amino)-4-nitrobenzoate (100 mg, 15.5% yield). LC-MS m/z : 346 $[M+H]^+$.

7). Synthesis of methyl 4-amino-3-((1-ethyl-1H-pyrazol-5-yl)methyl)amino)benzoate:

To solution of methyl 3-((1-ethyl-1H-pyrazol-5-yl)methyl)amino)-4-nitrobenzoate (130 mg, 0.43 mmol) in methanol (12 mL) palladium on carbon (50 mg, 30.42 mmol) was added at room temperature. The resulting mixture was degassed and flushed with hydrogen three times, and the reaction was stirred at room temperature for 16 hours. After completion, the reaction solution was filtered, the filter cake was rinsed with methanol. The filtrate was concentrated in

vacuo to obtain methyl 4-amino-3-((1-ethyl-1H-pyrazol-5-yl)methyl)amino)benzoate (70 mg, 59.4% yield), LC-MS m/z: 275 [M+H]⁺.


8). Synthesis of methyl 4-(2-chloroacetamide)-3-(1-ethyl-1H-pyrazol-5-yl)methyl)aminobenzoate:



To a solution of methyl 4-amino-3-((1-ethyl-1H-pyrazol-5-yl)methyl)amino)benzoate (70 mg, 0.26 mmol) in tetrahydrofuran (3 mL) chloroacetic anhydride (111 mg, 0.65 mmol) was slowly added. The reaction was stirred at room temperature for 2 hours. After completion, the solvent was removed by concentration in vacuo to give a residue. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-chloroacetamido)-3-(1-ethyl-1H-pyrazol-5-yl)methyl)aminobenzoate (60 mg, 65.7% yield). LC-MS m/z: 351 [M+H]⁺.


Example 1-28. Synthesis of methyl 4-(2-chloroacetamide)-3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)-amino)benzoate (Intermediate A-28):

1). Synthesis of methyl 1-ethyl-3-methyl-1H-pyrazole-5-carboxylate:




To a solution of 1-Ethyl-3-methyl-1H-pyrazole-5-carboxylic acid (1.00 g, 6.49 mmol) in methanol (10 mL) (diazomethyl)trimethylsilane (32.45 mL, 64.90 mmol, 2.0 M in THF) was added dropwise at 0°C. The resulting mixture was stirred at room temperature for 1 hour. After completion, the mixture was quenched with water (300 mL) and extracted with ethyl acetate (100 mL×3). The combined organic layers were washed with brine (100 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give methyl 1-ethyl-3-methyl-1H-pyrazole-5-carboxylate (800 mg, 73.4% yield). LC-MS m/z: 169 [M+H]⁺.

2). Synthesis of (1-ethyl-3-methyl-1H-pyrazol-5-yl)methanol:




To solution of methyl 1-ethyl-3-methyl-1H-pyrazole-5-carboxylate (800 mg, 4.76 mmol) in dry THF (10 mL) Aluminum lithium hydride (543 mg, 14.28 mmol) was added at 0 °C. The reaction was stirred at room temperature for 1 hour. After completion, the mixture was quenched with water (2 mL) and aqueous sodium hydroxide solution (2 mL, 15%w/w). The mixture was filtered, and the filtrate was concentration in vacuo to give (1-ethyl-3-methyl-1H-pyrazol-5-yl)methanol (550 mg, 82.5% yield). LC-MS m/z: 141. $[M+H]^+$.

3). Synthesis of 5-(chloromethyl)-1-ethyl-3-methyl-1H-pyrazole:




To a mixture of (1-ethyl-3-methyl-1H-pyrazol-5-yl)methanol (550 mg, 3.93 mmol) in dichloromethane (20 mL) triethylamine (794 mg, 7.86 mmol) and methanesulfonyl chloride (679 mg, 5.90 mmol) was added at 0 °C. The reaction was stirred at room temperature for 2 hours. After completion, the mixture was quenched with water (100 mL) and extracted with dichloromethane (50 mL×2). The combined organic layer was washed with brine (50 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain 5-(chloromethyl)-1-ethyl-3-methyl-1H-pyrazole (500 mg, 80.0% yield). LC-MS m/z: 159 $[M+H]^+$.

4). Synthesis of 5-(azidomethyl)-1-ethyl-3-methyl-1H-pyrazole:



The mixture of 5-(chloromethyl)-1-ethyl-3-methyl-1H-pyrazole (450 mg, 2.83 mmol) and sodium azide (368 mg, 5.66 mmol) in N, N-dimethylformamide (4 mL) was stirred at 120 °C for 16 hours. After completion, it was diluted with saturated sodium bicarbonate solution (10 mL) and extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to obtain 5-(azidomethyl)-1-ethyl-3-methyl-1H-pyrazole (350 mg, 75.0% yield). LC-MS m/z: 166 $[M+H]^+$.


5). Synthesis of (1-ethyl-3-methyl-1H-pyrazol-5-yl)methanamine:



To a mixture of 5-(azidomethyl)-1-ethyl-3-methyl-1H-pyrazole (350 mg, 2.12 mmol) in


THF(7 mL) and water (0.7 mL) triphenylphosphine (1.1 g, 4.24 mmol) was added, then stirred at room temperature for 5 hours. After completion, the solvent was removed in vacuo to obtain a colorless oil compound (1-ethyl-3-methyl-1H-pyrazol-5-yl)methanamine (286 mg, 97.1% yield). LC-MS m/z: 140 [M+H]⁺.

5 **6) Synthesis of methyl 3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)-4-nitrobenzoate:**




The mixture of (1-ethyl-3-methyl-1H-pyrazol-5-yl)methanamine (286 mg, 2.06 mmol), methyl 3-fluoro-4-nitrobenzoate (410 mg, 2.06 mmol) and potassium carbonate (569 mg, 4.12 mmol) in N,N-dimethylformamide (8 mL). was stirred at room temperature for 16 hours. After completion, it was diluted with water (50 mL) and extracted with ethyl acetate (25 mL×2). The combined organic layers were washed with brine (25 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give methyl 3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)-4-nitrobenzoate (300 mg, 45.8% yield). LC-MS m/z: 319 [M+H]⁺.

7). **Synthesis of methyl 4-amino-3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)benzoate:**



To a solution of methyl 3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)-4-nitrobenzoate (330 mg, 1.04 mmol) dissolved in methanol (24 mL) palladium on carbon (50 mg, 30.42 mmol) was added at room temperature. The resulting mixture was degassed and flushed with hydrogen three times and stirred at room temperature for 16 hours. After completion, the reaction solution was filtered, the filter cake was rinsed with methanol. The filtrate was concentrated in vacuo to obtain methyl 4-amino-3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)benzoate (200 mg, 67.1% yield), LC-MS m/z: 289 [M+H]⁺.

8). Synthesis of methyl 4-(2-chloroacetamide)-3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)benzoate:








To a solution of methyl 4-amino-3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)benzoate (200 mg, 0.69 mmol) in THF (4 mL) chloroacetic anhydride (296 mg, 1.73 mmol) was slowly added at room temperature. The reaction was stirred at room temperature for 2 hours. After completion, the solvent was removed in vacuo to give a residue. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-chloroacetamide)-3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)benzoate (200 mg, 79.4% yield). LC-MS m/z: 365 [M+H]⁺.







Example 1-29. Synthesis of other Part A Intermediates:





The following intermediates can be obtained with similar to the synthetic steps of each intermediate from Example 1-1 to Example 1-28:

Number	Structure	Name	MS m/z: [M+H] ⁺
Intermediate A-29		Methyl (E)-3-(4-(2-chloroacetamido)-3-(((1-cyanomethyl)cyclopropyl)methyl)amino)phenyl)acrylate	362
Intermediate A-30		Methyl (E)-3-(5-(2-chloroacetamido)-6-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)pyridin-2-yl)acrylate	378

Intermediate A-31		Methyl 2-(chloromethyl)-1-((1-ethyl-1H-imidazol-4-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate	333
Intermediate A-32		Methyl (E)-3-(4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorophenyl)acrylate	395
Intermediate A-33		Methyl (E)-3-(5-(2-chloroacetamido)-6-(((1-cyanomethyl)cyclopropyl)methyl)amino)pyridin-2-yl)acrylate	363
Intermediate A-34		Methyl (E)-3-(4-(2-chloroacetamido)-3-((1-cyanomethyl)cyclopropyl)methyl)amino)-5-fluorophenyl)acrylate	380
Intermediate A-35		Methyl (S,E)-3-(5-(2-chloroacetamido)-6-((oxetan-2-ylmethyl)amino)pyridin-2-yl)acrylate	340


Intermediate A-36		Methyl (S,E)-3-(4-(2-chloroacetamido)-3-fluoro-5-((oxetan-2-ylmethyl)amino)phenyl)acrylate	357
Intermediate A-37		Methyl (E)-3-(5-(2-chloroacetamido)-6-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)pyridin-2-yl)acrylate	378
Intermediate A-38		Methyl 2-(5-(2-chloroacetamido)-6-(((1-ethyl-1H-imidazol-5-yl)methyl)aminopyridin-2-yl)acetate	366
Intermediate A-39		Methyl 2-(4-(2-chloroacetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)phenyl)acetate	365
Intermediate A-40		Methyl 2-(4-(2-chloroacetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorophenyl)acetate	383

Intermediate A-41		(S)-Methyl 5-(2-chloroacetamido)-6-((oxetan-2-ylmethyl)amino)-picolinate	314
Intermediate A-42		Methyl (S)-4-(2-chloroacetamido)-3-fluoro-5-((oxetan-2-ylmethyl)amino)-benzoate	331
Intermediate A-43		Methyl (S)-2-(4-(2-chloroacetamido)-3-fluoro-5-((oxetan-2-ylmethyl)amino)phenyl)-acetate	345
Intermediate A-44		Methyl (S)-2-(5-(2-chloroacetamido)-6-((oxetan-2-ylmethyl)amino)pyridin-2-yl)acetate	328
Intermediate A-45		Methyl 2-(4-(2-chloroacetamido)-3-(((1-(cyanomethyl)cyclopropyl)methyl)amino)phenyl)acetate	350
Intermediate A-46		Methyl 2-(4-(2-chloroacetamido)-3-(((1-(cyanomethyl)cyclopropyl)methyl)amino)-5-	368

		fluorophenyl)acetate	
Intermediate A-47		Methyl 2-(5-(2-chloroacetamido)-6-(((1-(cyanomethyl)cyclopropyl)methyl)aminopyridin-2-yl)acetate	351
Intermediate A-48		Methyl (R)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate	295
Intermediate A-49		2-(chloromethyl)-4-fluoro-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid	351
Intermediate A-50		2-(chloromethyl)-1-(1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid	333


Example 2-1. Synthesis of 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (Intermediate B-1):

1). Synthesis of tert-butyl 4-(6-bromopyridin-2-yl)oxy)piperidine-1-carboxylate:




To a solution of compound tert-butyl 4-hydroxypiperidine-1-carboxylate (2.00 g, 9.95 mmol) in tetrahydrofuran (30 mL) sodium hydride (60% w/w dispersed in mineral oil, 597 mg, 14.93 mmol) was added at 0 °C. The mixture was stirred at 0 °C for 30 min, then 2-bromo-6-fluoropyridine (2.09 g, 11.94 mmol) was added slowly to the mixture. The reaction mixture was stirred at 70 °C for 4 hours. After completion, the reaction was quenched with water (30 mL) at room temperature and extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (30 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=10/1) to obtain tert-butyl 4-(6-bromopyridin-2-yl)oxy)piperidine-1-carboxylate (1.80 g, 5.06 mmol, 50.9% yield). LC-MS m/z: 356.9, 358.9 [M+H]⁺.

2). Synthesis of methyl 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)picolinate:




To a solution of 4-(6-bromopyridin-2-yl)oxy)piperidine-1-carboxylic acid tert-butyl ester (1.80 g, 5.06 mmol) in methanol (5 mL) potassium acetate (1.49 g, 15.18 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (373 mg, 0.51 mmol) were added. The mixture was stirred at 90 °C for 16 h under CO (58.76psi) atmosphere. The reaction was quenched by water (15 mL) and then extracted ethyl acetate (30 mL×3). The combined organic layers were washed with brine (30 ml ×2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions: (Column: spherical C18, 20- 40 μm, 120 g; mobile phase A: 10 mM NH₄OH in water); Mobile Phase B: Acetonitrile; Flow rate: 80 mL/min; Gradient: 60%B-80%B in 20 minutes; detector: 254 nm.) The mobile phase containing the desired product was collected at 70% B and then concentrated in vacuo to give methyl 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)picolinate (1.50 g, 4.46 mmol, 88.1% yield). LC-MS m/z: 337 [M+H]⁺.

3). Synthesis of tert-butyl 4-(6-(hydroxymethyl)pyridin-2-yl)oxy)piperidine-1-carboxylate:




To a solution of methyl 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)picolinate (500 mg, 1.49 mmol) in methanol (5 mL) sodium borohydride (170 mg, 4.47 mmol) and lithium chloride (6 mg, 0.15 mmol) were added at 0°C. The mixture was stirred at 50°C for 16 hours. The reaction was quenched by water (5 mL) and then extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions: (Column: spherical C18, 20-40 μm, 120 g; Mobile Phase A: 10 mM NH₄OH in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 60%B-80%B in 20 minutes; detector: 254 nm) The mobile phase containing the desired product was collected and concentrated in vacuo to give tert-butyl 4-(6-(hydroxymethyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (200 mg, 0.65 mmol, 43.6% yield). LC-MS m/z: 309 [M+H]⁺.

4). Synthesis of tert-butyl 4-(6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidine-1-carboxylate



To a solution of tert-butyl 4-(6-(hydroxymethyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (200 mg, 0.65 mmol) and 3-fluoro-4-hydroxybenzonitrile (89 mg, 0.65 mmol) in tetrahydrofuran (10 mL) triphenylphosphine (257 mg, 0.98 mmol) was added at 0 °C. Diisopropyl azodicarboxylate (198 mg, 0.98 mmol) was added dropwise at 0 °C. The mixture was then stirred at room temperature for 16 hours. The resulting mixture was concentrated and purified by silica gel column chromatography (ethyl acetate/petroleum ether=1/1) to obtain tert-butyl 4-(6-((4-cyano-2-fluorophenoxy)methyl)pyridine-2-yl)oxy)piperidine-1-carboxylate (250 mg, 0.59 mmol, 90.8% yield). LC-MS m/z: 428 [M+H]⁺.


5). Synthesis of 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (Intermediate B-1):



To a solution of tert-butyl 4-(6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (250 mg, 0.59 mmol) in dichloromethane (15 mL) dropwise trifluoroacetic acid (3 mL) was added at room temperature. The mixture stirred at room temperature for 2 hours. After completion, the mixture was concentrated in vacuo to give the crude product, which was further purified by reverse-phase flash chromatography under the following conditions: (Column: spherical C18, 20-40 μ m, 120 g; Mobile Phase A: 10 mM NH_4OH in water; Mobile phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 40%B-60%B in 20 minutes; Detector: 254 nm.) The mobile phase containing the desired product at 52%B was collected and concentrated in vacuo to obtain 3-fluoro-4-((6-(piperidin-4-ylmethoxy)pyridin-2-yl)methoxy)benzonitrile (180 mg, 0.55 mmol, 93.2% yield), LC-MS m/z : 328 $[\text{M}+\text{H}]^+$.


Example 2-2. Synthesis of 3-fluoro-4-((6-((piperidin-4-yl)oxy)methyl)pyridin-2-yl)oxy)methyl)benzonitrile (Intermediate B-2):

1). Synthesis of tert-butyl 4-(6-fluoropyridin-2-yl)methoxy)piperidine-1-carboxylate:




To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (1.06 g, 5.26 mmol) in tetrahydrofuran (15 mL) sodium hydride (252 mg, 6.31 mmol, 60% w/w dispersed in mineral oil) was added at 0°C. Then the mixture was stirred for 30 min. After this, the 2-(bromomethyl)-6-fluoropyridine (500 mg, 2.63 mmol) was added slowly to above mixture. The mixture was stirred at room temperature for 16 hours, quenched with methanol (10 mL) at room temperature and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to give tert-butyl 4-(6-fluoropyridin-2-yl)methoxy)piperidine-1-carboxylate (447 mg, 54.8% yield), LC-MS m/z : 311 $[\text{M}+\text{H}]^+$.

2). Synthesis of tert-butyl 4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)methoxy)piperidine-1-carboxylate



To a solution of 3-fluoro-4-(hydroxymethyl)benzonitrile (581 mg, 3.85 mmol) in tetrahydrofuran (10 mL) sodium hydride (185 mg, 4.62 mmol, 60% w/w dispersed in mineral oil) was added at 0 °C, the mixture was stirred for 30 min, then the tert-butyl 4-(6-fluoropyridin-2-yl)methoxy)piperidine-1-carboxylate (240 mg, 0.77 mmol) was added slowly at 0 °C. The mixture was stirred at 70 °C for 16 hours. After completion, the mixture was quenched with water (20 mL) at room temperature and extracted with ethyl acetate (20 mL × 2). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give tert-butyl 4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)methoxy)piperidine-1-carboxylate (281 mg, 82.4% yield). LC-MS m/z: 442 [M+H]⁺


3). Synthesis of 3-fluoro-4-((6-((piperidin-4-yloxy)methyl)pyridin-2-yloxy)methyl)benzonitrile:



To a solution of tert-butyl 4-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)methoxy)piperidine-1-carboxylate (400 mg, 0.91 mmol) in dichloromethane (2 mL) trifluoroacetic acid (1 mL) was added. The mixture was stirred at room temperature for 16 hours. After complete, the mixture was concentrated to remove the dichloromethane and then adjusted pH to 8-9 with NH₃/MeOH (7 M). After this, the mixture was directly concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to give 3-fluoro-4-((6-((piperidin-4-yloxy)methyl)pyridin-2-yl oxy)methyl)benzonitrile (301 mg, 97.4% yield). LC-MS m/z: 342 [M+H]⁺.


Example 2-3. Synthesis of 3-fluoro-4-((6-(piperidin-4-ylmethoxy)pyridin-2-yl)oxy)methyl)benzonitrile (Intermediate B-3):

1). Synthesis of tert-butyl 4-((6-fluoropyridin-2-yl)oxy)methyl)piperidine-1-carboxylate:




To a solution of tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (3.0 g, 13.93 mmol) in dry THF (50 mL) sodium hydride (837 mg, 20.93 mmol, 60% w/w dispersion in mineral oil) was added at 0 °C. The mixture was stirred at 0 °C for 30 minutes, then 2,6-difluoropyridine (2.41 g, 20.94 mmol) was slowly added at 0 °C. The mixture was stirred at 70 °C for 5 hours. After completion, the mixture was quenched with water (200 mL) at 0 °C and extracted with dichloromethane (50 mL × 3). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (PE/EA=4/1) to give tert-butyl 4-((6-fluoropyridin-2-yl)oxy)methylpiperidine-1-carboxylate (2.0 g, 6.44 mmol, 46.2% yield). LC-MS m/z: 311 [M+H]⁺.

2). Synthesis of tert-butyl 4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)methylpiperidine-1-carboxylate:



To a solution of 3-fluoro-4-(hydroxymethyl)benzonitrile (365 mg, 2.41 mmol) in dry THF (50 mL) sodium hydride (97 mg, 2.42 mmol, 60% w/w dispersion in mineral oil) was added at 0 °C. The mixture was stirred at 0 °C for 30 min, then the tert-butyl 4-((6-fluoropyridin-2-yl)oxy)methylpiperidine-1-carboxylate (500 mg, 1.61 mmol) was slowly added to above mixture at 0 °C. The mixture was stirred at 70 °C for 5 hours. After this, the mixture was quenched with water (30 mL) at 0 °C and extracted with dichloromethane (10 mL × 3). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (PE/EA=5/1) to give tert-butyl 4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)methylpiperidine-1-carboxylate (400 mg, 0.91 mmol, 56.3% yield). LC-MS m/z: 442 [M+H]⁺.

3). Synthesis of 3-fluoro-4-((6-(piperidin-4-ylmethoxy)pyridin-2-yl)oxy)methylbenzonitrile:




To a solution of tert-butyl 4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)methyl)piperidine-1-carboxylate (400 mg, 0.91 mmol) in dichloromethane (5 mL) trifluoroacetic acid (1 mL) was added and stirred at room temperature for 16 hours. When
 5 completed, The reaction was quenched with saturated sodium bicarbonate (30 mL) solution and then extracted with dichloromethane (10 mL $\times$ 2). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (DCM/MeOH=10/1) to give 3-fluoro-4-(((6-(piperidin-4-ylmethoxy)pyridin-2-yl))oxy)methyl)benzonitrile (250 mg, 0.73 mmol, 80.6% yield). LC-MS m/z : 342 $[M+H]^+$.

10

Example 2-4. Synthesis of 3-fluoro-4-(((6-(piperidin-4-oxy)pyridin-2-yl)oxy)methyl)benzonitrile (Intermediate B-4)

1). Synthesis of tert-butyl 4-(((6-fluoropyridin-2-yl)oxy)piperidine-1-carboxylate:




To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (3.50 g, 17.39 mmol) in dry tetrahydrofuran (20 mL) sodium hydride (870 mg, 21.74 mmol, 60% w/w dispersion in mineral oil) was added at 0 °C. The mixture was stirred at 0 °C for 30 min, then 2,6-difluoropyridine (2.00 g, 17.38 mmol) was slowly added to above mixture at 0 °C. The mixture was warmed to 80 °C and stirred for 4 hours. The mixture was quenched with water (20 mL) at room
 20 temperature and then extracted with ethyl acetate (20 mL $\times$ 2). The combined organic layers were washed with brine (10 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography(PE/EA=10 /1) to obtain tert-butyl 4-(((6-fluoropyridin-2-yl)oxy)piperidine-1-carboxylate (5.10 g, 17.21 mmol, 99.2% yield).

^1H NMR (400 MHz, DMSO- d_6) δ 7.86(dd, J = 16.8, 8.0 Hz, 1H), 6.73(dd, J = 8.0, 1.6 Hz, 1H), 6.68(dd, J = 7.6, 2.4 Hz, 1H), 5.06 – 5.02(m, 1H), 3.70 – 3.64(m, 2H), 3.20 – 3.15(m, 2H), 1.96 – 1.90(m, 2H), 1.58 – 1.49(m, 2H), 1.40(s, 9H).


25

2). Synthesis of tert-butyl 4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidine-1-carboxylate:



5 Sodium hydride (541 mg, 13.52 mmol, 60% w/w dispersion in mineral oil) was added to a solution of 3-fluoro-4-(hydroxymethyl)benzonitrile (1.22 g, 8.07 mmol) in dry THF (20 mL). The mixture was stirred at 0°C for 30 minutes, then the tert-butyl 4-((6-fluoropyridin-2-yl)oxy)piperidine-1-carboxylate (2.00 g, 6.75 mmol) was slowly added to the above mixture at 0°C. The reaction mixture was warmed to 70 °C and stirred for 3 hours. After completion, the
 10 reaction solution was cooled to room temperature, quenched with water (20 mL), and extracted with EA (20 mL×2). The combined organic layers were washed with brine (10 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (PE/EA=10/1) to give tert-butyl 4-(((6-((4-Cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidine-1-carboxylate (1.52 g, 3.56
 15 mmol, 55.6% yield) . LC-MS m/z: 428 [M+H]⁺.


3). Synthesis of 3-fluoro-4-(((6-(piperidin-4-oxypiperidin-2-yl)oxy)methyl)benzonitrile:



To a solution of tert-butyl 4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidine-1-carboxylate (1.52 g, 3.56 mmol) in dichloromethane (15 mL) trifluoroacetic acid (3 mL) was added. The reaction solution was stirred at room temperature for 16 hours. After completion, the reaction mixture was adjusted pH to 8-9 with NH₃/MeOH(7M) and then concentrated to give a residue in vacuo. The residue was purified
 20 by silica gel column chromatography (DCM/MeOH=10/1) to give 3-fluoro-4-(((6-(piperidin-4-oxypiperidin-2-yl)oxy)methyl)benzonitrile (1.00 g, 3.05 mmol, 86.2% yield). LC-MS m/z: 328
 25 [M+H]⁺.


Example 2-5. Synthesis of 3-fluoro-4-((6-((piperidin-4-oxy)methyl)pyridin-2-yl)methoxy)benzonitrile (Intermediate B-5):

1). Synthesis of methyl 6-(chloromethyl)picolinate:




5 To a solution of methyl 6-(hydroxymethyl)picolinate (2.00 g, 11.98 mmol) in dichloromethane (20 mL) triethylamine (2.42 g, 23.96 mmol) and methanesulfonyl chloride (1.65 g, 14.38 mmol) was sequentially added at 0 °C slowly. The mixture was stirred at room temperature for 3 hours. The mixture was quenched with water (10 mL) and then extracted with dichloromethane (20 mL $\times$ 2). The combined organic layers were washed with brine (10
10 ml $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain methyl 6-(chloromethyl)picolinate (1.2 g, 54.2% yield). LC-MS m/z: 188 [M+H]⁺.

2). Synthesis of 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)methyl)picolinic acid:




15 To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (4.92 g, 24.50 mmol) in tetrahydrofuran (50 mL) sodium hydride (1.18 g, 29.40 mmol, 60% w/w dispersed in mineral oil) was added at 0 °C. The mixture was stirred for 30 min, then the methyl 6-(chloromethyl)picolinate (454 mg, 2.45 mmol) was slowly added above mixture at 0 °C. The mixture was stirred at room temperature for 16 hours. The reaction was then quenched with
20 water (10 mL) at room temperature and extracted with ethyl acetate (20 mL $\times$ 2). The combined organic layers were washed with brine (10 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to give 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)methyl)picolinic acid (356 mg, 43.2% yield). LC-MS m/z:
25 337 [M+H]⁺.

3). Synthesis of methyl 6-((piperidine-4-oxy)methyl)picolinate:




To a solution of 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)methylpicolinic acid (356 mg, 1.06 mmol) in methanol (5 mL) thionyl chloride (189 mg, 1.59 mmol) was added dropwise at 0 °C. The mixture was stirred at 60 °C for 2 hours. The mixture was quenched with water (10 mL) at room temperature and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with saturated sodium bicarbonate (10 mL), brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 6-((piperidin-4-yl)oxy)methylpicolinate (260 mg, 98.1% yield). LC-MS m/z: 251 [M+H]⁺.

4). Synthesis of methyl 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)methylpicolinate



To a mixture of methyl 6-((piperidin-4-yl)oxy)methylpicolinate (260 mg, 1.04 mmol) and triethylamine (315 mg, 3.12 mmol) in THF(3 mL) di-tert-butyl dicarbonate (453 mg, 2.08 mmol) was added at room temperature. The mixture was stirred at room temperature for 16 hours. The mixture was quenched with water (10 mL) at room temperature and then extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)methylpicolinate ester (255 mg, 70.1% yield). LC-MS m/z: 351 [M+H]⁺.


5). Synthesis of tert-butyl 4-(6-(hydroxymethyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate



To a solution of methyl 6-((1-(tert-butoxycarbonyl)piperidin-4-yl)oxy)methylpicolinate (244 mg, 0.70 mmol) in tetrahydrofuran (3 mL) Aluminum lithium hydride (27 mg, 0.70 mmol)


was added at 0 °C. The mixture was stirred at room temperature for 16 hours. The mixture was quenched with water (10 mL) at room temperature and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain tert-butyl 4-(6-(hydroxymethyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate (107 mg, 39.6% yield). LC-MS m/z: 323 [M+H]⁺.

6). Synthesis of tert-butyl 4-(6-(chloromethyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate:



To a solution of tert-butyl 4-(6-(hydroxymethyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate (47 mg, 0.15 mmol) in dichloromethane (1 mL) triethylamine (30 mg, 0.30 mmol) and methanesulfonyl chloride (21 mg, 0.18 mmol) was added sequentially at 0 °C. The mixture was stirred at room temperature for 16 hours. After completion, water (10 mL) was added to mixture and then extracted with DCM (20 mL × 2). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain tert-butyl 4-(6-(chloromethyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate (40 mg, 80.6% yield). LC-MS m/z: 341 [M+H]⁺.


7). Synthesis of tert-butyl 4-(6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate



To a mixture of tert-butyl 4-(6-(chloromethyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate (40 mg, 0.12 mmol) and 3-fluoro-4-hydroxybenzonitrile (33 mg, 0.24 mmol) in N,N-dimethylformamide (1 mL) potassium carbonate (541 mg, 13.52 mmol) was added at room temperature. The mixture was stirred at 60 °C for 16 hours. The mixture was quenched with water (10 mL) at room temperature and extracted with ethyl acetate (10 mL × 2). The

combined organic layers were washed with saturated ammonium chloride (20 mL×3), brine (10 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain tert-butyl 4-(6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate (35 mg, 67.4% yield). LC-MS m/z: 442 [M+H]⁺.


8). Synthesis of 3-fluoro-4-((6-((piperidin-4-oxymethyl)pyridin-2-yl)methoxy)benzonitrile:



To a solution of tert-butyl 4-(6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methoxy)piperidine-1-carboxylate (35 mg, 0.08 mmol) in dichloromethane (2 mL) trifluoroacetic acid (1 mL) was added. The mixture was stirred at room temperature for 16 hours. The reaction mixture was adjusted to pH=8-9 with NH₃/MeOH (7 M) and then concentrated to give a residue under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to give 3-fluoro-4-((6-((piperidin-4-oxymethyl)pyridin-2-yl)methoxy)benzonitrile (27 mg, 99% yield). LC-MS m/z: 342 [M+H]⁺.

Example 2-6. Synthesis of 4-((6-(azetidin-3-yloxy)pyridin-2-yloxy)methyl)-3-fluorobenzonitrile (Intermediate B-6):


1). Synthesis of tert-butyl 3-(6-fluoropyridin-2-yl)oxy)azetidine-1-carboxylate:



To a solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (2.00 g, 11.55 mmol) in dry THF (30 mL) sodium hydride (694 mg, 17.34 mmol, 60% w/w dispersion in mineral oil) was added at 0 °C. The mixture was stirred at 0 °C for 30 min, then the 2,6-difluoropyridine (1.60 g, 13.90 mmol) was added slowly to the mixture at 0 °C. The mixture was warmed to 70 °C and stirred for 4 hours. After completion, it was quenched with water (20 mL) at room temperature and extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ ethyl acetate=10/1) to obtain tert-butyl 3-(6-fluoropyridin-2-yl)oxy)azetidine-1-


carboxylate (3.00 g, 11.18 g mmol, 96.7% yield). LC-MS m/z: 269 [M+H]⁺.

2). Synthesis of tert-butyl 3-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)azetidine-1-carboxylate:



To a solution of 3-fluoro-4-(hydroxymethyl)benzonitrile (1.00 g, 6.62 mmol) in dry THF (20 mL) sodium hydride (397 mg, 9.93 mmol, 60% w/w dispersion in mineral oil) was added at 0°C. The mixture was stirred at 0°C for 30 minutes, then the tert-butyl 3-(6-fluoropyridin-2-yl)oxy)azetidine-1-carboxylate (1.33 g, 4.96 mmol) was added to above mixture. The mixture was stirred at 70 °C for 4 hours. The reaction mixture was quenched with water (20 mL) at room temperature and extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with brine (2 × 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ ethyl acetate=5/1) to give 3-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)azetidine-1-carboxylate tert-butyl ester (1.52 g, 3.81 mmol, 57.4% yield), LC-MS m/z: 400 [M+H]⁺.


3). Synthesis of 4-((6-(azetidin-3-yloxy)pyridin-2-yloxy)methyl)-3-fluorobenzonitrile:



To a solution of tert-butyl 3-(6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)azetidine-1-carboxylate (900 mg, 2.25 mmol) in dichloromethane (10 mL) trifluoroacetic acid (2 mL) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was adjusted to pH=8-9 with NH₃/MeOH (7M) and then concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (DCM/MeOH=10/1) to obtain 4-((6-(azetidin-3-yloxy)pyridin-2-yloxy)methyl)-3-fluorobenzonitrile (650 mg, 2.17 mmol, 96.0% yield). LC-MS m/z: 300 [M+H]⁺.


Example 2-7. Synthesis of 3-fluoro-4-((3-(piperidin-4-oxy)phenoxy)methyl)benzonitrile (Intermediate B-7):

1). Synthesis of 3-fluoro-4-((3-hydroxyphenoxy)methyl)benzonitrile:




The mixture of resorcinol (1.04 g, 9.52 mmol), potassium carbonate (1.31 g, 9.52 mmol) and 4-bromomethyl-3-fluorobenzonitrile (1.00 g, 4.76 mmol) in acetonitrile (10 mL) was stirred at 100 °C for 16 hours and cooled to room temperature. The mixture was diluted with water (20 mL) and then extracted with ethyl acetate (30 mL × 3). The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum/ethyl acetate = 4/1) to obtain 3-fluoro-4-((3-hydroxyphenoxy)methyl)benzonitrile (514 mg, 44.0% yield). LC-MS m/z : 244 $[M+H]^+$.

2). Synthesis of tert-butyl 4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidine-1-carboxylate



The mixture of 3-fluoro-4-((3-hydroxyphenoxy)methyl)benzonitrile (200 mg, 0.82 mmol), tert-butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate (919 mg, 3.29 mmol) and Cs_2CO_3 (805 mg, 2.47 mmol) in N,N -dimethylformamide (5 mL) was stirred at 100 °C for 16 hours. The mixture was concentrated in vacuo and purified by reverse-phase flash chromatography (Column: Spherical C18, 20-40 μm , 120 g; Mobile Phase A: water 10 mM NH_4OH in water, Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 40% B - 80% B in 20 minutes; Detector: 254 nm). The fractions containing the desired product were collected at 65% B and concentrated in vacuo to give tert-butyl 4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidine-1-carboxylate (180.0 mg, 79.8% yield). LC-MS m/z : 371 $[M+H]^+$.


3). Synthesis of 3-fluoro-4-((3-(piperidin-4-oxyl)methyl)phenoxy)methylbenzonitrile:



To a solution of tert-butyl 4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidine-1-carboxylate (120.0 mg, 0.282 mmol) in DCM (3 mL) trifluoroacetic acid (1 mL) was added dropwise. The reaction mixture was stirred at room temperature for 2 hours. The mixture was quenched with saturated sodium bicarbonate (30 mL), then extracted with DCM (2 × 10 mL). The combined organic layers were concentrated in vacuo and purified by silica gel column chromatography (DCM/MeOH=20/1) to obtain 3-fluoro-4-((3-(piperidin-4-oxy)phenoxy)methyl)benzonitrile (89.0 mg, 96.8% yield). LC-MS m/z: 327 [M+H]⁺.


Example 2-8. Synthesis of 2-((4-Chloro-2-fluorobenzyl)oxy)-3-fluoro-6-(piperidin-4-oxy)pyridine (Intermediate B-8):

1). Synthesis of tert-butyl 4-(6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxypiperidine-1-carboxylate



The sodium hydride (264 mg, 0.56 mmol) was added to solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (1.10 g, 5.50 mmol) in tetrahydrofuran (15 mL) at 0 °C. The mixture was stirred at 0°C for 30 minutes. Then 2-((4-chloro-2-fluorobenzyl)oxy)-3,6-difluoropyridine (100 mg, 0.28 mmol) was added to above mixture at 0 °C. The mixture was warmed to 70°C and stirred for 16 hours. The desired product was detected by LC-MS, then the reaction was quenched with methanol (10 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate=5:1) to obtain tert-butyl 4-(6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxypiperidine-1-carboxylate (447 mg, 53.7% yield). LC-MS m/z: 399 [M+H]⁺.

2). Synthesis of 2-((4-Chloro-2-fluorobenzyl)oxy)-3-fluoro-6-(piperidin-4-oxy)pyridine:




To a solution of tert-butyl 4-(6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-

yl)oxypiperidine-1-carboxylate (447 mg, 0.98 mmol) in dichloromethane (10 mL) trifluoroacetic acid (3 mL) was added. The mixture was stirred at room temperature for 1 hour. The desired product was detected by LC-MS, then the mixture was quenched with water (5 mL) and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with
 5 brine (20 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane: methanol=10:1) to give 2-((4-chloro-2-fluorobenzyl)oxy)-3-fluoro-6-(piperidin-4-oxy)pyridine (199 mg, 57.2% yield). LC-MS m/z: 355 [M+H]⁺.


Example 2-9. Synthesis of 3-fluoro-4-((3-fluoro-6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (Intermediate B-9):
 10

1). Synthesis of methyl 3,6-difluoropicolinate:




To a solution of 3,6-difluoropicolinic acid (3.6 g, 22.64 mmol) in methanol (80 mL) thionyl chloride (4.0 g, 33.96 mmol) was added. The mixture was stirred at 60°C for 2 hours.
 15 The reaction mixture was directly concentrated in vacuo and then purification by silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain methyl 3,6-difluoropicolinate (3.15 g, 80.4% yield). LC-MS m/z: 174 [M+H]⁺.

2). Synthesis of (3,6-difluoropyridin-2-yl)methanol:



To a solution of methyl 3,6-difluoropicolinate (3.15 g, 18.21 mmol) in methanol (55 mL) sodium borohydride (2.07 g, 54.63 mmol) and lithium chloride (153 mg, 3.64 mmol) was added. The solution was stirred at 50°C for 4 hours. The reaction mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=2:1) to obtain (3,6-difluoropyridin-2-yl)methanol (2.0 g, 91.1% yield). LC-
 20 MS m/z: 146 [M+H]⁺.


3). Synthesis of methyl (3,6-difluoropyridin-2-yl) methanesulfonate:



To a solution of (3,6-difluoropyridin-2-yl)methanol (300 mg, 2.07 mmol) in dry


dichloromethane (20 mL) triethylamine (460 mg, 4.55 mmol) and methanesulfonyl chloride (358 mg, 3.11 mmol) was added slowly. The mixture was stirred at 0 °C for 1 hour and then stirred at room temperature for another 2 hours. The mixture was diluted with dichloromethane (50 mL) and washed with brine (25 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=2/1) to obtain methyl (3,6-difluoropyridin-2-yl) methanesulfonate (272 mg, 58.9% yield). LC-MS m/z: 224 [M+H]⁺.

4). Synthesis of 4-((3,6-difluoropyridin-2-yl)methoxy)-3-fluorobenzonitrile:



To a mixture of methyl (3,6-difluoropyridin-2-yl) methanesulfonate (272 mg, 1.22 mmol) and 3-fluoro-4-hydroxybenzonitrile (167 mg, 1.22 mmol) in N,N-dimethylformamide (5 mL) potassium carbonate (505 mg, 3.66 mmol) was added. The reaction mixture was stirred at 60 °C for 2 hours. The reaction mixture was quenched by adding water (15 mL), then was extracted with ethyl acetate (30 mL×3). The combined organic layers were washed with brine (30 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=2/1) to obtain 4-((3,6-difluoropyridin-2-yl)methoxy)-3-fluorobenzonitrile (270 mg, 83.6% yield). LC-MS m/z: 265 [M+H]⁺.


5). Synthesis of tert-butyl 4-(6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxypiperidine-1-carboxylate:



To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (246 mg, 1.22 mmol) in THF (30 mL) sodium hydride (61 mg, 1.53 mmol, 60% w/w dispersed in mineral oil) was added at 0 °C. The mixture was stirred at 0 °C for 30 minutes, then 4-((3,6-difluoropyridin-2-yl)methoxy)-3-fluorobenzonitrile (270 mg, 1.02 mmol) was added to above mixture .The mixture was stirred at 70 °C for 2 hours. After this, the mixture was quenched with water (20 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic layers were washed

with brine (10 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=2/1) to obtain tert-butyl 4-(6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxypiperidine-1-carboxylate (200 mg, 36.9% yield). LC-MS m/z: 390 [M+H]⁺.


6). Synthesis of 3-fluoro-4-((3-fluoro-6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile:



To a solution of tert-butyl 4-(6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxypiperidine-1-carboxylate (200 mg, 0.45 mmol) in dichloromethane (10 mL) trifluoroacetic acid (2 mL) was added. The mixture was stirred at room temperature for 16 hours. The reaction mixture was adjusted to pH=8-9 with NH₃/MeOH(7M) and then concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain 3-fluoro-4-((3-fluoro-6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (140 mg, 91.1% yield). LC-MS m/z: 346 [M+H]⁺.


Example 2-10. Synthesis of 2-((4-Chloro-2-fluorophenylthio)methyl)-6-(piperidin-4-oxy)pyridine (Intermediate B-10):

1) Synthesis of 1,2-bis(4-chloro-2-fluorophenyl)disulfane:




The mixture of 4-chloro-1,2-difluorobenzene (1.00 g, 6.76 mmol) and sodium sulfide (1.05 g, 13.52 mmol) in dimethylsulfoxide (10 mL) was stirred at 80°C for 2 hours. The mixture was quenched with water (100 mL) and then extracted with dichloromethane (50 mL × 2). The aqueous phase was acidified with HCl to pH=2, and extracted with ethyl acetate (50 mL × 3). The combined organic layers were washed with brine (100 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 1,2-bis(4-chloro-2-fluorophenyl)disulfane (700 mg, 32.1% yield).

2). Synthesis of 4-chloro-2-fluorobenzenethiol




The mixture of 1,2-bis(4-chloro-2-fluorophenyl)disulfane (700 mg, 2.17 mmol) and zinc powder (423 mg, 6.51 mmol) in methanol (10 mL) and HCl (10 mL, 10% in H₂O) was stirred at room temperature for 2 hours. The mixture was diluted with water (50 mL) and then extracted with dichloromethane (20 mL × 3). The combined organic layer was concentrated in vacuo to obtain 4-chloro-2-fluorobenzenethiol (400 mg, 56.9% yield), LC-MS *m/z*: 161 [M+H]⁺.

3). Synthesis of tert-butyl 4-(6-((4-chloro-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxypiperidine-1-carboxylate:



The mixture of 4-chloro-2-fluorobenzenethiol (400 mg, 2.47 mmol), potassium carbonate (682 mg, 4.94 mmol) and tert-butyl 4-(((6-((methylsulfonyl)oxy)methyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (956 mg, 2.47 mmol) in N,N-dimethylformamide (20 mL) was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (200 mL) and then extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with saturated brine (100 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether=1/4) to obtain 4-(6-((4-chloro-2-fluorophenyl)thio)methyl)pyridin-2-yl) Oxypiperidine-1-carboxylate tert-butyl ester (1.00 g, 89.6% yield), LC-MS *m/z*: 453 [M+H]⁺.

4). Synthesis of 2-((4-chloro-2-fluorophenylthio)methyl)-6-(piperidin-4-oxypyridine:




To a solution of tert-butyl 4-(6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxypiperidine-1-carboxylate (1.00 g, 2.21 mmol) in dichloromethane (10 mL) trifluoroacetic acid (3 mL) was added. The solution was stirred at room temperature for 2 hours. The mixture was quenched with saturated sodium bicarbonate (50 mL), then extracted with

dichloromethane (20 mL $\times$ 3). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain 2-((4-chloro-2-fluorophenylthio)methyl)-6-(piperidin-4-oxy)pyridine (700 mg, 90.0% yield). LC-MS m/z : 353 $[M+H]^+$.


5 **Example 2-11. Synthesis of 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methylthio)benzonitrile (Inter-mediate B-11):**

1). Synthesis of 4,4'-dithiobis(3-fluorobenzonitrile):




To a solution of 3,4-difluorobenzonitrile (10.00 g, 71.89 mmol) in dimethylsulfoxide (100 mL) was added sodium sulfide (11.22 g, 143.88 mmol). The resulting mixture was stirred at 80 °C for 2 hours. After completion, the reaction was quenched with water (500 mL) and extracted with dichloromethane (200 mL $\times$ 2). The aqueous phase was acidified to pH=2 with aqueous hydrochloric acid, and extracted with ethyl acetate (200 mL $\times$ 3). The combined organic layers were washed with brine (400 mL $\times$ 3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo to give 4,4'-dithiobis(3-fluorobenzonitrile) (5.70 g, 26.1% yield).

2). Synthesis of 3-fluoro-4-mercaptobenzonitrile:




To a mixture of 4,4'-dithionylbis(3-fluorobenzonitrile) (2.00 g, 6.57 mmol) in methanol (10 mL) and hydrochloric acid (10% in water, 10 mL) zinc powder (1.28 g, 19.58 mmol) was added and the mixture was stirred at room temperature for 2 hours. After this, the mixture was diluted with water (200 mL) and then extracted with dichloromethane (80 mL $\times$ 3). The organic layer was concentrated to give 3-fluoro-4-mercaptobenzonitrile (1.20 g, 59.6% yield).

3). Synthesis of tert-butyl 4-((6-((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidine-1-carboxylate:



To a mixture of 3-fluoro-4-mercaptobenzonitrile (474 mg, 3.10 mmol) and tert-butyl 4-(((6-((methylsulfonyl)oxy)methyl)pyridin-2-yl)oxy)piperidine-1-carboxylate in N,N-dimethylformamide (20 mL) potassium carbonate (856 mg, 6.20 mmol) was added. The mixture was stirred at room temperature for 16 hours. The mixture was diluted with water (200 mL) and then extracted with ethyl acetate (80 mL × 3). The combined organic layers were washed with brine (100 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (ethyl acetate/petroleum ether=1/4) to obtain 4-(((6-((4-cyano-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidine-1-carboxylate tert-butyl ester (600 mg, 43.7% yield). LC-MS m/z: 444 [M+H]⁺.


4). Synthesis of 3-fluoro-4-(((6-(piperidin-4-oxy)pyridin-2-yl)methylthio)benzonitrile:



To a solution of tert-butyl 4-(((6-((4-cyano-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidine-1-carboxylate (500 mg, 1.13 mmol) in dichloromethane (5 mL) 2,2,2-trifluoroacetic acid (1 mL) was added. The mixture was stirred at room temperature for 2 hours. After completion, the reaction mixture was quenched with saturated sodium bicarbonate (10 mL) and extracted with dichloromethane (5 mL × 3). The combined layer was concentrated and then purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give 3-fluoro-4-(((6-(piperidin-4-oxy)pyridin-2-yl)methylthio)benzonitrile (334 mg, 86.4% yield). LC-MS m/z: 344 [M+H]⁺.

Example 2-12. Synthesis of 3-fluoro-4-(((3-(piperidin-4-oxy)benzyl)oxy)benzonitrile (Intermediate B-12):


1). Synthesis of tert-butyl 4-(3-(methoxycarbonyl)phenoxy)piperidine-1-carboxylate:



To a mixture of methyl 3-hydroxybenzoate (3.00 g, 19.73 mmol), tert-butyl 4-hydroxypiperidine-1-carboxylate (3.97 g, 19.73 mmol) and triphenylphosphine (7.76 g, 29.60 mmol) in tetrahydrofuran (30 mL) diisopropyl azodicarboxylate (5.98 g, 29.60 mmol) was added at 0 °C. The mixture was stirred at room temperature for 3 hours. After completion, water (50 mL) was added to quench the reaction, and extracted with ethyl acetate (50 mL × 2). The


combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=5/1) to give tert-butyl 4-(3-(methoxycarbonyl)phenoxy)piperidine-1-carboxylate (2.44 g, 36.9% yield). LC-MS m/z: 358 [M+H]⁺.

2). Synthesis of tert-butyl 4-(3-(hydroxymethyl)phenoxy)piperidine-1-carboxylate:




To a solution of tert-butyl 4-(3-(methoxycarbonyl)phenoxy)piperidine-1-carboxylate (1.40 g, 4.18 mmol) in tetrahydrofuran (15 mL) lithium aluminum hydride (238 mg, 6.27 mmol) was slowly added at 0 °C. The resulting mixture was stirred at room temperature for 3 hours. After completion, water (5 mL) was added to quench the reaction, then extracted with ethyl acetate (20 mL × 2). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=5/1) to obtain tert-butyl 4-(3-(hydroxymethyl)phenoxy)piperidine-1-carboxylate (400 mg, 31.2% yield).

3). Synthesis of tert-butyl 4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidine-1-carboxylate:



To a mixture of 3-fluoro-4-hydroxybenzonitrile (178 mg, 1.30 mmol), triphenylphosphine (409 mg, 1.56 mmol) and tert-butyl 4-(3-(hydroxymethyl)phenoxy)piperidine-1-carboxylate (400 mg, 1.30 mmol) in tetrahydrofuran (15 mL) azodicarboxylate (315 mg, 1.56 mmol) was added diisopropyl at 0 °C. The mixture was stirred at room temperature for 3 hours. After completion, the mixture was diluted with water (20 mL) and then extracted with ethyl acetate (30 mL × 2). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain tert-butyl 4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidine-1-carboxylate (312 mg, 56.3% yield). LC-MS m/z: 371 [M+H-56]⁺.


4). Synthesis of 3-fluoro-4-((3-(piperidin-4-oxyl)benzyl)oxy)benzonitrile:



To a solution of tert-butyl 4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidine-1-carboxylate (312 mg, 0.73 mmol) in dichloromethane (5 mL) trifluoroacetic acid (1 mL) was added at room temperature. The mixture was stirred at room temperature for 3 hours. After completion, the mixture was diluted with water (20 mL), and then extracted with ethyl acetate (20 mL $\times$ 2). The combined organic layers were washed with brine (20 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to give 3-fluoro-4-((3-(piperidin-4-oxy)benzyl)oxy)benzonitrile (230 mg, 96.6% yield). LC-MS m/z: 327 [M+H]⁺.

Example 2-13. Synthesis of 4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidine (Intermediate B-13)

1). Synthesis of tert-butyl 4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidine-1-carboxylate



To a mixture of 4-chloro-2-fluorophenol (144 mg, 0.98 mmol), triphenylphosphine (308 mg, 1.18 mmol) and tert-butyl 4-(3-(hydroxymethyl)phenoxy)piperidine-1-formate (300 mg, 0.98 mmol) in tetrahydrofuran (8 mL) diisopropyl azodicarboxylate (238 mg, 1.18 mmol) was added slowly at 0 °C. The mixture was stirred at room temperature for 3 hours. After completion, water (20 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (20 mL $\times$ 2). The combined organic layers were washed with brine (20 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 5/1) to obtain tert-butyl 4-(3-((4-chloro-2-fluorophenoxy)methyl)-phenoxy)piperidine-1-carboxylate (381 mg, 89.2%yield).


2). Synthesis of 4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidine:



To a solution of tert-butyl 4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidine-1-carboxylate (381 mg, 0.88 mmol) in dichloromethane (5 mL) trifluoroacetic acid (1 mL) was added at room temperature. The resulting mixture was stirred at room temperature for 1 hour. After completion, the mixture was adjusted to pH=7-8 with NH_3/MeOH (7 M). The reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain 4-(3-((4-Chloro-2-fluorophenoxy)methyl)phenoxy)-piperidine (271 mg, 91.6% yield). LC-MS m/z: 336 $[\text{M}+\text{H}]^+$.


Example 2-14. Synthesis of methyl 2-(4-((6-((methylsulfonyl)oxy)methyl)pyridin-2-yl)oxy)phenyl)acetate (Intermediate B-14):

1). Synthesis of methyl 2-(4-((6-bromopyridin-2-yl)oxy)phenyl)acetate:




To a solution of methyl 2-(4-hydroxyphenyl)acetate (2.00 g, 12.05 mmol) in acetonitrile (20 mL) added 2-bromo-6-fluoropyridine (2.53 g, 14.46 mmol) and cesium carbonate (5.89 g, 18.07 mmol) was at room temperature. The mixture was stirred at 90°C for 16 hours. After completion, it was diluted by water (5 mL) and then extracted with ethyl acetate (40 mL $\times$ 3). The combined organic layers were washed with brine (30 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=10/1) to give methyl 2-(4-((6-bromopyridin-2-yl)oxy)phenyl)acetate (3.17 g, 81.7% yield). LC-MS m/z: 322, 324 $[\text{M}+\text{H}]^+$.


2). Synthesis of 2-(4-((6-Bromopyridin-2-yl)oxy)phenyl)acetic acid:




To a mixture of methyl 2-(4-((6-bromopyridin-2-yl)oxy)phenyl)acetate (3.17 g, 9.84 mmol) in tetrahydrofuran (20 mL) and water (15 mL) lithium hydroxide monohydrate (4.13 g, 98.40 mmol) was added at room temperature. The mixture was stirred at room temperature for 5 hours. After completion, the mixture was diluted with water (5 mL), and then extracted with ethyl acetate (40 mL $\times$ 3). The combined organic layers were washed with brine (30 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give 2-(4-((6-bromopyridin-2-yl)oxy)-phenyl)acetic acid (1.8 g, 59.4 % yield). LC-MS m/z: 308, 310 $[\text{M}+\text{H}]^+$.

3). Synthesis of 2-(4-((6-(methylcarboxylate)pyridin-2-yl)oxy)phenyl)acetic acid:

The mixture of 2-(4-((6-bromopyridin-2-yl)oxy)phenyl)acetic acid (900 mg, 2.92 mmol), 1,1'-bis(diphenyl)-phosphinoferrocene palladium dichloride (213 mg, 0.29 mmol) and potassium acetate (859 mg, 8.76 mmol) in methanol (10 mL) was degassed with CO three times at room temperature. The mixture was warmed up to 90 °C and stirred for 16 hours under CO (56 Psi) atmosphere. After completion, water (5 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (40 mL×3). The combined organic layers were washed with brine (30 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to give 2-(4-((6-(methylcarboxylate)pyridin-2-yl)oxy)phenyl)acetic acid (385 mg, 45.9% yield). LC-MS m/z: 288 [M+H]⁺.

4). Synthesis of 2-(4-((6-(hydroxymethyl)pyridin-2-yl)oxy)phenyl)acetic acid:


To a solution of 2-(4-((6-(methylcarboxylate)pyridin-2-yl)oxy)phenyl)acetic acid (385 mg, 1.34 mmol) in tetrahydrofuran (5 mL) lithium aluminum hydride (76 mg, 2.01 mmol) was added at 0 °C. The mixture was stirred at room temperature for an additional 2 hours. After completion, the mixture was adjusted to pH=5-6 with hydrochloric acid (1M), and then extracted with ethyl acetate (20 mL×3). The combined organic layer were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain 2-(4-((6-(hydroxymethyl)pyridin-2-yl)oxy)phenyl)acetic acid (118 mg, 33.9% yield). LC-MS m/z: 260 [M+H]⁺.

5). Synthesis of methyl 2-(4-(6-(hydroxymethyl)pyridin-2-yl)oxy)phenyl)acetate:

To a solution of 2-(4-((6-(Hydroxymethyl)pyridin-2-yl)oxy)phenyl)acetic acid (118 mg, 0.45 mmol) in methanol (3 mL) p-toluenesulfonic acid (12 mg, 0.32 mmol) was added at room

temperature. The resulting mixture was stirred at 60°C for 1 hour. When completion, the reaction mixture was quenched by adding water (5 mL) and then was extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=15/1) to obtain methyl 2-(4-(6-(hydroxymethyl)pyridin-2-yl)oxy)phenyl)acetate (89 mg, 72.4% yield). LC-MS m/z: 274 [M+H]⁺.

6. Synthesis of methyl 2-(4-((6-((methylsulfonyl)oxy)methyl)pyridin-2-yl)oxy)phenyl)acetate:









To a mixture of 2-(4-(6-(hydroxymethyl)pyridin-2-yl)oxy)phenyl)acetate (89 mg, 0.33 mmol) and triethylamine (74 mg, 0.73 mmol) in dichloromethane (3 mL), methanesulfonyl chloride was added slowly at 0 °C. The reaction mixture was stirred at room temperature for 3 hours. After completion, the reaction was quenched by adding water (5 mL) and extracted with ethyl acetate (20 mL×3). The combined organic layers were washed with brine (20 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain 2-(4-((6-((methylsulfonyl)oxy)methyl)-pyridin-2-yl)oxy (56 mg, 48.3% yield). LC-MS m/z: 352 [M+H]⁺.






Example 2-15. Synthesis of other B intermediates:







The following intermediates can be obtained with similar to the synthetic steps of each intermediate from example 2-1 to Example 2-14:


Number	Structure	Name	MS m/z: [M+H] ⁺
Intermediate B-15		3-Fluoro-4-(((3-fluoro-6-(piperidin-4-oxy)pyridin-2-yl)oxy)methyl)benzonitrile	346

Intermediate B-16		3-Fluoro-4-((2-fluoro-5-(piperidin-4-oxy)phenoxy)methyl)benzonitrile	345
Intermediate B-17		2-((4-Chloro-2-fluorobenzyl)oxy)-6-((piperidin-4-oxy)methyl)pyridine	351
Intermediate B-18		4-(3-((4-Chloro-2-fluorobenzyl)oxy)-4-fluorophenoxy)piperidine	354
Intermediate B-19		2-((4-Chloro-2-fluorophenoxy)methyl)-3-fluoro-6-(piperidin-4-oxy)pyridine	355
Intermediate B-20		2-((4-Chloro-2-fluorophenoxy)methyl)-6-(piperidin-4-oxy)pyridine	337
Intermediate B-21		4-(3-((4-Chloro-2-fluorophenoxy)methyl)-4-fluorophenoxy)piperidine	354

Intermediate B-22		3-Fluoro-4-((2-fluoro-5-(piperidin-4-oxy)benzyl)oxy)benzonitrile	345
Intermediate B-23		4-((6-((3-azabicyclo[3.2.1]octan-8-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile	354
Intermediate B-24		8-((6-((4-Chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)-3-azabicyclo[3.2.1]octane	363
Intermediate B-25		3-Fluoro-4-((6-((3-methylpiperidin-4-yl)oxy)pyridin-2-yl)methoxy)benzonitrile	342
Intermediate B-26		2-((4-Chloro-2-fluorophenoxy)methyl)-6-((3-methylpiperidin-4-yl)oxy)pyridine	351
Intermediate B-27		3-Fluoro-4-((6-((3-fluoropiperidin-4-yl)oxy)pyridin-2-yl)methoxy)benzonitrile	346

		yl)methoxy)benzonitrile	
Intermediate B-28		2-((4-Chloro-2-fluorophenoxy)methyl)-6-((3-fluoropiperidin-4-yl)oxy)pyridine	355
Intermediate B-29		3-Fluoro-4-((3-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile	328
Intermediate B-30		2-((4-Chloro-2-fluorophenoxy)methyl)-3-(piperidin-4-oxy)pyridine	337
Intermediate B-31		3-Fluoro-4-((2-(piperidin-4-oxy)pyridin-3-yl)methoxy)benzonitrile	328
Intermediate B-32		3-((4-Chloro-2-fluorophenoxy)methyl)-2-(piperidin-4-oxy)-pyridine	337


Intermediate B-33		3-Fluoro-4-((5-(piperidin-4-oxy)pyridin-3-yl)methoxy)-benzonitrile	328
Intermediate B-34		3-((4-Chloro-2-fluorophenoxy)methyl)-5-(piperidin-4-oxy)pyridine	337
Intermediate B-35		4-(3-((2-Fluoro-4-(1H-imidazol-1-yl)phenoxy)methyl)phenoxy)piperidine	368
Intermediate B-36		2-((2-Fluoro-4-(1H-imidazol-1-yl)phenoxy)methyl)-6-(piperidin-4-oxy)pyridine	369
Intermediate B-37		2-((2,4-Difluorophenoxy)methyl)-6-(piperidin-4-oxy)pyridine	321
Intermediate B-38		6-((6-(Piperidin-4-oxy)pyridin-2-yl)methoxy)-benzonitrile	311

		nicotinonitrile	
Intermediate B-39		5-Chloro-2-((6-(piperidin-4-oxy)-pyridin-2-yl)methoxy)-pyridine	320

Example 3. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-


5 benzo[d]imidazole-6-carboxylic acid (compound 1):

1). Synthesis of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamide)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino) benzoate:




To a mixture of 3-fluoro-4-((6-(piperidin-4-oxymethyl)pyridin-2-yl)methoxy)benzonitrile (100 mg, 0.31 mmol) and methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (109 mg, 0.31 mmol) in N,N-dimethylformamide (2 mL) potassium carbonate (86 mg, 0.62 mmol) was added. The mixture was stirred at 60 °C for 3 hours. The resulting mixture was poured into brine (20 mL) and extracted with dichloromethane (5 mL × 2). The combined organic layer was concentrated in vacuo and purified by reverse-phase flash chromatography under the following conditions (Column: spherical C18, 20-40 μm, 120 g; Mobile Phase A: 0.1% NH₄OH in Water; Mobile Phase B: Acetonitrile; Flow rate: 80 mL/min; Gradient: 0%B-95%B over 30 minutes; Detector: 254 nm). The fractions containing desired product were collected at 72% B and concentrated in vacuo to afford methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamide)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (40 mg, 20.1% yield). LC-MS m/z: 642.5 [M+H]⁺.

2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a solution of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (40 mg, 0.06 mmol) in toluene (1 mL) acetic acid (0.1 mL) was added dropwise. The reaction mixture was stirred at 110°C for 3 hours. After completion, the mixture was poured into brine (10 mL) and extracted with dichloromethane (5 mL × 2). The combined organic layer was concentrated in vacuo to give methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (30 mg, 80.3% yield). LC-MS m/z: 624 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (30 mg, 0.05 mmol) in THF (1 mL) and water (1 mL) lithium hydroxide (2.4 mg, 0.10 mmol) was added. The mixture was stirred at room temperature for 16 hours. The reaction mixture was directly concentrated in vacuo to remove the solvent, and then purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10μm 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (7.67 mg, 25.2% yield). LC-MS m/z: 610

$[M+H]^+$.

^1H NMR(400 MHz, $\text{DMSO}-d_6$): δ 8.04(s, 1 H), 7.89-7.80(m, 2 H), 7.74-7.60(m, 4 H), 7.43(m, 1 H), 7.04(d, $J=7.2$ Hz, 1 H), 6.72(d, $J=8.0$ Hz, 1 H), 6.39(s, 1 H), 5.69(s, 2 H), 5.30(s, 2 H), 4.88-4.83(m, 1 H), 4.01-4.00(m, 2 H), 3.79(s, 2 H), 2.68-2.65(m, 2 H), 2.25-2.20(m, 2 H), 1.81-1.76(m, 2 H), 1.47-1.44(m, 2 H), 1.16(t, $J=7.2$ Hz, 3 H).


Example 4. Synthesis of (S)-2-(((4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)methoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound S22)

1. Synthesis of methyl (S)-2-(((4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)methoxy)piperidin-1-yl)-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 0.51 mmol), 3-fluoro-4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)methoxy)methyl)benzonitrile (173 mg, 0.51 mmol) and potassium carbonate (140 mg, 1.02 mmol) in N,N -dimethylformamide (2 mL) was stirred at 60 °C for 3 hours. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL $\times$ 2). The combined organic layers were washed successively with saturated ammonium chloride (20 mL $\times$ 3) and brine (10 mL $\times$ 2) in turn, dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give methyl (S)-2-(((4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)methoxy)-piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 32.9% yield). LC-MS m/z : 600 $[M+H]^+$.

2. Synthesis of (S)-2-(((4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)methoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-(((4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)methoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.17 mmol) in water (4 mL) and THF (4 mL) lithium hydroxide monohydrate (12 mg, 0.51 mmol) was added. The reaction mixture was stirred at 40 °C for 16 hours. The reaction mixture was adjusted to pH=5-6 with formic acid. The solvent was removed in vacuo and the residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S)-2-(((4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridine-2-yl)methoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound S22) (19.26 mg, 19.7% yield). LC-MS m/z: 586 [M+H]⁺.

¹HNMR(400 MHz, DMSO-d₆): 8.08-8.06(m, 1 H), 7.90(d, *J*=10.0 Hz, 1 H), 7.77-7.70(m, 4 H), 7.46-7.44(m, 1 H), 7.07(d, *J*=7.2 Hz, 1 H), 6.80(d, *J*=8.4 Hz, 1 H), 5.44(s, 2 H), 5.10-5.05(m, 1 H), 4.73-4.68(m, 1 H), 4.59-4.51(m, 1 H), 4.49-4.46(m, 3 H), 4.39-4.34(m, 1 H), 3.86(d, *J*=13.2 Hz, 1 H), 3.73-3.69(m, 1 H), 3.47-3.41(m, 1 H), 2.76-2.64(m, 3 H), 2.49-2.41(m, 1 H), 2.23-2.17(m, 2 H), 1.89-1.85(m, 2 H), 1.56-1.49(m, 2 H).


Example 5. Synthesis of (S)-2-(((4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)methyl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound S1)

1). Synthesis of methyl (S)-2-(((4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)methyl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate



The mixture of 3-fluoro-4-((6-(piperidin-4-ylmethoxy)pyridin-2-yl)oxy)methyl)benzonitrile (100 mg, 0.29 mmol), methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (85 mg, 0.29 mmol) and potassium carbonate (80 mg, 0.58 mmol) in N,N-dimethylformamide (2 mL) was heated to 50 °C and stirred for 3 hours. After completion, the resulting mixture was diluted with water (20 mL) and extracted with ethyl acetate (10 mL×2). The combined organic layers were washed with brine (30 mL), dried over sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (DCM/MeOH=20/1) to give methyl (S)-2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridine-2-yl)oxy)methyl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.17 mmol, 57.6% yield). LC-MS m/z: 600 [M+H]⁺.

2). Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)methyl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)methyl)piperidine-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.17 mmol) in water (1.0 mL) and THF (1.0 mL) lithium hydroxide (8 mg, 0.33 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The solvent was removed in vacuo and the residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19×250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelengths: 254 nm/214 nm; Flow rate: 20 mL/min) to give (S)-2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)methyl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (15.48 mg, 15.6% yield). LC-MS m/z: 586 [M+H]⁺.

¹H NMR(400 MHz, DMSO-*d*₆): δ8.28(s, 1 H), 8.24(s, 1 H), 7.92-7.87(m, 1 H), 7.80(d, *J*=8.4 Hz, 1 H), 7.71(dd, *J*=7.6, 1.2 Hz, 1 H), 7.66(d, *J*=6.4 Hz, 1 H), 7.64-7.60(m, 2 H), 6.46(d, *J*=8.0 Hz, 1 H), 6.37(d, *J*=8.0 Hz, 1 H), 5.45(s, 2 H), 5.11-5.03(m, 1 H), 4.80-4.72(m, 1 H), 4.66-4.58(m, 1 H), 4.52-4.45(m, 1 H), 4.40-4.33(m, 1 H), 4.00(d, *J*=6.0 Hz, 2 H), 3.89(d, *J*=13.6 Hz, 1 H), 3.73(d, *J*= 13.6 Hz, 1 H), 2.90(d, *J*=10.4 Hz, 1 H), 2.80-2.70(m, 1 H), 2.72-

2.64(m, 1 H), 2.45-2.37(m, 1 H), 2.13-1.95(m, 2 H), 1.70-1.60(m, 3 H), 1.27-1.13(m, 2 H).


Example 6. Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound S2)

5 **1). Synthesis of methyl (S)-2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate**



The mixture of methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (200 mg, 0.68 mmol), 3-fluoro-4-((6-(piperidin-4-oxymethyl)pyridin-2-yl)oxy)benzonitrile (245 mg, 0.75 mmol) and potassium carbonate (188 mg, 1.36 mmol) in N,N-dimethylformamide (2 mL) was stirred at 60 °C for 3 hours. The resulting mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic layers were washed successively with saturated ammonium chloride (20 mL × 3) and brine (10 mL × 2), then dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (DCM/MeOH=20/1) to give methyl (S)-2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridine-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (205 mg, 0.35 mmol, 51.5% yield). LC-MS m/z: 586 [M+H]⁺.

2). Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




25 To a mixture of methyl (S)-2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate

(150 mg, 0.26 mmol) in water (1 mL) and THF (1 mL) lithium hydroxide (62 mg, 2.59 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was adjusted to pH=5-6 with formic acid. Then the solvent was removed by concentration in vacuo to give a residue. The residue was purified prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10 μ m 19 $\times$ 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength 254 nm/214 nm; Flow rate: 20 mL/min) to give (S)-2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (38.01 mg, 0.07 mmol, 26.0 % yield). LC-MS m/z: 572 [M+H]⁺.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.26(s, 1 H), 7.93-7.90(m, 1 H), 7.80(d, *J*=8.0 Hz, 1 H), 7.72-7.69(m, 1 H), 7.65-7.61(m, 3 H), 6.46(d, *J*=7.6 Hz, 1 H), 6.36(d, *J*=8.0 Hz, 1 H), 5.45(s, 2 H), 5.09-5.07(m, 1 H), 4.81-4.75(m, 2 H), 4.66-4.61(m, 1 H), 4.52-4.47(m, 1 H), 4.40-4.36(m, 1 H), 3.94(d, *J* = 13.6 Hz, 1 H), 3.78(d, *J* = 13.6 Hz, 1 H), 2.78-2.67(m, 3 H), 2.45-2.41(m, 1 H), 2.31-2.27(m, 2 H), 1.86-1.83(m, 2 H), 1.58-1.53(m, 2 H).

Example 7. Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C1):


1): Synthesis of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate



The mixture of 3-fluoro-4-((6-((piperidin-4-oxy)methyl)pyridin-2-yl)methoxy)benzonitrile (27 mg, 0.08 mmol), methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (24 mg, 0.08 mmol) and potassium carbonate (22 mg, 0.16 mmol) in N,N-dimethylformamide (1 mL) was stirred at 60 °C for 3 hours. The resulting mixture was diluted with water (10 mL) and extracted with ethyl acetate (20 mL $\times$ 2). The combined organic layers were combined, washed with saturated ammonium chloride (20 mL $\times$ 3) and brine (10 mL $\times$ 2) in turn, dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl (S)-2-((4-((6-((4-cyano-

2-fluorophenoxy)methyl)-pyridin-2-yl)methoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (23 mg, 47.0% yield). LC-MS m/z : 600 $[M+H]^+$.

2). Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (23 mg, 0.04 mmol) in water (1mL) and THF (1 mL) lithium hydroxide (10 mg, 0.40 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was adjusted to pH=5-6 with formic acid. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to give (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methoxy)piperidine-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (14.73 mg, 65.5% yield). LC-MS m/z : 586 $[M+H]^+$.

¹H NMR(400 MHz, DMSO-*d*₆) δ 8.26(s, 1 H), 8.22(s, 1 H), 7.91-7.86(m, 2H), 7.82-7.79(m, 1H), 7.69(d, J =8.8 Hz, 1H), 7.63(d, J =8.4 Hz, 1H), 7.46-7.42(m, 3H), 5.35(s, 2H), 5.10-5.08(m, 1H), 4.81-4.76(m, 1H), 4.66-4.59(m, 3H), 4.52-4.47(m, 1H), 4.40-4.35(m, 1H), 3.92(d, J =13.6 Hz, 1H), 3.75(d, J =13.6 Hz, 1H), 3.51-3.46(m, 1H), 2.79-2.67(m, 3H), 2.46-2.41(m, 1H), 2.27-2.24(m, 2H), 1.91-1.89(m, 2H), 1.56-1.51(m, 2H).


Example 8. Synthesis of (S)-2-((3-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)azetidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound S3):

1). Synthesis of methyl (S)-2-((3-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)azetidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 0.51 mmol), 4-((6-(azetidin-3-yloxy)pyridin-2-yloxy)methyl)-3-fluorobenzonitrile (153 mg, 0.51 mmol) and potassium carbonate (211 mg, 1.530 mmol) in N,N-dimethylformamide (2 mL) was warmed to 60 °C for 4 hours. The resulting mixture was diluted with water (10 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed sequentially with saturated ammonium chloride (30 mL) and brine (2 × 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (DCM/MeOH=20/1) to give methyl (S)-2-((3-((6-((4-cyano-2-fluorobenzyl)oxy)pyridine-2-yl)oxy)azetidine-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (180.0 mg, 0.32 mmol, 63.3% yield). LC-MS m/z: 558 [M+H]⁺.

2). Synthesis of (S)-2-((3-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)azetidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-((3-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)azetidine-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (90 mg, 0.16 mmol) in water (4 mL) and THF (4 mL) lithium hydroxide monohydrate (68 mg, 1.63 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was adjusted to pH=5-6 with formic acid. The solvent was removed to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10μm 19×250 mm; Gradient elution with ACN/0.1% NH₄OH in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate : 20 mL/min) to obtain (S)-2-((3-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)azetidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound S3) (10.23 mg, 11.7% yield). LC-MS m/z: 544 [M+H]⁺.

^1H NMR(400 MHz, DMSO- d_6): δ 12.56(brs, 1H), 8.24(d, J =0.8 Hz, 1 H), 7.86-7.78(m, 2 H), 7.71-7.63(m, 4 H), 6.49(d, J =7.6 Hz, 1 H), 6.42(d, J =7.6 Hz, 1 H), 5.41(s, 2 H), 5.08-5.02(m, 2 H), 4.72(dd, J = 15.4, 7.2 Hz, 1 H), 4.59(dd, J =15.4, 2.8 Hz, 1 H), 4.47-4.43(m, 1 H), 4.33-4.28(m, 1 H), 4.05(d, J = 13.6 Hz, 1 H), 3.95(d, J =13.6 Hz, 1 H), 3.77-3.69(m, 2 H), 3.20-3.16(m, 2 H), 2.70-2.66(m, 1 H), 2.40-2.35(m, 1 H).


Example 9. Synthesis of (S)-2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound S5):

1). Synthesis of methyl (S)-2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate



To a mixture of 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)oxy)methylbenzonitrile (89.0 mg, 0.273 mmol) and methyl (S)- 2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (80.3 mg, 0.273 mmol) in N,N-dimethylformamide (4 mL) potassium carbonate (113.0 mg, 0.819 mmol) was added. The mixture was heated to 60 °C for 3 hours. The mixture was diluted with water (5 mL) and extracted with EA (3 × 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na_2SO_4 , filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give methyl (S)-2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy))-piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (94 mg, 59.0% yield). LC-MS m/z : 585 $[\text{M}+\text{H}]^+$.

2).(S)-2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid



To a mixture of methyl (S)-2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (94 mg, 0.16 mmol) in THF (4 mL) and H_2O (4 mL) $\text{LiOH}\cdot\text{H}_2\text{O}$ (68 mg, 1.60 mmol) was added. The mixture was


warmed to 40 °C and stirred for 16 hours. The mixture was adjusted to pH=5-6 with hydrochloric acid (1 M) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse phase column chromatography (Spherical C18 column, 20-40 μm, 40 g; Mobile Phase A: 10 mM in NH₃·H₂O water; Mobile Phase B: acetonitrile; Flow rate: 40 mL/min; Gradient: 20% B - 50% B in 20 minutes; Detector: 254 nm). The mobile phase containing the desired product was collected under 32% B and then concentrated in vacuo to give (S)-2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)yl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-

benzo[d]imidazole-6-carboxylic acid (26.27 mg, 28.6% yield). LC-MS m/z: 571 [M+H]⁺

¹H NMR(400 MHz, DMSO-*d*₆)δ 8.16(s, 1 H), 7.92(d, *J*=8.0 Hz, 1 H), 7.80-7.77(m, 1 H), 7.76-7.75(m, 2 H), 7.53-7.51(m, 1 H), 7.17(t, *J*=8.0 Hz, 1 H), 6.62-6.57(m, 3 H), 5.21(s, 2 H), 5.11-5.06(m, 1 H), 4.77-4.71(m, 1 H), 4.63-4.59(m, 1 H), 4.52-4.47(m, 1 H), 4.40-4.36(m, 2 H), 3.90(d, *J*=13.6 Hz, 1 H), 3.76(d, *J*=13.5 Hz, 1 H), 2.78-2.68(m, 3 H), 2.50-2.33(m, 3 H), 1.93-1.91(m, 2 H), 1.62-1.58(m, 2 H).

Example 10. Synthesis of 2-((4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound S4):


1. Synthesis of methyl 4-(2-(4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



To a mixture of methyl 4-(2-chloroacetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (140 mg, 0.40 mmol) and 3-fluoro-4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)methyl)benzonitrile (131 mg, 0.40 mmol) in N,N-dimethylformamide (3 mL) potassium carbonate (110 mg, 0.80 mmol) was added. The mixture was stirred at 60 °C for 3 hours. The resulting mixture was poured into brine (50 mL) and extracted with DCM (10 mL × 2). After the combined organic phases were concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (DCM/MeOH=10/1) to obtain methyl 4-(2-(4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (140 mg, 54.6% yield).


LC-MS m/z: 642 [M+H]⁺.

2). Synthesis of 4-(2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoic acid:



To a mixture of methyl 4-(2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (140 mg, 0.22 mmol) in THF (1 mL) and H₂O (1 mL) lithium hydroxide (11 mg, 0.46 mmol) was added. The mixture was stirred at room temperature for 5 hours. The resulting mixture was poured into brine (10 mL) and extracted with DCM (5 mL × 2). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (DCM/MeOH=10/1) to obtain 4-(2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoic acid (80 mg, 58.0% yield). LC-MS m/z: 628 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound 4):




The mixture of 4-(2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoic acid (80 mg, 0.13 mmol) in toluene (1 mL) and AcOH (0.2 mL), stirred at 110 °C for 3 hours. The solvent was removed in vacuo to give a residue. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19×250 mm; Gradient eluted ACN/0.1% NH₄OH in H₂O solvent system; Detection Wavelength 254 nm/214 nm; Flow rate 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound S4) (20.72 mg, 26.2% yield). LC-MS m/z: 610 [M+H]⁺.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.07(s, 1 H), 7.92-7.89(m, 1 H), 7.83-7.80(m, 1 H),

7.71-7.67(m, 3 H), 7.64-7.59(m, 2 H), 6.45(d, $J=8.0$ Hz, 1 H), 6.41(s, 1 H), 6.34(d, $J=8.0$ Hz, 1 H), 5.71(s, 2 H), 5.43(s, 2 H), 4.73-4.71(m, 1 H), 4.03-3.97(m, 2 H), 3.81(s, 2 H), 2.68-2.65(m, 2 H), 2.25-2.20(m, 2 H), 1.75-1.71(m, 2 H), 1.43-1.39(m, 2 H), 1.16(t, $J = 7.2$ Hz, 3 H).


Example 11. Synthesis of 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound S23):

1). Synthesis of methyl 4-(2-(4-(3-((4-cyano-2-fluorobenzyl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



To a mixture of methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (100 mg, 0.29 mmol) and 3-fluoro-4-((3-(piperidin-4-oxo)phenoxy)methyl)benzonitrile (95 mg, 0.29 mmol) in N,N-dimethylformamide (5 mL) potassium carbonate (120 mg, 0.87 mmol) was added at room temperature. The mixture was stirred at 60°C for 3 hours. The reaction was diluted with water (5 mL) and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with brine (20 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo, The residue was purified by silica gel column chromatography (dichloromethane/methanol=15/1) to obtain methyl 4-(2-(4-(3-((4-cyano-2-fluorobenzyl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (45 mg, 24.1% yield). LC-MS m/z : 641 $[M+H]^+$.


2). Synthesis of methyl 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a solution of methyl 4-(2-(4-(3-((4-cyano-2-fluorobenzyl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (45 mg, 0.07 mmol) in toluene (10 mL) acetic acid (2 mL) was added. The mixture was stirred at 110 °C for 16 hours.

The mixture was concentrated to give the crude product, which was further purified by reverse-phase flash chromatography under the following conditions: (Column: spherical C18, 20-40, 120 g; Mobile Phase A: 10 mM $\text{NH}_3 \cdot \text{H}_2\text{O}$ in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 60%B-80%B in 20 minutes; Monitor: 254nm.). The mobile phase containing desired product was collected at 72%B and concentrated in vacuo to obtain methyl 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (22 mg, 57.1% yield). LC-MS m/z : 623 $[\text{M}+\text{H}]^+$.

3). Synthesis of 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl)methyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (22 mg, 0.04 mmol) in THF (4 mL) and water (4 mL) lithium hydroxide monohydrate (17 mg, 0.40 mmol) was added. The mixture was stirred at room temperature for 3 hours. The resulting mixture was adjusted to pH=5-6 with hydrochloric acid solution (1 N) and extracted with ethyl acetate (10 mL $\times$ 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions: (Column: spherical C18, 20- 40 μm , 40 g; Mobile Phase A: 10 mM $\text{NH}_3 \cdot \text{H}_2\text{O}$ in water; Mobile Phase B: acetonitrile; Flow rate: 40 mL/min; Gradient: 20%B-50%B in 20 minutes; Detector: 254 nm.). The mobile phase containing the desired product was collected at 29% B and concentrated in vacuo to obtain 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)yl)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]im-idazole-6-carboxylic acid (11.42 mg, 0.019 mmol, 47.5% yield). LC-MS m/z : 609 $[\text{M}+\text{H}]^+$.

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.00(s, 1 H), 7.91(d, $J=9.6$ Hz, 1 H), 7.80-7.73(m, 3 H), 7.66(s, 1 H), 7.52(d, $J=8.0$ Hz, 1 H), 7.16(t, $J=8.0$ Hz, 1H), 6.60-6.54(m, 3 H), 6.37(s, 1H), 5.66(s, 2 H), 5.20(s, 2 H), 4.36-4.32(m, 1H), 4.00(q, $J=7.2$ Hz, 2 H), 3.76(s, 2 H), 2.67-2.65(m,

2 H), 2.31-2.26(m, 2 H), 1.82-1.79(m, 2 H), 1.49-1.37(m, 2 H), 1.17 (t, $J=7.2$ Hz, 3 H).


Example 12. Synthesis of (S,E)-3-(2-(((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylic acid formate:

5 **1). Synthesis of methyl (S,E)-3-(2-(((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylate:**



To a mixture of methyl (methyl (S, E)-3-(2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylate (90 mg, 0.28 mmol) and 2-(((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylate (100 mg, 0.28 mmol) in N,N-dimethylformamide (3 mL) potassium carbonate (78 mg, 0.56 mmol) was added. The mixture was stirred at 60 °C for 3 hours. The desired product was detected by LC-MS. The mixture was quenched by adding water (5 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane: methanol=10:1) to obtain methyl (S, E)-3-(2-(((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylate (60 mg, 33.5% yield). LC-MS m/z : 639 $[M+H]^+$.

20 **2). Synthesis of (S,E)-3-(2-(((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)-methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylic acid formate salt**




To a mixture of methyl (S,E)-3-(2-(((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylate (60 mg, 0.094 mmol) in THF(2 mL) and water (2 2 mL) lithium hydroxide monohydrate (6 mg, 0.24 mmol) was added. The mixture was stirred at room temperature for

5 hours. The resulting mixture was adjusted to pH=5-6 with formic acid. The mixture was concentrated to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19×250 mm; Gradient elution with ACN/0.1% FA in H₂O Solvent system; Detection Wavelength 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S,E)-3-(2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-6-yl)acrylic acid formate salt (13.10 mg, 27% yield). LC-MS m/z: 625 [M+H]⁺.

¹H NMR(400 MHz, DMSO-d₆): δ 8.27(s, 1 H), 8.00(s, 1 H), 7.66-7.47(m, 6 H), 7.32(dd, *J*=10.0 Hz, 2.0 Hz, 1 H), 6.54(d, *J*=15.6 Hz, 1 H), 6.34(dd, *J*=8.8 Hz, 2.0 Hz, 1 H), 5.44(s, 2 H), 5.11-5.09(m, 1 H), 4.79-4.75(m, 2 H), 4.62-4.58(m, 1 H), 4.51-4.40(m, 2 H), 3.95-3.92(m, 1 H), 3.80-3.76(m, 1 H), 2.80-2.68(m, 3 H), 2.50-2.41(m, 1 H), 2.36-2.29(m, 2 H), 1.91-1.89(m, 2 H), 1.62-1.57(m, 2 H).


Example 13. Synthesis of (E)-3-(2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-6-yl)acrylic acid (compound C2):

1). Synthesis of methyl (E)-3-(4-(2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)phenyl)acrylate:




To a mixture of methyl (E)-3-(4-(2-chloroacetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)phenyl)acrylate (100 mg, 0.27 mmol) and 3-fluoro-4-((6-(piperidin-4-yloxy)pyridin-2-yl)oxy)methyl)benzonitrile (88 mg, 0.27 mmol) in N,N-dimethylformamide (5 mL) potassium carbonate (75 mg, 0.54 mmol) was added. The mixture was stirred at room temperature for 16 hours. The resulting mixture was poured into brine (50 mL) and extracted with ethyl acetate (2 × 15 mL). The combined organic was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl (E)-3-(4-(2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)phenyl)acrylate (100 mg, 55.5% yield). LC-MS m/z: 668 [M+H]⁺.

2). Synthesis of methyl (E)-3-(2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-6-yl)acrylate:



5 The mixture of methyl (E)-3-(4-(2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidine-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)phenyl)acrylate (100 mg, 0.15 mmol) in toluene (2 mL) and acetic acid (0.2 mL) was stirred at 110 °C for 3 hours. The resulting mixture was poured into brine (20 mL) and extracted with dichloromethane (3 × 5 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give methyl (E)-3-(2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-6-yl)acrylate (70 mg, 71.9% yield). LC-MS m/z : 650 $[M+H]^+$.

3). Synthesis of (E)-3-(2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-6-yl)acrylic acid:




To A mixture of methyl (E)-3-(2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-6-yl)acrylate (70 mg, 0.11 mmol) in THF (2 mL) and water (2 mL) lithium hydroxide (5 mg, 0.21 mmol) was added. The mixture was stirred at room temperature for 16 hours. The mixture was concentrated to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to give (E)-3-(2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-6-

yl)acrylic acid (13.86 mg, 19.8% yield). LC-MS m/z : 636 $[M+H]^+$.

^1H NMR (400 MHz, DMSO- d_6): δ 7.91(d, $J=9.6$ Hz, 1H), 7.81(s, 1H), 7.71-7.69(m, 2H), 7.64-7.59(m, 4H), 7.52-7.50(m, 1H), 6.50(d, $J=8.4$ Hz, 1H), 6.45(d, $J=7.6$ Hz, 1H), 6.34(d, $J=8.0$ Hz, 1H), 5.66(s, 2H), 5.43(s, 2H), 4.74-4.70(m, 1H), 4.00-3.95(m, 2H), 3.76(s, 2H), 2.67-2.64(m, 2H), 2.23-2.19(m, 2H), 1.76-1.73(m, 2H), 1.44-1.38(m, 2H), 1.14-1.10(m, 3H).


Example 14. Synthesis of 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C3):

1). Synthesis of methyl 4-(2-(4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



The mixture of methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (540 mg, 1.54 mmol), 2-((4-bromo-2-fluorophenoxy)methyl)-6-(piperidin-4-yl)pyridine (586 mg, 1.54 mmol) and potassium carbonate (637 mg, 4.62 mmol) in dry N,N-dimethylformamide (15 mL) was stirred at room temperature for 16 hours. After completion, the reaction was quenched with water (10 mL) and extracted with ethyl acetate (3 $\times$ 10 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 4-(2-(4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (500 mg, 46.8% yield). LC-MS m/z : 695 $[M+H]^+$.

2). Synthesis of methyl 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:




The mixture of methyl 4-(2-(4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (500 mg, 0.72 mmol) in toluene (6 mL) and acetic acid (1 mL) was stirred at 110 °C for 3 hours.

The mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-(((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (470 mg, 96.5% yield). LC-MS

5 m/z: 679 [M+H]⁺.

3). Synthesis of 2-(((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:



10 To a mixture of methyl 2-(((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (80 mg, 0.12 mmol) in THF(1 mL) and water (1 mL) lithium hydroxide (9 mg, 0.36 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was adjusted to pH=5-6 with formic acid. The mixture was concentrated to

15 give a residue in vacuo. The residue was eluted by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to give 2-(((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (30.96 mg, 39% yield). LC-MS m/z: 665 [M+H]⁺.


20

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.19(s, 1 H), 8.07(s, 1 H), 7.81(dd, *J*=8.8 Hz, 1.6 Hz, 1 H), 7.72-7.67(m, 3 H), 7.54(dd, *J*=6.8 Hz, 2.4 Hz, 1 H), 7.30(d, *J*=8.8 Hz, 1 H), 7.21(t, *J*=8.8 Hz, 1 H), 7.03(d, *J*=7.2 Hz, 1 H), 6.70(d, *J*=8.4 Hz, 1 H), 6.41(s, 1 H), 5.72(s, 2 H), 5.17(s, 2 H), 4.88-4.86(m, 1 H), 4.03-3.98(m, 2 H), 3.81(s, 2 H), 2.69-2.67(m, 2 H), 2.33-2.23(m, 2 H), 1.81-1.78(m, 2 H), 1.47-1.44(m, 2 H), 1.16(t, *J*=7.2 Hz, 3 H).

25


Example 15. Synthesis of (S)-2-(((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C4):

1). Synthesis of methyl (S)-2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.34 mmol), 2-((4-bromo-2-fluorophenoxy)methyl)-6-(piperidin-4-yl)pyridine (130 mg, 0.34 mmol) and potassium carbonate (140 mg, 1.02 mmol) in N,N-dimethylformamide (4 mL) was stirred at 60 °C for 3 hours. The mixture was quenched with water (10 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl (S)-2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 46.1% yield). LC-MS m/z: 639 [M+H]⁺.

2). Synthesis of (S)-2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:




To a mixture of methyl (S)-2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.16 mmol) in THF (2 mL) and water (2 mL) lithium hydroxide (12 mg, 0.48 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was adjusted to pH=5-6 with formic acid. The solvent was removed by concentration to give residue in vacuo. The residue purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S)-2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid.

(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (20.08 mg, 20.5% yield). LC-MS m/z : 627 $[M+H]^+$.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.28-8.23(m, 1 H), 7.80(d, J =8.8 Hz, 1 H), 7.71(t, J =7.6 Hz, 1 H), 7.63(d, J =8.4 Hz, 1 H), 7.54(dd, J =10.4 Hz, 2.0 Hz, 1 H), 7.31(d, J =9.2 Hz, 1 H), 7.22(t, J =8.8 Hz, 1 H), 7.04(d, J =7.2 Hz, 1 H), 6.72(d, J =8.4 Hz, 1 H), 5.18(s, 2 H), 5.13-5.06(m, 1 H), 4.97-4.89(m, 1 H), 4.83-4.73(m, 1 H), 4.68-4.60(m, 1 H), 4.54-4.46(m, 1 H), 4.41-4.33(m, 1 H), 3.98-3.90(m, 1 H), 3.82-3.75(m, 1 H), 2.82-2.66(m, 4 H), 2.46-2.36(m, 1 H), 2.33-2.26(m, 2 H), 1.97-1.88(m, 2 H), 1.66-1.56(m, 2 H).


Example 16. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C82):

1). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 2-(chloromethyl)-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.34 mmol), 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (111 mg, 0.34 mmol) and potassium carbonate (94 mg, 0.68 mmol) in N,N-dimethylformamide (2 mL) was stirred at 60 °C for 3 hours. The resulting mixture was diluted with water (30 mL) and extracted with ethyl acetate (10 mL $\times$ 3). The combined organic layers were washed with brine (30 mL), concentrated under to give a residue reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-3-ylmethyl))-1H-benzo[d]imidazole-6-carboxylate (100 mg, 50.3% yield). LC-MS m/z : 586 $[M+H]^+$.

2). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.17 mmol) in THF (1.0 mL) and water (1.0 mL) lithium hydroxide (8 mg, 0.34 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-3-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (25.81 mg, 26.6% yield). LC-MS *m/z*: 572 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.22(s, 1 H), 7.88(dd, *J*=11.2, 2.0 Hz, 1 H), 7.81(dd, *J*=8.4, 1.2 Hz, 1 H), 7.73(t, *J*=8.0 Hz, 1 H), 7.67-7.61(m, 2 H), 7.45(t, *J*=8.4 Hz, 1 H), 7.06(d, *J*=7.2 Hz, 1 H), 6.74(d, *J*=8.4 Hz, 1 H), 5.31(s, 2 H), 4.94-4.91(m, 1 H), 4.72(d, *J*=7.6 Hz, 2 H), 4.64-4.61(m, 2 H), 4.56-4.53(m, 2 H), 3.81(s, 2 H), 3.67-3.61(m, 1 H), 2.80-2.77(m, 2 H), 2.33-2.27(m, 2 H), 1.93-1.90(m, 2 H), 1.64-1.59(m, 2 H).

Example 17. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((3-methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C5):


1). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((3-methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 2-(chloromethyl)-1-((3-methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.32 mmol), 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (105 mg, 0.32 mmol) and potassium carbonate (88 mg, 0.64 mmol) in N,N-dimethylformamide (2 mL) was stirred at 60 °C for 3 hours. The resulting mixture was diluted with water (30 mL) and extracted with ethyl acetate (10 mL × 3). The

combined organic layers were washed with saturated brine (30mL) and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((3-methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (50 mg, 26.0% yield). LC-MS m/z: 600 [M+H]⁺.

2). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((3-methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((3-methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (50 mg, 0.08 mmol) in THF (5 mL) and water (5 mL) lithium hydroxide (10 mg, 0.42 mmol) was added. The mixture was stirred at room temperature for 16 hours. The solvent was removed to give a residue by concentration in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((3-methyloxetan-3-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (9.50 mg, 20.3 % yield). LC-MS m/z: 586 [M+H]⁺.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.21(s, 1 H), 7.88(dd, *J*=11.2, 1.6 Hz, 1 H), 7.81(d, *J*=9.2 Hz, 1 H), 7.73(t, *J*=8.0 Hz, 1 H), 7.66(d, *J*=8.4 Hz, 2 H), 7.44(t, *J*=8.8 Hz, 1 H), 7.05(d, *J*=7.2 Hz, 1 H), 6.73(d, *J*=8.4 Hz, 1 H), 5.30(s, 2 H), 4.92-4.90(m, 1 H), 4.65-4.61(m, 4 H), 4.22(d, *J*=6.0 Hz, 1 H), 3.78(s, 2 H), 2.76-2.74(m, 2 H), 2.31-2.26(m, 2 H), 1.92-1.87(m, 2 H), 1.62-1.58(m, 2 H), 1.25(s, 3 H).


Example 18. Synthesis of (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid(compound 67):

1). Synthesis of methyl (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



To A mixture of methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.34 mmol) and 3-fluoro-4-((3-(piperidin-4-oxy)benzyl)oxy)benzonitrile (122 mg, 0.37 mmol) in N,N-dimethylformamide (5 mL) potassium carbonate (94 mg, 0.68 mmol) was added. The mixture was stirred at room temperature for 16 hours. The mixture was quenched by adding water (5 mL) and extracted with ethyl acetate (40 mL $\times$ 3). The combined organic layers were washed with brine (30 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (71 mg, 35.8% yield). LC-MS m/z: 585 [M+H]⁺.

2). Synthesis of (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (71 mg, 0.12 mmol) in THF (2 mL) and water (2 mL) lithium hydroxide monohydrate (50 mg, 1.20 mmol) was added at room temperature. The reaction was stirred at room temperature for 5 hours. The resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1M), and then extracted with ethyl acetate (10 mL $\times$ 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μ m, 40 g;

Mobile Phase A: 10 mM NH₃·H₂O in water; Mobile Phase B: acetonitrile; Flow rate: 40 mL/min; Gradient: 20%B-50%B in 20 minutes; Detector: 254 nm) to obtain (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (4.69 mg, 7.3% yield). LC-MS m/z: 571 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆) 8.25(s, 1 H), 7.88-7.80(m, 2 H), 7.68(d, *J*=8.4 Hz, 1 H), 7.61(d, *J*=8.0 Hz, 1 H), 7.42(t, *J*=8.4 Hz, 1 H), 7.30(t, *J*=7.6 Hz, 1 H), 7.05-6.93(m, 3 H), 5.25(s, 2 H), 5.10-5.07(m, 1 H), 4.80-4.75(m, 1 H), 4.63(d, *J*=13.2 Hz, 1 H), 4.52-4.47(m, 1 H), 4.42-4.35(m, 2 H), 3.94(d, *J*=13.2 Hz, 1 H), 3.78(d, *J*=13.2 Hz, 1 H), 2.79-2.67(m, 3 H), 2.46-2.35(m, 3 H), 1.95-1.93(m, 2H), 1.64-1.60(m, 2 H).


Example 19. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1,2-dimethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C6):

1). Synthesis of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



To a mixture of methyl 4-(2-chloroacetamido)-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)benzoate (150 mg, 0.43 mmol) and 3-fluoro-4-((6-(piperidin-4-yl)pyridin-2-yl)methoxy)benzonitrile (141 mg, 0.43 mmol) in N,N-dimethylformamide (5 mL) potassium carbonate (119 mg, 0.86 mmol) was added. The mixture was stirred at room temperature for 16 hours. After completion, the mixture was poured into brine (50 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino) benzoate (150 mg, 54.3% yield). LC-MS m/z: 642 [M+H]⁺.


2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1,2-dimethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1,2-dimethyl-1H-imidazol-5-yl)methyl)amino)benzoate (150 mg, 0.08 mmol) in toluene (5 mL) and acetic acid (1 mL) was stirred at 110 °C for 3 hours.

- 5 The mixture was poured into brine (20 mL) and extracted with dichloromethane (2 × 10 mL). The combined organic layer was concentrated in vacuo to give methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1,2-dimethyl-1H-imidazol-5-yl)methyl)-1H-benzo-[d]imidazole-6-carboxylate (100 mg, 69.8% yield). LC-MS m/z : 624 $[M+H]^+$.

10 **3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1,2-dimethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid formate salt:**




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1,2-dimethyl-1H-imidazol-5-yl)methyl)-1H-benzo-[d]imidazole-6-carboxylate (100 mg, 0.17 mmol) in THF(5 mL) and water (5 mL) lithium hydroxide (8 mg, 0.34 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength : 254 nm/214 nm; Flow rate: 20 mL/min) to obtained 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidine-1-yl)methyl)-1-((1,2-dimethyl-1H-imidazol-5-yl)me-tyl)-1H-benzo[d]imidazole-6-carboxylic acid formate salt (71.07 mg,68.6% yield). LC-MS m/z : 610 $[M+H]^+$.

- 25 ¹H NMR(400 MHz, DMSO-*d*₆): δ 8.16(s, 2 H), 8.09(s, 1 H), 7.88(dd, *J*=11.2, 1.6 Hz, 1 H), 7.81(dd, *J*=8.4, 1.2 Hz, 1 H), 7.74-7.65(m, 3 H), 7.44(t, *J*=8.4 Hz, 1 H), 7.05(d, *J*=7.2 Hz, 1 H), 6.72(d, *J*=8.4 Hz, 1 H), 6.41(s, 1 H), 5.67(s, 2 H), 5.30(s, 2 H), 4.90-4.86(m, 1 H), 3.82(s,

2 H), 3.44(s, 3 H), 2.72-2.69(m, 2 H), 2.33-2.24(m, 5 H), 1.84-1.82(m, 2 H), 1.54-1.47(m, 2 H).


Example 20. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound 135):

1). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate



To a mixture of methyl 2-(chloromethyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (160 mg, 0.50 mmol) and 3-fluoro-4-((3-fluoro-6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (173 mg, 0.50 mmol) in N,N-dimethylformamide (4 mL) potassium carbonate (207 mg, 1.50 mmol) was added at room temperature. The mixture was stirred at 60°C for 2 hours. The mixture was quenched with water (5 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (17 mg, 6.0% yield). LC-MS m/z: 627 [M+H]⁺.

2). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (17 mg, 0.03 mmol) in THF(3 mL) and water(10 mL) lithium hydroxide monohydrate (12 mg, 0.30 mmol) was added. The mixture was stirred at room temperature for 3 hours. The resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1 M), and then extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 120 g; Mobile Phase A: 10 mM NH₃·H₂O in water); Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 30%B-50%B in 20 minutes; Detector: 254 nm) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (7.02 mg, 33.3% yield). LC-MS m/z: 613 [M+H]⁺.

¹H NMR(400 MHz, DMSO-d₆)δ 8.23(s, 1 H), 7.87(dd, *J*=11.2, 1.6 Hz, H), 7.82-7.80(m, 1 H), 7.74-7.63(m, 3 H), 7.51(t, *J*=8.4 Hz, 1 H), 6.84(dd, *J*=8.8, 2.8 Hz, 1 H), 5.40(s, 2 H), 4.74-4.72(m, 1 H), 4.59(s, 2 H), 3.83(s, 2 H), 2.78-2.75(m, 2 H), 2.68(s, 2 H), 2.24(t, *J*=9.2 Hz, 2 H), 1.84(d, *J*=10.0 Hz, 2 H), 1.60-1.55(m, 2 H), 0.74-0.67(m, 4 H).

Example 21. Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C83):


1). Synthesis of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



To a mixture of 3-fluoro-4-((3-fluoro-6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (90 mg, 0.26 mmol) and methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (81 mg, 0.26 mmol) in N,N-

dimethylformamide (4 mL) potassium carbonate (108 mg, 0.78 mmol) was added at room temperature. The mixture was stirred at room temperature for 16 hours. The reaction was quenched with water (5 mL) and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with brine (20 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μ m, 120 g; Mobile Phase A: 10 mM hexachlorocyclohexane in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 30%B-50%B in 20 minutes; Detector: 254 nm) to obtain methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (85 mg, 53.8% yield). LC-MS m/z: 604 [M+H]⁺.

2). (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid




To a mixture of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (85 mg, 0.14 mmol) in THF (3 mL) and water (3 mL) lithium hydroxide monohydrate (56 mg, 1.4 mmol) was added. The reaction was stirred at room temperature for 3 hours. The resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1M), and then extracted with ethyl acetate (10 mL $\times$ 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μ m, 120 g; Mobile Phase A: water 10 mMNH₃·H₂O in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 30%B-50%B in 20 minutes; Detector: 254 nm) to obtain (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (50.26 mg, 64.3% yield). LC-MS m/z: 590

$[M+H]^+$.

^1H NMR(400 MHz, DMSO- d_6) δ 8.25(s, 1 H), 7.88(dd, $J=11.2$, 1.6 Hz, 1 H), 7.79(dd, $J=8.4$, 1.6 Hz, 1 H), 7.74-7.67(m, 2 H), 7.63(d, $J=8.4$ Hz, 1 H), 7.50(t, $J=8.8$ Hz, 1 H), 6.84(dd, $J=8.8$, 3.2 Hz, 1 H), 5.41(s, 2 H), 5.09-5.07(m, 1 H), 4.80-4.70(m, 2 H), 4.62(dd, $J=16.0$, 2.8 Hz, 1 H), 4.49(q, $J=7.6$, 1 H), 4.39-4.34(m, 1 H), 3.92(d, $J=13.6$ Hz, 1 H), 3.76(d, $J=13.6$ Hz, 1 H), 2.76-2.66(m, 3 H), 2.45-2.40(m, 1 H), 2.25-2.20(m, 1 H), 1.84-1.81(m, 2 H), 1.57-1.53(m, 2 H).


Example 22. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H benzo[d]imidazole-6-carboxylic acid (compound 3):

1). methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:




To a mixture of methyl 4-(2-chloroacetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (130 mg, 0.37 mmol) and 3-fluoro-4-((3-fluoro-6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (128 mg, 0.37 mmol) in N,N-dimethylformamide (4 mL) potassium carbonate (153 mg, 1.11 mmol) was added at room temperature. The mixture was stirred at room temperature for 16 hours. The reaction was quenched with water (5 mL) and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with brine (20 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to give methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)-piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (116 mg, 48.6% yield). LC-MS m/z : 660 $[M+H]^+$.

2). methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a solution of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (116 mg, 0.18 mmol) in dioxane (6 mL) acetic acid (2 mL) was added at room temperature. The mixture was stirred at 100°C for 3 hours. The reaction was quenched with water (5 mL) and extracted with ethyl acetate (40 mL × 3). The combined organic layers were washed with brine (40 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (18 mg, 15.6% yield). LC-MS m/z : 642 $[M+H]^+$.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (18 mg, 0.028 mmol) in THF (3 mL) and water (3 mL) lithium hydroxide monohydrate (11 mg, 0.28 mmol) was added. The mixture was stirred at room temperature for 3 hours. The resulting mixture was adjusted to pH=5-6 with hydrochloric acid 1 (1 M) and then extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in

vacuo. The residue was purified by reversed-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm , 120 g; Mobile Phase A: 10 mM $\text{NH}_3\cdot\text{H}_2\text{O}$ in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 30%B-50%B in 20 min; Detector: 254 nm) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-6-carboxylic acid (5.37 mg, 32% yield). LC-MS m/z : 628 $[\text{M}+\text{H}]^+$.

^1H NMR(400 MHz, $\text{DMSO}-d_6$) δ 8.06(s, 1 H), 7.87(dd, $J=11.6, 2.0$ Hz, 1 H), 7.81(d, $J=8.4$ Hz, 1 H), 7.73-7.66(m, 4 H), 7.49(t, $J=8.4$ Hz, 1 H), 6.83(dd, $J=9.2, 2.8$ Hz, 1 H), 6.40(s, 1 H), 5.70(s, 2 H), 5.40(s, 2 H), 4.67-4.65(m, 1 H), 4.02-3.97(m, 2 H), 3.80(s, 2 H), 2.67-2.63(m, 2 H), 2.19-2.15(m, 2 H), 1.72-1.70(m, 2 H), 1.43-1.34(m, 2 H), 1.16(t, $J=7.2$ Hz, 3 H).


Example 23. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-((1-(cyanomethyl)cyclopropyl)methyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid (compound 138):

1). Synthesis of methyl 5-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-6-((1-(cyanomethyl)cyclopropyl)methyl)amino)picolinate:




To a mixture of methyl 5-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-6-((1-(cyanomethyl)cyclopropyl)methyl)amino)picolinate (150 mg, 0.45 mmol) and 3-fluoro-4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methoxybenzonitrile (175 mg, 0.54 mmol) in N,N -dimethylformamide (5 mL) potassium carbonate (185 mg, 1.34 mmol) was added. The mixture was stirred at room temperature for 16 hours. The resulting mixture was poured into brine (20 mL) and extracted with ethyl acetate (20 mL $\times$ 2). The combined organic layers were concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 5-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-6-((1-(cyanomethyl)cyclopropyl)methyl)amino)picolinate: (220 mg, 78.6 % yield). LC-MS m/z : 628 $[\text{M}+\text{H}]^+$.

2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-((1-(cyanomethyl)cyclopropyl)methyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate:



5 The mixture of methyl 5-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-6-((1-(cyanomethyl)cyclopropyl)methyl)amino)picolinate (220 mg, 0.35 mmol) in toluene (10 mL) and acetic acid (10 mL) was stirred at 110 °C for 16 h under nitrogen atmosphere. After completion, the resulting mixture was filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=40/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)-methyl)pyridin-2-yl)oxy)-piperidin-1-yl)methyl)-3-((1-(cyanomethyl)cyclopropyl)methyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (200 mg, 93.5% yield). LC-MS m/z: 610 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-((1-(cyanomethyl)cyclopropyl)methyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)-methyl)pyridin-2-yl)oxy)-piperidin-1-yl)methyl)-3-((1-(cyanomethyl)cyclopropyl)methyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (100 mg, 0.16 mmol) in THF (5 mL) and water (5 mL) lithium hydroxide monohydrate (69 mg, 1.60 mmol) was added. The mixture was stirred at 40 °C for 3 hours. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10 μm 19 × 250 mm; Gradient elution with ACN/0.05% NH₄OH in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidine-1-yl)methyl)-3-((1-

(cyanomethyl)cyclopropyl)methyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid (48.10 mg, 49.2 % yield). LC-MS m/z : 596 $[M+H]^+$.

^1H NMR(400 MHz, DMSO- d_6) δ 8.03 (d, $J=8.4$ Hz, 1 H), 7.94-7.86(m, 2 H), 7.73(t, $J=8.0$ Hz, 1 H), 7.66(d, $J=8.8$ Hz, 1 H), 7.45(t, $J=8.8$ Hz, 1 H), 7.05(d, $J=7.2$ Hz, 1 H), 6.73(d, $J=8.4$ Hz, 1 H), 5.31(s, 2 H), 4.94-4.90(m, 1 H), 4.52(s, 2 H), 3.86(s, 2 H), 2.83-2.76(m, 4 H), 2.33-2.29(m, 2 H), 1.93-1.91(m, 2 H), 1.66-1.59(m, 2 H), 1.05(s, 2 H), 0.62-0.61(m, 2 H).


Example 24. Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid (compound 60):

1). Synthesis of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate:



To a mixture of methyl (S)-2-(chloromethyl)-3-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (180 mg, 0.61 mmol) and potassium carbonate (248 mg, 1.83 mmol) in N,N-dimethylformamide (5 mL) 3-fluoro-4-((6-(piperidine-4-oxy)pyridin-2-yl)methoxy)benzonitrile (216 mg, 0.67 mmol) was added. The mixture was stirred at 60 °C for 3 hours under nitrogen atmosphere. After completion, the mixture was poured into water (10 mL) and extracted with ethyl acetate (10 mL $\times$ 2). The combined organic layers were washed with saturated brine (10 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)-methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (190 mg, 48.7% yield). LCMS m/z : 587 $[M+H]^+$.

2). Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid:




To a solution of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (90 mg, 0.15 mmol) in THF (3 mL) and water (3 mL) with lithium hydroxide (36 mg, 1.50 mmol) was added. The reaction was stirred at 25 °C for 16 hours. The resulting mixture was adjusted to pH=5-6 with formic acid, and then extracted with ethyl acetate (10 mL×2). The combined organic layers were washed with saturated brine (5 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 120 g; Mobile Phase A: Water 10 mM formic acid in Water); Mobile Phase B: acetonitrile; Flow rate: 80 mL/min ; Gradient: 30%B-50%B in 16 min; Detector: 254 nm) to obtain (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-(oxetan-2-ylmethyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid (10.82 mg, 13.8% yield). LC-MS m/z: 573 [M+H]⁺.

¹HNMR(400 MHz, DMSO-d₆)δ8.12(d, *J*=8.4 Hz, 1H), 7.98(d, *J*=8.4 Hz, 1H), 7.88(dd, *J*=11.6 Hz, 2.0 Hz, 1H), 7.73(t, *J*=8.0 Hz, 1H), 7.66(d, *J*=8.8 Hz, 1H), 7.45(t, *J*=8.4 Hz, 1H), 7.05(d, *J*=7.6 Hz, 1H), 6.74(d, *J*=8.4 Hz, 1H), 5.31(s, 2H), 5.18-5.15(m, 1H), 4.94-4.81(m, 2H), 4.74-4.69(m, 1H), 4.52-4.47(m, 1H), 4.38-4.33(m, 1H), 4.00-3.90(m, 2H), 2.76-2.67(m, 4H), 2.35-2.31(m, 2H), 1.93-1.91(m, 2H), 1.66-1.62(m, 2H).

Example 25. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-((1-ethyl-1H-imidazol-5-yl)methyl)-3H-imidazo[4,5-b]pyridine-5-carboxylic acid (compound 6):


1). Synthesis of methyl 5-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-6-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)picolinate:



To a mixture of methyl 5-(2-chloroacetamido)-6-(((1-ethyl-1H-imidazol-5-


yl)methyl)amino)picolinate (180 mg, 0.51 mmol) and 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (167 mg, 0.51 mmol) in N,N-dimethylformamide (10 mL) potassium carbonate (211 mg, 1.53 mmol) was added at room temperature. The mixture was stirred at 25°C for 16 hours. The reaction mixture was quenched with H₂O (5 mL) and extracted with ethyl acetate (20 mL×3). The combined organic layers were washed with saturated brine (20 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 5-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-6-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)picolinate (230 mg, 71.6% yield). LC-MS m/z: 643 [M+H]⁺.

2). methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-((1-ethyl-1H-imidazol-5-yl)methyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate



The mixture of methyl 5-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-6-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)picolinate (230 mg, 0.36 mmol) in toluene (3 mL) and acetic acid (0.5 mL) was stirred at 100 °C for 16 hours. The resulting mixture was poured into saturated brine (10 mL) and extracted with dichloromethane (5 mL × 2). The combined organic layer was concentrated to give methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-((1-ethyl-1H-imidazol-5-yl)methyl)-3H-imidazo[4,5-b]pyridine-5-carboxylate (180 mg, 81% yield). LC-MS m/z: 625 [M+H]⁺.

3). Synthesis of 2 - ((4 - ((6 - ((4-cyano-2-fluorophenoxy) methyl) pyridin-2-yl) oxy) piperidin-1-yl) methyl) - 3 - ((1-ethyl-1h-imidazol-5-yl) methyl) - 3H imidazole[4,5-b] pyridin-5-carboxylic acid:




To a mixture of methyl 2 - ((4-((6-((4-cyano-2-fluorophenoxy) methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-((1-ethyl-1h-imidazol-5-yl) methyl)-3H imidazole[4,5-b]pyridine-5-carboxylate (130 mg, 0.20 mmol) in THF(3 mL) and water (3mL) lithium hydroxide (32 mg, 2.0 mmol) was added. The mixture was stirred at room temperature for 16 hours. The resulting mixture was adjusted to pH 5-6 with hydrochloric acid (1 M) and extracted with ethyl acetate (10 ml $\times$ 3) The combined organic layers were washed with saturated brine (10 ml), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reversed-phase flash chromatography (Column: sphere C18, 20-40 μ m, 120 g; Mobile phase A: 10 mm $\text{NH}_3\cdot\text{H}_2\text{O}$ in water; Mobile phase B: acetonitrile; Flow rate: 80 ml/min; Gradient: 30% B-50% B in 20 min; Detector: 254 nm) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy) methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-3-((1-ethyl-1h-imidazol-5-yl)methyl)-3H-imidazole[4,5-b]pyridine-5-carboxylic acid (30.28 mg, 24.5% yield). LC-MS m/z : 611 $[\text{M}+\text{H}]^+$.

^1H NMR(400 MHz, $\text{DMSO}-d_6$) δ 8.16-8.13(m, 1H), 8.02-7.99(m, 1H), 7.88(d, J =11.6 Hz, 1H), 7.74-7.70(m, 1H), 7.67-7.65(m, 2H), 7.46-7.42(m, 1H), 7.05(d, J =7.6 Hz, 1H), 6.74-6.71(m, 2H), 5.72(s, 2H), 5.30(s, 2H), 4.90-4.87(m, 1H), 4.17-4.12(m, 2H), 3.80(s, 2H), 2.73-2.67(m, 2H), 2.28-2.24(m, 2H), 1.87-1.84(m, 2H), 1.57-1.55(m, 2H), 1.12-1.08(m, 3H).

Example 26. Synthesis of 2-((4-((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C7):


1). Synthesis of methyl 4-(2-(4-((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate:



To a mixture of methyl 4-(2-(4-((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate:


(cyanomethyl)cyclopropyl)methyl)amino)benzoate (200 mg, 0.60 mmol) and 2-((4-chloro-2-fluorophenylthio)methyl)-6-(piperidin-4-oxy)pyridine (210 mg, 0.60 mmol) in N,N-dimethylformamide (4 mL) potassium carbonate (247 mg, 1.80 mmol) was added. The reaction was stirred at room temperature for 16 hours. After completion, the resulting mixture was poured into brine (10 mL) and extracted with ethyl acetate (2 × 5 mL). The combined organic layer was concentrated to give residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-(4-((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl) amino)benzoate (300 mg, 77.3% yield). LC-MS m/z: 652 [M+H]⁺.

2). Synthesis of methyl 2-((4-((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 4-(2-(4-((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (300 mg, 0.46 mmol) in toluene (10 mL) and acetic acid (4 mL) was stirred at 110 °C for 16 hours under nitrogen atmosphere. After completion, the mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-((6-((4-chloro-2-fluorophenylthio)methyl)-pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (210 mg, 80.0% yield). LC-MS m/z: 634 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-Chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-(((4-(((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (210 mg, 0.33 mmol) in THF (1 mL) and water (1 mL) lithium hydroxide (79 mg, 3.30 mmol) was added. The mixture was stirred at 40 °C for 16 hours. The solvent was removed by concentration in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.05% NH₄OH in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-(((4-(((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidine-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (19.36 mg, 9.4% yield). LC-MS m/z: 620 [M+H]⁺.

¹H NMR(400 MHz, DMSO-d₆)δ 8.23(s, 1 H), 7.81(d, *J*=8.8 Hz, 1 H), 7.65-7.61(m, 3 H), 7.29-7.21(m, 2 H), 6.98(d, *J*=7.2 Hz 1 H), 6.63(d, *J*=8.4 Hz, 1 H), 4.87-4.85(m, 1 H), 4.59(s, 2 H), 4.30(s, 2H), 3.83(s, 2 H), 2.78-2.75(m, 2 H), 2.68(d, *J*=6.8 Hz, 2 H), 2.32-2.28(m, 2 H), 1.90-1.88(m, 2 H), 1.60-1.57(m, 2 H), 0.74-0.67(m, 4 H).

Example 27. Synthesis of 2-(((4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound 133):

1). Synthesis of methyl 4-(2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate:




To a mixture of methyl 4-(2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (160 mg, 0.48 mmol) and 3-fluoro-4-(((6-((Piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (187 mg, 0.57 mmol) in N,N-dimethylformamide (10 mL) potassium carbonate (197 mg, 1.43 mmol) was added. The

reaction mixture was stirred at room temperature for 16 hours. The mixture was poured into brine (20 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy))

5 methylpyridin-2-yl)oxy)-piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (290 mg, 94.2% yield). LC-MS m/z: 627 [M+H]⁺.

2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate:

10




The mixture of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (290 mg, 0.46 mmol) in toluene (10 mL) and acetic acid (10 mL) was stirred at 110°C for 16

15 hours under nitrogen atmosphere. The mixture was concentrated and purified by silica gel column chromatography (dichloromethane/methanol=40/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)-methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (250 mg, 88.9% yield). LC-MS m/z: 609 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:

20



To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)-methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (125 mg, 0.21 mmol) in THF (5 mL) and water (5 mL)


25

lithium hydroxide monohydrate (86 mg, 2.10 mmol) was added. The mixture was stirred at 40 °C for 3 hours. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.05% NH₄OH in H₂O solvent system; Detection Wavelength 254 nm/214 nm; Flow rate 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (40.09 mg, 32.8% yield). LC-MS m/z: 595 [M+H]⁺.

¹H NMR(400 MHz, DMSO-d₆)δ 8.22(s, 1 H), 7.89-7.86(m, 1 H), 7.81(d, *J*=8.4 Hz, 1H), 7.73(t, *J* = 7.6 Hz, 1H), 7.67-7.61(m, 2 H), 7.45(t, *J*=8.8 Hz, 1 H), 7.05(d, *J*=7.6 Hz, 1H), 6.73(d, *J*=8.0 Hz, 1 H), 5.31(s, 2H), 4.94-4.90(m, 1 H), 4.60(s, 2 H), 3.84(s, 2 H), 2.80-2.77(m, 2 H), 2.70(s, 2 H), 2.33-2.28(m, 2 H), 1.92-1.90(m, 2 H), 1.65-1.58(m, 2 H), 0.74-0.69(m, 4 H).


Example 28. Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound 56):

1). Synthesis of (S)-N-(4-bromo-2-fluoro-6-((oxetan-2-ylmethyl)amino)phenyl)-2-((6-((4-cyano-2-fluoro-phenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido




The mixture of (S)-N-(4-bromo-2-fluoro-6-((oxetan-2-ylmethyl)amino)phenyl)-2-chloroacetamido (230 mg, 0.65 mmol), 3-fluoro-4-((6-(piperidin-4-yl)pyridin-2-yl)methoxy)benzonitrile (214 mg, 0.65 mmol) and potassium carbonate (271 mg, 1.95 mmol) in dry N,N-dimethylformamide (7 mL) was stirred at room temperature for 16 hours. After completion, the reaction mixture was quenched with water (10 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to give (S)-N-(4-bromo-2-fluoro-6-((oxetan-2-ylmethyl)amino)phenyl)-2-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido (300 mg, 71.9% yield). LC-MS m/z: 644 [M+H]⁺.

2). Synthesis of (S)-4-((6-((1-((6-bromo-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile:



5 The mixture of (S)-N-(4-bromo-2-fluoro-6-((oxoalk-2-ylmethyl)amino)phenyl)-2-(4-((6-((4-cyano-2-fluorophen-oxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido (230 mg, 0.36 mmol) in dioxane (5 mL) and acetic acid (0.5 mL) was stirred at 110 °C for 16 hours. The mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain (S)-4-((6-((1-((6-bromo-4-fluoro-1)-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluoroben-zonitrile (80 mg, 35.7% yield). LC-MS m/z: 626 [M+H]⁺.


3). Synthesis of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



To a mixture of (S)-4-((6-((1-((6-bromo-4-fluoro-1-(oxetan-2-ylmethyl))-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile (61 mg, 0.10 mmol) in N,N-dimethylformamide (2 mL) and methanol (2 mL) triethylamine (30 mg, 0.30 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (7 mg, 0.01 mmol) were added. The mixture was stirred at 80 °C for 16 hours under carbon monoxide atmosphere. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with saturated brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain

methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (30 mg, 50.8% yield). LC-MS m/z : 604 $[M+H]^+$.

4). Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (37 mg, 0.06 mmol) in water (1 mL) and THF (1 mL) lithium hydroxide (14 mg, 0.60 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction solution was adjusted to pH=5-6 with formic acid and extracted with ethyl acetate (10 mL $\times$ 2). The combined organic layers were washed saturated brine (10 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μ m, 120 g; Mobile Phase A: 10 mmol FA in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 30%B-50%B in 20 min; Detector: 254 nm) to obtain (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (6.63 mg, 18.3% yield). LC-MS m/z : 590 $[M+H]^+$.

^1H NMR (400 MHz, DMSO- d_6): δ 8.09(s, 1H), 7.89(dd, $J=11.2$ Hz, 1.6 Hz 1H), 7.75-7.66(m, 2H), 7.52-7.43(m, 2H), 7.06(d, $J=7.6$ Hz, 1H), 6.74(d, $J=8.4$ Hz, 1H), 5.31(s, 2H), 5.11-5.06(m, 1H), 4.95-4.89(m, 1H), 4.81-4.76(m, 1H), 4.66-4.63(m, 1H), 4.52-4.47(m, 1H), 4.40-4.34(m, 1H), 3.96-3.92(m, 1H), 3.81-3.78(m, 1H), 2.79-2.67(m, 3H), 2.46-2.41(m, 1H), 2.33-2.27(m, 2H), 1.93-1.89(m, 2H), 1.64-1.57(m, 2H).


Example 29. Synthesis of (S)-2-((4-((6-((4-chloro-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C8)

1). Synthesis of methyl (S)-2-((4-(((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



5 The mixture of 2-((4-chloro-2-fluorophenylthio)methyl)-6-(piperidin-4-oxy)pyridine (144 mg, 0.41 mmol), methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (120 mg, 0.41 mmol) and potassium carbonate (168 mg, 1.23 mmol) in N,N-dimethylformamide (4 mL) was stirred at 60 °C for 3 hours. The mixture was diluted with water (30 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic
10 layers were washed with brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give methyl (S)-2-((4-(((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (80 mg, 32.0% yield). LC-MS m/z: 611 [M+H]⁺.

2). Synthesis of (S)-2-((4-(((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-((4-(((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (80 mg, 0.13 mmol) in water (1.0 mL) and THF (1.0 mL) lithium hydroxide (9 mg, 0.39 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10μm 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm;
25

Flow rate: 20 mL/min) to obtain (S)-2-((4-(((6-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (20.29 mg, 26.2% yield). LC-MS *m/z*: 597 [M+H]⁺.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.26(s, 1 H), 7.81-7.79(m, 1 H), 7.65-7.61(m, 3 H), 7.28-7.22(m, 2 H), 6.98(d, *J*=7.2 Hz, 1 H), 6.64(d, *J*=8.0 Hz, 1 H), 5.10-5.07(m, 1 H), 4.86(s, 1 H), 4.81-4.75(m, 1 H), 4.65-4.61(m, 1 H), 4.51-4.49(m, 1 H), 4.38-4.34(m, 1 H), 4.30(s, 2 H), 3.93(d, *J*=13.6 Hz, 1 H), 3.77(d, *J*=13.6 Hz, 1 H), 2.75-2.67(m, 3 H), 2.46-2.39(m, 1 H), 2.31-2.26(m, 2 H), 1.88-1.87(m, 2 H), 1.60-1.56(m, 2 H).


Example 30. Synthesis of (S)-2-((4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound 55):

1). Synthesis of methyl (S)-2-((4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 0.51 mmol), 3-fluoro-4-(((6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (184 mg, 0.56 mmol) and potassium carbonate (176 mg, 1.27 mmol) in N,N-dimethylformamide (8 mL) was stirred at 60 °C for 3 hours. The mixture was quenched with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl (S)-2-((4-(((6-((4-cyano-2-fluorophenoxy)methyl))pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carbox-ylate (100 mg, 33.5% yield). LCMS *m/z*: 586 [M+H]⁺.

2). Synthesis of (S)-2-((4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-(((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.17 mmol) in THF (2 mL) and water (2 mL) lithium hydroxide (13 mg, 0.51 mmol) was added. The reaction was stirred at room temperature for 16 hours. The resulting mixture was adjusted to pH=5-6 with formic acid. The solvent was removed by concentration to give a residue in vacuo. The residue was eluted by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S)-2-(((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (56.80 mg, 58.6% yield). LC-MS m/z: 572 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.23(s, 1 H), 7.88(dd, *J*=2.0 Hz, 11.6 Hz, 1 H), 7.80(dd, *J*=1.6, 8.8 Hz, 1 H), 7.73(t, *J*=8.0 Hz, 1 H), 7.67(d, *J*=8.4 Hz, 1 H), 7.60(d, *J*=8.8 Hz, 1 H), 7.45(t, *J*=8.4 Hz, 1 H), 7.06(d, *J*=7.6 Hz, 1 H), 6.74(d, *J*=8.4 Hz, 1 H), 5.31(s, 2 H), 5.10-5.08(m, 1 H), 4.92-4.90(m, 1 H), 4.80-4.74(m, 1 H), 4.65-4.61(m, 1 H), 4.50-4.47(m, 1 H), 4.40-4.35(m, 1 H), 3.93(d, *J*=13.6 Hz, 1 H), 3.78(d, *J*=13.6 Hz, 1 H), 2.79-2.67(m, 3 H), 2.51-2.41(m, 1 H), 2.32-2.27(m, 2 H), 1.92-1.89(m, 2 H), 1.63-1.58(m, 2 H).

Example 31. Synthesis of 2-(((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid (Compound S41)


1). Synthesis of N-(4-bromo-2-((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)acetamide:



The mixture of N-(4-bromo-2-((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-chloroacetamide (189 mg, 0.50 mmol), 2-((4-chloro-2-fluorobenzyl)oxy)-3-fluoro-6-(piperidin-4-oxy)pyridine (90 mg, 0.50 mmol) and potassium carbonate (140 mg, 1.00 mmol) in dry N,N-dimethylformamide (4 mL) was stirred at room temperature for 16 hours.


5 When completion, it was quenched with water (10 mL) and extracted with dichloromethane (3×10 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to give N-(4-bromo-2-((1-(cyanomethyl)-cyclopropyl)methyl))amino)-6-fluorophenyl)-2-(4-(((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)acetamide (218 mg, 62.6% yield). LC-MS m/z : 694 $[M+H]^+$.

2). Synthesis of 2-(1-(((6-bromo-2-((4-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidine-1-yl)methyl)-4-fluoro-1H-benzo[d]imidazol-1-yl)methyl)cyclopropyl)acetonitrile:



15 The mixture of N-(4-bromo-2-((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-(4-(((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)acetamide (218 mg, 3.17 mmol) in toluene (4 mL) and acetic acid (1 mL) was stirred at 110°C for 16 hours. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain 2-(1-(((6-bromo-2-((4-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1H-benzo[d]-imidazol-1-yl)methyl)cyclopropyl)acetonitrile (45 mg, 21.2% yield). LC-MS m/z : 676 $[M+H]^+$.


3). Synthesis of methyl 2-((4-(((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate:



To a mixture of 2-(1-(((6-bromo-2-((4-(((6-((4-chloro-2-fluorobenzyl)oxy)-5-

fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1H-benzo[d]imidazol-1-yl)methyl)cyclopropyl)acetonitrile (220 mg, 0.33 mmol) in N,N-dimethylformamide (10 mL) and methanol (10 mL) triethylamine (60 mg, 0.6 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (20 mg, 0.03 mmol) were added under carbon monoxide atmosphere. The mixture was stirred at 80°C for 16 hours, diluted with water (50 mL) and extracted with ethyl acetate (100 mL × 2). The combined organic layers were washed with brine (50 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=2/1) to obtain methyl 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate (93.7 mg, 43.5% yield). LC-MS m/z: 654 [M+H]⁺.

4). Synthesis of 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate (18 mg, 0.03 mmol) in THF (1 mL) and water (1 mL) lithium hydroxide (7 mg, 0.30 mmol) was added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was adjusted to pH=5-6 with formic acid. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient eluted ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidine-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid (4.84 mg, 27.5% yield). LC-MS m/z: 640 [M+H]⁺.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.07(s, 1H), 7.66-7.61(m, 1H), 7.54-7.47(m, 3H), 7.32(dd, *J*=8.4 Hz, 2.0 Hz 1H), 6.34(dd, *J*=8.8 Hz, 2.0 Hz 1H), 5.44(s, 2H), 4.81-4.76(m, 1H), 4.60(s, 2H), 3.86(s, 2H), 2.81-2.78(m, 2H), 2.70(s, 2H), 2.36-2.32(m, 2H), 1.92-1.90(m, 2H), 1.64-1.56(m, 2H), 0.76-0.69(m, 4H).


Example 32. Synthesis of 2-((4-((6-((4-chloro-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C9):

1). Synthesis of 4-(2-(4-((6-((4-chloro-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



To a mixture of methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (190 mg, 0.54 mmol) and 2-((4-chloro-2-fluorophenylthio)methyl)-6-(piperidin-4-oxy)pyridine (190 mg, 0.54 mmol) in N,N-dimethylformamide (5 mL) potassium carbonate (224 mg, 1.62 mmol) was added. The reaction was stirred at room temperature for 16 hours. After completion, the mixture was quenched with water (5 mL) and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with brine (20 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 4-(2-(4-((6-((4-chloro-2-fluorophenyl)thio)methyl)pyridine-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (149 mg, 41.5% yield). LC-MS m/z : 667 $[M+H]^+$.


2). Synthesis of methyl 2-((4-((6-((4-chloro-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate



The mixture of methyl 4-(2-(4-((6-((4-chloro-2-fluorophenyl)thio)methyl)pyridine-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (149 mg, 0.22 mmol) in toluene (6 mL) and acetic acid (1 mL) was stirred at 110 °C for 2 hours. The resulting mixture was poured into water (10 mL) and extracted with ethyl acetate (10 mL $\times$ 2). The combined organic layers were washed successively with saturated sodium

bicarbonate (10 mL × 2), brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=15/1) to obtain methyl 2-((4-((6-((4-chloro-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (129 mg, 90.5% yield). LC-MS m/z: 649 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-Chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((4-chloro-2-fluorophenylthio)methyl)pyridin-2-yl)oxypiperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (129 mg, 0.20 mmol) in THF (4 mL) and water (4 mL) lithium hydroxide monohydrate (47 mg, 1.99 mmol) was added. The reaction was stirred at room temperature for 16 hours. The resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1M) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: spherical C18, 20-40 μm, 120 g; Mobile Phase A: 10 mM NH₄OH in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 30%B-50%B in 20 min; Detector: 254 nm) to obtain 2-((4-((6-((4-chloro-2-fluorophenylthio)methyl)pyridine-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (58.36 mg, 0.09 mmol, 46% yield). LC-MS m/z: 635 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 8.08 (s, 1 H), 7.82 (dd, *J*=8.4 Hz, 1.2 Hz, 1 H), 7.69-7.67 (m, 2 H), 7.64-7.60 (m, 2 H), 7.30-7.22 (m, 2 H), 6.98 (d, *J*=7.2 Hz, 1 H), 6.62 (d, *J*=8.4 Hz, 1 H), 6.41 (s, 1 H), 5.72 (s, 2 H), 4.83-4.78 (m, 1 H), 4.29 (s, 2 H), 4.03-3.98 (m, 2 H), 3.80 (s, 2 H), 2.66-2.63 (m, 2 H), 2.25-2.21 (m, 2 H), 1.74 (s, 2 H), 1.45-1.42 (m, 2 H), 1.16 (t, *J*=7.2 Hz, 3 H).

Example 33. Synthesis of 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-


yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound 43):

1) Synthesis of methyl 4-(2-(4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



To a mixture of methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (190 mg, 0.54 mmol) and 2-((4-chloro-2-fluorophenoxy)methyl)-6-(piperidin-4-acyloxy)pyridine (181 mg, 0.54 mmol) in N,N-dimethylformamide (4 mL) potassium carbonate (224 mg, 1.62 mmol) was added at room temperature. The mixture was stirred for 16 hours at room temperature. After completion, the water (5 mL) was added to quench the reaction mixture, and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with brine (20 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=15/1) to obtain methyl 4-(2-(4-((6-((4-chloro-2-fluoro phenoxy)methyl)pyridine-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (241 mg, 0.37 mmol, 68.5% yield). LC-MS m/z: 651 [M+H]⁺.

2). Synthesis of methyl 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:




To a mixture of methyl 4-(2-(4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidine-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (241 mg, 0.37 mmol) in toluene (10 mL) acetic acid (1 mL) was added, and the reaction mixture was stirred at 110 °C for 16 hours. After completion, the obtained mixture was poured into water (10 mL) and extracted with ethyl acetate (10 mL $\times$ 2). The organic layer were washed

successively with saturated sodium bicarbonate (10 mL $\times$ 2) and brine (10 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=15/1) to obtain methyl

2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (87 mg, 37.8% yield). LC-MS m/z: 633 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (87 mg, 0.14 mmol) in THF(3 mL) and water (3 mL) lithium hydroxide monohydrate (56 mg, 1.40 mmol) was added and the reaction was stirred at room temperature for 16 hours. The resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1 N) and extracted with ethyl acetate (10 mL $\times$ 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μ m, 120 g; Mobile Phase A:10 mM NH₄OH in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min ; Gradient: 30%B-50%B in 20 min; Detector: 254 nm) to obtain 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridine-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]i-midazole-6-carboxylic acid (46.87 mg,55.4% yield). LC-MS m/z: 619 [M+H]⁺.

¹H NMR(400 MHz, DMSO-d₆) δ 8.02(s, 1 H), 7.80(d, *J*=8.4 Hz, 1 H), 7.72-7.67(m, 2 H), 7.56(d, *J*=8.4 Hz, 1 H), 7.44(dd, *J*=10.8, 2.0 Hz, 1 H), 7.27(t, *J*=9.2 Hz, 1 H), 7.18(d, *J*=8.8 Hz, 1 H), 7.03(d, *J*=7.2 Hz, 1 H), 6.70(d, *J*=8.4 Hz, 1 H), 6.38(s, 1 H), 5.67(s, 2 H), 5.17(s, 2H), 4.89-4.86(m, 1 H), 4.00(q, *J*=7.2 Hz, 2 H), 3.78(s, 2 H), 2.67(s, 2 H), 2.24(t, *J*=8.0 Hz, 2 H), 1.79(d, *J*=9.6 Hz, 2 H), 1.46(m, 2 H), 1.17(t, *J*=7.2 Hz, 3 H).


Example 34. Synthesis of (S)-2-((4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound 49):

1). Synthesis of methyl (S)-2-((4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of 2-((4-chloro-2-fluorophenoxy)methyl)-6-(piperidin-4-yl)pyridine (115 mg, 0.34 mmol), (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.34 mmol) and potassium carbonate (140 mg, 1.02 mmol) in N,N-dimethylformamide (4 mL) was stirred at 60 °C for 16 hours. After completion, the resulting mixture was diluted with water (40 mL) and extracted with ethyl acetate (20 mL × 2). The organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl (S)-2-((4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (110 mg, 54.5% yield). LC-MS m/z: 595 [M+H]⁺.

2). Synthesis of (S)-2-((4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:




To a mixture of methyl (S)-2-((4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-

carboxylate(110 mg, 0.19 mmol) in THF(2 mL)and water (2 mL) lithium hydroxide (9 mg, 0.38 mmol) was added, and the reaction mixture was stirred at room temperature for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S)-2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (52.13 mg, 47.2 %yield). LC-MS m/z: 581 [M+H]⁺.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.27(s, 1 H), 7.80(dd, *J*=8.4 Hz, 1.2 Hz, 1 H), 7.72(t, *J*=7.6 Hz, 1 H), 7.64(d, *J*=8.4 Hz, 1 H), 7.44(dd, *J*=11.2 Hz, 2.0 Hz, 1 H), 7.28(t, *J*=8.8 Hz, 1 H), 7.18(d, *J*=8.4 Hz, 1 H), 7.04(d, *J*=7.2 Hz, 1 H), 6.72(d, *J*=8.0 Hz, 1 H), 5.18(s, 2 H), 5.12-5.06(m, 1 H), 4.95-4.93(m, 1 H), 4.81-4.76(m, 1 H), 4.66-4.62(m, 1 H), 4.51-4.49(m, 1 H), 4.38-4.36(m, 1 H), 3.94(d, *J*=13.6 Hz, 1 H), 3.78(d, *J*=13.6 Hz, 1 H), 2.79-2.67(m, 2 H), 2.46-2.41(m, 1 H), 2.32(s, 2 H), 1.92-1.91(m, 2 H), 1.63-1.59(m, 2 H).

Example 35. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid (compound 2):

1). Synthesis of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorobenzoate:




The mixture of methyl 4-(2-chloroacetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorobenzoate(130 mg, 0.35 mmol), 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (115 mg, 0.35 mmol) and potassium carbonate (146 mg, 1.05 mmol) in N,N-dimethylformamide(5 mL) was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (50 mL) and extracted with ethyl acetate (10 mL × 3). The organic layer were washed with brine (10 mL × 3), and concentrated to give a residue in vacuo. The residue was purified by column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)

methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorobenzoate (70 mg, 30.3% yield). LC-MS m/z: 660 [M+H]⁺.


2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-4-fluoro-1H-

5 benzo[d]imidazole-6-carboxylate



The mixture of methyl 4-(2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl-1H-imidazol-5-yl)methyl)amino)-5-fluorobenzoate (70 mg, 0.11 mmol) in toluene (2 mL) and acetic acid (0.5 mL) was stirred at 110°C for 3 hours. After completion, The mixture was diluted with water (20 mL) and extracted with dichloromethane (2 × 25 mL). The organic phase was concentrated to give methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-4-fluoro-1H-benz-o[d]imidazole-6-carboxylate (40 mg, 56.7% yield). LC-MS m/z: 642 [M+H]⁺.

15 3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxypiperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate (40 mg, 0.062 mmol) in THF(4 mL) and water (4 mL) lithium hydroxide (4 mg) was added, and the reaction was stirred at room temperature for 16 hours. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10

um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid (8.49 mg, 22.6% yield). LC-MS m/z: 628 [M+H]⁺.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.20(s, 1 H), 7.93-7.86(m, 2 H), 7.74-7.65(m, 3 H), 7.52(d, *J*=11.6 Hz 1 H), 7.43(t, *J*=8.4 Hz 1 H), 7.04(d, *J*=7.2 Hz 1 H), 6.72(d, *J*=8.0 Hz 1 H), 6.42(s, 1 H), 5.74(s, 2 H), 5.30(s, 2 H), 4.86-4.84(m, 1 H), 4.03-3.98(m, 2 H), 3.83(s, 2 H), 2.67(s, 2 H), 2.27-2.22(m, 2 H), 1.79-1.76(m, 2 H), 1.46-1.44(m, 2 H), 1.17(t, *J*=7.2 Hz, 3 H).


Example 36. Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C10):

1). Synthesis of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methylthio)benzonitrile (152 mg, 0.44 mmol), methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.34 mmol) and potassium carbonate (140 mg, 1.02 mmol) in N,N-dimethylformamide (4 mL) was stirred at 60 °C for 3 hours. The resulting mixture was diluted with water (30 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to give methyl (S)-2-((4-((6-((4-cyano-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 56.6% yield). LC-MS m/z: 602 [M+H]⁺.

2). Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




5 To a mixture of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 0.25 mmol) in THF(2 mL) and water (2 mL) lithium hydroxide (10 mg, 0.75 mmol) was added. The mixture was stirred at room temperature for 16 hours. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters
10 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10 um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S)-2-((4-((6-((4-cyano-2-fluorophenylthio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (40.33 mg, 27.4% yield). LC-MS m/z: 588 [M+H]⁺.

15 ¹H NMR(400 MHz, DMSO-*d*₆): δ 8.26(s, 1 H), 7.84-7.75(m, 3 H), 7.68-7.62(m, 3 H), 7.02(d, *J*=7.2 Hz, 1 H), 6.65(d, *J*=8.4 Hz, 1 H), 5.10-5.08(m, 1 H), 4.81-4.75(m, 2 H), 4.66-4.61(m, 1 H), 4.53-4.47(m, 1 H), 4.41(s, 2 H), 4.39-4.36(m, 1 H), 3.93(d, *J*=13.6, 1 H), 3.77(d, *J*=13.6 Hz, 1 H), 2.77-2.67(m, 4 H), 2.46-2.41(m, 1 H), 2.28-2.23(m, 2 H), 1.91-1.86(m, 2 H), 1.59-1.55(m, 2 H).

20 **Example 37. Synthesis of 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)yl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid (compound S6):**


1). Synthesis of N-(4-bromo-2-(((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-(4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)acetamido:



25


To a mixture of 3-fluoro-4-((3-(piperidin-4-oxy)phenoxy)methyl)benzonitrile (130 mg, 0.40 mmol) and N-(4-bromo-2-((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-chloroacetamido (149 mg, 0.40 mmol) in N,N-dimethylformamide (4 mL) K_2CO_3 (165 mg, 1.20 mmol) was added. The mixture was stirred at 60 °C for 2 hours. The mixture was diluted with water (5 mL) and extracted with EA (2 × 30 mL). The combined organic phases were washed with brine (20 mL), dried over anhydrous Na_2SO_4 , filtered, and concentrated in vacuo to give N-(4-bromo-2-(((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-(4-(3-(((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)acetamido (180 mg, 67.9% yield). LC-MS m/z: 666, 664 $[M+H]^+$.

2). Synthesis of 4-((3-((1-((6-bromo-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-2-yl)methyl)piperidin-4-yl)oxy)phenoxy)methyl)-3-fluorobenzonitrile:




To a mixture of N-(4-bromo-2-((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-(4-(3-(((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)acetamido (160 mg, 0.24 mmol) in toluene (6 mL) AcOH (1 mL) was added, and the mixture was stirred at 110 °C for 32 hours. The resulting mixture was poured into H_2O (10 mL) and extracted with EA (2 × 10 mL). The combined organic layers were sequentially washed with saturated $NaHCO_3$ (2 × 10 mL), brine (10 mL × 2), dried over anhydrous Na_2SO_4 , filtered, and concentrated to give residue in vacuo. The residue was purified by reverse-phase column chromatography (Column: Spherical C18 column, 20-40 μm , 120 g; Mobile Phase A: 10 mM NH_4OH in water; Mobile Phase B: Acetonitrile; Flow Rate: 80 mL/min; Gradient: 60% B - 80% B in 20 min; Detector: 254 nm). The fractions containing the desired product were collected at 69% B and concentrated in vacuo to obtain 4-((3-((1-((6-bromo-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)oxy)phenoxy)methyl)-3-fluorobenzonitrile (142 mg, 91.3% yield). LC-MS m/z: 646, 648 $[M+H]^+$.

3). Synthesis of methyl 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)-cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate:



To a mixture of 4-((3-((1-((6-bromo-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)oxy)phenoxy)methyl)-3-fluorobenzonitrile (130 mg, 0.20 mmol) in methanol (5 mL)) KOAc (59 mg, 0.60 mmol) and Pd(dppf)Cl₂ (15 mg, 0.02 mmol) were added at room temperature under carbon monoxide atmosphere. The mixture was stirred at 90°C for 16 hours. The mixture was diluted with water (15 mL) and extract with ethyl acetate (3 × 30 mL). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na₂SO₄, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse phase column chromatography (Column: Spherical C18 column, 20-40 μm, 120 g; Mobile Phase A: 10 mM NH₄OH in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 60% B - 80% B in 20 min; Detector: 254 nm) to obtain methyl 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate (60 mg, 47.5% yield). LC-MS m/z: 626 [M+H]⁺.

4). Synthesis of 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate (60 mg, 0.10 mmol) in THF (2 mL) and H₂O (2 mL) lithium hydroxide monohydrate (40 mg, 1.00 mmol) was added and stirred at 40 °C for 3 hours. The resulting mixture was adjusted to pH=5-6 with HCl (1 M) and extracted with EA (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 40

g; Mobile Phase A: 10 mM NH₄OH in water ; Mobile Phase B: acetonitrile; Flow rate: 40 ml/min ; Gradient: 20%B-50%B in 20 min; Detection Wavelength: 254 nm) to obtain 2-((4-(3-((4-cyano-2-fluorobenzyl)oxy)phenoxy))piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid (26.23 mg, 43.5% yield). LC-MS m/z: 612 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆) δ 8.04 (s, 1 H), 7.91 (d, *J*=10.4 Hz, 1 H), 7.75 (d, *J*=3.2 Hz, 2 H), 7.49 (d, *J*=11.2 Hz, 1 H), 7.17 (t, *J*=8.0 Hz, 1 H), 6.62-6.57 (m, 3 H), 5.21 (s, 2 H), 4.60 (s, 2 H), 4.42-4.40 (m, 1 H), 3.85 (s, 2 H), 2.79-2.77 (m, 2 H), 2.70 (s, 2 H), 2.38 (t, *J*=10.0 Hz, 2 H), 1.93 (d, *J*=10.8 Hz, 2 H), 1.64-1.60 (m, 2 H), 0.75-0.67 (m, 4 H).


Example 38. Synthesis of 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C11):

1). Synthesis of methyl 4-(2-(4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:




The mixture of 2-((4-chloro-2-fluorobenzyl)oxy)-3-fluoro-6-(piperidin-4-oxy)pyridine (175 mg, 0.49 mmol), methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (184 mg, 0.49 mmol) and potassium carbonate (144 mg, 1.04 mmol) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. The resulting mixture was diluted with water (50 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-(4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (180 mg, 51.82% yield). LC-MS m/z: 669 [M+H]⁺.

2). Synthesis of methyl 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 4-(2-(4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (180 mg, 0.27 mmol) in toluene (3 mL) and acetic acid (1 mL) was stirred at 110 °C for 2 hours. The resulting mixture was poured into brine (20 mL) and extracted with dichloromethane (2 × 10 mL). The combined organic layer was concentrated to give a residue in vacuo to obtain methyl 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (140 mg, 77.9% yield). LC-MS *m/z*: 651 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (70 mg, 0.11 mmol) in THF (4 mL) and water (4 mL) lithium hydroxide (8 mg, 0.33 mmol) was added. The mixture was stirred at room temperature for 16 hours. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10μm 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength 254 nm/214 nm; Flow rate 20 mL/min) to give 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidine-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (37.86 mg, 54.1 % yield). LC-MS *m/z*: 637 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.08(s, 1 H), 7.82(d, *J*=8.4 Hz, 1 H), 7.69-7.60(m, 3 H), 7.53-7.46(m, 2 H), 7.31(dd, *J*=8.4 Hz, 2.0 Hz, 1 H), 6.42(s, 1 H), 6.33(dd, *J*=8.8 Hz, 2.0 Hz, 1 H), 5.72(s, 2 H), 5.43(s, 2 H), 4.74-4.71(m, 1 H), 4.03-3.98(m, 2 H), 3.82(s, 2 H), 2.69-2.67(m, 2 H), 2.29-2.24(m, 2 H), 1.79-1.77(m, 2 H), 1.46-1.42(m, 2 H), 1.16(t, *J*=7.2 Hz, 3 H).


Example 39. Synthesis of 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound S66):

1). Synthesis of 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a mixture of methyl 2-((4-((6-((4-chloro-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (132 mg, 0.20 mmol) and zinc cyanide (234 mg, 2.00 mmol) in N-methylpyrrolidone (2 mL) methanesulfonato(2-dicyclohexylphosphino-2',6'-di-i-propoxy-1,1'-biphenyl)(2'-amino-1,1'-biphenyl-2-yl)palladium(II) (17 mg, 0.02 mmol) and 2-dicyclohexylphosphine-2',4',6'-triisopropylbiphenyl (10 mg, 0.02 mmol) were added. The reaction mixture was stirred at 130 °C for 3 hours. After completion, the mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by pre-TLC chromatography (dichloromethane/methanol = 20/1) to give methyl 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridine-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (40 mg, 31.2% yield). LC-MS m/z: 642 [M+H]⁺.

2). Synthesis of 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-

yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate(40 mg, 0.06 mmol) in THF (4 mL) and water(4 mL) lithium hydroxide (4 mg, 0.17 mmol) was added . The mixture was stirred at room temperature for 16 hours. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-
 5 HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength 254 nm/214 nm; Flow rate: 20 mL/min) to give 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)-5-fluoropyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]-imidazole-6-carboxylic acid (6.35 mg, 16.9% yield). LC-MS m/z: 628 [M+H]⁺.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.07(s, 1 H), 7.93(dd, *J*=9.6 Hz, 0.8 Hz, 1 H), 7.81(dd, *J*=8.4 Hz, 1.2 Hz, 1 H), 7.73-7.62(m, 5 H), 6.40(s, 1 H), 6.34(dd, *J*=8.4 Hz, 2.0 Hz, 1 H), 5.71(s, 2 H), 5.52(s, 2 H), 4.65-4.63(m, 1 H), 4.03-3.97(m, 2 H), 3.81(s, 2 H), 2.67-2.65(m, 2 H), 2.25-2.20(m, 2 H), 1.74-1.71(m, 2 H), 1.43-1.36(m, 2 H), 1.16(t, *J*=7.2 Hz, 3 H).

Example 40. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C12):

1). Synthesis of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:




To a solution of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate(176 mg, 0.50 mmol) in N,N-dimethylformamide (5 mL) potassium carbonate (138 mg, 1.00 mmol) and 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methyl)sulfanyl)benzonitrile were added at room temperature (223 mg, 0.65 mmol). The mixture was stirred at room temperature for 3 hours. After completion, water (10 mL) was
 25 added to quench the reaction, and then it was extracted with ethyl acetate (15 mL × 2). The combined organic layers were washed with brine (15 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography(dichloromethane/methanol=10/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenylthio)-methyl))pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-

ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (141 mg, 42.9% yield). LC-MS m/z: 658 [M+H]⁺.

2). Synthesis of methyl 2-((4-((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-


5 benzo[d]imidazole-6-carboxylate:



To a mixture of 4-(2-(4-((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (141 mg, 0.21 mmol) in dioxane (5 mL) acetic acid (0.5 mL) was added at room temperature. The mixture was stirred at 100°C for 2 hours. After completion, the mixture was diluted with water (15 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic layers were washed with brine (20 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (130 mg, 96.7% yield). LC-MS m/z: 640 [M+H]⁺.

3). Synthesis of 2-((4-((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-

20 benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridine-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (130 mg, 0.20 mmol) in THF(2 mL) and water (2 mL) lithium hydroxide monohydrate (85 mg, 2.00 mmol) was added at room temperature. The mixture was stirred at

room temperature for 5 hours. After completion, the mixture was adjusted to pH=5-6 with formic acid, and extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 40 g; Mobile Phase A: 10 mM NH₄OH in water; Mobile Phase B: acetonitrile; Flow rate: 40 mL/min ; Gradient: 20%B-50%B in 20 min; Detector: 254 nm) to obtain 2-(((4-(((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (29.92 mg, 23.9% yield). LC-MS m/z: 626 [M+H]⁺.

¹H NMR(400 MHz, DMSO-d₆)δ 8.07(s, 1 H), 7.83(d, *J*=8.8 Hz, 2 H), 7.76(t, *J*=8.0 Hz, 1 H), 7.69-7.61(m, 4 H), 7.02(d, *J*=7.2 Hz, 1 H), 6.64(d, *J*=8.4 Hz, 1 H), 6.41(s, 1 H), 5.71(s, 2H), 4.75-4.74(m, 1 H), 4.40(s, 2 H), 4.04-3.98(m, 2 H), 3.80(s, 2 H), 2.67-2.64(m, 2 H), 2.21-2.17(m, 2 H), 1.76-1.74(m, 2 H), 1.44-1.41(m, 2 H), 1.16(t, *J*=7.2 Hz, 3 H).

Example 41. Synthesis of 2-(((4-(((6-(((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid (compound S20):


1). Synthesis of N-(4-bromo-2-(((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-(4-(((6-(((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)acetamide:



To a solution of N-(4-bromo-2-(((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-chloroacetamide (100 mg, 0.27 mmol) in N,N-dimethylformamide (5 mL) 3-fluoro-4-(((6-(piperidin-4-yl)oxy)pyridin-2-yl)oxy)methylbenzonitrile (88 mg, 0.27 mmol) and potassium carbonate (112 mg, 0.81 mmol) was added at room temperature. The mixture was stirred at room temperature for 16 hours. LCMS indicated the mixture was completed. The reaction was quenched by adding water (5 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give N-(4-bromo-2-(((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-(4-(((6-(((4-cyano-2-


fluorobenzyl)oxy)pyridin-2-yl)oxy)-piperidin-1-yl)acetamide (120 mg, 66.7% yield). LC-MS m/z : 665, 667 $[M+H]^+$.

2). Synthesis of 4-((6-((1-((6-bromo-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile:



To a mixture of N-(4-bromo-2-((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl-2-((4-((6-((1-((6-bromo-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (120 mg, 0.18 mmol) in toluene (6 mL) acetic acid (1 mL) was added. The mixture was stirred at 120 °C for overnight. After completion, the mixture was poured into water (10 mL) and extracted with ethyl acetate (10 mL $\times$ 2). The combined organic layer was washed with saturated sodium bicarbonate (10 mL $\times$ 2) and brine (10 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μ m, 120 g; Mobile Phase A: 10 mM NH_4OH in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 60%B-80%B in 20 min; Detector: 254 nm) to obtain 4-((6-((1-((6-bromo-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (100 mg, 83.3% yield). LC-MS m/z : 647, 649 $[M+H]^+$.


3). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate:



To a solution of 4-((6-((1-((6-bromo-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (100 mg, 0.15 mmol) in methanol/ N,N -dimethylformamide (5 mL/5 mL) triethylamine (45 mg, 0.45 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium

dichloride (15 mg, 0.02 mmol) were added at room temperature. The mixture was stirred at 90 °C for 16 hours under carbon monoxide atmosphere. After completion, water (15 ml) was added to quench the reaction. The mixture was extracted with ethyl acetate (30 mL×3). The combined organic layers were washed with brine (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 120 g; Mobile Phase A: water 10 mM NH₄OH in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min ; Gradient: 60%B-80%B in 20 min; Detector: 254 nm) to obtain methyl 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate (60 mg, 66.7% yield). LC-MS m/z: 627 [M+H]⁺.

4. Synthesis of 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridine-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyano-methyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate (60 mg, 0.10 mmol) in THF (3 mL) and water (3 mL) lithium hydroxide monohydrate (32 mg, 1.0 mmol) was added. The mixture was stirred at room temperature for 5 hours. After completion, the resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1 M) and extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 120 g; Mobile Phase A: 10 mM NH₄OH in water ; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min ; Gradient: 30%B-50%B in 20 min; Detector: 254 nm) to obtain 2-((4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridine-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyano-methyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylic acid (19.01 mg, 30% yield). LC-MS m/z: 613 [M+H]⁺.

¹H NMR(400 MHz, DMSO-d₆): δ 8.10(s, 1 H), 7.91(dd, *J*=10.4, 1.6 Hz, 1 H), 7.70(dd, *J*

=8.0, 1.2 Hz, 1 H), 7.63(t, $J=8.0$ Hz, 2 H), 7.53(d, $J=11.2$ Hz, 1 H), 6.45(d, $J=8.0$ Hz, 1 H), 6.35(d, $J=8.0$ Hz, 1 H), 5.45(s, 2 H), 4.81-4.77(m, 1 H), 4.61(s, 2 H), 3.87(s, 2 H), 2.80-2.77(m, 2 H), 2.70(s, 2 H), 2.30(t, $J=9.6$ Hz, 2 H), 1.87(d, $J=9.6$ Hz, 2 H), 1.60-1.54(m, 2 H), 0.77-0.68(m, 4 H).


Example 42. Synthesis of 2-((4-((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C13):

1). Synthesis of methyl 4-(2-(4-((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate:




The mixture of methyl 4-(2-chloroacetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (210 mg, 0.63 mmol), 3-fluoro-4-((6-((piperidin-4-oxy)pyridin-2-yl)methyl)thio)benzonitrile (214 mg, 0.63 mmol) and potassium carbonate (259 mg, 1.89 mmol) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. After completion, the resulting mixture was diluted with water (40 mL) and extracted with ethyl acetate (20 mL $\times$ 2). The combined organic layers were washed with brine (20 mL $\times$ 2) and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/ethyl acetate = 20/1) to obtain methyl 4-(2-(4-((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (300 mg, 28.6% yield). LC-MS m/z : 643[M+H]⁺.

2). Synthesis of methyl 2-((4-((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 4-(2-(4-(((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)-acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (300 mg, 0.47 mmol) in toluene (5 mL) and acetic acid (0.5 mL) was stirred at 110 °C for 3 hours. After completion, the resulting mixture was diluted with water (60 mL) and extracted with ethyl acetate (30 mL × 2). The combined organic layers were washed with brine (30 mL × 2), and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 2-(((4-(((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)-piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (200 mg, 68.1% yield). LC-MS m/z: 625 [M+H]⁺.

3). Synthesis of 2-(((4-(((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-(((4-(((6-(((4-cyano-2-fluorosulfanyl)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (200 mg, 0.33 mmol) in THF (2 mL) and water (2 mL) lithium hydroxide (24 mg, 0.99 mmol) was added at room temperature. The mixture was stirred at room temperature for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10 μm 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) purification to obtain 2-(((4-(((6-(((4-cyano-2-fluorophenyl)thio)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid formic salt (51.79 mg, 25.7% yield). LC-MS m/z: 611 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.25(s, 1 H), 8.19(s, 1 H), 7.84-7.75(m, 3 H), 7.68-7.62(m, 3 H), 7.02(d, *J*=6.8 Hz, 1 H), 6.65(d, *J*=8.0 Hz, 1 H), 4.83-4.79(m, 1 H), 4.60(s, 2 H), 4.41(s, 2 H), 3.85(s, 2 H), 2.79-2.76(m, 2 H), 2.68(s, 2 H), 2.29-2.24(m, 2 H), 1.89-1.87(m, 2 H), 1.61-1.55(m, 2 H), 0.75-0.68(m, 4 H).


Example 43. Synthesis of 1-((1-ethyl-1H-imidazol-5-yl)methyl)-2-((4-((4-ethynyl-2-fluorophenoxy)-methyl)pyridin-2-yl) oxypiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C14):

1). Synthesis of 1-((1-ethyl-1H-imidazol-5-yl)methyl)-2-((4-((6-((2-fluoro-4-((trimethylsilyl)ethynyl)benzene) methyl)oxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (240 mg, 0.35 mmol), ethynyltrimethylsilane (343 mg, 3.50 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (26 mg, 0.035 mmol) and triethylamine (354 mg, 3.50 mmol) was stirred at 90 °C for 2 hours. After the reaction mixture was completed, it was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 1-((1-ethyl-1H-imidazol-5-yl)methyl)-2-((4-((6-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzene[d]-imidazole-6-carboxylate (190 mg, 77.2% yield). LC-MS m/z : 695[M+H]⁺.

2). Synthesis of 1-((1-ethyl-1H-imidazol-5-yl)methyl)-2-((4-((4-ethynyl-2-fluorophenoxy)methyl)pyridin-2-yl) oxypiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 1-((1-ethyl-1H-imidazol-5-yl)methyl)-2-((4-((6-((2-fluoro-4-((trimethylsilyl)ethynyl)phen-oxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (160 mg, 0.23 mmol) in methanol (1.0 mL), water (1.0 mL)

and THF (1.0 mL) lithium hydroxide (44 mg, 1.84 mmol) was added. The reaction mixture was stirred at room temperature for 5 hours. After the completion of the reaction, the reaction mixture was adjusted to pH=5-6 by with formic acid. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to give 1-((1-ethyl-1H-imidazol-5-yl)methyl)-2-(((4-ethynyl-2-fluorophenoxy)))methyl)pyridin-2-yl)oxypiperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (14.25 mg, 10.2% yield). LC-MS m/z: 609 [M+H]⁺.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.06(s, 1 H), 7.81(dd, *J*=8.4 Hz, *J*=1.2 Hz, 1 H), 7.73-7.65(m, 3 H), 7.39-7.36(m, 1 H), 7.24-7.23(m, 2 H), 7.03(d, *J*=7.2 Hz, 1 H), 6.71(d, *J*=8.0 Hz, 1 H), 6.41(s, 1 H), 5.71(s, 2 H), 5.20(s, 2 H), 4.92-4.84(m, 1 H), 4.11(s, 1 H), 4.01-3.99(m, 2 H), 3.81(s, 2 H), 2.68-2.66(m, 2 H), 2.26-2.20(m, 2 H), 1.83-1.75(m, 2 H), 1.52-1.42(m, 2 H), 1.16(t, *J* = 7.2 Hz, 3 H).

Example 44. Synthesis of (S)-2-(((4-(((6-((4-ethynyl-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C15):


1). Synthesis of methyl (S)-2-(((4-(((6-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)methyl)pyridin-2-yl)oxy)pi-peridin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of ethynyltrimethylsilane (304 mg, 3.10 mmol), triethylamine (313 mg, 3.10 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (22 mg, 0.03 mmol) and methyl (S)-2-(((4-(((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (200 mg, 0.31 mmol) in DMSO (6 mL)) was stirred at 90 °C for 2 hours. After completion, the reaction was quenched with water (10 mL) at room temperature, and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl (S)-

2-((4-((6-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (260 mg, crude). LC-MS m/z: 657[M+H]⁺.

2). Synthesis of (S)-2-((4-((6-((4-ethynyl-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-((4-((6-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (210 mg, 0.32 mmol) in water (1 mL), THF (1 mL) and methanol (1 mL) lithium hydroxide (61 mg, 2.56 mmol) was added. The reaction mixture was stirred at room temperature for 5 hours. After the completion of the reaction, the reaction mixture was adjusted to pH=5-6 with formic acid. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm ; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S)-2-((4-((6-((4-ethynyl-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (10.76 mg, 5.9% yield). LC-MS m/z: 571[M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.27(s, 1 H), 7.80(d, *J*=8.0 Hz, 1 H), 7.74-7.70(m, 1 H), 7.64(d, *J*=8.8 Hz, 1 H), 7.38(d, *J*=11.2 Hz, 1 H), 7.25(s, 2 H), 7.05(d, *J*=6.8 Hz, 1 H), 6.73(d, *J*=8.0 Hz, 1 H), 5.21(s, 2 H), 5.10-5.08(m, 1 H), 4.96-4.94(m, 1 H), 4.79-4.75(m, 1 H), 4.64(d, *J*=15.2 Hz, 1 H), 4.52-4.49(m, 1 H), 4.38-4.36(m, 1 H), 4.13(d, *J*=2.8 Hz, 1 H), 3.94(d, *J*=14.0 Hz, 1 H), 3.78(d, *J*=13.2 Hz, 1 H), 2.79-2.69(m, 3 H), 2.44-2.32(m, 3 H), 1.93-1.87(m, 2 H), 1.63-1.61(m, 2 H).


Example 45. Synthesis of 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound 13):

1). Synthesis of methyl 4-(2-(4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



To a solution of methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (190 mg, 0.54 mmol) in N,N-dimethylformamide (5 mL) 3-fluoro-4-((3-(piperidin-4-oxy)benzyl)oxy)benzonitrile (196 mg, 0.60 mmol) and potassium carbonate (149 mg, 1.08 mmol) were added at room temperature. The mixture was stirred at room temperature for 16 hours. After completion, the mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL×3). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 4-(2-(4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (60 mg, 17.4% yield). LC-MS m/z: 641[M+H]⁺.


2). Synthesis of methyl 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a mixture of methyl 4-(2-(4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (60 mg, 0.09 mmol,) in dioxane (5 mL) acetic acid (0.5 mL) was added. The resulting mixture was stirred and reacted at 100 °C for 3 hours. After completion, the mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography

(dichloromethane/methanol=10/1) to obtain methyl 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]-imidazole-6-carboxylate (50 mg, 89.2% yield). LC-MS m/z : 623[M+H]⁺.


5 **3). Synthesis of 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:**




To a mixture of methyl 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (50 mg, 0.08 mmol) in THF (5 mL) and water (4 mL) lithium hydroxide monohydrate (34 mg, 0.80 mmol) was added. The resulting mixture was stirred at room temperature for 5 hours. After completion, the resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1 N) and extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following condition (Column: Spherical C18, 20-40 μm, 40 g; Mobile Phase A: 10 mM NH₄OH in water; Mobile Phase B: acetonitrile; Flow rate: 40 mL/min; Gradient: 20%B-50%B in 20 min; Detector: 254 nm) to obtain 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (10.33 mg, 21.2% yield). LC-MS m/z : 609 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 8.06 (s, 1 H), 7.88-7.80 (m, 2 H), 7.69-7.64 (m, 3 H), 7.42 (t, J =8.8 Hz, 1 H), 7.29 (t, J =8.0 Hz, 1 H), 7.02-6.98 (m, 2 H), 6.92 (dd, J =8.0 Hz, 2.0 Hz, 1 H), 6.41 (s, 1 H), 5.71 (s, 2 H), 5.24 (s, 2 H), 4.36-4.35 (m, 1 H), 4.03-3.97 (m, 2 H), 3.81 (s, 2 H), 2.69-2.67 (m, 2 H), 2.33-2.28 (m, 2 H), 1.83-1.81 (m, 2 H), 1.49-1.47 (m, 2 H), 1.15 (t, J =7.2 Hz, 3 H).

Example 46. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-

benzimidazole-6-carboxylic acid (compound 134):**1). Synthesis of N-(4-bromo-2-(((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamide:**


The mixture of N-(4-bromo-2-(((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-chloroacetamide (350 mg, 1.04 mmol), 3-fluoro-4-(((6-(piperidin-4-oxymethyl)pyridin-2-yl)methoxy)benzonitrile (389 mg, 1.04 mmol) and potassium carbonate (287 mg, 2.08 mmol)) in N, N-dimethylformamide (8 mL) was stirred at room temperature for 16 hours. Upon completion of the reaction, the resulting mixture was poured into brine (20 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layers were concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain N-(4-bromo-2-(((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophen-yl)-2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidine-1-yl)acetamide (693 mg, 99.0% yield). LC-MS m/z: 667 [M+H]⁺.

2). Synthesis of 4-(((6-(((1-((6-bromo-1-(((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile:

The mixture of N-(4-bromo-2-(((1-(cyanomethyl)cyclopropyl)methyl)amino)-6-fluorophenyl)-2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamide (690 mg, 1.04 mmol) in toluene(12 mL) and acetic acid (2 mL)) was warmed to 110 °C and stirred for 3 hours under nitrogen atmosphere. After completion, the resulting mixture was concentrated to give a residue. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain 4-(((6-(((1-((6-bromo-1-(((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile.


(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile (330 mg, 49.1% yield). LC-MS m/z : 649 $[M+H]^+$.

3). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate:



To a solution of 4-((6-((1-((6-bromo-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-2-yl)methyl)-piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile (200 mg, 0.31 mmol) in N,N-dimethylformamide (10 mL) and methanol (10 mL) triethylamine (94 mg, 0.93 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (25 mg, 0.03 mmol) were added at room temperature under carbon monoxide atmosphere. The mixture was stirred at 80 °C for 16 hours. After completion, the mixture was diluted with water (5 mL) and extracted with ethyl acetate (10 mL $\times$ 2). The combined organic layers were washed with brine (10 mL $\times$ 3), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzo[d]imidazole-6-carboxylate (150 mg, 77.5% yield). LC-MS m/z : 627 $[M+H]^+$.

4). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzimidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-

benzo[d]imidazole-6-carboxylate (150 mg, 0.24 mmol) in THF (3 mL) water (3 mL) lithium hydroxide (57 mg, 2.40 mmol) was added at room temperature. The resulting mixture was stirred and reacted at 40 °C for 3 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% NH₄OH in H₂O solvent system; Detection Wavelength 254 nm/214 nm; Flow rate: 20 mL/min) purification to give 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-4-fluoro-1H-benzimidazole-6-carboxylic acid (16.90 mg, 11.5% yield). LC-MS m/z: 613 [M+H]⁺.

¹H NMR(400 MHz, DMSO-d₆)δ 8.07(s, 1 H), 7.88(dd, *J*=11.2 Hz, 1.6 Hz, 1 H), 7.73(d, *J*=8.0 Hz, 1 H), 7.66(d, *J*=8.8 Hz, 1 H), 7.52-7.43(m, 2 H), 7.05(d, *J*=7.2 Hz, 1 H), 6.73(d, *J*=8.4 Hz, 1 H), 5.31(s, 2 H), 4.95-4.90(m, 1H), 4.61(s, 2 H), 3.86(s, 2 H), 2.81-2.78(m, 2 H), 2.70(s, 2 H), 2.34-2.29(m, 2 H), 1.94-1.91(m, 2 H), 1.66-1.61(m, 2 H), 0.76-0.67(m, 4 H).


Example 47. Synthesis of 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C84):

1). Synthesis of methyl 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 2-(chloromethyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (57 mg, 0.18 mmol), 2-((4-chloro-2-fluorophenoxy)methyl)-6-(piperidin-4-acyloxy)pyridine (61 mg, 0.18 mmol), and potassium carbonate (50 mg, 0.36 mmol) in N, N-dimethylformamide (5 mL) was stirred at to 60 °C for 2 hours. After completion, the resulting mixture was poured into brine (20 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to methyl 2-((4-((6-((4-chloro-2-fluorophenoxy) -methyl)pyridine-2-yl)oxypiperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (20 mg, 18.0% yield). LC-MS m/z: 618 [M+H]⁺.

2). Synthesis of 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




5 The mixture of methyl 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (20 mg, 0.03 mmol) and lithium hydroxide (7 mg, 0.30 mmol) in THF (2 mL) and (2 mL) was stirred at 40 °C and stirred for 3 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by
 10 prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% NH₄OH in H₂O solvent system; Detection Wavelength 254 nm/214 nm; Flow rate: 20 ml/min) to obtain 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (16.58 mg, 84.8 %
 15 yield). LC-MS m/z: 604 [M+H]⁺.

¹H NMR(400 MHz, DMSO-d₆)δ 8.26(s, 1 H), 7.82(d, *J*=8.4 Hz, 1 H), 7.74-7.66(m, 2 H), 7.44(d, *J*=11.2 Hz, 1H), 7.28(t, *J*=8.4 Hz, 1H), 7.19(d, *J*=8.8 Hz, 1 H), 7.05(d, *J*=6.8 Hz, 1 H), 6.72(d, *J*=8.4 Hz, 1H), 5.19(s, 2 H), 4.98-4.92(m, 1 H), 4.61(s, 2 H), 3.86(s, 2 H), 2.81-2.79(m, 2 H), 2.69(s, 2 H), 2.36-2.31(m, 2 H), 1.94-1.92(m, 2 H), 1.66-1.59(m, 2 H), 0.76-0.70(m, 4
 20 H).

Example 48. Synthesis of 2-((4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound 7):


1). Synthesis of methyl 4-(2-(4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)methyl benzoate:

25




The mixture of 4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidine (198 mg, 0.59 mmol), methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (190 mg, 0.54 mmol) and potassium carbonate (149 mg, 1.08 mmol) in N,N-dimethylformamide (7 mL) was stirred at room temperature for 16 hours. After completion, water (20 mL) was added to quench the reaction. The mixture was extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with brine (20 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 4-(2-(4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy))piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (210 mg, 59.8% yield). LC-MS m/z: 650 [M+H]⁺.

2). Synthesis of methyl 2-((4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzimidazole-6-carboxylate:



The mixture of methyl 4-(2-(4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (210 mg, 0.32 mmol) was dissolved in dioxane (10 mL) and acetic acid (1 mL) was stirred at 100 °C for 2 hours. After completion, the reaction solution was concentrated to give a residue. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzimidazole-6-carboxylate (158 mg, 78.1% yield). LC-MS m/z: 632 [M+H]⁺.

3). Synthesis of 2-((4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




5 The mixture of lithium hydroxide monohydrate (105 mg, 2.50 mmol) and methyl 2-((4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidine-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (158 mg, 0.25 mmol) in THF (5 mL) and water (4 mL) was stirred at room temperature for 16 hours. After completion, the resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1M) and extracted with ethyl acetate (10 mL×3). The combined organic phases were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 40 g; Mobile Phase A: 10 mM NH₄OH in water ; Mobile Phase B: Acetonitrile; Flow rate: 40 mL/min ; Gradient: 20%B-50%B in 20 min; Detector: 254 nm) to obtain 2-((4-(3-((4-chloro-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid formic acid (10.32 mg, 6.7% yield). LC-MS m/z: 618 [M+H]⁺.

¹H NMR(400 MHz, DMSO-d₆)δ 8.17(s, 1 H), 8.07(s, 1 H), 7.81(dd, *J*=8.4, 1.2 Hz, 1 H), 7.68(d, *J*=8.4 Hz, 2 H), 7.43(dd, *J*=11.6, 2.8 Hz, 1 H), 7.30-7.18(m, 3 H), 6.99-6.96(m, 2 H), 6.90(dd, *J*=8.0, 1.6 Hz, 1 H), 6.42(s, 1 H), 5.72(s, 2 H), 5.14(s, 2 H), 4.37-4.34(m, 1 H), 4.03-3.97(m, 2 H), 3.81(s, 2 H), 2.70-2.67(m, 2 H), 2.33-2.29(m, 2 H), 1.83-1.80(m, 2 H), 1.49-1.46(m, 2 H), 1.16(t, *J*=7.2 Hz, 3 H).


Example 49. Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C16):

1). Synthesis of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.34 mmol), 3-fluoro-4-((6-(piperidin-4-ylamino)pyridin-2-yl)methoxy)benzonitrile (110 mg, 0.34 mmol) and potassium carbonate (94 mg, 0.68 mmol) in N,N-dimethylformamide (4 mL) was stirred and reacted at 60 °C for 3 hours. After completion, the mixture was diluted with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl))pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (120 mg, 63.2% yield). LC-MS m/z: 585 [M+H]⁺.

2). Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl))pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (120 mg, 0.21 mmol) in THF (3 mL) and water (3 mL) lithium hydroxide (25 mg, 1.05 mmol) was added. The reaction was stirred at room temperature for 16 hours. After completion, the resulting mixture was adjusted to pH=5-6 with formic acid. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to give (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl))pyridin-2-

yl)amino)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (16.75 mg, 14.1% yield). LC-MS m/z : 571 $[M+H]^+$.

^1H NMR(400 MHz, $\text{DMSO}-d_6$): δ 8.27(s, 1 H), 7.88-7.79(m, 2 H), 7.66-7.64(m, 2 H), 7.45-7.34(m, 2 H), 6.55-6.51(m, 1 H), 6.39(d, $J=8.4$ Hz, 1 H), 5.15(s, 2 H), 5.10-5.09(m, 1 H), 4.81-4.76(m, 1 H), 4.64(d, $J=15.6$ Hz, 1 H), 4.51-4.49(m, 1 H), 4.40-4.38(m, 1 H), 3.93(d, $J=13.2$ Hz, 1 H), 3.75(d, $J=12.8$ Hz, 1 H), 3.63-3.62(m, 1 H), 2.87-2.84(m, 1 H), 2.74-2.67(m, 2 H), 2.46-2.41(m, 1 H), 2.21-2.11(m, 2 H), 1.85-1.82(m, 2 H), 1.40-1.34(m, 2 H).


Example 50. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound C17):

1). Synthesis of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:




To a mixture of methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (170 mg, 0.48 mmol) and 3-fluoro-4-((6-(piperidin-4-ylamino)pyridin-2-yl)methoxy)benzonitrile (158 mg, 0.48 mmol) in N,N -dimethylformamide (5 mL) potassium carbonate (132 mg, 0.96 mmol) was added at room temperature. The mixture was stirred at room temperature for 16 hours. After completion, the mixture was extracted with ethyl acetate ($10\text{ mL} \times 3$). The combined organic layers were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (65 mg, 41.8% yield). LC-MS m/z : 641 $[M+H]^+$.

2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (65 mg, 0.10 mmol) in toluene (3 mL) and acetic acid (0.5 mL) was stirred at 110 °C for 3 hours. After the completion of the reaction, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-6-carboxylate (45 mg, 71.4% yield). LC-MS m/z : 623 $[M+H]^+$.

3) Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)aminopiperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (45 mg, 0.07 mmol) in water (3.0 mL) and THF (3.0 mL) lithium hydroxide (7 mg, 0.28 mmol) was added. The reaction mixture was stirred at room temperature for 5 hours. After the completion of the reaction, the reaction mixture was adjusted to pH=5-6 with formic acid. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)amino)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (14.70 mg, 33.5% yield). LC-MS m/z : 609 $[M+H]^+$.

¹H NMR(400 MHz, DMSO-*d*₆): δ 8.05(s, 1 H), 7.87-7.79(m, 2 H), 7.68-7.63(m, 3 H), 7.44-7.34(m, 2 H), 6.53(d, *J*=7.2 Hz, 1 H), 6.47-6.44(m, 2 H), 6.40-6.38(m, 1 H), 5.72-5.69(m, 2 H), 5.14(s, 2 H), 4.02-3.97(m, 2 H), 3.78-3.76(m, 2 H), 3.59-3.54(m, 1 H), 2.76-2.67(m, 2 H), 2.14-2.07(m, 2 H), 1.77-1.72(m, 2 H), 1.29-1.20(m, 2 H), 1.14(t, *J* = 7.2 Hz, 3 H).


Example 51. Synthesis of 1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-(((4-(((4-ethynyl-2-fluorophenoxy))methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C18):

1). Synthesis of methyl 4-(2-(4-(((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino)benzoate:




The mixture of methyl 4-(2-chloroacetamido)-3-(((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino)benzoate (300 mg, 0.80 mmol), 2-(((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidine (305 mg, 0.80 mmol) and potassium carbonate (221 mg, 1.60 mmol) in N,N-dimethylformamide (8 mL) was stirred at room temperature for 16 hours. After completion, the resulting mixture was diluted with water (30 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-(4-(((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino)benzoate (350 mg, 60.6% yield). LC-MS *m/z*: 723 [M+H]⁺.

2). Synthesis of methyl 2-(((4-(((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 4-(2-(4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino)benzoate (350 mg, 0.48 mmol) in toluene (4 mL) and acetic acid (0.4 mL) was stirred at 110° for 3 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (300 mg, 89.6% yield). LC-MS m/z: 705 [M+H]⁺.


3). Synthesis of methyl 1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-((4-((6-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 0.21 mmol), ethynyltrimethylsilane (206 mg, 2.10 mmol), triethylamine (212 mg, 2.10 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (15 mg, 0.02 mmol) in dry DMSO (5 mL) was purged with nitrogen at room temperature. The resulting mixture was warmed to 90 °C and stirred at 90 °C for 2 hours. After completion, the reaction solution was cooled to room temperature and quenched with water (60 mL), and then extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=15/1) to give methyl 1-((1-(cyclopropylmethyl)-1H-imidazol-5-

yl)methyl)-2-(((cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-((4-(((6-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carbox-ylate (80 mg, 52.8% yield). LC-MS m/z : 721 $[M+H]^+$.


4). Synthesis of 1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-((4-(((6-((4-ethynyl-2-fluorophenoxy)-methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:



To a mixture of methyl 1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-((4-(((6-((2-fluoro-4-(((trimethyl-silyl)ethynyl)phenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (80 mg, 0.11 mmol) in THF (2 mL), water (2 mL) and MeOH (2 mL) lithium hydroxide (8 mg, 0.33 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-2-((4-(((6-((4-ethynyl-2-fluorophenoxy)-methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (3.59 mg, 5.1% yield). LC-MS m/z : 635 $[M+H]^+$.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.05 (s, 1 H), 7.82 (dd, J =8.4 Hz, 1.2 Hz, 1 H), 7.73-7.65 (m, 3 H), 7.39-7.36 (m, 1 H), 7.24-7.23 (m, 2 H), 7.03 (d, J =7.2 Hz, 1 H), 6.71 (d, J =8.0 Hz, 1 H), 6.36 (s, 1 H), 5.74 (s, 2 H), 5.20 (s, 2 H), 4.88 (s, 1 H), 4.11 (s, 1 H), 3.89-3.82 (m, 4 H), 2.70-2.67 (m, 2 H), 2.28-2.24 (m, 2 H), 1.81-1.79 (m, 2 H), 1.48-1.46 (m, 2 H), 1.06-0.97 (m, 1 H), 0.49-0.46 (m, 2 H), 0.34-0.31 (m, 2 H).

Example 52. Synthesis of 2-((4-(((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C19):




To a mixture of methyl 2-((4-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxypiperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (60 mg, 0.09 mmol) in THF (4 mL) and water (4 mL) lithium hydroxide (6 mg, 0.27 mmol) was added at room temperature. The mixture was stirred at room temperature for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; flow rate 20 ml/min) to obtain 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (19.27 mg, 31.0% yield). LC-MS m/z: 691 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.17 (s, 1 H), 8.06 (s, 1 H), 7.81 (dd, *J*=8.4 Hz, 1.2 Hz, 1 H), 7.72-7.67 (m, 3 H), 7.54 (dd, *J*=10.8 Hz, 2.0 Hz, 1 H), 7.30 (d, *J*=9.2 Hz, 1 H), 7.21 (t, *J*=9.2 Hz, 1 H), 7.03 (d, *J*=7.2 Hz, 1 H), 6.70 (d, *J*=8.4 Hz, 1 H), 6.36 (s, 1 H), 5.75 (s, 2 H), 5.17 (s, 2 H), 4.88-4.87 (m, 1 H), 3.87-3.83 (m, 4 H), 2.70-2.67 (m, 2 H), 2.28-2.23 (m, 2 H), 1.80-1.78 (m, 2 H), 1.47-1.45 (m, 2 H), 1.06-0.97 (m, 1 H), 0.51-0.46 (m, 2 H), 0.34-0.32 (m, 2 H).


Example 53. Synthesis of 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyclopropyl methyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C20):

1). Synthesis of methyl 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 2-(chloromethyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.28 mmol), 3-fluoro-4-((3-(piperidin-4-oxy)benzyl)oxy)benzonitrile (92 mg, 0.28 mmol) and potassium carbonate (77 mg, 0.56 mmol) in N, N-dimethylformamide (3 mL) was warmed to 60 °C and stirred at 60 °C for 3 hours. After completion, the mixture was diluted with water (20 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (30 mg, 16.5% yield). LC-MS m/z: 649 [M+H]⁺.

2). Synthesis of 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (30 mg, 0.046 mmol) in THF (2 mL) and water (2 mL) lithium hydroxide (4 mg, 0.15 mmol) was added. The reaction was stirred at room temperature for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/ 2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1 % FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-(3-((4-cyano-2-

fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-(cyclopropyl-methyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (5.16 mg, 16.3% yield). LC-MS m/z : 635 $[M+H]^+$.

^1H NMR (400 MHz, DMSO- d_6): δ 8.19 (s, 1 H), 8.05 (s, 1 H), 7.88-7.80 (m, 2 H), 7.72-7.66 (m, 3 H), 7.42 (t, $J=8.8$ Hz, 1 H), 7.29 (t, $J=8.4$ Hz, 1 H), 7.02-6.98 (m, 2 H), 6.93-6.91 (m, 1 H), 6.36 (s, 1 H), 5.75 (s, 2 H), 5.24 (s, 2 H), 4.36 (s, 1 H), 3.86-3.82 (m, 4 H), 2.70-2.67 (m, 2 H), 2.33-2.29 (m, 2 H), 1.83-1.80 (m, 2 H), 1.48-1.46 (m, 2 H), 1.06-0.99 (m, 1 H), 0.49-0.46 (m, 2 H), 0.34-0.31 (m, 2 H).


Example 54. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid (compound C21):

1). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 2-(chloromethyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate (120 mg, 0.50 mmol), 3-fluoro-4-((6-(piperidin-4-yl)pyridin-2-yl)methoxy)benzonitrile (163 mg, 0.50 mmol) and potassium carbonate (138 mg, 1.0 mmol) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. After completion, the mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)-pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate (135 mg, 50.7% yield). LC-MS m/z : 530 $[M+H]^+$.

2). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate (135 mg, 0.25 mmol) in water (5 mL) and THF (5 mL) hydroxide lithium (60 mg, 2.50 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by Prep HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) purification to give 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid (72.01 mg, 55.9% yield). LC-MS m/z: 516 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 12.75 (s, 1H), 8.16-8.15 (m, 1H), 7.90-7.87 (m, 1H), 7.81 (dd, *J*=8.4, 1.6 Hz, 1H), 7.73 (t, *J*=8.0 Hz, 1H), 7.68-7.64 (m, 2H), 7.45 (t, *J*=8.4 Hz, 1H), 7.06 (d, *J*=7.2 Hz, 1H), 6.74 (d, *J*=8.4 Hz, 1H), 5.31 (s, 2H), 4.94-4.89 (m, 1H), 3.92 (s, 3H), 3.84 (s, 2H), 2.77-2.74 (m, 2H), 2.33-2.29 (m, 2H), 1.92-1.90 (m, 2H), 1.65-1.59 (m, 2H).


Example 55.: Synthesis of 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid (compound C22):

1). Synthesis of methyl 2-((4-((6-((4-Chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 2-(chloromethyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate (120 mg, 0.50 mmol), 2-((4-chloro-2-fluorophenoxy)methyl)-6-(piperidin-4-oxo)pyridine (170 mg, 0.50 mmol) and potassium carbonate (210 mg, 1.05 mmol) in N,N-dimethylformamide (10 mL) was stirred at room temperature for 16 hours. After completion, the mixture was concentrated to give a residue in vacuo. The residue was separated and purified by silica gel column (dichloromethane/methanol=19/1) to obtain methyl 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate (120 mg, 44.3% yield). LC-MS m/z: 539 [M+H]⁺.

2). Synthesis of 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylate (120 mg, 0.22 mmol) in water (4 mL) and THF (4 mL) lithium hydroxide (53 mg, 2.20 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazole-6-carboxylic acid (89.02 mg, 77.2% yield). LC-MS m/z: 525 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.15 (s, 1H), 7.81 (dd, *J*=8.4 Hz, 1.6 Hz, 1H), 7.71 (t, *J*=8.0 Hz, 1H), 7.64 (d, *J*=8.4 Hz, 1H), 7.44 (dd, *J*=11.2 Hz, 2.4 Hz, 1H), 7.28 (t, *J*=9.2 Hz, 2H), 7.18 (d, *J*=8.8 Hz, 1H), 7.04 (d, *J*=7.2 Hz, 1H), 6.71 (d, *J*=8.4 Hz, 1H), 5.18 (s, 2H), 4.94-4.92 (m, 1H), 3.92 (s, 3H), 3.83 (s, 2H), 2.77-2.74 (m, 2H), 2.34-2.29 (m, 2H), 1.93-1.91 (m, 2H), 1.65-1.61 (m, 2H).

Example 56. Synthesis of (S)-2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C23):

1). Synthesis of (S)-N-(4-bromo-2-fluoro-6-((oxetan-2-ylmethyl)amino)phenyl)-2-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamide:




The mixture of 2-((4-chloro-2-fluorophenoxy)methyl)-6-(piperidin-4-oxy)pyridine (1.63 g, 4.85 mmol), (S)-N-(4-bromo-2-fluoro-6-((oxetan-2-yl-methyl)amino)phenyl)-2-chloroacetamide (1.70 g, 4.85 mmol) and potassium carbonate (1.34 g, 9.70 mmol) in N,N-dimethylformamide (20 mL) was stirred at room temperature for 16 hours. After completion, the mixture was diluted with ethyl acetate (100 mL) and washed with saturated ammonium

chloride (20 mL × 3) and brine (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and reduced in pressure concentrate. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain (S)-N-(4-bromo-2-fluoro-6-((oxetan-2-yl-methyl)amino)phenyl)-2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamide (2.10 g, 66.6% yield). LC-MS m/z: 653 [M+H]⁺.

5 yloxy)piperidin-1-yl)acetamide (2.10 g, 66.6% yield). LC-MS m/z: 653 [M+H]⁺.

2). Synthesis of methyl (S)-6-bromo-2-(((4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl))-4-fluoro-1-(oxetan-2-yl-methyl)-1H-benzo[d]imidazole:




10 To a solution of (S)-N-(4-bromo-2-fluoro-6-((oxetan-2-yl-methyl)amino)phenyl)-2-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamide (500 mg, 0.77 mmol) in dioxane (10 mL) acetic acid (1 mL) was added at room temperature. The resulting mixture was stirred for at 100°C 16 hours. After completion, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain (S)-6-bromo-2-(((4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-yl-methyl)-1H-benzo[d]imidazole (220 mg, 45.2% yield). LC-MS m/z: 635 [M+H]⁺.

15 chromatography (petroleum ether/ethyl acetate=1/1) to obtain (S)-6-bromo-2-(((4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-yl-methyl)-1H-benzo[d]imidazole (220 mg, 45.2% yield). LC-MS m/z: 635 [M+H]⁺.

3). Synthesis of methyl (S)-2-(((4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-yl-methyl)-1H-benzo[d]imidazole-6-carboxylate:

20 carboxylate:




To a mixture of (S)-6-bromo-2-(((4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-yl-methyl)-1H-benzo[d]imidazole (100 mg, 0.16 mmol) in N,N-dimethylformamide (5 mL) and methanol (5 mL) triethylamine (48 mg, 0.48 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (15 mg, 0.02

25 mg, 0.48 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (15 mg, 0.02

mmol) were added at room temperature under carbon monoxide atmosphere. The mixture was stirred at 80 °C for 16 hours. After completion, the mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl (S)-2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-yl-methyl)-1H-benzo[d]imidazole-6-
 5 carboxylate (48 mg, 50.0% yield). LC-MS m/z: 613 [M+H]⁺.

4). Synthesis of (S)-2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:



To a mixture of methyl (S)-2-((4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-yl-methyl)-1H-benzo[d]imidazole-6-
 carboxylate (48 mg, 0.08 mmol) in THF (2 mL) and water (2 mL) lithium hydroxide
 monohydrate (34 mg, 0.80 mmol) was added at room temperature. The resulting mixture was
 15 stirred at room temperature for 5 hours. After completion, the resulting mixture was adjusted
 to pH=5-6 with hydrochloric acid (1 M) and extracted with ethyl acetate (10 mL×3). The
 combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate,
 filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase
 flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 40
 20 g; Mobile Phase A:10 mM NH₄OH in water; Mobile Phase B: acetonitrile; Flow rate: 40
 mL/min ; Gradient: 20%B-50%B in 20 min; Detector: 254 nm) to give (S)-2-((4-((6-((4-chloro-
 2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-4-fluoro-1-(oxetan-2-
 ylmethyl)-1H-benzo[d]imidazole -6-carboxylic acid (20.87 mg, 43.6% yield). LC-MS m/z:
 599 [M+H]⁺.


¹H NMR (400 MHz, DMSO-d₆) δ 8.11 (s, 1 H), 7.72 (t, *J*=7.6 Hz, 1 H), 7.54 (d, *J*=11.6 Hz, 1 H), 7.45 (dd, *J*=11.2 Hz, 2.8 Hz, 1 H), 7.28 (t, *J*=9.2 Hz, 1 H), 7.20-7.17 (m, 1 H), 7.04 (d, *J*=7.2 Hz, 1 H), 6.72 (d, *J*=8.4 Hz, 1 H), 5.19 (s, 2 H), 5.12-5.07 (m, 1 H), 4.97-4.92 (m, 1 H), 4.82-4.76 (m, 1 H), 4.65 (d, *J*=12.8 Hz, 1 H), 4.52-4.47 (m, 1 H), 4.39-4.34 (m, 1 H), 3.94 (d, *J*=13.6 Hz, 1 H), 3.79 (d, *J*=13.6 Hz, 1 H), 2.80-2.67 (m, 3 H), 2.46-2.41 (m, 1 H), 2.35-2.32

(m, 2 H), 1.93-1.91 (m, 2 H), 1.63-1.59 (m, 2H).

Example 57. Synthesis of 2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazole-5-yl)methyl)-1H-benzo[d]imidazole-6-


5 carboxylic acid (compound C24):

1). Synthesis of methyl 2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetate:



The mixture of methyl 2-(4-(((6-((methylsulfonyl)methyl)pyridin-2-yl)oxy)phenyl)acetate (410 mg, 1.17 mmol), 3-fluoro-4-hydroxybenzonitrile (171 mg, 1.17 mmol) and potassium carbonate (323 mg, 2.34 mmol) in N,N-dimethylformamide (6 mL) was stirred at room temperature for 16 hours. After completion, water (5 mL) was added to dilute the mixture, and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with brine (15 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetate (406 mg, 86.4% yield). LC-MS m/z: 402 [M+H]⁺.


2). Synthesis of 2-(4-(((6-((4-Chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetic acid:



To a mixture of methyl 2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridine-2-yl)oxy)phenyl)acetate (406 mg, 1.01 mmol) in THF(5 mL) and water (5 mL) lithium hydroxide monohydrate (424 mg, 10.10 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 5 hours. After completion, the resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1 M). The mixtures was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain 2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetic acid (248 mg, 63.3% yield). LC-MS


m/z: 388 [M+H]⁺.

3). Synthesis of methyl 4-(2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:



To a mixture of 2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetic acid (248 mg, 0.64 mmol), 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate(V) (365 mg, 0.96 mmol) and N,N-diisopropylethylamine (330 mg, 2.56 mmol) in N,N-dimethylformamide (3 mL) methyl 4-amino-3-((1-ethyl-1H-imidazol-5-yl)methyl)benzoate (175 mg, 0.64 mmol) was added at room temperature. The mixture was stirred at room temperature for 16 hours. After completion, the reaction was quenched by adding water (5 mL) and extracted with ethyl acetate (20 mL × 2). The combined organic layers washed with brine (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 4-(2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridine)-2-yl)oxy)phenyl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (232 mg, 56.3% yield). LC-MS m/z: 644 [M+H]⁺.


4). Synthesis of methyl 2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazole-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a solution of methyl 4-(2-(4-(((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (232 mg, 0.36 mmol) in dioxane (5 mL) acetic acid (0.5 mL) was added at room temperature. The resulting mixture was stirred at 100 °C for 2 hours. After completion, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-(4-(((6-((4-chloro-2-

fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-6-carboxylate (190 mg, 84.3% yield). LC-MS m/z: 626 [M+H]⁺.

5). Synthesis of 2-(4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazole-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a solution of methyl 2-(4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (190 mg, 0.30 mmol) dissolved in THF (2 mL) and water (2 mL) lithium hydroxide monohydrate (128 mg, 3.00 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 5 hours. After completion, the resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1 M) and extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by prep-HPLC (Gilson CA 258 system; Column: Agilent Prep C18 OBD 10um 21.2×250 mm; Gradient elution with ACN/0.1% NH₄OH solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-(4-((6-((4-chloro-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (20.10 mg, 10.9% yield). LC-MS m/z: 612 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 8.03 (s, 1 H), 7.88 (t, *J*=8.0 Hz, 1 H), 7.79 (dd, *J*=8.4 Hz, 1.6 Hz, 1 H), 7.63-7.58 (m, 2 H), 7.43 (dd, *J*=11.2 Hz, 2.4 Hz, 1 H), 7.30 (d, *J*=8.4 Hz, 2 H), 7.24-7.14 (m, 3 H), 7.04 (d, *J*=8.8 Hz, 2 H), 6.91 (d, *J*=8.4 Hz, 1 H), 6.35 (s, 1 H), 5.62 (s, 2 H), 5.10 (s, 2 H), 4.35 (s, 2 H), 3.93-3.87 (m, 2 H), 1.11 (t, *J*=7.6 Hz, 3 H).


Example 58. Synthesis of 1-((1-(cyanomethyl)cyclopropyl)methyl)-2-((4-((6-((4-ethynyl-2-fluorophenoxy)-methyl)pyridine-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C25):

1). Synthesis of methyl 4-(2-(4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate:




The mixture of methyl 4-(2-chloroacetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (513 mg, 2.50 mmol), 2-((4-bromo-2-fluorophenoxy)methyl)-6-(piperidin-4-yl)pyridine (950 mg, 2.50 mmol) and potassium carbonate (1.00 g, 7.50 mmol) in N,N-dimethylformamide (10 mL) was stirred at room temperature for 16 hours. Upon completion of the reaction, the resulting mixture was poured into brine (20 mL) and extracted with ethyl acetate (2 × 20 mL). The combined organic layer was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl 4-(2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)-benzoate (347 mg, 28.0% yield). LC-MS m/z: 680 [M+H]⁺.

2). Synthesis of methyl 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate:




To a solution of methyl 4-(2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidine-1-yl)acetamido)-3-((1-(cyanomethyl)cyclopropyl)methyl)amino)benzoate (347 mg, 0.51 mmol) in toluene (6 mL) acetic acid (1 mL) was added at room temperature. The resulting mixture was stirred for 2 hours at 110 °C under N₂ atmosphere. After completion, the reaction solution was concentrated to give a residue. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (336 mg, 99.7% yield). LC-MS m/z: 664 [M+H]⁺.

3). Synthesis of 1-((1-(cyanomethyl)cyclopropyl)methyl)-2-((4-((6-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)methyl)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (336 mg, 0.51 mmol), ethynyltrimethylsilane (500 mg, 5.10 mmol), triethylamine (515 mg, 5.10 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (37 mg, 0.05 mmol) in DMSO (5 mL) was stirred for 2 hours at 90°C under nitrogen protection. After completion, the resulting mixture was diluted with water (10 mL) at room temperature, and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 1-((1-(cyanomethyl)cyclopropyl)methyl)-2-((4-((6-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (258 mg, 76.1% yield). LC-MS *m/z*: 680 [M+H]⁺.

4). Synthesis of 1-((1-(cyanomethyl)cyclopropyl)methyl)-2-((4-((6-((4-ethynyl-2-fluorophenoxy)methyl)pyridine-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 1-((1-(cyanomethyl)cyclopropyl)methyl)-2-((4-((6-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (50 mg, 0.08 mmol) in THF (1 mL), water (1 mL) and methanol (1 mL) lithium hydroxide (19 mg, 0.80 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10μm 19 × 250 mm Column; Gradient elution with ACN/0.05% NH₄OH in H₂O solvent system; Detection

Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 1-((1-(cyanomethyl)cyclopropyl)methyl)-2-((4-((6-((4-ethynyl)-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (3.20 mg, 6.7% yield). LC-MS m/z: 594 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 8.24 (s, 1 H), 7.82 (d, *J*=8.0 Hz, 1 H), 7.72 (t, *J*=8.4 Hz, 1 H), 7.64 (d, *J*=8.4 Hz, 1 H), 7.40-7.37 (m, 1 H), 7.26-7.25 (m, 2 H), 7.05 (d, *J*=7.6 Hz, 1 H), 6.73 (d, *J*=8.0 Hz, 1 H), 5.22 (s, 2 H), 4.98-4.94 (m, 1 H), 4.61 (s, 2 H), 4.12 (s, 1 H), 3.86 (s, 2 H), 2.82-2.79 (m, 2 H), 2.69 (s, 2 H), 2.37-2.32 (m, 2 H), 1.95-1.91 (m, 2 H), 1.66-1.59 (m, 2 H), 0.76-0.68 (m, 4 H).


Example 59. Synthesis of 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C26):




To a mixture of 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylate (50 mg, 0.08 mmol) in THF (3 mL) and water (3 mL) lithium hydroxide (19 mg, 0.80 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 16 hours. After completion, the residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.05% NH₄OH in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-bromo-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyanomethyl)cyclopropyl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (16.81 mg, 32.5% yield). LC-MS m/z: 650 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 8.22 (s, 1 H), 7.81 (d, *J*=8.4 Hz, 1 H), 7.71 (t, *J*=8.0 Hz, 1 H), 7.61 (d, *J*=8.4 Hz, 1 H), 7.54 (dd, *J*=11.2 Hz, 2.0 Hz, 1 H), 7.30 (d, *J*=8.4 Hz, 1 H), 7.22 (t, *J*=8.8 Hz, 1 H), 7.03 (d, *J*=7.2 Hz, 1 H), 6.72 (d, *J*=8.0 Hz, 1 H), 5.18 (s, 2 H), 4.96-4.92 (m, 1 H), 4.60 (s, 2 H), 3.85 (s, 2 H), 2.81-2.78 (m, 2 H), 2.69 (s, 2 H), 2.35-2.30 (m, 2 H), 1.94-1.91 (m, 2 H), 1.66-1.61 (m, 2 H), 0.72-0.67 (m, 4 H).

Example 60. Synthesis of (S)-2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid


(Compound C27):**1). Synthesis of methyl (S)-4-(2-(4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetamido)-3-((oxetan-2-ylmethyl)amino)benzoate:**

5 To a mixture of 2-(4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetic acid (288 mg, 0.76 mmol) 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluroni-um hexafluorophosphate(V) (433 mg, 1.14 mmol) and N,N-diisopropylethylamine (392 mg, 3.04 mmol) in N,N-dimethylformamide (3 mL) methyl (S)-4-amino-3-((oxetan-2-ylmethyl)amino)benzoate (179 mg, 0.76 mmol) was added at room
10 temperature. The resulting mixture was stirred at room temperature for 16 hours. After completion, the mixture was quenched by adding water (5 mL) and extracted with ethyl acetate (20 mL×2). The combined organic layers were washed with brine (20 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain
15 methyl (S)-4-(2-(4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetamido)-3-((oxetan-2-ylmethyl)amino)benzoate (301 mg, 66.6% yield). LC-MS m/z: 597 [M+H]⁺.

2). Synthesis of methyl (S)-2-(4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:

20 To a mixture of (S)-4-(2-(4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetamido)-3-((oxetan-2-ylmethyl)amino)benzoate (301 mg, 0.51 mmol) in dioxane (10 mL) acetic acid (1 mL) was added at room temperature. The resulting mixture was stirred and reacted at 100 °C for 2 hours. After completion, the reaction solution was
25 concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl (S)-2-(4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (223 mg, 75.6% yield). LC-MS m/z: 579 [M+H]⁺.

3). Synthesis of (S)-2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (223 mg, 0.39 mmol) in THF (2 mL) and water (2 mL) lithium hydroxide (93 mg, 3.90 mmol) was added. The resulting mixture was stirred at room temperature for 5 hours. After completion, the obtained mixture was adjusted to pH=5-6 with formic acid, and extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by prep-HPLC (Gilson CA 258 system; Column: Agilent Prep C18 OBD 10um 21.2×250 mm; Gradient elution with ACN/0.1% NH₃.H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S)-2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (75.28 mg, 34.2% yield). LC-MS m/z: 565 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 8.14 (s, 1 H), 7.90 (t, *J*=7.6 Hz, 1 H), 7.84 (dd, *J*=11.2 Hz, 2.0 Hz, 1 H), 7.79 (dd, *J*=8.4 Hz, 1.2 Hz, 1 H), 7.62 (d, *J*=8.8 Hz, 1 H), 7.53 (d, *J*=8.4 Hz, 1 H), 7.38-7.33 (m, 3 H), 7.25 (d, *J*=7.2 Hz, 1 H), 7.07 (d, *J*=8.8 Hz, 2 H), 6.97 (d, *J*=8.0 Hz, 1 H), 5.21 (s, 2 H), 4.97-4.92 (m, 1 H), 4.65-4.59 (m, 1 H), 4.53-4.43 (m, 2 H), 4.39-4.32 (m, 3 H), 2.68-2.58 (m, 1 H), 2.38-2.30 (m, 1 H).

Example 61. Synthesis of 2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C28):


1). Synthesis of methyl 2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetate:



The mixture of 3-fluoro-4-hydroxybenzonitrile (22 mg, 0.16 mmol), potassium carbonate


(44 mg, 0.32 mmol) and methyl 2-(4-(((6-((methylsulfonyl)oxy)methyl)pyridin-2-yl)oxy)phenyl)acetate in N,N-dimethylformamide (2 mL) was stirred and reacted at 60°C for 3 hours. After completion, the mixture was diluted with water (5 mL) and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with brine (15 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ ethyl acetate=7/3) to obtain 2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridine-2-yl)oxy)phenyl)acetate (31 mg, 49.4% yield). LC-MS m/z: 393 [M+H]⁺.

2). Synthesis of 2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetic acid:



To a solution of methyl 2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetate (31 mg, 0.08 mmol) in THF (1.5 mL) and water (1.5 mL) lithium hydroxide monohydrate (33 mg, 0.80 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 5 hours. After completion, the resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1 M), then concentrated to give a residue. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain 2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetic acid (30 mg, 99.2% yield). LC-MS m/z: 379 [M+H]⁺.


3). Synthesis of methyl 4-(2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino) benzoate:



To a mixture of 2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetic acid (30 mg, 0.08 mmol), 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate(V) (65 mg, 0.12 mmol) and N,N-diisopropylethylamine (57 mg, 0.32 mmol) in N,N-dimethylformamide (2 mL) methyl 4-amino-3-((1-ethyl-1H-imidazole-5-yl)methyl)aminobenzoate (22 mg, 0.08 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 16 hours. When


completion, the mixture was quenched by adding water (5 mL) and extracted with ethyl acetate (20 mL $\times$ 3). The combined organic layers were washed with brine (15 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether: ethyl acetate=1/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl))pyridin-2-yl)oxy)phenyl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (27 mg, 54.7% yield). LC-MS m/z: 635 [M+H]⁺.

4). Synthesis of methyl 2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a solution of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)phenyl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (27 mg, 0.04 mmol) in dioxane (3 mL) acetic acid (0.3 mL) was added at room temperature. The resulting mixture solution was stirred at 100°C for 3 hours. After completion, the reaction solution was concentrated to give a residue under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (20 mg, 76.3% yield). LC-MS m/z: 617 [M+H]⁺.

5). Synthesis of 2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of (4 mg, 0.09 mmol) methyl 2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridine-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (20 mg, 0.03 mmol) in THF (2 mL) and water (2 mL) lithium

hydroxide monohydrate was added at room temperature. The resulting mixture solution was stirred at room temperature for 5 hours. After completion, the resulting mixture was adjusted to pH=5-6 with hydrochloric acid (1 M) and extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 40 g; mobile phase A: 10 mM NH₄OH in water; Mobile Phase B: acetonitrile; Flow rate: 40 mL/min; Gradient: 20%B-50%B in 20 min; Detector: 254 nm to obtain 2-((4-((4-cyano-2-fluorophenoxy)methyl)pyridine-2-yl)oxy)benzyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (2.77 mg, 15.1% yield). LC-MS m/z: 603 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 7.93 (s, 1 H), 7.89 (t, *J*=8.0 Hz, 1 H), 7.84 (dd, *J*=11.2 Hz, 2.0 Hz, 1 H), 7.78 (dd, *J*=8.0 Hz, 0.8 Hz, 1 H), 7.64-7.61 (m, 2 H), 7.43 (d, *J*=8.0 Hz, 1 H), 7.37 (t, *J*=8.4 Hz, 1 H), 7.29 (d, *J*=8.4 Hz, 2 H), 7.24 (d, *J*=7.6 Hz, 1 H), 7.02 (d, *J*=8.8 Hz, 2 H), 6.92 (d, *J*=8.4 Hz, 1 H), 6.29 (s, 1 H), 5.53 (s, 2 H), 5.22 (s, 2 H), 4.30 (s, 2 H), 3.95-3.90 (m, 2 H), 1.14 (t, *J*=7.2 Hz, 3 H).

Example 62. Synthesis of 2-((4-(3-((4-ethynyl-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C29):


1). Synthesis of methyl 4-(2-(4-(3-((4-bromo-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamido)-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate:



The mixture of methyl 4-(2-chloroacetamido)-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate (450 mg, 1.23 mmol), 4-(3-((4-bromo-2-fluorophenoxy)methyl)phenoxy)piperidine (467 mg, 1.23 mmol) and potassium carbonate (339 mg, 2.46 mmol) in dry N,N-dimethylformamide (10 mL) was stirred at room temperature for 16 hours. After completion, the reaction was quenched with water (10 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain


methyl 4-(2-(4-(3-((4-bromo-2-fluorophenoxy)methyl)phenoxy))piperidin-1-yl)acetamido)-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate (400 mg, 51.4% yield). LC-MS m/z : 710 $[M+H]^+$.

2). Synthesis of methyl 2-((4-(3-((4-bromo-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a solution of methyl 4-(2-(4-(3-((4-bromo-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamido)-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino) benzoate (400 mg, 0.56 mmol) in toluene (5 mL) acetic acid (0.5 mL) was added at room temperature. The resulting mixed solution was stirred and reacted at 110°C for 2 hours. After completion, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-(3-((4-bromo-2-fluorophenoxy)yl)methyl)phenoxy)piperidin-1-yl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazol-6-carboxylate (380 mg, 97.4% yield). LC-MS m/z : 692 $[M+H]^+$.

3). Synthesis of methyl 2-((4-(3-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)phenoxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:




The mixture of methyl 2-((4-(3-((4-bromo-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (280 mg, 0.41 mmol), ethynyltrimethylsilane (402 mg, 4.10 mmol), triethylamine (414 mg, 4.10 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (29 mg, 0.04 mmol) in DMSO (6 mL) was stirred at 90 °C for 2 hours under N₂ atmosphere. After completion, the reaction was quenched with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium

sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-(3-(((2)-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)phenoxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H benzo[d]imidazole-6-carboxylate (420 mg, crude). LC-MS

5 m/z: 708 [M+H]⁺.

4). Synthesis of 2-((4-(3-((4-ethynyl-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-(3-((2-fluoro-4-((trimethylsilyl)ethynyl)phenoxy)phenoxy)piperidin-1-yl)methyl)-1-((1-Isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (420 mg, 0.59 mmol) in methanol(1 mL), water (1 mL) and THF(1 mL) lithium hydroxide (113 mg, 4.72 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 5 hours.

15 After completion, the reaction mixture was adjusted to pH with formic acid = 5-6. The mixture was concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 40 g; Mobile Phase A: 10 mM NH₄OH in water; Phase B: acetonitrile; Flow rate: 40 mL/min; gradient: 20%B-50%B in 20 min; Detector: 254 nm) to obtain 2-((4-(3-((4-ethynyl-2-

20 fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo [d]Imidazole-6-carboxylic acid (23.6 mg, 6.4% yield). LC-MS m/z: 622 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.02 (s, 1H), 7.81-7.78 (m, 2H), 7.65 (d, *J*=7.6 Hz, 1H), 7.38-7.35 (m, 1H), 7.30-7.20 (m, 3H), 7.01-6.97 (m, 2H), 6.92-6.89 (m, 1H), 6.37 (s, 1H), 5.72 (s, 2H), 5.16 (s, 2H), 4.45-4.35 (m, 2H), 4.12 (s, 1H), 3.80 (s, 2H), 2.70-2.65 (m, 2H), 2.35-2.27 (m, 2H), 1.86-1.79 (m, 2H), 1.51-1.44 (m, 2H), 1.33-1.27 (m, 6H).

Example 63. Synthesis of 2-((4-(3-((4-bromo-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C30):




To a solution of 2-((4-(3-((4-bromo-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.16 mmol) in water (1 mL) and THF (1 mL), lithium hydroxide (10 mg, 0.42 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 16 hours. After completion, the reaction mixture was adjusted to pH=5-6 with formic acid. The mixture was concentrated to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1 % FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-(3-((4-bromo-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (13.21 mg, 12.2% yield). LC-MS m/z: 678 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.02 (s, 1H), 7.81-7.79 (m, 2H), 7.65 (d, *J*=8.4 Hz, 1H), 7.54 (dd, *J*= 10.8 Hz, 2.4Hz, 1H), 7.33-7.26 (m, 2H), 7.22-7.18 (m, 1H), 6.99-6.96 (m, 2H), 6.91-6.89 (m, 1H), 6.37 (s, 1H), 5.72 (s, 2H), 5.14 (s, 2H), 4.46-4.36 (m, 2H), 3.80 (s, 2H), 2.70-2.65 (m, 2H), 2.33-2.29 (m, 2H), 1.82-1.80 (m, 2H), 1.49-1.43 (m, 2H), 1.36-1.30 (m, 6H).

Example 64. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C31):


1). Synthesis of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate:



The mixture of 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (160


mg, 0.49 mmol), methyl 4-(2-chloroacetamido))-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate (178 mg, 0.49 mmol) and potassium carbonate (135 mg, 0.98 mmol) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. After completion, water (5 mL) was added to quench the reaction, and extracted with ethyl acetate (40 mL × 3). The combined organic layers were washed with brine (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate (155 mg, 48.3% yield). LC-MS m/z: 656 [M+H]⁺.

2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a solution of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate (155 mg, 0.27 mmol) in toluene (3 mL) acetic acid (0.5 mL) was added at room temperature. The reaction was stirred at 110°C for 2 hours. After completion, water (5 mL) was added to quench the reaction, and extracted with ethyl acetate (40 mL × 3). The combined organic layers were washed with brine (40 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (131 mg, yield: 87.3%). LC-MS m/z: 638 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (131 mg, 0.20 mmol) in THF (2 mL) and water (2 mL) lithium hydroxide (15 mg, 0.60 mmol) was added at room temperature. The mixture was stirred at room temperature for 16 hours. After completion, the resulting mixture was adjusted to pH=5-6 with acetic acid (1M), and then extracted with ethyl acetate (10 mL $\times$ 3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μ m, 40 g; Mobile Phase A: 10 mM NH_4OH in water; Mobile phase B: acetonitrile; Flow rate: 40 mL/min; Gradient: 20%B-50%B in 20 min; Detector: 254 nm) to give 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (35.02 mg, 28.0% yield). LC-MS m/z : 624 $[\text{M}+\text{H}]^+$.

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.03 (s, 1 H), 7.89-7.78 (m, 3 H), 7.74-7.64 (m, 3 H), 7.44 (t, $J=8.4$ Hz, 1 H), 7.05 (d, $J=7.2$ Hz, 1 H), 6.72 (d, $J=8.4$ Hz, 1 H), 6.37 (s, 1 H), 5.73 (s, 2 H), 5.30 (s, 2 H), 4.88-4.82 (m, 1 H), 4.46-4.40 (m, 1 H), 3.81 (s, 2 H), 2.74-2.57 (m, 2 H), 2.27-2.22 (m, 2 H), 1.86-1.79 (m, 2 H), 1.48-1.46 (m, 2 H), 1.34-1.29 (m, 6 H).

Example 65. Synthesis of 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C32):


1). Synthesis of methyl 4-(2-(4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamido)-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate:



The mixture of methyl 4-(2-chloroacetamido)-3-((1-isopropyl-1H-imidazol-5-


yl)methyl)amino)benzoate (120 mg, 0.33 mmol), 3-fluoro-4-((3-(piperidin-4-oxy)benzyl)oxy)benzonitrile (108 mg, 0.33 mmol) and potassium carbonate (91 mg, 0.66 mmol) in dry N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. After completion, the reaction was quenched with water (10 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic layers were washed with brine (10 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 4-(2-(4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamido-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate (130 mg, 60.5% yield). LC-MS m/z: 655 [M+H]⁺.

2). Synthesis of methyl 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a solution of methyl 4-(2-(4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamido-3-((1-isopropyl-1H-imidazol-5-yl)methyl)amino)benzoate (130 mg, 0.20 mmol) in toluene (3 mL) acetic acid (0.5 mL) was added at room temperature. The mixture was stirred at 110 °C for 2 hours. After completion, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)-1-((1-isopropyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 79.4% yield). LC-MS m/z: 637 [M+H]⁺.

3). Synthesis of 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid




To a mixture of methyl 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)-1-((1-isopropyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.16 mmol) in water (2 mL) and THF (2 mL) lithium hydroxide (12 mg, 0.48 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 16 hours. After completion, the reaction mixture was adjusted pH to 5-6 with formic acid. The mixture was concentrated to give a residue in vacuo. The residue was purified by prep-PLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1 % FA in H₂O solvent system; Detection Wavelength : 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)-1-((1-ethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (17.60 mg, 18.0% yield). LC-MS *m/z*: 623 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.03 (s, 1H), 7.88-7.80 (m, 3H), 7.67 (t, *J*=8.8 Hz, 2H), 7.42 (t, *J*=8.4 Hz, 1H), 7.29 (t, *J*=7.6 Hz, 1H), 7.03-6.98 (m, 2H), 6.93 (d, *J*=8.4 Hz, 1H), 6.38 (s, 1H), 5.73 (s, 2H), 5.24 (s, 2H), 4.45-4.37 (m, 2H), 3.81 (s, 2H), 2.69-2.68 (m, 2H), 2.34-2.29 (m, 2H), 1.82 (s, 2H), 1.49-1.47 (m, 2H), 1.34-1.32 (m, 6H).

Example 66. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound C33):


1). Synthesis of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino)benzoate:



The mixture of methyl 4-(2-chloroacetamido)-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)aminobenzoate (180 mg, 0.48 mmol), 3-fluoro-4-((6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (156 mg, 0.48 mmol) and potassium carbonate (133 mg, 0.96 mmol)


in N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. After completion, it was diluted with water (30 mL) and extracted with ethyl acetate (20 mL×3). The combined organic layers were washed with brine (30 mL) and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=15/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino) benzoate (200 mg, 62.8% yield). LC-MS m/z: 668 [M+H]⁺.

2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a solution of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)amino)benzoate (200 mg, 0.30 mmol) in dioxane (10 mL) acetic acid (1 mL) was added at room temperature. The resulting mixture was stirred and reacted at 100 °C for 3 hours. After completion, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=15/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 77.1% yield). LC-MS m/z: 650 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-

yl)oxypiperidin-1-yl)methyl)-1-(((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 0.23 mmol) in water (5 mL) and THF (5 mL) lithium hydroxide (56 mg, 2.30 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 16 hours. After completion, the reaction was adjusted to pH=5-6 with formic acid. The mixture was concentrated to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-(((4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(((1-(cyclopropylmethyl)-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (77.69 mg, 53.1% yield). LC-MS m/z: 636 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 12.76 (br, 1H), 8.06 (s, 1H), 7.90-7.81 (m, 2H), 7.74-7.65 (m, 4H), 7.44 (t, *J*=8.4 Hz, 1H), 7.05 (d, *J*=7.2 Hz, 1H), 6.72 (d, *J*=8.0 Hz, 1H), 6.37 (s, 1H), 5.75 (s, 2H), 5.30 (s, 2H), 4.85-4.84 (m, 1H), 3.87-3.83 (m, 4H), 2.69-2.67 (m, 2H), 2.27-2.22 (m, 2H), 1.79-1.77 (m, 2H), 1.47-1.41 (m, 2H), 1.04-1.00 (m, 1H), 0.51-0.46 (m, 2H), 0.35-0.31 (m, 2H).

Example 67. Synthesis of 2-(((4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(((1-ethyl-5-oxopyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound C34):


1). Synthesis of methyl 4-(2-(4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl)-5-oxopyrrolidin-2-yl)methyl)amino)benzoate:



The mixture of methyl 4-(2-chloroacetamido)-3-(((1-ethyl-5-oxopyrrolidin-2-yl)methyl)amino)benzoate (100 mg, 0.27 mmol), 3-fluoro-4-(((6-(piperidin-4-yl)pyridin-2-yl)methoxy)benzonitrile (88 mg, 0.27 mmol) and potassium carbonate (75 mg, 0.54 mmol) in N,N-dimethylformamide (2 mL) was stirred at room temperature for 16 hours. After completion, the mixture was diluted with water (30 mL) and extracted with ethyl acetate (10 mL×2). The combined organic layers were washed with brine (20 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified


by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl)-5-oxopyrrolidin-2-yl)methyl)amino)benzoate (90 mg, 50.7% yield). LC-MS m/z : 659 $[M+H]^+$.

5 **2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:**



10 The mixture of 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-(((1-ethyl)-5-oxopyrrolidin-2-yl)methyl)amino)benzoate (90 mg, 0.14 mmol) in toluene (3 mL) and acetic acid (0.5 mL) was stirred at 110° C for 3 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (70 mg, 78.1% yield). LC-MS m/z : 641 $[M+H]^+$.

15 **3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:**



20 To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxypiperidin-1-yl)methyl)-1-(((1-ethyl-5-oxopyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (70 mg, 0.11 mmol) in THF(5 mL) and water (5 mL) lithium hydroxide (8 mg, 0.33 mmol) was added at room temperature. The reaction was stirred at room temperature for 16 hours. After completion and concentrated to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep


C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength : 254 nm/214 nm; Flow rate : 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-5-oxopyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (32.33 mg, 46.9% yield).

5 LC-MS m/z: 627 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.27 (s, 1 H), 7.90-7.82 (m, 2 H), 7.75-7.66 (m, 3 H), 7.45 (t, *J*=8.8 Hz, 1 H), 7.06 (d, *J*=7.2 Hz, 1 H), 6.74 (d, *J*=8.4 Hz, 1 H), 5.31 (s, 2 H), 4.93-4.91 (m, 1 H), 4.77-4.72 (m, 1 H), 4.51-4.46 (m, 1 H), 4.33-4.31 (m, 1 H), 3.91-3.81 (m, 2 H), 3.51-3.46 (m, 1 H), 2.76-2.67 (m, 3 H), 2.47-2.39 (m, 1 H), 2.34-2.30 (m, 2 H), 2.16-2.14 (m, 10 1 H), 1.94-1.79 (m, 4 H), 1.62-1.55 (m, 2 H), 1.00 (t, *J*=7.2 Hz, 3 H).


Example 68. Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethylpyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (Compound C35):

15 **1). Synthesis of methyl (S)-4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethylpyrrolidin-2-yl)methyl)amino)benzoate:**




The mixture of methyl (S)- 4-(2-chloroacetamido)-3-((1-ethylpyrrolidin-2-yl)methyl)aminobenzoate (140 mg, 0.40 mmol), 3-fluoro-4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methoxy)benzonitrile (142 mg, 0.44 mmol) and potassium carbonate (165 mg, 1.20 mmol) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. After completion, it was diluted with water (50 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic layers washed with brine (120 mL × 2). The organic layer was concentrated in vacuo and purified by silica gel column chromatography (dichloromethane/methanol=13/1) to give methyl (S)-4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)-pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethylpyrrolidin-2-yl)methyl)amino)benzoate (180 mg, 70.4% yield). LC-MS m/z: 645 [M+H]⁺. 20 25

2). Synthesis of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethylpyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



To a mixture of methyl (S)-4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethylpyrrolidin-2-yl)methyl)amino)benzoate (180 mg, 0.28 mmol) in dioxane (10 mL) acetic acid (2 mL) was added. The resulting mixture was stirred and reacted at 100°C for 3 hours. After completion, the reaction mixture was concentrated to give a residue in vacuo. The residue was purified by silica gel (dichloromethane/methanol=10/1) to obtain methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethylpyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (80 mg, 45.7% yield). LC-MS m/z: 627 [M+H]⁺.

3). Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethylpyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethylpyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (80 mg, 0.13 mmol) was dissolved in H₂O (4 mL) and THF (4 mL) lithium hydroxide (32 mg, 1.30 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 16 hours. After completion, the reaction solution was adjusted to pH=5-6 with formic acid. The mixture was concentrated to give a residue in vacuo to remove the solvent. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethylpyrrolidin-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (19.20 mg, 24.6% yield). LC-MS m/z: 613 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.21 (s, 1 H), 7.88 (dd, *J*=11.2 Hz, 2.0 Hz, 1H), 7.79 (dd, *J*=8.8 Hz, 1.2 Hz, 1H), 7.73 (t, *J*=8.0 Hz, 1H), 7.68-7.62 (m, 2 H), 7.45 (t, *J*=8.8 Hz, 1H), 7.06 (d, *J*=7.6 Hz, 1H), 6.74 (d, *J*=8.4 Hz, 1H), 5.31 (s, 2H), 4.93-4.89 (m, 1H), 4.44-4.39 (m, 1H), 4.33-4.28 (m, 1H), 4.04 (d, *J*=13.2 Hz, 1H), 3.76 (d, *J*=13.2 Hz, 1H), 3.11-3.07 (m, 2H), 2.77-2.70 (m, 2H), 2.34-2.26 (m, 2H), 2.22-2.14 (m, 2H), 1.91-1.89 (m, 2H), 1.80-1.62 (m, 3H), 1.61-1.55 (m, 3H), 0.80 (t, *J*=7.2 Hz, 3H).


Example 69. Synthesis of (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-4-methyl-1-(oxan-2-ylmethyl)-1H benzo[d]imidazole-6-carboxylic acid (compound C36):

1). Synthesis of (S)-N-(4-bromo-2-methyl-6-((oxetan-2-ylmethyl)amino)phenyl)-2-(4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamide:




The mixture of (S)-N-(4-bromo-2-methyl-6-((oxetan-2-ylmethyl)amino)phenyl)-2-chloroacetamide (98 mg, 0.28 mmol), 3-fluoro-4-((3-(piperidin-4-oxyl)benzyl)oxy)benzonitrile (119 mg, 0.37 mmol) and potassium carbonate (77 mg, 0.56 mmol) in N,N-dimethylformamide (3 mL) was stirred at room temperature for 16 hours. After completion, the reaction was quenched by adding water (5 mL) and extracted with ethyl acetate (20 mL×3). The combined organic layers were washed with brine (20 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain (S)-N-(4-bromo-2-methyl-6-((oxetan-2-ylmethyl)amino)phenyl)-2-(4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)acetamide (65 mg, 35.7% yield) as yellow solid. LC-MS *m/z*: 639 [M+H]⁺.

2). Synthesis of (S)-4-((3-((1-((6-bromo-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-2-yl)methyl)-piperidin-4-yl)oxy)benzyl)oxy)-3-fluorobenzonitrile:




To a solution of (S)-N-(4-bromo-2-methyl-6-((oxetan-2-ylmethyl)amino)phenyl)-2-(4-(3-((4-cyano-2-fluorophenoxy)-methyl)phenoxy)piperidin-1-yl)acetamide (65 mg, 0.10 mmol) in dioxane (5 mL) acetic acid (0.5 mL) was added at room temperature. The resulting mixed solution was stirred at 100 °C for 2 hours. After completion, the reaction solution was concentrated to give a residue under reduced pressure. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain compound (S)-4-(((1-((6-bromo-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)oxy)benzyl)oxy)-3-fluorobenzonitrile (60 mg, 96.9% yield) as yellow solid. LC-MS m/z: 621 [M+H]⁺.

3). Synthesis of methyl (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:




The mixture of (S)-4-(((1-((6-bromo-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazol-2-yl)methyl)piperidin-4-yl)oxy)benzyl)oxy)-3-fluorobenzonitrile (60 mg, 0.10 mmol), 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (7 mg, 0.01 mmol) and potassium acetate (29 mg, 0.30 mmol) in N,N-dimethylformamide (1 mL) and methanol (1 mL) was stirred at 90 °C for 16 hours under carbon monoxide (58.76 psi) atmosphere. After completion, the reaction mixture was concentrated to give a residue. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (11 mg, 17.8% yield). LC-MS m/z: 599 [M+H]⁺.

4). Synthesis of (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidine-1-yl)methyl)-4-methyl-1-(oxocyclobutan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester:



The mixture of (S)-2-(chloromethyl)-4-methyl-1-(oxocyclobutan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (20 mg, 0.07 mmol), 3-fluoro-4-(3-(piperidin-4-oxo)benzyl)oxy benzonitrile (30 mg, 0.09 mmol) and potassium carbonate (29 mg, 0.21 mmol) in N, N-dimethylformamide (1 mL) was stirred at 60 °C for 2 hours. After completion, the mixture was diluted with water (3 mL), and extract with ethyl acetate (15 mL × 3). The combined organic layer was washed with brine (10 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain (S)-2-(((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-4-methyl-1-(oxocyclobutan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid methyl ester (11 mg, yield: 28.6%). LC-MS m/z:599 [M+H]⁺.

5). Synthesis of (S)-2-(((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-(((4-(3-((4-cyano-2-fluorophenoxy)methyl)phenoxy)piperidin-1-yl)methyl)-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (22 mg, 0.04 mmol) in THF (4 mL) and water (4 mL) lithium hydroxide (16 mg, 0.40 mmol) was added at room temperature. The resulting mixture solution was stirred and reacted at room temperature for 5 hours. After completion, the resulting mixture was adjusted to pH=5-6 with acetic acid (1 M) and extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 40

g; Mobile Phase A: 10 mM NH₄OH in water; Mobile Phase B: acetonitrile; Flow rate: 40 mL/min; Gradient: 20%B-50%B in 20 min; Detector: 254 nm) to obtain (S)-2-((4-(3-((4-cyano-2-fluorophenoxy)methyl))phenoxy)piperidin-1-yl)methyl)-4-methyl-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (9.33 mg, 39.9% yield). LC-MS m/z: 585 [M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 7.90-7.85 (m, 2 H), 7.69-7.63 (m, 2 H), 7.42 (t, *J*=8.4 Hz, 1 H), 7.30 (t, *J*=8.0 Hz, 1 H), 7.05 (m, 1 H), 7.00 (d, *J*=7.2 Hz, 1 H), 6.95 (dd, *J*=8.0 Hz, 1.6 Hz, 1 H), 5.25 (s, 2 H), 5.11-5.05 (m, 1 H), 4.70-4.65 (m, 1H), 4.58-4.54 (m, 1H), 4.51-4.45 (m, 1 H), 4.41-4.33 (m, 2H), 3.89 (d, *J*=13.6 Hz, 1 H), 3.77 (d, *J*=13.6 Hz, 1 H), 2.74-2.63 (m, 3 H), 2.49 (s, 3 H), 2.45-2.35 (m, 3 H), 1.93 (s, 2 H), 1.64-1.60 (m, 2 H).

Example 70. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)thio)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C37):

1). Synthesis of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)mercapto)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:




The mixture of methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (100 mg, 0.29 mmol), 3-fluoro-4-((6-(piperidin-4-ylthio)pyridin-2-yl)methoxy)benzonitrile (99 mg, 0.29 mmol) and potassium carbonate (80 mg, 0.58 mmol) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. After completion, the resulting mixture was poured into saturated ammonium chloride solution (20 mL) and extracted with ethyl acetate (10 mL × 2). The combined organic layers were washed with brine (20 mL × 3) and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)mercapto)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (70 mg, 38.1% yield). LC-MS m/z: 658 [M+H]⁺.

2). Synthesis of methyl 12-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-


yl)mercapto)piperidin-1-yl)methyl)-1-((
benzo[d]imidazole-6-carboxylate:

-ethyl-1H-imidazol-5-yl)methyl)-1H-



To a mixture of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)mercapto)piperidin-1-yl)acetamido)-methyl 3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (70 mg, 0.11 mmol) in toluene (5 mL) acetic acid (1 mL) was added at room temperature. The resulting mixture was stirred at 110 °C for 3 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by preparative thin layer chromatography (dichloromethane/methanol=30/1) to give methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)mercapto)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (60 mg, 85.4% yield). LC-MS m/z: 640 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)mercapto)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a solution of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)mercapto)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (60 mg, 0.09 mmol) in H₂O (5 mL) and THF (5 mL) lithium hydroxide (7 mg, 0.27 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 16 hours; after completion concentrated to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% NH₄OH in H₂O solvent system; Detection Wavelength 254 nm/214 nm; Flow rate 20 mL/min to obtain 2-((4-((6-((4-

cyano-2-fluorophenoxy)-methyl)pyridin-2-yl)mercapto)piperidin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (28.45 mg, 50.6 % yield). LC-MS m/z: 626 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.06 (s, 1 H), 7.89 (dd, *J*=11.2 Hz, 2.0 Hz, 1 H), 7.81 (dd, *J*=8.8 Hz, 1.6 Hz, 1 H), 7.69-7.65 (m, 4 H), 7.41 (t, *J*=8.8 Hz, 1 H), 7.22-7.19 (m, 2 H), 6.38 (s, 1 H), 5.69 (s, 1 H), 5.36 (s, 2 H), 4.02-3.96 (m, 2 H), 3.79 (s, 2 H), 3.68-3.60 (m, 1 H), 2.71-2.68 (m, 2 H), 2.19-2.14 (m, 2 H), 1.86-1.84 (m, 2 H), 1.41-1.32 (m, 2 H), 1.16 (t, *J*=7.2 Hz, 3 H).


Example 71. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C38):

1). Synthesis of methyl 4-(2-(4-((6-((4-Cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methyl)piperazin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate:




The mixture of potassium carbonate (135 mg, 0.98 mmol), methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (172 mg, 0.49 mmol) and 4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methyl)piperazine (176 mg, 0.54 mmol) in N,N-dimethylformamide (5 mL) was stirred and reacted at room temperature for 3 hours. After completion, the mixture was diluted with water (5 mL) and extracted with ethyl acetate (40 mL × 3). The combined organic layers were washed with brine (30 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methyl)piperazin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (120 mg, 38.3% yield). LC-MS m/z: 641 [M+H]⁺.

2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate



To a solution of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methyl)piperazin-1-yl)acetamido)-3-((1-ethyl-1H-imidazol-5-yl)methyl)amino)benzoate (120 mg, 0.19 mmol) in toluene (6 mL) acetic acid (1 mL) was added at room temperature. The resulting mixture solution was stirred and reacted at 110°C for 2 hours. After completion, the reaction solution was concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 84.5% yield). LC-MS m/z: 623 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.16 mmol) in water (3.0 mL) and THF (3.0 mL) lithium hydroxide monohydrate (67 mg, 1.60 mmol) was added at room temperature. The resulting mixture solution was stirred and reacted at room temperature for 5 hours. After completion, the resulting mixture was adjusted to pH=5-6 using hydrochloric acid (1M) and concentrated to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% NH₄OH in H₂O solvent system; Detection Wavelength: 254 nm/214 nm) ; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methyl)piperazin-1-yl)methyl)-1-((1-ethyl-1H-imidazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (18.66 mg, 19.2% yield). LC-MS m/z: 609 [M+H]⁺.

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.05 (s, 1 H), 7.90-7.79 (m, 3 H), 7.68-7.62 (m, 3 H), 7.46-7.38 (m, 3 H), 6.38 (s, 1 H), 5.68 (s, 2 H), 5.33 (s, 2 H), 4.00-3.95 (m, 2 H), 3.79 (s, 2 H), 3.53 (s, 2 H), 2.50-2.42 (m, 4 H), 2.33-2.28 (m, 4 H), 1.15 (t, $J=7.2$ Hz, 3 H).


Example 72. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C39):

1). Synthesis of 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-pyrazol-5-yl)methyl)amino)methyl benzoate:



The mixture of methyl 4-(2-chloroacetamido)-3-((1-ethyl-1H-pyrazol-5-yl)methyl)aminobenzoate (50 mg, 0.14 mmol), 3-fluoro-4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)methoxy)benzonitrile (46 mg, 0.14 mmol) and potassium carbonate (39 mg, 0.28 mmol) in N,N -dimethylformamide (2 mL) was stirred at room temperature for 16 hours. After completion, it was diluted with water (10 mL) and extracted with ethyl acetate (5 mL $\times$ 2). The combined organic layers were washed with brine (5 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-pyrazol-5-yl)methyl)amino)benzoate (60 mg, 66.8% yield). LC-MS m/z : 642 $[\text{M}+\text{H}]^+$.


2). Synthesis of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl 4-(2-(4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-1H-pyrazol-5-yl)methyl)amino)benzoate (60 mg,

0.09 mmol) in toluene (2 mL) and acetic acid (0.5 mL) was stirred at 110 °C for 3 hours. After completion, the solvent was removed to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazol-6-carboxylate (50 mg, 89.0% yield). LC-MS m/z: 624 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazol-6-carboxylate (50 mg, 0.08 mmol) in THF(5 mL) and water(5 mL) lithium hydroxide (6 mg, 0.24 mmol) was added at room temperature. The reaction was stirred at room temperature for 16 hours. After completion, the resulting mixture was adjusted to pH=5-6 with formic acid. The mixture was concentrated to give a residue. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength:254 nm/214 nm) ; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidine-1-yl)methyl)-1-((1-ethyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (14.38 mg,29.5% yield) . LC-MS m/z: 610 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.06 (s, 1 H), 7.89-7.82 (m, 2 H), 7.73-7.64 (m, 3 H), 7.43 (t, *J*=8.4 Hz, 1 H), 7.29 (s, 1 H), 7.04 (d, *J*=7.2 Hz, 1 H), 6.71 (d, *J*=8.4 Hz, 1 H), 5.80 (s, 2 H), 5.51 (s, 1 H), 5.29 (s, 2 H), 4.81 (s, 1 H), 4.25-4.20 (m, 2 H), 3.82 (s, 2 H), 2.65-2.62 (m, 2 H), 2.22-2.17 (m, 2 H), 1.73-1.71 (m, 2 H), 1.39-1.37 (m, 2 H), 1.30 (t, *J*=7.2 Hz, 3 H).


Example 73. Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C40):

1). Synthesis of methyl 4-(2-(4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)benzoate:




5 The mixture of methyl 4-(2-chloroacetamido)-3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)benzoate (200 mg, 0.55 mmol), 3-fluoro-4-(((6-(piperidin-4-oxy)pyridin-2-yl)methoxy)benzonitrile (180 mg, 0.55 mmol) and potassium carbonate (152 mg, 1.10 mmol) in N,N-dimethylformamide (5 mL) was stirred at room temperature for 16 hours. After completion, it was diluted with water (30 mL) and extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography(dichloromethane/methanol=20/1) to obtain methyl 4-(2-(4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)benzoate (200 mg, 55.4% yield). LC-MS m/z: 656 [M+H]⁺.

2). Synthesis of methyl 2-(((4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate:



20 The mixture of methyl 4-(2-(4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)acetamido)-3-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)amino)benzoate (200 mg, 0.30 mmol) in toluene (2 mL) and acetic acid (0.5 mL) was stirred at 110 °C for 3 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=20/1) to obtain 2-(((4-(((6-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazol-6-carboxylate (150 mg, 78.4% yield). LC-MS m/z: 638 [M+H]⁺.

3). Synthesis of 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylate (150 mg, 0.24 mmol) in THF (5 mL) and water (5 mL) lithium hydroxide (6 mg, 0.24 mmol) was added at room temperature and the reaction was stirred at room temperature for 16 hours. After completion, the resulting mixture was adjusted to pH=5-6 with formic acid. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10um 19 × 250 mm; Gradient elution with ACN/0.1% FA in H₂O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-((1-ethyl-3-methyl-1H-pyrazol-5-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid (59.70 mg, 39.9% yield). LC-MS m/z: 624 [M+H]⁺.

¹H NMR (400 MHz, DMSO-*d*₆): δ 8.09 (s, 1 H), 7.89-7.82 (m, 2 H), 7.74-7.64 (m, 3 H), 7.43 (t, *J*=8.8 Hz, 1 H), 7.05 (d, *J*=7.2 Hz, 1 H), 6.72 (d, *J*=8.0 Hz, 1 H), 5.75 (s, 2 H), 5.30 (s, 2 H), 5.26 (s, 1 H), 4.83 (s, 1 H), 4.16-4.11 (m, 2 H), 3.81 (s, 2 H), 2.66-2.63 (m, 2 H), 2.23-2.19 (m, 2 H), 2.00 (s, 3 H), 1.75-1.73 (m, 2 H), 1.43-1.40 (m, 2 H), 1.29 (t, *J*=7.2 Hz, 3 H).


Example 74. Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)thio)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C41):

1). Synthesis of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)thio)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



A mixture of 3-fluoro-4-((6-(piperidin-4-ylmercapto)pyridin-2-yl)methoxy)benzonitrile (86 mg, 0.29 mmol) and methyl (S)-2-(chloromethyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.29 mmol) in N,N-dimethylformamide (5 mL) potassium carbonate (80 mg, 0.58 mmol) was added at room temperature. The reaction was stirred at room temperature for 16 hours. Upon completion of the reaction, the resulting mixture was poured into brine (20 mL) and extracted with ethyl acetate (20 mL $\times$ 2). The combined organic layers were concentrated and then purified by silica gel column chromatography (dichloromethane/methanol=10/1) to give methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy))methyl)pyridin-2-yl)thio)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 57.5% yield). LC-MS m/z : 602 $[M+H]^+$.

2). Synthesis of (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)thio)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:




To a mixture of methyl (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)mercapto)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (100 mg, 0.17 mmol) in THF (5 mL) and water (5 mL) lithium hydroxide (40 mg, 1.70 mmol) was added at room temperature. The reaction was stirred at room temperature for 16 hours. After completion, the resulting mixture was adjusted to pH=5-6 using hydrochloric acid (1M). The solvent was removed by concentration to give a residue in vacuo. The residue was purified by prep-HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10 μ m 19 $\times$ 250 mm; Gradient elution with ACN/0.1% NH_4OH in H_2O solvent system; Detection Wavelength: 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S)-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)thio)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (37.32 mg, 37.4% yield). LC-MS m/z : 588

[M+H]⁺.

¹H NMR (400 MHz, DMSO-d₆) δ 8.26 (s, 1 H), 7.89 (dd, *J*=11.2 Hz, 1.6 Hz, 1 H), 7.81 (d, *J*=8.4 Hz, 1 H), 7.70-7.63 (m, 3 H), 7.43 (t, *J*=8.4 Hz, 1 H), 7.22 (t, *J*=8.4 Hz, 2 H), 5.37 (s, 2 H), 5.08-5.06 (m, 1 H), 4.80-4.75 (m, 1 H), 4.65-4.61 (m, 1 H), 4.50-4.48 (m, 1 H), 4.38-4.35 (m, 1 H), 3.92 (d, *J*=13.6 Hz, 1 H), 3.78-3.70 (m, 2 H), 2.82-2.68 (m, 3 H), 2.42-2.38 (m, 1 H), 2.30-2.23 (m, 2 H), 1.94 (s, 2 H), 1.58-1.53 (m, 2 H).

Example 75. Synthesis of 2-(((4-(((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-indole-6-carboxylic acid (compound C42):


1). Synthesis of oxetan-2-ylmethanesulfonate:



To a mixture of oxetan-2-ylmethanol (250 mg, 2.84 mmol) and triethylamine (574 mg, 5.68 mmol) in anhydrous dichloromethane (15 mL) methanesulfonyl chloride (557 mg, 5.68 mmol) was added dropwise at 0 °C under nitrogen atmosphere. The mixture was stirred at for 3 hours. After completion, water (10 mL) was added to quench the reaction, and it was extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed with brine (20 mL × 3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo to obtain oxetan-2-ylmethanesulfonate (300 mg, yield: 63.7%).

¹H-NMR (400MHz, CDCl₃) δ 5.05-5.01 (m, 1H), 4.70-4.66 (m, 1H), 4.61-4.56 (m, 1H), 4.36 (d, *J*=4.0Hz, 2 H), 3.11 (s, 3 H), 2.81-2.74 (m, 1H), 2.66-2.61 (m, 1H).

2). Synthesis of 1-(tert-butyl) 2-methyl 6-bromo-1H-indole-1,2-dicarboxylate:




To a solution of methyl 6-bromo-1H-indole-2-carboxylate (2.00 g, 7.91 mmol) in dichloromethane (30 mL) 4-dimethylaminopyridine (193 mg, 1.58 mmol) and di-tert-butyl dicarbonate (2.41 g, 11.07 mmol) were added at room temperature. The resulting mixture was stirred at room temperature for 16 hours. After completion, the mixture was concentrated in vacuo to obtain a crude product. The crude product was further purified by silica gel column chromatography (petroleum ether/ethyl acetate=5/1) to obtain 1-(tert-butyl) 2-methyl 6-bromo-1H-indole-1,2-dicarboxylate (2.2 g, 78.8% yield).

¹H-NMR (400 MHz, CDCl₃) δ 8.31 (s, 1 H), 7.46 (d, *J*=8.4 Hz, 1 H), 7.38 (dd, *J*= 8.4, 2.0

Hz, 1H), 7.05(d, $J = 0.8$ Hz, 1H), 3.92 (s, 3 H), 1.62 (s, 9 H).


3). Synthesis of tert-butyl 6-bromo-2-(hydroxymethyl)-1H-indole-1-carboxylate:



To a solution of 1-(tert-butyl) 2-methyl 6-bromo-1H-indole-1,2-dicarboxylate (1.00 g, 2.83 mmol) in dichloromethane (15 mL) diisobutylaluminum hydride (7 mL, 7.08 mol) was slowly added at -78°C under nitrogen atmosphere. The resulting mixture was stirred at -40°C for 2 hours. After completion, the reaction was quenched by adding methanol (15 mL) and water (9 mL) and then extracted with ethyl acetate (30 mL $\times$ 3). The combined organic layers were washed with brine (50 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain tert-butyl 6-bromo-2-(hydroxymethyl)-1H-indole-1-carboxylate (650 mg, 70.7% yield).

^1H NMR (400 MHz, CDCl_3) δ 8.18 (d, $J=0.8$ Hz, 1 H), 7.37–7.32 (m, 2 H), 6.54 (s, 1 H), 4.79 (d, $J=5.6$ Hz, 2 H), 3.62 (s, 1 H), 1.73 (s, 9 H).


4). Synthesis of tert-butyl ester 6-bromo-2-(chloromethyl)-1H-indole-1-carboxylate:



To a mixture of tert-butyl 6-bromo-2-(hydroxymethyl)-1H-indole-1-carboxylate (650 mg, 2.00 mmol), triethylamine (343 mg, 3.40 mmol), and lithium chloride (840 mg, 20.00 mmol) in dichloromethane (20 mL) methanesulfonyl chloride (333 mg, 3.40 mmol) was slowly added at room temperature. The resulting mixture was stirred at room temperature for 16 hours. After completion, water (10 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (30 mL $\times$ 3). The combined organic layers were washed with brine (50 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=15/1) to obtain tert-butyl 6-bromo-2-(chloromethyl)-1H-indole-1-carboxylate (500 mg, 73.0% yield).

^1H NMR (400 MHz, CDCl_3) δ 8.39 (s, 1 H), 7.36–7.35 (m, 2 H), 6.66 (d, $J=0.8$ Hz, 1 H), 4.95 (dd, $J=0.4$ Hz, 2 H), 1.73 (s, 9 H).


5). Synthesis of tert-butyl 6-bromo-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-indole-1-carboxylate:



The mixture of tert-butyl 6-bromo-2-(chloromethyl)-1H-indole-1-carboxylate (300 mg, 0.87 mmol), 3-fluoro-4-((6-(piperidine-4-yl)pyridin-2-yl)methoxy)benzonitrile (284 mg, 0.87 mmol), and potassium carbonate (360 mg, 2.61 mmol) in N,N-dimethylformamide (5 mL) was stirred and reacted at 60 °C for 3 hours. After completion, the resulting mixture was cooled to room temperature, then poured into brine (5 mL) and extracted with ethyl acetate (2×20 mL). The combined organic layers were washed with brine (2×20 mL) and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain tert-butyl 6-bromo-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridine-2-yl)oxy)piperidin-1-yl)methyl)-1H-indole-1-carboxylate (400 mg, 63.1% yield). LC-MS m/z : 635 $[M+H]^+$.

^1H NMR (400 MHz, CDCl_3) δ 8.26 (s, 1 H), 7.58 (t, $J=8.0$ Hz, 1 H), 7.40-7.30 (m, 4 H), 7.10 (t, $J=8.0$ Hz, 1 H), 7.00 (d, $J=7.2$ Hz, 1 H), 6.66 (d, $J=8.0$ Hz, 1 H), 6.55 (s, 1 H), 5.18 (s, 2 H), 5.05-5.03 (m, 1 H), 3.86 (s, 2 H), 2.85-2.82 (m, 2 H), 2.40-2.36 (m, 2 H), 2.05-2.00 (m, 2 H), 1.82-1.78 (m, 2 H), 1.70 (s, 9 H).

6). Synthesis of 4-((6-((1-((6-bromo-1H-indol-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluoro-benzonitrile:




To a solution of tert-butyl 6-bromo-2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1H-indole-1-carboxylate (400 mg, 0.63 mmol) in dichloromethane (10 mL) trifluoroacetic acid (4 mL) was added at room temperature. And the mixture was stirred at room temperature for 3 hours. After completion, the reaction mixture

was concentrated in vacuo to obtain a crude product. The crude product was further purified by silica gel column chromatography (dichloromethane/methanol=15/1) to obtain 4-(((6-((1-((6-bromo-1H-indol-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile (280 mg, 82.5% yield).

¹HNMR (400 MHz, CDCl₃) δ 11.09 (s, 1H), 7.67-7.62 (m, 2 H), 7.42-7.37 (m, 3 H), 7.20 (dd, *J*=8.4, 1.6 Hz, 1 H), 7.10-7.03 (m, 2 H), 6.70 (d, *J*=8.4 Hz, 1 H), 6.48 (s, 1 H), 5.34 (s, 1 H), 5.15 (s, 2 H), 4.18 (s, 2 H), 3.08 (s, 2 H), 2.96 (s, 1 H), 2.88 (s, 1 H), 2.31-2.22 (m, 2 H), 1.31-1.24 (m, 2 H).


7). Synthesis of 4-(((6-((1-((6-bromo-1-(oxetan-2-ylmethyl)-1H-indol-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile:



The mixture of 4-(((6-((1-((6-bromo-1H-indol-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile (280 mg, 0.52 mmol), oxetan-2-ylmethanesulfonate (259 mg, 1.56 mmol) and cesium carbonate (509 mg, 1.56 mmol) in N,N-dimethylformamide (5 mL) was stirred at 110 °C for 16 hours. Upon completion of the reaction, the resulting mixture was cooled to room temperature, poured into brine (5 mL) and then extracted with ethyl acetate (2 × 20 mL). The combined organic layers were washed with brine (2 × 20 mL) and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (dichloromethane/methanol=10/1) to obtain 4-(((6-((1-((6-bromo-1-(oxetan-2-ylmethyl)-1H-indol-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile (150 mg, 48.0% yield). LC-MS *m/z*: 607 [M+H]⁺.

¹HNMR (400 MHz, CDCl₃) δ 7.60-7.55 (m, 2 H), 7.41-7.36 (m, 3 H), 7.17 (dd, *J*=8.4, 1.6 Hz, 1 H), 7.09 (t, *J*=8.0 Hz, 1 H), 7.00 (d, *J*=7.2 Hz, 1 H), 6.65 (d, *J*=8.0 Hz, 1 H), 6.36 (s, 1 H), 5.18-5.14 (m, 3 H), 5.02 (s, 1 H), 4.64-4.48 (m, 3 H), 4.43-4.38 (m, 1 H), 3.75-3.67 (m, 2 H), 2.75-2.64 (m, 3 H), 2.47-2.42 (m, 1 H), 2.32-2.24 (m, 2 H), 1.95 (s, 2 H), 1.74 (d, *J*=8.8 Hz, 2 H).

8). Synthesis of 2-(((4-(((6-((4-cyano-2-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-indole-6-carboxylic acid:




To a mixture of 4-((6-((1-((6-bromo-1-(oxetan-2-ylmethyl)-1H-indole-2-yl)methyl)piperidin-4-yl)oxy)pyridin-2-yl)methoxy)-3-fluorobenzonitrile (150 mg, 0.25 mmol) in N,N-dimethylformamide (5 mL) and water (5 mL) triethylamine (76 mg, 0.75 mmol) and 1,1'-bis(diphenylphosphino)ferrocene palladium dichloride (18 mg, 0.025 mmol) were added at room temperature. The resulting mixture was heated to 90°C under carbon monoxide gas atmosphere. The reaction was stirred for 16 hours. After completion, water (15 mL) was added to quench the reaction, and extracted with ethyl acetate (30 mL $\times$ 3). The combined organic layers were washed with brine (30 mL $\times$ 2), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μ m, 40 g; Mobile Phase A: 10 mM NH_4OH in water; Mobile Phase B: acetonitrile; Flow rate: 40 mL/min; Gradient: 20%B-50%B in 20 min; Detector: 254 nm) to obtain 2-((4-((6-((4-cyano-2-fluorophenoxy)methyl)piperidin-1-yl)methyl)-1-(oxetan-2-ylmethyl)-1H-indole-6-carboxylic acid (9.07 mg, 6.4% yield). LC-MS m/z : 571 $[\text{M}+\text{H}]^+$.

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 8.13 (s, 1H), 7.89 (dd, $J=11.2, 2.0$ Hz, 1H), 7.73 (t, $J=8.0$ Hz, 1H), 7.67 (d, $J=8.4$ Hz, 1H), 7.61 (d, $J=8.4$ Hz, 1H), 7.52-7.43 (m, 2H), 7.05 (d, $J=7.2$ Hz, 1H), 6.73 (d, $J=8.4$ Hz, 1H), 6.45 (s, 1H), 5.32 (s, 2H), 5.05-5.02 (m, 1H), 4.91-4.87 (m, 1H), 4.71-4.66 (m, 1H), 4.56-4.45 (m, 2H), 4.37-4.32 (m, 1H), 3.80 (d, $J=13.6$ Hz, 1H), 3.63 (d, $J=13.6$ Hz, 1H), 2.73-2.65 (m, 3H), 2.43-2.38 (m, 1H), 2.23-2.18 (m, 2H), 1.89-1.88 (m, 2H), 1.62-1.57 (m, 2H).


Example 76. Synthesis of (S)-2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorobenzyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid (compound C43):

1). Synthesis of 2-(4-Bromo-2,5-difluorophenoxy)-6-fluoropyridine:




4-Bromo-2,5-difluorophenol (2.00 g, 9.57 mmol), 2,6-difluoropyridine (2.20 g, 19.14 mmol) and cesium carbonate (6.24 g, 19.14 mmol) were dissolved in acetonitrile (50 mL) at room temperature. The resulting mixture was warmed to 80°C and stirred for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain 2-(4-bromo-2,5-difluorophenoxy)-6-fluoropyridine (2.00 g, 68.7% yield). LC-MS m/z: 304 [M+H]⁺.

2). Synthesis of 4-((6-(4-Bromo-2,5-difluorophenoxy)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile:



To a solution of 3-fluoro-4-(hydroxymethyl)benzonitrile (1.49 g, 9.87 mmol) in dry tetrahydrofuran (50 mL) sodium hydride (395 mg, 9.87 mmol 60% w/w in mineral oil) was slowly added at 0 °C. The resulting mixture was stirred at 0 °C for 30 min, then 2-(4-bromo-2,5-difluorophenoxy)-6-fluoropyridine (2.00 g, 6.58 mmol) was slowly added to above mixture at 0 °C. The resulting mixture was stirred for 3 hours at 70°C. After completion,, the reaction was quenched with water (100 mL) at 0 °C and then extracted with dichloromethane (3 × 50 mL). The combined organic layers were washed with brine (20 mL×3), dried over anhydrous sodium sulfate, filtered, and concentrated to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=4/1) to obtain 4-((6-(4-bromo-2,5-difluorophenoxy)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (2.00 g, 69.9% yield). LC-MS m/z: 437 [M+H]⁺.


3). Synthesis of tert-butyl 2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorophenyl)acetate :



To a mixture of (2-(tert-butoxy)-2-oxoethyl)zinc bromide (1.20 g, 4.60 mmol), 1,2,3,4,5-pentylphenyl- 1'-(di-tert-butylphosphonium)ferrocene (164 mg, 0.23 mmol) and tris(dibenzylideneacetone)dipalladium (211 mg, 0.23 mmol) in tetrahydrofuran (20 mL) 4-((6-


(4-bromo-2,5-difluorophenoxy)pyridin-2-yl)oxy)methyl)-3-fluorobenzonitrile (1.00 g, 2.30 mmol) was added at room temperature. The resulting mixture was stirred at 70 °C for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=5/1) to obtain tert-butyl 2-(4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorophenyl)acetate (1.00 g, 92.5% yield). LC-MS m/z: 471 [M+H]⁺.

4). Synthesis of 2-(4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorophenyl)acetic acid



To a solution of tert-butyl 2-(4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorophenyl)acetate (1.00 g, 2.13 mmol) in dichloromethane (10 mL) trifluoroacetic acid (5 mL) was added at room temperature. The resulting mixture was stirred at room temperature for 2 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by reverse-phase flash chromatography under the following conditions (Column: Spherical C18, 20-40 μm, 120 g; Mobile Phase A: 10 mM hexachlorocyclohexane in water; Mobile Phase B: acetonitrile; Flow rate: 80 mL/min; Gradient: 5%B-95%B in 30 minutes; Detector: 254 nm). The mobile phase containing the desired product was collected at 82% B and then concentrated in vacuo to give 2-(4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorophenyl)acetic acid (800 mg, 90.7% yield). LC-MS m/z: 415 [M+H]⁺.

5). Synthesis of methyl (S)-4-(2-(4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorophenyl)-acetamido)-3-fluoro-5-((oxetan-2-ylmethyl)amino) benzoate:




The mixture of 2-(4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorophenyl)acetic acid (400 mg, 0.97 mmol), methyl (S)-4-amino-3-fluoro-5-((oxetan-2-ylmethyl)amino)benzoate (246 mg, 0.97 mmol), N,N-diisopropylethylamine (250 mg, 1.94 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (954 mg, 1.50 mmol,

50% in ethyl acetate) in THF (10 mL) was stirred at room temperature for 16 hours. After completion, the solvent was removed by concentration to give a residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl


(S)-4-(2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorophenyl)acetamido)-3-fluoro-5-((oxetan-2-ylmethyl)amino)benzoate (400 mg, 63.4% yield). LC-MS m/z: 651 [M+H]⁺.

6). Synthesis of methyl (S)-2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorobenzyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate:



The mixture of methyl (S)-4-(2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorophenyl)acetamido)-3-fluoro-5-((oxetan-2-ylmethyl)amino)benzoate (200 mg, 0.31 mmol) in toluene (5 mL) and acetic acid (0.5 mL) was stirred at 110°C for 3 hours. After completion, the solvent was removed by concentration to give residue in vacuo. The residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate=1/1) to obtain methyl (S)-2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorobenzyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (180 mg, 91.9% yield). LC-MS m/z: 633 [M+H]⁺.

7). Synthesis of (S)-2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorobenzyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylic acid:



To a mixture of methyl (S)-2-(4-((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorobenzyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo[d]imidazole-6-carboxylate (180 mg, 0.28 mmol) in water (5 mL) and THF (5 mL), lithium hydroxide (20 mg, 0.84 mmol) was added at room temperature. The resulting mixture was stirred at room temperature for 16 hours. After completion, the reaction mixture was adjusted to pH=5-6 with formic acid. The solvent was removed by concentration to give a residue in vacuo. The residue was purified by




prep- HPLC (Waters 2767/2545/2489 system; Column: SunFire Prep C8 OBD 10 μ m 19 $\times$ 250 mm Column; Gradient elution with ACN/0.1% FA in H₂O solvent system) ; Detection Wavelength 254 nm/214 nm; Flow rate: 20 mL/min) to obtain (S)-2-(4-(((6-((4-cyano-2-fluorobenzyl)oxy)pyridin-2-yl)oxy)-2,5-difluorobenzyl)-4-fluoro-1-(oxetan-2-ylmethyl)-1H-benzo-[d]imidazole-6-carboxylic acid (148.49 mg, 85.8% yield). LC-MS m/z: 619 [M+H]⁺.




¹H NMR (400 MHz, DMSO-*d*₆): δ 8.13 (d, *J*=1.2 Hz, 1 H), 7.83 (t, *J*=8.0 Hz, 1 H), 7.76 (dd, *J*=10.0 Hz, 1.2 Hz, 1H), 7.54 (dd, *J*=8.0 Hz, 1.2 Hz, 1 H), 7.47 (dd, *J*=11.2 Hz, 1.2 Hz, 1 H), 7.42-7.38 (m, 1 H), 7.26 (t, *J*=8.0 Hz, 2 H), 6.72-6.67 (m, 2 H), 5.19 (s, 2 H), 5.09-5.04 (m, 1 H), 4.81-4.76 (m, 1 H), 4.67-4.63 (m, 1 H), 4.54-4.42 (m, 3 H), 4.38-4.33 (m, 1 H), 2.74-2.67 (m, 1 H), 2.45-2.33 (m, 1 H).




Example 77. Synthesis of other compounds:





Similar to the synthesis steps in Example 3-74 , the following compounds can be obtained from the A-type intermediates and the B-type intermediates:




Number	Structure	MS m/z: [M+H] ⁺
Compound 4		646
Compound 5		629




Compound 8		636
Compound 9		636
Compound 10		654




Compound 11		637
Compound 12		619
Compound 14		627




Compound 15		627
Compound 16		645
Compound 17		628




Compound 18		610
Compound 19		645
Compound 20		663
Compound 21		663




Compound 22		681
Compound 23		664
Compound 24		646




Compound 25		636
Compound 26		654
Compound 27		654





Compound 28		672
Compound 29		655
Compound 30		637





Compound 31		644
Compound 32		662
Compound 33		662





Compound 34		680
Compound 35		663
Compound 36		645





Compound 37		635
Compound 38		653
Compound 39		653





Compound 45		637
Compound 46		655
Compound 47		638





Compound 48		620
Compound 51		599
Compound 52		617
Compound 53		600





Compound 54		582
Compound 58		608
Compound 59		591
Compound 61		580





Compound 62		598
Compound 63		598
Compound 64		616
Compound 65		599





Compound 66		581
Compound 68		589
Compound 69		589
Compound 70		607





Compound 71		590
Compound 72		572
Compound 73		607
Compound 74		625

Compound 75		625
Compound 76		643
Compound 77		626
Compound 78		608





Compound 79		598
Compound 80		616
Compound 81		616
Compound 82		634





Compound 83		617
Compound 84		599
Compound 85		606
Compound 86		624





Compound 87		624
Compound 88		642
Compound 89		625
Compound 90		607





Compound 91		597
Compound 92		615
Compound 93		615
Compound 94		633

Compound 95	 <chem>O=C(O)/C=C/c1ccc2nc3c(n2)CN(C3)C4CCOC(C4)Oc5ccc(cc5)COc6ccc(cc6F)C#N</chem>	616
Compound 96	 <chem>O=C(O)/C=C/c1ccc2nc3c(n2)CN(C3)C4CCOC(C4)Oc5ccc(cc5)COc6ccc(cc6F)C#N</chem>	598
Compound 97	 <chem>O=C(O)c1ccc2nc3c(n2)CN(C3)C4CCOC(C4)Oc5ccc(cc5)COc6ccc(cc6F)C#N</chem>	594
Compound 98	 <chem>O=C(O)c1ccc2nc3c(n2)CN(C3)C4CCOC(C4)Oc5ccc(cc5)COc6ccc(cc6F)C#N</chem>	612





Compound 99		612
Compound 100		630
Compound 101		613
Compound 102		595





Compound 103		630
Compound 104		648
Compound 105		648
Compound 106		666





Compound 107		649
Compound 108		631
Compound 109		621
Compound 110		639





Compound 111		639
Compound 112		657
Compound 113		640
Compound 114		622





Compound 115	 <chem>O=C(O)/C=C/c1ccc2nc(CCN3CCOC(c4ccc(cc4)OC5=CC=C(C=C5)Cl)cc3)cnc2c1F</chem>	629
Compound 116	 <chem>O=C(O)/C=C/c1ccc2nc(CCN3CCOC(c4ccc(cc4)OC5=CC=C(C=C5)Cl)cc3)cnc2c1F</chem>	647
Compound 117	 <chem>O=C(O)/C=C/c1ccc2nc(CCN3CCOC(c4ccc(cc4)OC5=CC=C(C=C5)Cl)cc3)cnc2c1F</chem>	647
Compound 118	 <chem>O=C(O)/C=C/c1ccc2nc(CCN3CCOC(c4ccc(cc4)OC5=CC=C(C=C5)Cl)cc3)cnc2c1F</chem>	665





Compound 119		648
Compound 120		630
Compound 121		620
Compound 122		638





Compound 123		638
Compound 124		656
Compound 125		639
Compound 126		621





Compound 128		622
Compound 129		622
Compound 130		640
Compound 131		623





Compound 132		605
Compound 136		631
Compound 137		614
Compound 139		603





Compound 140		621
Compound 141		621
Compound 142		639
Compound 143		622





Compound 144		604
Compound 145		608
Compound 146		626
Compound 147		626





Compound 148		644
Compound 149		627
Compound 150		609
Compound 151		618





Compound 152		636
Compound 153		636
Compound 154		654
Compound 155		637





Compound 156		619
Compound 157		609
Compound 158		627
Compound 159		627





Compound 160		645
Compound 161		628
Compound 162		610
Compound 163		617





Compound 164		635
Compound 165		635
Compound 166		653
Compound 167		636





Compound 168		618
Compound 169		585
Compound 170		603
Compound 171		603




Compound 172		621
Compound 173		604
Compound 174		586
Compound 175		595




Compound 176		613
Compound 177		613
Compound 179		614
Compound 180		596




Compound 181		586
Compound 182		604
Compound 183		604
Compound 184		622




Compound 185		605
Compound 186		587
Compound 187		594
Compound 188		612




Compound 189		612
Compound 190		630
Compound 191		613
Compound 192		595




Compound 193		633
Compound 194		651
Compound 195		651




Compound 196	 <chem>CC1=CN=C(C1CN(C2=CC=C(C=C2)C(=O)O)N3C(=NC(=C3)CN(C3CCN(C3)COc4cc(F)c(COc5ccc(Cl)cc5F)cc4F)CC6=CC=CC=C6N7C=CC=N7C8=CC=C(C=C8)C(=O)O)C9=CC=C(C=C9)F)C10=CC=CC=C10F</chem>	669
Compound 197	 <chem>CC1=CN=C(C1CN(C2=CC=C(C=C2)C(=O)O)N3C(=NC(=C3)CN(C3CCN(C3)COc4cc(F)c(COc5ccc(Cl)cc5F)cc4F)CC6=CC=CC=C6N7C=CC=N7C8=CC=C(C=C8)C(=O)O)C9=CC=C(C=C9))C10=CC=C(C=C10)C(=O)O</chem>	652
Compound 198	 <chem>CC1=CN=C(C1CN(C2=CC=CC(=C2)C(=O)O)N3C(=NC(=C3)CN(C3CCN(C3)COc4cc(F)c(COc5ccc(Cl)cc5F)cc4F)CC6=CC=CC=C6N7C=CC=N7C8=CC=C(C=C8)C(=O)O)C9=CC=C(C=C9)N)C10=CC=CC=C10N</chem>	634




Compound 199		624
Compound 200		642
Compound 201		642





Compound 202	 Chemical structure of Compound 202: A benzimidazole core substituted with a 2-fluorophenyl group, a 2-((4-(4-cyano-2-fluorophenoxy)pyridin-2-yl)methyl)piperidin-1-ylmethyl group, and a 1H-imidazol-2-ylmethyl group. A carboxymethyl group is attached to the 6-position of the benzimidazole ring.	660
Compound 203	 Chemical structure of Compound 203: A benzimidazole core substituted with a 2-fluorophenyl group, a 2-((4-(4-cyano-2-fluorophenoxy)pyridin-2-yl)methyl)piperidin-1-ylmethyl group, and a 1H-imidazol-2-ylmethyl group. A carboxymethyl group is attached to the 6-position of the benzimidazole ring.	643
Compound 204	 Chemical structure of Compound 204: A benzimidazole core substituted with a 2-fluorophenyl group, a 2-((4-(4-cyano-2-fluorophenoxy)pyridin-2-yl)methyl)piperidin-1-ylmethyl group, and a 1H-imidazol-2-ylmethyl group. A carboxymethyl group is attached to the 6-position of the benzimidazole ring.	625





Compound 205		632
Compound 206		650
Compound 207		650





Compound 208	 <chem>CC1=CN=C(C1CN(C2=CC=C(C=C2)C(=O)O)C3=NC4=CC=C(C=C4)N3CN(C5=CC=C(C=C5)C(=O)O)C6=CC=C(C=C6)OC7=CC=C(C=C7)OC8=CC=C(C=C8)F)C9=CC=C(C=C9)F</chem>	668
Compound 209	 <chem>CC1=CN=C(C1CN(C2=CC=C(C=C2)C(=O)O)C3=NC4=CC=C(C=C4)N3CN(C5=CC=C(C=C5)C(=O)O)C6=CC=C(C=C6)OC7=CC=C(C=C7)OC8=CC=C(C=C8)F)C9=CC=C(C=C9)F</chem>	651
Compound 210	 <chem>CC1=CN=C(C1CN(C2=CC=C(C=C2)C(=O)O)C3=NC4=CC=C(C=C4)N3CN(C5=CC=C(C=C5)C(=O)O)C6=CC=C(C=C6)OC7=CC=C(C=C7)OC8=CC=C(C=C8)F)C9=CC=C(C=C9)F</chem>	633




Compound 211		623
Compound 212		641
Compound 213		641





Compound 214		659
Compound 215		642
Compound 216		624





Compound S7		589
Compound S8		607
Compound S9		590
Compound S10		616





Compound S11		597
Compound S14		608
Compound S15		631
Compound S16		630




Compound S17		639
Compound S21		620
Compound S24		627
Compound S25		646





Compound S26		645
Compound S27		628
Compound S28		654





Compound S29		635
Compound S32		598
Compound S33		617
Compound S34		616





Compound S35		599
Compound S37		606
Compound S40		621
Compound S42		639





Compound S43		622
Compound S44		648
Compound S45		629
Compound S48		636





Compound S49	 <chem>CC1=CN=C(C1CN(C2=CC=C(C=C2)C(=O)O)CN3CCN(CC3)COc4ccc(Oc5cc(Cl)cc(F)c5)c(F)c4</chem>	655
Compound S50	 <chem>CC1=CN=C(C1CN(C2=CC=C(C=C2)C(=O)O)CN3CCN(CC3)COc4ccc(Oc5cc(Cl)cc(F)c5)c(F)c4</chem>	654
Compound S51	 <chem>CC1=CN=C(C1CN(C2=CC=C(C=C2)C(=O)O)CN3CCN(CC3)COc4ccc(Oc5cc(Cl)cc(F)c5)c(F)c4</chem>	637





Compound S52		663
Compound S53		644
Compound S56		595
Compound S57		611





Compound S58		614
Compound S59		573
Compound S60		573
Compound S61		609





Compound S62		627
Compound S63		624
Compound S64		642
Compound C44		641





Compound C45		624
Compound C46		640
Compound C47		642
Compound C48		581





Compound C49		572
Compound C50		598
Compound C51		607
Compound C52		586






Compound C53		595
Compound C54		590
Compound C55		599
Compound C56		624





Compound C57		633
Compound C58		628
Compound C59		637
Compound C60		645

Compound C61		636
Compound C62		572
Compound C63		581
Compound C64		581

Compound C65		572
Compound C66		581
Compound C67		572
Compound C68		619

Compound C69		610
Compound C70		619
Compound C71		610
Compound C72		621

Compound C73		630
Compound C74		595
Compound C75		604
Compound C76		604
Compound C77		595

Compound C78		555
Compound C79		564
Compound C80		613
Compound C81		565

Test Example 1. Detection of agonist activity of the test compounds on GLP-1R**1). Reagents:**

Name	Manufacturer
cAMP Detection Kit	Cisbio
Bovine Serum Albumin(BSA)	Sigma
Hanks' Balanced Salt Solution 1X(HBSS)	Gibco
1M HEPES	Invitrogen
3-Isobutyl-1-methylxanthine(IBMx)	Invitrogen
PP-384 well plate	Greiner
OptiPlate-384	PerkinElmer
GLP-1(7-37)	Hao Yuan

5 **2). Equipment:**

Instrument	Model	Factory
EnVision	Envision2014	PerkinElmer
Vi-cell counter	Vi-CELL™ XR Cell Viability Analyzer	Beckman
Bravo	Bravo V11	Agilent
Centrifuge	Allegra™ 25R Centrifuge	Beckman
ECHO	ECHO 555	Labcyte

3). Cell line:

Target	Host cell	Source
GLP-1R	HEK293	WuXi

4). Methods and procedures:

- 10 1) The test compound was dissolved in DMSO and diluted 4-fold with Bravo for a total of 10 concentration gradients (the starting concentration was 1 mM). The reference compound GLP-1(7-37) was dissolved in DMSO and diluted 4-fold with Bravo for a total of 10 concentration gradients (starting at 500 nM).
- 15 2) The stable transfection GLP-1R/HEK293 cells were resuscitated in a sterile water bath at 37°C and shaken gently until ice cubes were completely melted.

- 3) The recovered cells were transferred to a 15 mL sterile centrifuge tube to remove DMSO. HBSS(10 mL) pre-warmed at 37°C was added, mixed gently, and centrifuged at 1000 rpm for 5 minutes. The supernatant was discarded and another 10 mL of HBSS was added and mixed gently. The cells were counted to measure viability with Vi-cell counter.
- 4) The cells were re-suspended with assay buffer, counted with a Vi-cell counter, and diluted to $1.0 \times 10^5/\text{mL}$.
- 5) 10 μL of assay buffer containing cells was added to a 384-well plate with electronic multichannel pipette and the plate was shaken at 1000 rpm for 5 seconds.
- 6) The diluted test compound solution was transfer to the 384 cell plate with ECHO by 100nL of transfer volume. The plate was shaken to mix at 2000 rpm for 60 seconds.
- 7) The cells in the 384-well plate were incubated in CO₂ cell incubator at 37°C for 30min.
- 8) 10 μL of HTRF cAMP detection solution was added to the 384-well plate, stick with sealing film, and incubated at room temperature for 1 hour.
- 9) After 1 hour of incubation, the sealing film was removed. The plate was put into the EnVision microplate reader to read the values of OD665nm and OD615nm.

4). Data analysis

- a) Calculation formula:

$$\% \text{ Activity} = (\text{cAMP level of testing sample} - \text{average cAMP level of LC}) / (\text{average cAMP level of HC} - \text{average cAMP level of LC}) \times 100\%$$

$$\text{Z factor: } 1 - 3 \times (\text{STD_ cAMP level of HC} + \text{STD_ cAMP level of LC}) / (\text{average cAMP level of HC} - \text{average cAMP level of LC})$$

$$\text{Assay Window: HC} / \text{LC}$$

HC: wells with adding the top concentration of reference compound

LC: wells with adding assay buffer

- b) Using “log(agonist) vs. response -- Variable slope” mode of GraphPad Prism 5.0 to fit the dose response curve of each sample and calculate the EC50 value.

Table 1. Data And Analysis of Some Representative Compounds

Numer	EC₅₀(nM)	Max activity(%)
GLP-1(7-37)	0.02	98.1
PF-06882961	0.229	99.7
Compound 1	0.088	116.8
Compound 2	0.0529	98.6
Compound 3	0.317	128.3
Compound 6	0.133	114.8
Compound 7	0.145	91.3
Compound 13	0.114	99.4
Compound 43	0.110	109.7
Compound 49	0.193	129.3
Compound 55	0.149	111.5
Compound 56	0.210	124.9
Compound 60	0.455	112.0
Compound 67	1.086	106.4
Compound 133	0.264	126.6
Compound 134	0.133	117.3
Compound 135	0.244	109.6
Compound 138	0.669	125.0
Compound S1	1401	93.7
Compound S2	5.578	139.9
Compound S3	2170	70.1
Compound S4	0.29	106.9
Compound S5	15.44	125.2
Compound S6	2.6	114.9
Compound S20	0.962	129.1
Compound S22	730.8	92.7
Compound S23	1.472	98.0
Compound S36	150.2	114.2
Compound S41	21.68	94.8
Compound S66	1.253	106.7

Compound C1	1194	76.6
Compound C2	0.614	123.1
Compound C3	0.278	122.3
Compound C4	0.560	147.9
Compound C5	2.409	112.6
Compound C6	13.77	99.8
Compound C7	23.48	90.1
Compound C8	25.58	117.4
Compound C9	3.743	97.2
Compound C10	4.157	110.2
Compound C11	1.484	114.8
Compound C12	0.233	125.5
Compound C13	1.819	141.7
Compound C14	0.315	101.9
Compound C15	0.807	109.1
Compound C16	2.544	99.2
Compound C17	0.668	127.7
Compound C18	0.472	103.8
Compound C19	1.067	134.3
Compound C20	0.425	137.0
Compound C21	46.24	N/A
Compound C22	30.37	N/A
Compound C23	0.249	109.1
Compound C24	1.67	76.88
Compound C25	0.512	133.4
Compound C26	0.215	117.3
Compound C27	8.03	N/A
Compound C28	5.051	N/A
Compound C29	6.831	121.6
Compound C30	5.851	121.2
Compound C31	0.833	106.6
Compound C32	0.768	114.3

Compound C33	0.068	99.1
Compound C34	10.98	113.6
Compound C35	> 100	N/A
Compound C36	3.919	104.0
Compound C37	0.223	121.0
Compound C38	> 100	N/A
Compound C39	7.93	142.8
Compound C40	6.50	90.7
Compound C41	4.164	122.3
Compound C42	> 100	N/A
Compound C43	5.306	88.8
Compound C82	7.483	90.7
Compound C83	0.705	111.1
Compound C84	0.246	136.4

Data in Table 1 indicated that most of the compounds of the present invention had potent agonistic effects on hGLP1R receptors, and were excellent hGLP1R agonists. Its maximal agonistic effect could reach or even exceed that of GLP1 polypeptide or the control molecule PF-06882961 currently under clinical research.

Test Example 2. Pharmacokinetic study of the test compounds in mice:

The pharmacokinetic properties of some compounds of the present invention were evaluated in mice pharmacokinetic experiments. SPF male CD-1 mice from Beijing Vital River Laboratory Animal Technology Co., Ltd were used with 6 mice in each group. Compounds were dissolved in 10% solutol/90% saline. A single intravenous administration was given at a dose of 1 mg/kg in a volume of 1 mL/kg. A single intragastric administration was given at a dose of 5mg/kg in a volume of 1 mL/kg. Animals were fasted overnight prior to the administration and resumed feeding 4 hours after administration, *ad libitum* to water. Blood was collected at 0.0830, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after dosing. About 0.4 mL of whole blood was collected from the saphenous vein of animals and placed in an EDTA-K2 anticoagulation tube. The samples were centrifuged at 4°C and 4200 rpm for 5 min, and the plasma was transferred into a centrifuge tube and stored at -80°C until analysis. For plasma sample analysis, the test compounds and internal standards (Labetalol & tolbutamide &

Verapamil & dexamethasone & glyburide & Celecoxib) were extracted from mice plasma by protein precipitation method with acetonitrile, and the extracts were analyzed by LC/MS/MS. The measured plasma concentration-time data of individual animals were analyzed with the non-compartmental model of Phoenix WinNonlin 7.0 (Pharsight, USA) software, and the pharmacokinetic parameters of mice were obtained as follows: maximum (peak) plasma drug concentration C_{max}; Peak time T_{max}; half-life T_{1/2} and area under the plasma concentration-time curve extrapolated to infinity AUC_{0-inf}.

Table 2. Pharmacokinetic Parameters of Representative Compounds in Mice

Compound	Dose(mg/kg)	C _{max} (ng/mL)	AUC _{0-inf} (ng.h/mL)	Cl(mL/min/kg)	V _{dss} (L/kg)	T _{1/2} (h)	F (%)
PF-06882961	1(iv)	---	370	45.1	1	0.3	---
Compound 55		---	637	26.2	1.3	1.5	---
Compound 49		---	1350	12	1	1	---
Compound 56		---	771	21.7	1.2	2.3	---
Compound C23			1141	15	1	1	
PF-06882961	5(po)	299	366	---	---	2.0	19.8
Compound 55		483	1042	---	---	1.7	32.7
Compound 49		515	1760	---	---	3.2	20.7
Compound 56		1640	2097	---	---	1.0	54.4
Compound C23		2193	2575			1.4	45.1

The results in Table2 indicated that compared with the reference molecule PF-06882961, some representative compounds of the present invention such as compounds 56, 49, 55 and C23 had lower clearance rates higher exposure and larger oral bioavailability, and therefore more suitable as candidates for drug development.

5

Test Example 3. Pharmacokinetic study of the test compounds in monkeys:

The pharmacokinetic properties of compounds of the present invention were evaluated in monkey pharmacokinetic experiments with 3 male Non-naive cynomolgus monkeys per group. Compounds were dissolved in 10% solutol/90% saline. For single intravenous administration, the dose was 1mg/kg, and the administration volume was 1mL/kg. For single intragastric administration, the dose was 5mg/kg, and the administration volume was 1mL/kg. Animals were fasted overnight with free water before the experiment and resumed feeding 4 hours after administration. Blood was collected at 0.0830, 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after dosing. About 0.4 mL of whole blood was collected from the animal's forearm vein and placed in an EDTA-K2 anticoagulant tube. The samples were centrifuged at 4°C and 4200 rpm for 5 min, and the plasma was transferred to a centrifuge tube and stored at -80°C until analysis. For plasma sample analysis, the test compounds and internal standards (Labetalol & tolbutamide & Verapamil & dexamethasone & glyburide & Celecoxib) were extracted from monkey plasma by protein precipitation method with acetonitrile, and the extracts were analyzed by LC/MS/MS. Measured plasma concentration-time data in individual animals were analyzed using the non-compartmental model of Phoenix WinNonlin 7.0 (Pharsight, USA) software to obtain the following pharmacokinetic parameters: maximum (peak) plasma drug concentration C_{max}; time to peak T_{max} ; Half-life T_{1/2} and area under the plasma concentration-time curve extrapolated to infinity AUC_{0-inf}.

25

Table 3. Pharmacokinetic Parameters of Some Representative Compounds in Monkeys

Compound	Dose(mg/kg)	C _{max} (ng/mL)	AUC _{0-inf} (ng.h/mL)	Cl(mL/min/kg)	V _{dss} (L/kg)	T _{1/2} (h)	F (%)
PF-06882961	1(iv)	---	1167	14.4	0.3	1.1	---
Compound		---	1425	12.0	0.4	2.2	---

55							
Compound							
49	---	2381	7.26	0.29	1.34	---	
PF-							
06882961	58.8	344	---	---	2.8	5.9	
Compound							
55	5(po)	214	614	---	---	5.4	8.6
Compound							
49		235	1244	---	---	4.01	10.4

The results in Table 3 showed that, compared with the reference molecule PF-06882961, some representative compounds of the present invention, such as compound 49 and compound 55, had lower clearance rates, higher exposure, and greater oral bioavailability and half-life, thus more suitable as candidates for drug development.

Test Example 4. Intraperitoneal glucose tolerance (IPGTT) test in h-GLP1-R C57BL6J mice:

1) Formulation

The compounds to be tested were dissolved in 10% Solutol HS15+90% Saline, and vortexed by ultrasonic to dissolve.

2) Animals

Male SPF h-GLP1-R C57BL6J mice, 6-9 weeks old, weighing 20g-25g.

3) Animal acclimation and grouping

Upon arrival, animals were acclimated for 7 days before experiments. The body weight and random blood sugar of the animals were measured one day before administration. Animals were divided into 4 groups based on body weight and random blood glucose.

The animal grouping information was as follows:

Table 4. Animal Grouping Information

Group	Dose level (mg/kg)	Dose (ml/kg)	Route of administrati on	Frequency
Vehicle	-	10	PO	QD
PF- 06882961	0.3	10	PO	QD
Compound 55	0.3	10	PO	QD

4) IPGTT test

5 Mice were overnight fasted before IPGTT. Baseline fasting blood glucose and insulin level were measured before vehicle or compound dosing. 30 min post of compound dosing, glucose were injected intraperitonelly (2g/kg, 10ml/kg). Blood glucose levels were measured at -30, 0, 15, 30, 60, 120 min. Plasma 15ul were collected at 0 and 15 min for insulin analysis by Rat/Mouse Insulin Elisa Kit.

10 5) Data analysis

AUC _{0-120min} was the area under the blood glucose-time curve. Insulin change was the difference between 15min and 0 min plasma insulin concentration. Statistical analysis of data was performed with Graphpad Prism 6, and the statistical method was one-way ANOVA Dunnett test. Compared with the vehicle group, $p < 0.05$ was considered a significant difference. * means $p < 0.05$, ** means $p < 0.01$, *** means $p < 0.001$.

6) Experimental results

As shown in Figures 1 and 2, a single oral dose of compound 55 significantly reduced the blood glucose eduring IPGTT. AUC _{0-120min} results showed that 0.3mpk had a significant difference compared with the vehicle group. Insulin change results showed that 0.3mpk compound 55 could significantly increase insulin secretion. In conclusion, compound 55 showed similar or slightly better hypoglycemic and insulin-releasing effects compared with the control molecule PF-06882961.

Test Example 5. Intravenous glucose tolerance (IVGTT) experiment in cynomolgus monkey:

1) Formulation

The compounds were dissolved in 10% Solutol HS15+90% Saline by vortex ultrasound.

5 Vehicle was 10% Solutol HS15+90%Saline.

2) Animals

Male cynomolgus monkeys, 10-15 years old, weighing 6-13kg. Healthy animals were selected for efficacy studies according to alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL), glycosylated hemoglobin (HbA1c), body weight (BW).

3) Animal acclimation and grouping

After 1 week of acclimation, the IVGTT baseline before administration was measured, and the animals were grouped according to the insulin and blood glucose results of the IVGTT. The detailed information of treatment was as follows:

Table 5. Animal Grouping Information

Group	Dose level (mg/kg)	Dose (ml/kg)	Route of administration	Frequency
Vehicle	-	5	PO	QD
PF-06882961	100	5	PO	QD
Compound 49	60	5	PO	QD
Compound 49	100	5	PO	QD
Compound 55	100	5	PO	QD

4) IVGTT Test

IVGTT was started after 2 hours post of compound dosing. Blood were collected -at -15 min, 0 min (before sugar administration), and 2, 5, 7, 10, 20, and 30 min after sugar administration. And the blood glucose level were measured.

5) Data Analysis

Data was analyzed by Graphpad Prism 6 and the statistical method was one-way ANOVA Dunnett's test. Compared with the vehicle group, $p < 0.05$ was considered significant difference. * means $p < 0.05$, ** means $p < 0.01$, *** means $p < 0.001$.

6) Experimental results


5 As shown in Figure 3, in the IVGTT experiment, a single oral dose of 100 mg/kg compound 49, 55 or PF-06882961 could significantly lower the blood glucose level. Compared with PF-06882961, compound 49 was slightly more effective, and the effect of compound 55 was equivalent. Further more, compound 49 still had a significant hypoglycemic effect in the 60 mg/kg dose group.

10 .

The embodiments of the present invention have been described above. However, the present invention is not limited to the above-described embodiments. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included within the protection scope of the present invention.

CLAIMS

1. Compounds represented by Formula(I), pharmaceutically acceptable salts, solvates, enantiomers or isotopic variations thereof



Formula(I)

Wherein,

Ring A and ring B are optionally and independently selected from monocyclic or polycyclic structures of 3 to 18 carbon atoms, and the monocyclic or polycyclic structures can be optionally selected from aromatic rings, heteroaromatic rings, aliphatic rings, heterocyclic rings, fused, spirocyclic or bridged ring structures;

X and X' are independently selected from $-C(R_{d1})(R_{d2})-$, $-C(=O)N(R_{d3})-$, $-N(R_{d4})-$, $-C(=NR_{d5})-$, $-S(=O)_2N(R_{d6})-$, $-N(R_{d7})-$, $-O-$, $-S-$, $-C(=O)O-$, $-OC(=O)-$, $-C(=O)-$, $-C(=S)-$, $-S(=O)-$, or $-S(=O)_2-$;


L is independently selected from $-C(R_{d1})(R_{d2})-$, $-OC(R_{d1})(R_{d2})-$, $-C(R_{d1})(R_{d2})O-$, $-C(=O)N(R_{d3})-$, $-N(R_{d4})-$, $-C(=NR_{d5})-$, $-S(=O)_2N(R_{d6})-$, $-N(R_{d7})-$, $-O-$, $-S-$, $-C(=O)O-$, $-OC(=O)-$, $-C(=O)-$, $-C(=S)-$, $-S(=O)-$, or $-S(=O)_2-$;

$X_1, X_2, X_3, X_4, X_5, X_8$ and X_9 are each independently selected from $-CR_5-$ or $-N-$;

R_0 is independently selected from hydrogen, deuterium, halogen, $-CN$, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, $-NR_{d8}R_{d9}$, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R_0 representing C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{1-10} alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups; the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl,

Haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8-membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclic are optionally substituted with 1 to 3 substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH;

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate, preferably, the

carboxyl surrogate is ; Wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more substituents selected from H, Deuterium, Halogen, OCH₃, Carboxyl, OH, CN and NR_{d8}R_{d9}; Or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, a hydrogen on the aryl, saturated or the partially saturated cycloalkyl, or heterocycloalkyl is optionally substituted by hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R₂, R_{2'} and R_{d1}, R_{d2} are the same or different and are independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkylamino, N, N-

di(C₁₋₁₀ alkyl)amino, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₃₋₁₀ cycloalkylamino, C₃₋₁₀ heterocycloalkylamino, C₃₋₁₀ cycloalkoxy, C₃₋₁₀ cycloalkylacyl, C₃₋₁₀ cycloalkoxyacetyl, C₃₋₁₀ cycloalkylsulfonyl and C₃₋₁₀ cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally further substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃ and saturated or partially saturated C₃₋₆ cycloalkyl; Or optionally R₂ and R_{2'} or R_{d1} and R_{d2} may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl; or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- heteroaryl, 3- to 8- saturated or partially saturated cycloalkyl, 3- to 8- saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are

optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d3}, R_{d4}, R_{d5}, R_{d6}, R_{d7}, R_{d8}, R_{d9} and R_{d10} is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

the hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;


the halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;

m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5.

2. The compound according to claim 1, characterized in that it has the structure of Formula (IA),



Formula(IA)

5

Wherein,

Ring A and ring B are optionally and independently selected from monocyclic or polycyclic structures of 3 to 18 carbon atoms, and the monocyclic or polycyclic structures can be optionally selected from aromatic rings, heteroaromatic rings, aliphatic rings, heterocyclic rings, fused, spirocyclic or bridged ring structures;

X and X' are independently selected from -C(R_{d1})(R_{d2})-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;



L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂ N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;

X₁, X₃, X₈ and X₉ are independently selected from -CR₅- or -N-;

R₀ is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R₀ representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8-membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent

groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, Haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8-membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with 1 to 3 substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH;

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate, preferably, the

carboxyl surrogate is  or ; Wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ al

alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more substituents selected from H, Deuterium, Halogen, OCH₃, Carboxyl, OH, CN and NR_{d8}R_{d9}; Or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the hydrogen on the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R₂, R_{2'} and R_{d1}, R_{d2} is the same or different and is independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkylamino, N, N-di(C₁₋₁₀ alkyl)amino, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₃₋₁₀ cycloalkylamino, C₃₋₁₀ heterocycloalkylamino, C₃₋₁₀ cycloalkoxy, C₃₋₁₀ cycloalkylacyl, C₃₋₁₀ cycloalkoxyacetyl, C₃₋₁₀ cycloalkylsulfonyl and C₃₋₁₀ cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally further substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃ and saturated or partially saturated C₃₋₆ cycloalkyl; Or optionally R₂ and R_{2'} or R_{d1} and R_{d2} may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or Heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered

heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally further substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d3}, R_{d4}, R_{d5}, R_{d6}, R_{d7}, R_{d8}, R_{d9} and R_{d10} is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

the hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

the halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

3. The compound according to claim 1, characterized in that it has the structure of Formula (IB),



Formula(1B)

Wherein,

Ring B are optionally and independently selected from monocyclic or polycyclic structures of 3 to 18 carbon atoms, and the monocyclic or polycyclic structures can be optionally selected from aromatic rings, heteroaromatic rings, aliphatic rings, heterocyclic rings, fused, spirocyclic or bridged ring structures;

X and X' are independently selected from -C(R_{d1})(R_{d2})-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;


L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂ N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;

X₁, X₃, X₈, X₉, X₁₀, X₁₁ and X₁₂ are independently selected from -CR₅- or -N-;

R₀ is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R₀ representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8-membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent

groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, carboxyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with 1 to 3 substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH;

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate, preferably, the

carboxyl surrogate is ; wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ al

alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more substituents selected from H, Deuterium, Halogen, OCH₃, Carboxyl, OH, CN and NR_{d8}R_{d9}; Or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the hydrogen on the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R₂, R_{2'} and R_{d1}, R_{d2} is the same or different and is independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkylamino, N, N-di(C₁₋₁₀ alkyl)amino, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₃₋₁₀ cycloalkylamino, C₃₋₁₀ heterocycloalkylamino, C₃₋₁₀ cycloalkoxy, C₃₋₁₀ cycloalkylacyl, C₃₋₁₀ cycloalkoxyacetyl, C₃₋₁₀ cycloalkylsulfonyl and C₃₋₁₀ cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are further optionally substituted with one to more selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃ and saturated or partially saturated C₃₋₆ cycloalkyl; Or optionally R₂ and R_{2'} or R_{d1} and R_{d2} may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ Cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or Heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered

heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and wherein the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d3}, R_{d4}, R_{d5}, R_{d6}, R_{d7}, R_{d8}, R_{d9} and R_{d10} is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

The hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

4. The compound according to claim 1, characterized in that it has the structure of Formula(IC)



Formula(IC)

Wherein,

----- optionally represents a single bond or a double bond;

X and X' are independently selected from -C(R_{d1})(R_{d2})-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;


L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂ N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-;

X₁, X₃, X₈, X₉, X₁₀, X₁₁, X₁₂, X₁₃ or X₁₄ are independently selected from -CR₅- or -N-;

R₀ is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R₀ representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; Wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to

multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH;

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate, preferably, the

carboxyl surrogate is ; Wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more substituents selected from H, deuterium, Halogen, OCH₃, carboxyl, OH, CN and NR_{d8}R_{d9}; or any two

adjacent R₁ together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, a hydrogen on the aryl, saturated or the partially saturated cycloalkyl, or heterocycloalkyl is optionally substituted by hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R₂, R_{2'} and R_{d1}, R_{d2} is the same or different and is independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkylamino, N, N-di(C₁₋₁₀ alkyl)amino, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylsulfonyl, C₁₋₁₀ alkylsulfinyl, C₃₋₁₀ cycloalkylamino, C₃₋₁₀ heterocycloalkylamino, C₃₋₁₀ cycloalkoxy, C₃₋₁₀ cycloalkylacyl, C₃₋₁₀ cycloalkoxyacetyl, C₃₋₁₀ cycloalkylsulfonyl and C₃₋₁₀ cycloalkylsulfinyl;

and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally further substituted with one to more group selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃ and saturated or partially saturated C₃₋₆ cycloalkyl; Or optionally R₂ and R_{2'} or R_{d1} and R_{d2} may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more group selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl; or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and

C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d3}, R_{d4}, R_{d5}, R_{d6}, R_{d7}, R_{d8}, R_{d9} and R_{d10} is the same or different, and is optionally
 5 and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀
 10 heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

The hetero represents any heteroatom independently selected from O, N, S, P and isotopes
 15 thereof;

The halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

20 t is an integer optionally selected from 0, 1, 2, 3, and 4.

5. The compound according to claim 1, characterized in that it has the structure of Formula (ID),



Formula (ID)

Wherein,

----- optionally represents a single bond or a double bond;

X and X' are independently selected from -C(R_{d1})(R_{d2})-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-; preferred -C(R_{d1})(R_{d2})-, -N(R_{d4})-, -O-, -S-, -S(=O)- or -S(=O)₂-;

L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)-, or -S(=O)₂-; preferred -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -O-, -S- or -N(R_{d4})-;

X₁, X₃, X₈ and X₁₃ are independently selected from -CR₅- or -N-;

R₀ is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R₀ representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8-membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl,

Haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8-membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with 1 to t3 substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH;

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate; wherein C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkylcarboxyl or carboxyl surrogates are optionally substituted with one to more substituents selected from H, Deuterium, Halogen, OCH₃, Carboxyl, OH, CN and NR_{d8}R_{d9}; Or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, the aryl, saturated or the partially saturated cycloalkyl, heterocycloalkyl is optionally substituted with hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R₂, R_{2'} and R_{d1}, R_{d2} is the same or different and is independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkylamino, N, N-di(C₁₋₁₀ alkyl)amino, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkoxy, C₁₋₁₀ alkylsulfonyl, C₁₋₁₀

alkylsulfinyl, C₃₋₁₀ cycloalkylamino, C₃₋₁₀ heterocycloalkylamino, C₃₋₁₀ cycloalkoxy, C₃₋₁₀ cycloalkylacyl, C₃₋₁₀ cycloalkoxyacetyl, C₃₋₁₀ cycloalkylsulfonyl and C₃₋₁₀ cycloalkylsulfinyl; and the alkyl, alkenyl, alkynyl, aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally further substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃ and saturated or partially saturated C₃₋₆ cycloalkyl; Or optionally R₂ and R_{2'} or R_{d1} and R_{d2} may together with the carbon to which they are attached form 5- to 6-membered aryl or heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclic group, wherein the cycloalkyl and heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or Heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from

hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy is optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d4}, R_{d8}, and R_{d9} is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

the hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

the halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

6. The compound according to claim 1, characterized in that it has the structure of Formula (IE)



Formula (IE)

Wherein,

----- optionally represents a single bond or a double bond;

X and X' are independently selected from -C(R_{d1})(R_{d2})-, -N(R_{d4})-, -N(R_{d7})-, -O-, -S-, -S(=O)- or -S(=O)₂-; preferred -C(R_{d1})(R_{d2})-, -N(R_{d4})-, -O-, -S-, -S(=O)- or -S(=O)₂-;

L is independently selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -C(=O)N(R_{d3})-, -N(R_{d4})-, -C(=NR_{d5})-, -S(=O)₂ N(R_{d6})-, -N(R_{d7})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -C(=S)-, -S(=O)- or -S(=O)₂-; preferred -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -O-, -S- or -N(R_{d4})-;

X₁, X₃, X₈ and X₁₃ are independently selected from -CR₅- or -N-;

R is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8-membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, Haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8-

membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with one to three substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH;

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate; Or any two adjacent R₁ together with the carbon to which they are attached form a 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, a hydrogen on the aryl, saturated or the partially saturated cycloalkyl, or heterocycloalkyl is optionally substituted by hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, =O, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl

substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ Cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and where in the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d1}, R_{d2}, R_{d4}, R_{d8} and R_d is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

the hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

the halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;


q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

7. The compound according to claim 1, characterized in that, it has the structure of Formula (IF-1) or (IF-2),



Formula (IF-1)



Formula (IF-2)

Wherein,

----- optionally represents a single bond or a double bond;

X and X' are independently selected from -C(R_{d1})(R_{d2})-, -N(R_{d4})-, -O-, -S-, -S(=O)- or -

10 S(=O)₂-;

L is independently selected from -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -O-, -S- or -N(R_{d4})-;

X₁ and X₈ are independently selected from -CR₅- or -N-;

R is independently selected from hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered
 15 heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or

partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, Haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8-membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with 1 to 3 substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH;

Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ Alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

Each R₅ and R₆ is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ Cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally

substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d1}, R_{d2}, R_{d4}, R_{d8} and R_d is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

the hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

the halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;


m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

t is an integer optionally selected from 0, 1, 2, 3, and 4.

8. The compound according to claim 1, characterized in that it has the structure of Formula (IG),



Formula (IG)

Wherein,

X and X' are independently selected from -C(R_{d1})(R_{d2})-, -N(R_{d4})-, -O-, -S-, -S(=O)- or -S(=O)₂-;

L is independently selected from -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -O-, -S- or -N(R_{d4})-;

X₁ and X₈ are each independently selected from -CR₅- or -N-;

R is independently hydrogen, deuterium, halogen, -CN, C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, -NR_{d8}R_{d9}, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl, wherein R representing C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl, C₁₋₁₀ alkoxy, 6- to 10- membered aryl, 5- to 8-membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl and 3- to 8- membered saturated or partially saturated heterocyclyl are optionally substituted with one to multiple substituent groups, the substituent groups are optionally selected from hydrogen, deuterium, halogen, alkyl, haloalkyl, alkoxy, alkylamino, O=, CN, OH, -NR_{d8}R_{d9}, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocyclic group, 6- to 10- aryl and 5- to 8- membered heteroaryl; wherein the aryl, heteroaryl, saturated or partially saturated cycloalkyl, saturated or partially saturated heterocyclyl are further optionally substituted with one to multiple substituents, and the substituents are optionally selected from hydrogen, deuterium, Halogen, alkyl, haloalkyl, cyano, cyanoethyl, O=, OH, C₁₋₃ alkyl, C₁₋₃ alkoxy, saturated or partially saturated cycloalkyl or saturated or partially saturated heterocyclyl, wherein the C₁₋₃ alkyl

group, C₁₋₃ alkoxy group, saturated or partially saturated cycloalkyl group or saturated or partially saturated heterocyclic group are optionally substituted with 1 to 3 substituent groups, the substituent groups are optionally selected from H, deuterium, halogen, haloalkyl, cyano, OCH₃ and OH;

- 5 Each R₁ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, -CN, -OH, -SH and -NH₂, -COOH or from C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ saturated or partially saturated cycloalkyl, C₃₋₁₀ saturated or partially saturated heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, C₂₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocyclyl, C₁₋₁₀ alkyl substituted with carboxyl or carboxyl surrogate;

- 10 Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, CN, OH, SH and NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl, and C₁₋₁₀ heteroalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH, and C₃₋₁₀ saturated or partially saturated cycloalkyl or heterocyclyl;

- 15 Each R₅ and R₆ is the same or different and is independently hydrogen, deuterium, halogen, CN, OH, SH, NR_{d8}R_{d9}, NH₂, -COOH or C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkenyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocycloalkyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl; Or any adjacent two R₅ or R₆ together with the carbon to which they are attached form 5- to 6- membered heteroaryl, 3- to 8- membered saturated or partially saturated cycloalkyl, 3- to 8- membered saturated or partially saturated heterocyclyl, and the aryl, saturated or partially saturated cycloalkyl, heterocycloalkyl are optionally substituted with one to more groups selected from hydrogen, deuterium, halogen, -CN, -OH, CF₃, C₁₋₆ alkyl, C₁₋₆ alkoxy, -NH₂, -NHC₁₋₆ alkyl, -N(C₁₋₆ alkyl)₂, oxy, and saturated or partially saturated C₃₋₆ cycloalkyl, and the C₁₋₆ alkyl and C₁₋₆ alkoxy are optionally substituted with one to more groups selected from hydrogen,

deuterium, halogen, oxo, CN, CF₃, OH, OCH₃, OCH₂CH₃, saturated or partially saturated C₃₋₆ cycloalkyl;

Each R_{d1}, R_{d2}, R_{d4}, R_{d8} and R_d is the same or different, and is optionally and independently selected from hydrogen, deuterium, NH₂, C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl; wherein, the C₁₋₁₀ alkyl, C₂₋₁₀ alkynyl or C₁₋₁₀ alkoxy, C₁₋₁₀ alkylacyl, C₁₋₁₀ alkylsulfonyl, C₂₋₁₀ heteroalkyl, C₃₋₁₀ cycloalkyl, C₃₋₁₀ heterocycloalkyl, C₁₋₁₀ alkyl substituted by C₃₋₁₀ cycloalkyl, or C₃₋₁₀ heterocyclyl substituted by C₃₋₁₀ cycloalkyl or C₃₋₁₀ heterocycloalkyl are optionally substituted with one to multiple groups selected from hydrogen, deuterium, halogen, oxo, CN, OH and C₃₋₁₀ saturated or partially substituted saturated cycloalkyl or heterocyclyl;

the hetero represents any heteroatom independently selected from O, N, S, P and isotopes thereof;

the halogen is optionally and independently selected from F, Cl, Br, I and isotopes thereof;
m is an integer optionally selected from 1, 2, 3 and 4;
n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;
q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;
t is an integer optionally selected from 0, 1, 2, 3, and 4.

9. The compound according to any one of claims 1-8, wherein A is selected from unsubstituted or substituted C₆₋₂₀ aryl, 5- to 20-membered heteroaryl;

B is selected from unsubstituted or substituted 3- to 20- membered heterocyclyl, 6- to 18-membered bridged cyclyl or spirocyclyl, C₆₋₂₀ aryl;

X and X' are the same or different and are independently selected from -C(R_{d1})(R_{d2})-, -O-, -S-, -C(=O)O-, -OC(=O)-, -C(=O)-, -S(=O)- or -S(=O)₂-;

L is selected from -C(R_{d1})(R_{d2})-, OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -O-, -S-, -NH-, -C(=O)O-, -OC(=O)-, -C(=O)-, -S(=O)- or -S(=O)₂-; R_{d1} and R_{d2} are the same or different and are optionally and independently selected from hydrogen, deuterium, halogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

X₁, X₂, X₃, X₄, X₅, X₈ and X₉ are the same or different and are independently selected from -CR₅- or -N-; each R₅ is the same or different and is independently selected from hydrogen, deuterium, halogen, CN, OH, SH, NH₂, -COOH, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

R₀ is selected from C₁₋₁₀ alkyl unsubstituted or optionally substituted with one, two or

more R₀₁; each R₀₁ is the same or different and is independently selected from C₃₋₂₀ cycloalkyl, 3- to 20- membered heterocyclyl and 5- to 20- membered heteroaryl unsubstituted or optionally substituted with one, two or more R₀₂; each R₀₂ is the same or different, and is independently selected from halogen, deuterium, CN, oxo (= O), C₁₋₁₀ alkyl, halogenated C₁₋₁₀ alkyl, CN-C₁₋₁₀ alkyl, C₃₋₆ cycloalkyl-C₁₋₁₀ alkyl;

Each R₁ is the same or different and is independently selected from hydrogen, deuterium, halogen, -CN, -OH, -SH, -NH₂, COOH, unsubstituted or optionally substituted with one, two or more R₁₁ C₁₋₁₀ alkyl-COOH, -C₂₋₁₀ alkenyl-COOH; each R₁₁ is the same or different and is independently selected from H, deuterium, halogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

R₂, R_{2'} are the same or different, and are independently selected from hydrogen, deuterium, halogen, oxo (=O), C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, oxo (=O), CN, OH, SH and NH₂, -COOH, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

Each R₆ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, CN, OH, SH, NH₂, -COOH, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₂₋₁₀ alkynyl, 5- to 14-membered heteroaryl;

R_{d3}, R_{d4}, R_{d5}, R_{d6}, R_{d7}, R_{d8}, R_{d9} and R_{d10} are the same or different and are optionally and independently selected from hydrogen, deuterium, CN, OH, SH and NH₂, -COOH, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

m is an integer optionally selected from 1, 2, 3 and 4;

n is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

q is an integer optionally selected from 0, 1, 2, 3, 4 and 5;

Preferably, A is selected from unsubstituted or substituted C₆₋₁₄ aryl, 5- to 14- membered heteroaryl;

B is selected from unsubstituted or substituted 3- to 14- membered heterocyclyl or bridged cyclyl, C₆₋₁₄ aryl;

X and X' are the same or different and are independently selected from -C(R_{d1})(R_{d2})-, -O-, -S-;

L is selected from -C(R_{d1})(R_{d2})-, -OC(R_{d1})(R_{d2})-, -C(R_{d1})(R_{d2})O-, -O-, -S-, -NH-; R_{d1} and R_{d2} are the same or different, and are optionally and independently selected from hydrogen, deuterium, C₁₋₁₀ alkyl;

X₁, X₂, X₃, X₄, X₅, X₈ and X₉ are the same or different and are independently selected from -CR₅- or -N-; each R₅ is the same or different and is independently selected from hydrogen,

deuterium, halogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

R₀ is selected from C₁₋₁₀ alkyl unsubstituted or optionally substituted with one, two or more R₀₁; each R₀₁ is the same or different and is independently selected from C₃₋₂₀ cycloalkyl, 3- to 20- membered heterocyclyl and 5- to 20- membered heteroaryl unsubstituted or optionally substituted with one, two or more R₀₂; each R₀₂ is the same or different, independently selected from CN, deuterium, oxo (=O), C₁₋₁₀ alkyl, CN-C₁₋₁₀ alkyl, C₃₋₆ cycloalkyl-C₁₋₁₀ alkyl;

Each R₁ is the same or different and is independently selected from, halogen, COOH, unsubstituted or optionally substituted with one, two or more R₁₁ C₁₋₁₀ alkyl-COOH, -C₂₋₁₀ alkenyl-COOH; each R₁₁ is the same or different and is independently selected from H, deuterium, halogen, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

R₂, R_{2'} are the same or different, and are independently selected from hydrogen, deuterium, halogen, oxo (=O), C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

Each R₄ is the same or different and is optionally and independently selected from hydrogen, deuterium, halogen, oxo (=O), CN, OH, SH and NH₂, -COOH, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy;

Each R₆ is the same or different and is independently selected from the group consisting of hydrogen, deuterium, halogen, CN, C₁₋₁₀ alkyl, C₁₋₁₀ alkoxy, C₂₋₁₀ alkynyl, 5- to 14-membered heteroaryl;

m is an integer optionally selected from an integer of 1, 2 and 3;

n is an integer optionally selected from 0, 1, 2, 3 and 4;

q is an integer optionally selected from 0, 1, 2, 3 and 4;

Preferably, A is selected from phenyl or pyridyl;

B is piperidinyl, azetidiny, phenyl, (1R,5S)-3-azabicyclo[3.2.1]octyl, spirocyclic group or bridged cyclic group; the spirocyclic or the bridged ring contains one or more heteroatoms optionally and independently selected from N, O or S;

X and X' are the same or different and are independently selected from CH₂, O or S;

L is selected from O, S, NH, CH₂, OCH₂, CH₂O;

X₁, X₂, X₃, X₄, X₅, X₈ and X₉ are the same or different and are independently selected from CH, C-D, C-F or N;

R₀ is selected from C₁₋₃ alkyl unsubstituted or substituted with imidazolyl, pyrazolyl, pyrrolyl, azetidiny, oxetanyl, pyrrolidinyl or cyclopropyl; the imidazolyl, pyrazolyl, pyrrolyl, azetidiny, oxetanyl, pyrrolidinyl or cyclopropyl may be unsubstituted or substituted with oxo (=O) or C₁₋₃ alkyl, CN- C₁₋₃ alkyl, C₃₋₆ cycloalkyl-C₁₋₃ alkyl;

Each R₁ is the same or different and is independently selected from COOH, F, -C₁₋₃ alkyl-

COOH, -C₂₋₃ alkenyl-COOH;

R₂, R_{2'} are the same or different, and are independently selected from hydrogen, deuterium, halogen, oxo (=O), C₁₋₃ alkyl;


Each R₄ is the same or different and is optionally and independently selected from
5 hydrogen, deuterium, halogen, oxo (=O), C₁₋₃ alkyl;


Each R₆ is the same or different and is independently selected from hydrogen, deuterium, F, Cl, Br, CN, ethynyl, imidazolyl;


m is optionally selected from 1 or 2;

n is optionally selected from 0, 1 or 2;


10 q is optionally selected from 0, 1 or 2.

Preferably,  can be selected from the structures shown below:




B is selected from the following structures:  ;



L is selected from O, S, NH, CH₂, OCH₂, or CH₂O;




can be selected from the structures shown below:



R₀ is selected from the structures shown below:



5



R₁ is selected from COOH, F;




Both R₂ and R_{2'} are H;




R₄ is H, F, methyl; X₈ is selected from CH or N; X₉ is selected from CH or N;




m is selected from 1 or 2; n is selected from 1 or 2.




10




10. The compound according to any one of claims 1-9, wherein the compound is selected from the compounds of the following structures:




Compound NO.	Structure
Compound 1	
Compound 2	
Compound 3	




Compound 4	 Chemical structure of Compound 4: A benzimidazole ring system with a carboxylic acid group (HO-C(=O)-) at position 6 and a fluorine atom (F) at position 7. The benzimidazole ring is connected via its 2-position to a piperidine ring, which is further connected via its nitrogen atom to a pyridine ring. The pyridine ring has a fluorine atom (F) at position 6 and is connected via its 3-position to a methylene group (-CH2-), which is connected to a fluorophenyl group (a benzene ring with a fluorine atom at position 2 and a nitrile group (-C≡N) at position 4).
Compound 5	 Chemical structure of Compound 5: A pyridine ring system with a carboxylic acid group (HO-C(=O)-) at position 3 and a fluorine atom (F) at position 6. The pyridine ring is connected via its 2-position to a piperidine ring, which is further connected via its nitrogen atom to a pyridine ring. The pyridine ring has a fluorine atom (F) at position 6 and is connected via its 3-position to a methylene group (-CH2-), which is connected to a fluorophenyl group (a benzene ring with a fluorine atom at position 2 and a nitrile group (-C≡N) at position 4).
Compound 6	 Chemical structure of Compound 6: A pyridine ring system with a carboxylic acid group (HO-C(=O)-) at position 3 and a fluorine atom (F) at position 6. The pyridine ring is connected via its 2-position to a piperidine ring, which is further connected via its nitrogen atom to a pyridine ring. The pyridine ring has a fluorine atom (F) at position 6 and is connected via its 3-position to a methylene group (-CH2-), which is connected to a fluorophenyl group (a benzene ring with a fluorine atom at position 2 and a nitrile group (-C≡N) at position 4).




Compound 7	 Chemical structure of Compound 7: A benzimidazole ring system with a carboxylic acid group at position 6. The benzimidazole ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2 and a (4-(4-chloro-2-fluorophenoxy)phenyl)methyl group at position 4. The benzimidazole ring is also substituted with a (4-(4-chloro-2-fluorophenoxy)phenyl)methyl group at position 4.
Compound 8	 Chemical structure of Compound 8: A benzimidazole ring system with a carboxylic acid group at position 6. The benzimidazole ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2 and a (4-(4-chloro-2-fluorophenoxy)phenyl)methyl group at position 4. The benzimidazole ring is also substituted with a (4-(4-chloro-2-fluorophenoxy)phenyl)methyl group at position 4.
Compound 9	 Chemical structure of Compound 9: A benzimidazole ring system with a carboxylic acid group at position 6. The benzimidazole ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2 and a (4-(4-chloro-2-fluorophenoxy)phenyl)methyl group at position 4. The benzimidazole ring is also substituted with a (4-(4-chloro-2-fluorophenoxy)phenyl)methyl group at position 4.




Compound 10	
Compound 11	
Compound 12	




Compound 13	 Chemical structure of Compound 13: A benzimidazole ring system with a carboxylic acid group (HO-C(=O)-) at position 6. The benzimidazole ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2 and a (4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group at position 3. The piperidine ring is connected to a phenyl ring, which is further connected to a methylene group, which is connected to an oxygen atom, which is connected to a 4-cyano-2-fluorophenyl group.
Compound 14	 Chemical structure of Compound 14: A benzimidazole ring system with a carboxylic acid group (HO-C(=O)-) at position 6. The benzimidazole ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2 and a (4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group at position 3. The piperidine ring is connected to a phenyl ring, which is further connected to a methylene group, which is connected to an oxygen atom, which is connected to a 4-cyano-2-fluorophenyl group.
Compound 15	 Chemical structure of Compound 15: A benzimidazole ring system with a carboxylic acid group (HO-C(=O)-) at position 6. The benzimidazole ring is substituted with a 1-ethyl-1H-imidazol-2-ylmethyl group at position 2 and a (4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group at position 3. The piperidine ring is connected to a phenyl ring, which is further connected to a methylene group, which is connected to an oxygen atom, which is connected to a 4-cyano-2-fluorophenyl group.




Compound 16	 Chemical structure of Compound 16: A benzimidazole core substituted with a carboxylic acid group, a fluorine atom, and a 1-ethyl-1H-imidazol-2-ylmethyl group. The benzimidazole ring is connected via its 2-position to a piperidine ring, which is further connected via its nitrogen to a 4-fluorophenyl group. This phenyl group is linked via a methylene group to another phenyl ring, which is substituted with a fluorine atom and a cyano group.
Compound 17	 Chemical structure of Compound 17: A pyrimidine core substituted with a carboxylic acid group and a 1-ethyl-1H-imidazol-2-ylmethyl group. The pyrimidine ring is connected via its 2-position to a piperidine ring, which is further connected via its nitrogen to a 4-fluorophenyl group. This phenyl group is linked via a methylene group to another phenyl ring, which is substituted with a fluorine atom and a cyano group.
Compound 18	 Chemical structure of Compound 18: A pyrimidine core substituted with a carboxylic acid group and a 1-ethyl-1H-imidazol-2-ylmethyl group. The pyrimidine ring is connected via its 2-position to a piperidine ring, which is further connected via its nitrogen to a 4-fluorophenyl group. This phenyl group is linked via a methylene group to another phenyl ring, which is substituted with a fluorine atom and a cyano group.




Compound 19	 Chemical structure of Compound 19: A benzimidazole core substituted with a (E)-3-(4-chloro-3-fluorophenoxy)piperidin-1-ylmethyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 4, and a (E)-3-(4-chloro-3-fluorophenoxy)piperidin-1-ylmethyl group at position 6. The benzimidazole ring also has a carboxylic acid group at position 7.
Compound 20	 Chemical structure of Compound 20: A benzimidazole core substituted with a (E)-3-(4-chloro-3-fluorophenoxy)piperidin-1-ylmethyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 4, and a (E)-3-(4-chloro-3-fluorophenoxy)piperidin-1-ylmethyl group at position 6. The benzimidazole ring also has a carboxylic acid group at position 7 and a fluorine atom at position 5.
Compound 21	 Chemical structure of Compound 21: A benzimidazole core substituted with a (E)-3-(4-chloro-3-fluorophenoxy)piperidin-1-ylmethyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 4, and a (E)-3-(4-chloro-3-fluorophenoxy)piperidin-1-ylmethyl group at position 6. The benzimidazole ring also has a carboxylic acid group at position 7 and a fluorine atom at position 5.




Compound 22	 Chemical structure of Compound 22: A pyrazole ring substituted with a 4-(4-chloro-3-fluorophenoxy)piperidin-1-yl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 4-((E)-3-oxo-3-phenylprop-1-en-1-yl) group. The pyrazole ring also has a fluorine substituent at the 6-position.
Compound 23	 Chemical structure of Compound 23: A pyrazole ring substituted with a 4-(4-chloro-3-fluorophenoxy)piperidin-1-yl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 4-((E)-3-oxo-3-phenylprop-1-en-1-yl) group. The pyrazole ring also has a fluorine substituent at the 6-position.
Compound 24	 Chemical structure of Compound 24: A pyrazole ring substituted with a 4-(4-chloro-3-fluorophenoxy)piperidin-1-yl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 4-((E)-3-oxo-3-phenylprop-1-en-1-yl) group. The pyrazole ring also has a fluorine substituent at the 6-position.





Compound 25	
Compound 26	
Compound 27	




Compound 28	 Chemical structure of Compound 28: A pyridine ring substituted with a carboxylic acid group (HO-C(=O)-CH=CH-), a fluorine atom (F), and a 1-ethyl-1H-imidazol-2-ylmethyl group. The pyridine ring is connected via a piperidine ring to a 2-fluoro-5-(4-cyano-3-fluorophenoxy)pyridine moiety.
Compound 29	 Chemical structure of Compound 29: A pyridine ring substituted with a carboxylic acid group (HO-C(=O)-CH=CH-) and a 1-ethyl-1H-imidazol-2-ylmethyl group. The pyridine ring is connected via a piperidine ring to a 2-fluoro-5-(4-cyano-3-fluorophenoxy)pyridine moiety.
Compound 30	 Chemical structure of Compound 30: A pyridine ring substituted with a carboxylic acid group (HO-C(=O)-CH=CH-) and a 1-ethyl-1H-imidazol-2-ylmethyl group. The pyridine ring is connected via a piperidine ring to a 2-fluoro-5-(4-cyano-3-fluorophenoxy)pyridine moiety.





Compound 31	 Chemical structure of Compound 31: A benzimidazole core substituted with a (E)-3-oxo-3-phenylprop-1-en-1-yl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (4-(4-chloro-3-fluorophenoxy)phenyl)methyl group at position 4. The benzimidazole ring has a carboxylic acid group at position 5.
Compound 32	 Chemical structure of Compound 32: A benzimidazole core substituted with a (E)-3-oxo-3-phenylprop-1-en-1-yl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (4-(4-chloro-3-fluorophenoxy)phenyl)methyl group at position 4. The benzimidazole ring has a fluorine atom at position 5.
Compound 33	 Chemical structure of Compound 33: A benzimidazole core substituted with a (E)-3-oxo-3-phenylprop-1-en-1-yl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (3-(4-chloro-3-fluorophenoxy)phenyl)methyl group at position 4. The benzimidazole ring has a fluorine atom at position 5.





Compound 34	
Compound 35	
Compound 36	





Compound 37	 Chemical structure of Compound 37: A benzimidazole core substituted with a (E)-3-oxo-3-phenylprop-1-en-1-yl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group at position 3. The benzimidazole ring has a carboxylic acid group at position 4.
Compound 38	 Chemical structure of Compound 38: A benzimidazole core substituted with a (E)-3-oxo-3-phenylprop-1-en-1-yl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group at position 3. The benzimidazole ring has a fluorine atom at position 4.
Compound 39	 Chemical structure of Compound 39: A benzimidazole core substituted with a (E)-3-oxo-3-phenylprop-1-en-1-yl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a (3-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group at position 3. The benzimidazole ring has a fluorine atom at position 4.





Compound 40	
Compound 41	
Compound 42	
Compound 43	





Compound 44	 Chemical structure of Compound 44: A 4-fluorophenyl ring substituted with a carboxylic acid group (HO-C=O) and a 1-((4-(2-(4-chloro-3-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-2-yl)methyl-1H-imidazole-2-yl group.
Compound 45	 Chemical structure of Compound 45: A 4-fluorophenyl ring substituted with a carboxylic acid group (HO-C=O) and a 1-((4-(2-(4-chloro-3-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-2-yl)methyl-1H-imidazole-2-yl group.
Compound 46	 Chemical structure of Compound 46: A 4-fluorophenyl ring substituted with a carboxylic acid group (HO-C=O) and a 1-((4-(2-(4-chloro-3-fluorophenoxy)methyl)pyridin-2-yl)oxy)piperidin-2-yl)methyl-1H-imidazole-2-yl group.





Compound 47	
Compound 48	
Compound 49	
Compound 50	





Compound 51	
Compound 52	
Compound 53	
Compound 54	





Compound 55	
Compound 56	
Compound 57	
Compound 58	





Compound 59	
Compound 60	
Compound 61	
Compound 62	





Compound 63	
Compound 64	
Compound 65	
Compound 66	

Compound 67	
Compound 68	
Compound 69	
Compound 70	

Compound 71	
Compound 72	
Compound 73	
Compound 74	





Compound 75	
Compound 76	
Compound 77	
Compound 78	





Compound 79	
Compound 80	
Compound 81	
Compound 82	

Compound 83	 <chem>O=C(O)/C=C/c1ccc2nc(CN3CCCCC3Oc4ccc(F)c(C#N)c4)cnc2n1[C@H]3OCCO3</chem>
Compound 84	 <chem>O=C(O)/C=C/c1ccc2nc(CN3CCCCC3Oc4ccc(F)c(C#N)c4)cnc2n1[C@H]3OCCO3</chem>
Compound 85	 <chem>O=C(O)/C=C/c1ccc2nc(CN3CCCCC3Oc4ccc(Oc5cc(F)c(Cl)cc5)cc4)cnc2n1[C@H]3OCCO3</chem>
Compound 86	 <chem>O=C(O)/C=C/c1cc(F)cc2nc(CN3CCCCC3Oc4ccc(Oc5cc(F)c(Cl)cc5)cc4)cnc2n1[C@H]3OCCO3</chem>





Compound 87	 <chem>Clc1ccc(OCc2cc(F)ccc2Oc3ccccc3N4CCN(CC4)C5=CN6C(=C(C=C6)C(=O)O)C(=N5)C7OC7)cc1</chem>
Compound 88	 <chem>Clc1ccc(OCc2cc(F)ccc2Oc3ccccc3N4CCN(CC4)C5=CN6C(=C(C=C6)C(=O)O)C(=N5)C7OC7)cc1</chem>
Compound 89	 <chem>Clc1ccc(OCc2cc(F)ccc2Oc3ccccc3N4CCN(CC4)C5=CN6C(=C(C=C6)C(=O)O)C(=N5)C7OC7)cc1</chem>
Compound 90	 <chem>Clc1ccc(OCc2cc(F)ccc2Oc3ccccc3N4CCN(CC4)C5=CN6C(=C(C=C6)C(=O)O)C(=N5)C7OC7)cc1</chem>





Compound 91	 <chem>O=C(O)/C=C/c1ccc2nc(CCN3CCOC(c4ccc(OCC5=CC=CC=C5F)C=C5)CC3)c3nc2c1F</chem>
Compound 92	 <chem>O=C(O)/C=C/c1ccc2nc(CCN3CCOC(c4ccc(OCC5=CC=CC=C5F)C=C5)CC3)c3nc2c1F</chem>
Compound 93	 <chem>O=C(O)/C=C/c1ccc2nc(CCN3CCOC(c4cc(OCC5=CC=CC=C5F)cc4)CC3)c3nc2c1F</chem>
Compound 94	 <chem>O=C(O)/C=C/c1ccc2nc(CCN3CCOC(c4cc(OCC5=CC=CC=C5F)cc4F)CC3)c3nc2c1F</chem>





Compound 95	
Compound 96	
Compound 97	
Compound 98	





Compound 99	
Compound 100	
Compound 101	
Compound 102	





Compound 103	 <chem>Clc1ccc(OCc2nc(OCCn3ccccc3)c4cc(F)ccc4n2)c5ccccc5</chem>
Compound 104	 <chem>Clc1ccc(OCc2nc(OCCn3ccccc3)c4cc(F)ccc4n2)c5ccccc5</chem>
Compound 105	 <chem>Clc1ccc(OCc2nc(OCCn3ccccc3)c4cc(F)ccc4n2)c5ccccc5</chem>
Compound 106	 <chem>Clc1ccc(OCc2nc(OCCn3ccccc3)c4cc(F)ccc4n2)c5ccccc5</chem>





Compound 107	
Compound 108	
Compound 109	
Compound 110	





Compound 111	
Compound 112	
Compound 113	
Compound 114	





Compound 115	 <chem>O=C(O)/C=C/c1ccc2nc(CN3CCOC(c4ccc(OCc5ccc(F)c(Cl)c5)cc4)CC3)c(C#CC6CC6)c2n1</chem>
Compound 116	 <chem>O=C(O)/C=C/c1cc(F)ccc2nc(CN3CCOC(c4ccc(OCc5ccc(F)c(Cl)c5)cc4)CC3)c(C#CC6CC6)c2n1</chem>
Compound 117	 <chem>O=C(O)/C=C/c1cc(F)ccc2nc(CN3CCOC(c4cc(F)cc(OCc5ccc(F)c(Cl)c5)cc4)CC3)c(C#CC6CC6)c2n1</chem>
Compound 118	 <chem>O=C(O)/C=C/c1cc(F)ccc2nc(CN3CCOC(c4cc(F)cc(OCc5ccc(F)c(Cl)c5)cc4)CC3)c(C#CC6CC6)c2n1</chem>





Compound 119	
Compound 120	
Compound 121	
Compound 122	





Compound 123	
Compound 124	
Compound 125	
Compound 126	





Compound 127	
Compound 128	
Compound 129	
Compound 130	





Compound 131	
Compound 132	
Compound 133	
Compound 134	





Compound 135	
Compound 136	
Compound 137	
Compound 138	

Compound 139	 <chem>O=C(O)c1ccc2nc(CN3CCOC(c4ccc(cc4)COC5=CC=C(C=C5)Cl)cc3)c(C#CC6CC6)c2n1</chem>
Compound 140	 <chem>O=C(O)c1cc(F)c2nc(CN3CCOC(c4ccc(cc4)COC5=CC=C(C=C5)Cl)cc3)c(C#CC6CC6)c2n1</chem>
Compound 141	 <chem>O=C(O)c1cc(F)c2nc(CN3CCOC(c4cc(F)ccc4COC5=CC=C(C=C5)Cl)cc3)c(C#CC6CC6)c2n1</chem>
Compound 142	 <chem>O=C(O)c1cc(F)c2nc(CN3CCOC(c4cc(F)ccc4COC5=CC=C(C=C5)Cl)cc3)c(C#CC6CC6)c2n1</chem>





Compound 143	
Compound 144	
Compound 145	
Compound 146	





Compound 147	
Compound 148	
Compound 149	
Compound 150	





Compound 151	
Compound 152	
Compound 153	
Compound 154	





Compound 155	
Compound 156	
Compound 157	
Compound 158	





Compound 159	 <chem>O=C(O)CC1=CC=C2N=C(N1CCN2C3C4C(C3)CC4)CCN5CCOC6=CC=C(F)N=C6C7=CC=CC(=C7)C#N</chem>
Compound 160	 <chem>O=C(O)CC1=CC=C2N=C(N1CCN2C3C4C(C3)CC4)CCN5CCOC6=CC=C(F)N=C6C7=CC=CC(=C7)C#N</chem>
Compound 161	 <chem>O=C(O)CC1=CC=C2N=C(N1CCN2C3C4C(C3)CC4)CCN5CCOC6=CC=C(F)N=C6C7=CC=CC(=C7)C#N</chem>
Compound 162	 <chem>O=C(O)CC1=CC=C2N=C(N1CCN2C3C4C(C3)CC4)CCN5CCOC6=CC=C(F)N=C6C7=CC=CC(=C7)C#N</chem>

Compound 163	
Compound 164	
Compound 165	
Compound 166	





Compound 167	
Compound 168	
Compound 169	
Compound 170	





Compound 171	
Compound 172	
Compound 173	
Compound 174	




Compound 175	
Compound 176	
Compound 177	
Compound 178	




Compound 179	
Compound 180	
Compound 181	
Compound 182	




Compound 183	 <chem>O=C(O)Cc1ccc2nc3c(nc21)C(C3)CN4CCOC4Oc5cc(F)c(C#N)cn5</chem>
Compound 184	 <chem>O=C(O)Cc1cc(F)c2nc3c(nc12)C(C3)CN4CCOC4Oc5cc(F)c(C#N)cn5</chem>
Compound 185	 <chem>O=C(O)Cc1cc2nc3c(nc12)C(C3)CN4CCOC4Oc5cc(F)c(C#N)cn5</chem>
Compound 186	 <chem>O=C(O)Cc1cc2nc3c(nc12)C(C3)CN4CCOC4Oc5cc(F)c(C#N)cn5</chem>





Compound 187	
Compound 188	
Compound 189	
Compound 190	




Compound 191	
Compound 192	
Compound 193	
Compound 194	




Compound 195	 Chemical structure of Compound 195: A benzimidazole core substituted with a 2-oxo-2-(carboxymethyl)phenyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a 4-(2-(4-chloro-3-fluorophenoxy)-5-fluoropyridin-3-yl)piperidin-1-ylmethyl group at position 3.
Compound 196	 Chemical structure of Compound 196: A benzimidazole core substituted with a 2-oxo-2-(carboxymethyl)-5-fluorophenyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a 4-(2-(4-chloro-3-fluorophenoxy)-5-fluoropyridin-3-yl)piperidin-1-ylmethyl group at position 3.
Compound 197	 Chemical structure of Compound 197: A benzimidazole core substituted with a 2-oxo-2-(carboxymethyl)phenyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 1, and a 4-(2-(4-chloro-3-fluorophenoxy)-5-fluoropyridin-3-yl)piperidin-1-ylmethyl group at position 3.




Compound 198	 Chemical structure of Compound 198: A pyrazole ring substituted with a 2-(carboxymethyl)pyridin-3-ylmethyl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a (4-(2-(4-chloro-3-fluorophenoxy)methyl)pyridin-2-yloxy)methyl group.
Compound 199	 Chemical structure of Compound 199: A pyrazole ring substituted with a 2-(carboxymethyl)phenylmethyl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a (4-(2-(4-cyano-3-fluorophenoxy)methyl)pyridin-2-yloxy)methyl group.
Compound 200	 Chemical structure of Compound 200: A pyrazole ring substituted with a 2-(carboxymethyl)-3-fluorophenylmethyl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a (4-(2-(4-cyano-3-fluorophenoxy)methyl)pyridin-2-yloxy)methyl group.





Compound 201	 Chemical structure of Compound 201: A benzimidazole ring system. The benzimidazole has a carboxylic acid group (-CH₂COOH) at position 6. The imidazole ring is substituted with an ethyl group at position 2 and a (4-(4-cyano-2-fluorophenoxy)-2-fluorophenyl)piperidin-1-ylmethyl group at position 4. The piperidine ring is connected to the imidazole ring via its nitrogen atom.
Compound 202	 Chemical structure of Compound 202: A benzimidazole ring system. The benzimidazole has a carboxylic acid group (-CH₂COOH) at position 6 and a fluorine atom at position 7. The imidazole ring is substituted with an ethyl group at position 2 and a (4-(4-cyano-2-fluorophenoxy)-2-fluorophenyl)piperidin-1-ylmethyl group at position 4. The piperidine ring is connected to the imidazole ring via its nitrogen atom.
Compound 203	 Chemical structure of Compound 203: A benzimidazole ring system. The benzimidazole has a carboxylic acid group (-CH₂COOH) at position 6. The imidazole ring is substituted with an ethyl group at position 2 and a (4-(4-cyano-2-fluorophenoxy)-2-fluorophenyl)piperidin-1-ylmethyl group at position 4. The piperidine ring is connected to the imidazole ring via its nitrogen atom.





Compound 204	
Compound 205	
Compound 206	
Compound 207	

Compound 208	 Chemical structure of Compound 208: A benzimidazole core substituted with a 2-fluorophenyl group, a 2-((4-chloro-2-fluorophenyl)methoxy)piperidin-1-ylmethyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. A carboxylic acid group is attached to the 5-position of the benzimidazole ring.
Compound 209	 Chemical structure of Compound 209: A pyrimidine-benzimidazole core substituted with a 2-fluorophenyl group, a 2-((4-chloro-2-fluorophenyl)methoxy)piperidin-1-ylmethyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. A carboxylic acid group is attached to the 6-position of the pyrimidine ring.
Compound 210	 Chemical structure of Compound 210: A pyrimidine-benzimidazole core substituted with a 2-fluorophenyl group, a 2-((4-chloro-2-fluorophenyl)methoxy)piperidin-1-ylmethyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. A carboxylic acid group is attached to the 6-position of the pyrimidine ring.





Compound 211	 Chemical structure of Compound 211: A benzimidazole ring system. The benzimidazole has a carboxylic acid group (-CH₂COOH) at position 6. The imidazole ring is substituted with an ethyl group at position 2 and a (4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group at position 4.
Compound 212	 Chemical structure of Compound 212: A benzimidazole ring system. The benzimidazole has a carboxylic acid group (-CH₂COOH) at position 6 and a fluorine atom at position 7. The imidazole ring is substituted with an ethyl group at position 2 and a (4-(4-cyano-2-fluorophenoxy)phenyl)piperidin-1-ylmethyl group at position 4.
Compound 213	 Chemical structure of Compound 213: A benzimidazole ring system. The benzimidazole has a carboxylic acid group (-CH₂COOH) at position 6. The imidazole ring is substituted with an ethyl group at position 2 and a (3-(4-cyano-2-fluorophenoxy)-4-fluorophenyl)piperidin-1-ylmethyl group at position 4.





Compound 214	 Chemical structure of Compound 214: A benzimidazole core substituted with a 2-fluorophenyl group, a 2-((4-(2-cyano-4-fluorophenoxy)phenyl)piperidin-1-yl)methyl group, and a 1-ethyl-1H-imidazol-2-ylmethyl group. The benzimidazole ring also bears a 2-oxo-2-(carboxymethyl)phenyl substituent.
Compound 215	 Chemical structure of Compound 215: A pyrimidine core substituted with a 2-oxo-2-(carboxymethyl)phenyl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 2-((4-(2-cyano-4-fluorophenoxy)phenyl)piperidin-1-yl)methyl group.
Compound 216	 Chemical structure of Compound 216: A pyrimidine core substituted with a 2-oxo-2-(carboxymethyl)phenyl group, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a 2-((4-phenoxyphenyl)piperidin-1-yl)methyl group.




Number	Structure
Compound S1	
Compound S2	
Compound S3	
Compound S4	

Compound S5	
Compound S6	
Compound S7	
Compound S8	





Compound S9	 <chem>O=C(O)c1cc(F)c2nc(CN3CCCCC3Oc4ccc(OCC5=CC=CC=C5C#N)nn4)c2n1[C@H]3OCCO3</chem>
Compound S10	 <chem>O=C/C=C/c1ccc2nc(CN3CCCCC3Oc4ccc(OCC5=CC=CC=C5C#N)nn4)c2n1[C@H]3OCCO3</chem>
Compound S11	 <chem>O=C/C=C/c1ccc2nc(CN3CCCCC3Oc4ccccc4OCC5=CC=CC=C5C#N)cn2[C@H]3OCCO3</chem>
Compound S14	 <chem>O=C(O)c1cc(F)c2nc(CN3CCCCC3Oc4ccccc4F)nn1[C@H]3OCCO3</chem>





Compound S15	
Compound S16	
Compound S17	
Compound S20	





Compound S21	
Compound S22	
Compound S23	
Compound S24	




Compound S25	 Chemical structure of Compound S25: A 4-fluorophenyl ring substituted with a carboxylic acid group (HO-C=O) and a 1-((4-fluorophenyl)methyl)-1H-imidazole-2-ylmethyl group. The 1H-imidazole ring is substituted with an ethyl group. The 4-fluorophenyl ring is further substituted with a 4-cyano-2-fluorophenyl group via an ether linkage.
Compound S26	 Chemical structure of Compound S26: A 4-fluorophenyl ring substituted with a carboxylic acid group (HO-C=O) and a 1-((4-fluorophenyl)methyl)-1H-imidazole-2-ylmethyl group. The 1H-imidazole ring is substituted with an ethyl group. The 4-fluorophenyl ring is further substituted with a 4-cyano-2-fluorophenyl group via an ether linkage.
Compound S27	 Chemical structure of Compound S27: A 4-fluorophenyl ring substituted with a carboxylic acid group (HO-C=O) and a 1-((4-fluorophenyl)methyl)-1H-imidazole-2-ylmethyl group. The 1H-imidazole ring is substituted with an ethyl group. The 4-fluorophenyl ring is further substituted with a 4-cyano-2-fluorophenyl group via an ether linkage.





Compound S28	 <chem>CC1=CN=C(C1CN2C(=N2)C(=C(C=C2)C(=O)O)C=C)CN3CCO(C3)c4cc(F)c(C#N)cn4</chem>
Compound S29	 <chem>CC1=CN=C(C1CN2C(=N2)C(=C(C=C2)C(=O)O)C=C)CN3CCc4ccc(Oc5cc(F)c(C#N)cn5)cc43</chem>
Compound S32	 <chem>CC12OC1CC2N(C1)c3cc(F)ccc3N2CN4CCO(C4)c5ccc(Oc6cc(F)c(Cl)cn6)cc5</chem>
Compound S33	 <chem>CC12OC1CC2N(C1)c3cc(F)ccc3N2CN3CCc4cc(F)c(Oc5cc(F)c(Cl)cn5)cn43</chem>





Compound S34	
Compound S35	
Compound S36	
Compound S37	




Compound S40	
Compound S41	
Compound S42	
Compound S43	



Compound S44	
Compound S45	
Compound S48	
Compound S49	





Compound S50	 Chemical structure of Compound S50: A benzimidazole core substituted with a carboxylic acid group, a fluorine atom, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a (4-(2-chloro-4-fluorophenylethoxy)phenyl)methyl group.
Compound S51	 Chemical structure of Compound S51: A benzimidazole core substituted with a carboxylic acid group, a fluorine atom, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a (4-(2-chloro-4-fluorophenylethoxy)pyridin-2-yl)methyl group.
Compound S52	 Chemical structure of Compound S52: A benzimidazole core substituted with a carboxylic acid group, a fluorine atom, a 1-ethyl-1H-imidazol-2-ylmethyl group, and a (4-(2-chloro-4-fluorophenylethoxy)pyridin-2-yl)methyl group. The carboxylic acid group is attached via an (E)-alkene linker.





Compound S53	
Compound S56	
Compound S57	
Compound S58	





Compound S59	
Compound S60	
Compound S61	
Compound S62	





Compound S63	 Chemical structure of Compound S63: A benzimidazole core substituted with a 2-(carboxymethyl)phenyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 3, and a 4-(2-((4-cyano-2-fluorophenyl)methoxy)pyridin-4-yloxy)piperidin-1-ylmethyl group at position 4.
Compound S64	 Chemical structure of Compound S64: A benzimidazole core substituted with a 2-(carboxymethyl)phenyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 3, and a 4-(2-((4-cyano-2-fluorophenyl)methoxy)-6-fluoropyridin-4-yloxy)piperidin-1-ylmethyl group at position 4.
Compound S65	 Chemical structure of Compound S65: A benzimidazole core substituted with a 2-carboxyphenyl group at position 2, a 1-ethyl-1H-imidazol-2-ylmethyl group at position 3, and a 4-(2-((4-cyano-2-fluorophenyl)methoxy)pyridin-4-yloxy)piperidin-1-ylmethyl group at position 4.











Compound C3	
Compound C4	
Compound C5	
Compound C6	





Compound C7	
Compound C8	
Compound C9	
Compound C10	





Compound C11	
Compound C12	
Compound C13	
Compound C14	





Compound C15	
Compound C16	
Compound C17	
Compound C18	





Compound C19	
Compound C20	
Compound C21	
Compound C22	





Compound C23	
Compound C24	
Compound C25	
Compound C26	





Compound C27	
Compound C28	
Compound C29	
Compound C30	





Compound C31	
Compound C32	
Compound C33	
Compound C34	





Compound C35	
Compound C36	
Compound C37	
Compound C38	





Compound C39	
Compound C40	
Compound C41	
Compound C42	





Compound C43	
Compound C44	
Compound C45	
Compound C46	





Compound C47	
Compound C48	
Compound C49	
Compound C50	





Compound C51	
Compound C52	
Compound C53	
Compound C54	





Compound C55	 <chem>O=C(O)c1ccc2nc(CN3CC(F)CC(O3)c4ccc(OCC5=CC=CC=C5F)cc4)c(n2)C3OCCO3</chem>
Compound C56	 <chem>CC1=CN=C(C1)CN2C(=CN2)CN(CN3CC(C)CC(O3)c4ccc(OCC5=CC=CC=C5F)cc4)c6ccccc6C(=O)O</chem>
Compound C57	 <chem>CC1=CN=C(C1)CN2C(=CN2)CN(CN3CC(C)CC(O3)c4ccc(OCC5=CC=CC=C5F)cc4)c6ccccc6C(=O)O</chem>
Compound C58	 <chem>CC1=CN=C(C1)CN2C(=CN2)CN(CN3CC(F)CC(O3)c4ccc(OCC5=CC=CC=C5F)cc4)c6ccccc6C(=O)O</chem>





Compound C59	
Compound C60	
Compound C61	
Compound C62	



Compound C63	
Compound C64	
Compound C65	
Compound C66	

Compound C67	
Compound C68	
Compound C69	
Compound C70	

Compound C71	
Compound C72	
Compound C73	
Compound C74	

Compound C75	
Compound C76	
Compound C77	
Compound C78	

Compound C79	
Compound C80	
Compound C81	
Compound C82	

Compound C83	
Compound C84	

11. A pharmaceutical composition comprising at least one of the compound of any one of claims 1-10, a pharmaceutically acceptable salt, solvate, enantiomer or isotopic variations thereof in therapeutically effective amount.

- 5 12. Use of the compound of any one of claims 1-10, or pharmaceutically acceptable salt, solvate, enantiomer or isotopic variations thereof, for manufacturing a medicament for preventing or treating GLP1/GLP1R signaling pathway related diseases;

Preferably, the GLP1/GLP1R signaling pathway related diseases include but are not limited to overweight, obesity, diabetes (T1 D and/or T2DM, including pre-diabetes),
 10 idiopathic T1 D (type 1B), latent autoimmunity diabetes in adults (LADA), early-onset T2DM (EOD), atypical diabetes in youth (YOAD), diabetes in maturity of youth (MODY), malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, renal disease (e.g., acute kidney disease, renal tubular dysfunction, proinflammatory changes in proximal tubules), diabetic retinopathy, adipocyte dysfunction, visceral fat deposition, sleep
 15 apnea, obesity (including hypothalamic and monogenic obesity) and associated comorbidities (e.g., osteoarthritis and urinary incontinence), eating disorders (including binge drinking

syndrome, bulimia nervosa, and syndromic obesity , such as Prader-Willi and Bardet-Biedl syndromes), weight gain due to use of other drugs (e.g., steroid and antipsychotic use), hyperglycemia, dyslipidemia (including hyperlipidemia, hypertriglyceridemia, increased total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, hyperinsulinemia, NAFLD (including steatosis, NASH, fibrosis, liver cirrhosis, hepatocellular carcinoma and other related diseases), cardiovascular disease, atherosclerosis sclerosis (including coronary artery disease), peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction (e.g., necrosis and apoptosis), stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, postprandial lipids, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, PMS, angina, thrombosis, atherosclerosis, transient ischemic attack, restenosis , impaired glucose metabolism, impaired fasting glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcers, ulcerative colitis, hyperapolipoprotein B lipoproteinemia, Alzheimer's disease, schizophrenia, cognitive impairment, inflammatory bowel disease, short bowel syndrome, Crohn's disease, colitis, irritable bowel syndrome, polycystic ovary syndrome, and addiction treatment (e.g., alcohol and/or drug abuse) and other conditions.